No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, d4e4nB_, 1.0000, 0.00, 1.000, 280, 280, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
2, d4ei4B_, 0.9976, 0.30, 1.000, 280, 280, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
3, d4ivdB_, 0.9975, 0.31, 1.000, 280, 280, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
4, d4k77B_, 0.9967, 0.37, 1.000, 280, 280, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
5, d4k77A_, 0.9955, 0.47, 0.996, 282, 280, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
6, d5wo4A_, 0.9949, 0.51, 1.000, 292, 280, JAK1 COMPLEXED WITH COMPOUND 28
7, d5hx8A_, 0.9947, 0.52, 1.000, 291, 280, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
8, d4ehzB_, 0.9946, 0.46, 1.000, 280, 280, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
9, d4ivcB_, 0.9944, 0.49, 1.000, 280, 280, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
10, d4ivbB_, 0.9943, 0.52, 1.000, 280, 280, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
11, d4e4nA1, 0.9940, 0.37, 0.996, 290, 279, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
12, d5wo4B_, 0.9935, 0.57, 1.000, 280, 280, JAK1 COMPLEXED WITH COMPOUND 28
13, d4i5cA_, 0.9933, 0.35, 1.000, 279, 279, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
14, d4ehzD_, 0.9922, 0.56, 1.000, 280, 280, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
15, d4fk6B_, 0.9913, 0.58, 1.000, 284, 280, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
16, d4ehzA_, 0.9911, 0.46, 1.000, 290, 279, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
17, d5hx8B_, 0.9910, 0.50, 0.996, 279, 279, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
18, d5e1eB_, 0.9908, 0.51, 1.000, 280, 279, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
19, d5e1eA_, 0.9908, 0.51, 1.000, 279, 279, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
20, d4ivdA1, 0.9905, 0.30, 1.000, 289, 278, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
21, d4e4lE_, 0.9901, 0.50, 1.000, 280, 279, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
22, d4i5cB1, 0.9897, 0.62, 0.996, 290, 279, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
23, d4ivcA1, 0.9895, 0.59, 0.996, 290, 279, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
24, d4ivbA1, 0.9890, 0.64, 0.996, 290, 279, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
25, d4ehzC_, 0.9878, 0.44, 1.000, 278, 278, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
26, d4e4lB_, 0.9873, 0.47, 1.000, 279, 278, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
27, d4ei4A1, 0.9870, 0.29, 1.000, 288, 277, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
28, d4e5wA1, 0.9870, 0.69, 1.000, 291, 279, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
29, d4e4lD_, 0.9869, 0.49, 1.000, 281, 278, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
30, d4fk6A_, 0.9848, 0.56, 1.000, 285, 278, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
31, d4e4lA_, 0.9826, 0.52, 1.000, 277, 277, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
32, d4k6zA_, 0.9824, 0.81, 0.996, 279, 279, THE JAK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 37
33, d4e5wB_, 0.9798, 0.69, 1.000, 278, 277, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
34, d3q32B1, 0.9769, 0.99, 0.554, 293, 280, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
35, d5cf4B_, 0.9760, 1.01, 0.557, 291, 280, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
36, d4zimB1, 0.9758, 1.01, 0.557, 292, 280, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
37, d4aqcB_, 0.9755, 1.06, 0.557, 295, 280, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
38, d3e64A_, 0.9750, 1.03, 0.554, 291, 280, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
39, d5cf5B1, 0.9747, 1.03, 0.557, 292, 280, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
40, d4ji9B_, 0.9746, 1.10, 0.557, 288, 280, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
41, d4e6qB_, 0.9746, 1.04, 0.568, 296, 280, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
42, d4d0xA_, 0.9741, 1.05, 0.554, 291, 280, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
43, d3tjdB_, 0.9738, 1.03, 0.559, 287, 279, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
44, d5cf6B1, 0.9737, 1.05, 0.554, 288, 280, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
45, d3e62A_, 0.9735, 1.08, 0.554, 291, 280, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
46, d4e6qA_, 0.9734, 1.06, 0.568, 296, 280, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
47, d3tjcB_, 0.9732, 1.05, 0.559, 287, 279, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
48, d4hgeB_, 0.9731, 1.15, 0.554, 288, 280, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
49, d3krrA1, 0.9731, 1.00, 0.556, 290, 279, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT QUINOXALINE ATP SITE INHIBITOR
50, d3q32A_, 0.9730, 1.00, 0.552, 291, 279, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
51, d5cf8B1, 0.9725, 1.01, 0.559, 287, 279, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
52, d4e6dB_, 0.9711, 0.99, 0.572, 286, 278, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
53, d4d0wA_, 0.9711, 1.04, 0.556, 289, 279, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
54, d3fupB_, 0.9707, 1.11, 0.559, 287, 279, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
55, d5aepA_, 0.9705, 1.05, 0.556, 287, 279, NOVEL PYRROLE CARBOXAMIDE INHIBITORS OF JAK2 AS POTENTIAL TREATMENT OF MYELOPROLIFERATIVE DISORDERS
56, d2b7aB_, 0.9701, 1.11, 0.559, 287, 279, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
57, d4gfmA_, 0.9687, 1.13, 0.556, 289, 279, JAK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
58, d3eygA_, 0.9687, 1.20, 1.000, 280, 279, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
59, d4p7eB_, 0.9683, 1.09, 0.558, 285, 278, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
60, d3e63A_, 0.9682, 1.14, 0.556, 290, 279, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
61, d3eyhA_, 0.9680, 1.31, 0.996, 285, 280, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
62, d4bbfA_, 0.9679, 1.03, 0.547, 288, 278, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
63, d4e4mA_, 0.9678, 1.24, 0.554, 296, 280, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
64, d4bbfD_, 0.9678, 1.03, 0.547, 288, 278, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
65, d4e4mE_, 0.9677, 1.24, 0.554, 296, 280, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
66, d4e6dA_, 0.9674, 1.09, 0.572, 286, 278, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
67, d4zimA_, 0.9667, 0.98, 0.549, 285, 277, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
68, d4ivaA_, 0.9657, 1.10, 0.550, 290, 278, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-[(8AS)- 2-[(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(8AH)- YL]CYCLOHEXANECARBONITRILE
69, d5khwB_, 0.9654, 0.85, 0.996, 276, 275, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
70, d4f08A_, 0.9653, 0.95, 0.551, 288, 276, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
71, d4aqcA_, 0.9647, 1.07, 0.552, 289, 277, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
72, d5cf6A_, 0.9645, 1.03, 0.556, 285, 277, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
73, d4f08B_, 0.9644, 1.00, 0.551, 288, 276, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
74, d3tjdA_, 0.9640, 1.02, 0.554, 284, 276, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
75, d5cf5A1, 0.9636, 1.05, 0.556, 286, 277, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
76, d4e4mD_, 0.9631, 1.31, 0.550, 296, 280, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
77, d4e4mB_, 0.9625, 1.32, 0.550, 296, 280, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
78, d4ytiA_, 0.9624, 1.09, 0.549, 284, 277, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
79, d4f09A_, 0.9621, 1.01, 0.554, 288, 276, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
80, d5tq8A_, 0.9619, 1.28, 0.554, 291, 278, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
81, d3tjcA_, 0.9615, 1.09, 0.554, 284, 276, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
82, d3lpbB1, 0.9605, 0.96, 0.564, 283, 275, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
83, d5tq5A_, 0.9603, 1.34, 0.554, 291, 278, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
84, d5cf8A1, 0.9602, 1.07, 0.558, 284, 276, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
85, d4ji9A_, 0.9601, 1.10, 0.551, 284, 276, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
86, d4gmyA_, 0.9599, 1.32, 0.550, 298, 280, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH 26-DICHLORO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
87, d3fupA_, 0.9596, 1.13, 0.554, 284, 276, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
88, d4hgeA_, 0.9592, 1.15, 0.551, 284, 276, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
89, d5khxA_, 0.9591, 0.76, 1.000, 276, 272, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH PF-4950736
90, d4ythA_, 0.9591, 1.15, 0.552, 287, 277, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
91, d2b7aA_, 0.9591, 1.15, 0.554, 284, 276, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
92, d4jiaA_, 0.9586, 1.34, 0.557, 298, 280, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 9
93, d5cf4A_, 0.9585, 1.12, 0.551, 283, 276, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
94, d4p7eA_, 0.9579, 1.00, 0.558, 281, 274, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
95, d4bbeC_, 0.9570, 1.25, 0.547, 288, 278, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
96, d3io7A_, 0.9568, 1.05, 0.549, 282, 275, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
97, d4bbeB_, 0.9567, 1.25, 0.547, 288, 278, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
98, d4ytcA_, 0.9566, 1.05, 0.549, 284, 275, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
99, d4py1A_, 0.9563, 1.19, 0.594, 289, 276, CRYSTAL STRUCTURE OF TYK2 IN COMPLEX WITH COMPOUND 15 6-((25- DIMETHOXYPHENYL)THIO)-3-(1-METHYL-1H-PYRAZOL-4-YL)-[124]TRIAZOLO[4 3-B]PYRIDAZINE
100, d4bbfB_, 0.9558, 1.26, 0.547, 288, 278, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
101, d4bbfC_, 0.9555, 1.26, 0.547, 288, 278, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
102, d4ytfA_, 0.9550, 1.09, 0.549, 283, 275, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
103, d4gvjA1, 0.9549, 1.22, 0.591, 288, 276, TYK2 (JH1) IN COMPLEX WITH ADENOSINE DI-PHOSPHATE
104, d5khwA_, 0.9546, 1.11, 1.000, 276, 275, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
105, d3iokA_, 0.9546, 1.09, 0.549, 285, 275, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
106, d2w1iA_, 0.9537, 1.25, 0.551, 284, 276, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
107, d4bbeD_, 0.9535, 1.30, 0.543, 288, 278, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
108, d5l3aA_, 0.9534, 1.31, 0.558, 290, 278, FRAGMENT-BASED DISCOVERY OF 6-ARYLINDAZOLE JAK INHIBITORS
109, d4bbeA_, 0.9533, 1.31, 0.547, 288, 278, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
110, d3kckA_, 0.9533, 1.12, 0.549, 285, 275, A NOVEL CHEMOTYPE OF KINASE INHIBITORS
111, d3jy9A_, 0.9532, 1.11, 0.549, 282, 275, JANUS KINASE 2 INHIBITORS
112, d2w1iB_, 0.9528, 1.26, 0.547, 284, 276, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
113, d3rvgA_, 0.9515, 1.03, 0.560, 285, 273, CRYSTALS STRUCTURE OF JAK2 WITH A 1-AMINO-5H-PYRIDO[43-B]INDOL-4- CARBOXAMIDE INHIBITOR
114, d4rioA_, 0.9514, 1.43, 0.522, 285, 276, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE CARBOXAMIDE INHIBITOR
115, d4gihA1, 0.9507, 1.24, 0.589, 287, 275, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}BENZAMIDE
116, d4gj2A1, 0.9500, 1.25, 0.589, 287, 275, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
117, d5lwnA_, 0.9495, 1.43, 0.520, 290, 277, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 5 (FM409)
118, d4gj3A1, 0.9489, 1.26, 0.589, 287, 275, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
119, d4giiA1, 0.9489, 1.27, 0.589, 287, 275, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
120, d5wevA_, 0.9487, 1.34, 0.556, 293, 277, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
121, d5lwmA_, 0.9479, 1.46, 0.520, 290, 277, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 4 (FM381)
122, d3lxnA_, 0.9479, 1.35, 0.596, 287, 275, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
123, d4e1zA_, 0.9477, 1.40, 0.574, 288, 277, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
124, d3lpbA_, 0.9476, 1.06, 0.562, 278, 272, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
125, d5tq3B_, 0.9475, 1.25, 0.555, 285, 274, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
126, d1yvjA_, 0.9458, 1.74, 0.522, 288, 278, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN IN COMPLEX WITH A STAUROSPORINE ANALOGUE
127, d5usyA_, 0.9450, 1.45, 0.558, 287, 276, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
128, d3pjcA_, 0.9446, 1.64, 0.520, 286, 277, CRYSTAL STRUCTURE OF JAK3 COMPLEXED WITH A POTENT ATP SITE INHIBITOR SHOWING HIGH SELECTIVITY WITHIN THE JANUS KINASE FAMILY
129, d3lxlA_, 0.9443, 1.15, 0.533, 281, 272, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
130, d5tozA_, 0.9438, 1.33, 0.524, 278, 273, JAK3 WITH COVALENT INHIBITOR PF-06651600
131, d5walA1, 0.9424, 1.34, 0.588, 285, 274, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
132, d4hvgA_, 0.9423, 1.28, 0.527, 281, 273, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-2-HYDROXY-12-DIMETHYL-PROPYL)- AMIDE
133, d5ttvA_, 0.9416, 1.60, 0.529, 280, 274, JAK3 WITH COVALENT INHIBITOR 6
134, d4e20A_, 0.9412, 1.30, 0.593, 282, 273, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
135, d5ttsA_, 0.9405, 1.23, 0.531, 274, 271, JAK3 WITH COVALENT INHIBITOR 4
136, d5tq3A_, 0.9398, 1.17, 0.557, 282, 271, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
137, d4hvhA_, 0.9391, 1.15, 0.531, 278, 271, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-2-HYDROXY-12-DIMETHYL-PROPYL
138, d5tq7A_, 0.9389, 1.00, 0.565, 275, 269, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
139, d4c61B_, 0.9387, 1.08, 0.559, 274, 270, INHIBITORS OF JAK2 KINASE DOMAIN
140, d3lxkA_, 0.9386, 1.14, 0.530, 279, 270, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
141, d4i6qA_, 0.9385, 1.09, 0.530, 277, 270, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-PHENOXY-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-1-CYCLOPROPYL-ETHYL)-AMIDE
142, d2xa4A_, 0.9384, 1.13, 0.552, 276, 270, INHIBITORS OF JAK2 KINASE DOMAIN
143, d5usyB_, 0.9382, 1.64, 0.558, 287, 276, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
144, d2xa4B_, 0.9379, 1.17, 0.557, 275, 271, INHIBITORS OF JAK2 KINASE DOMAIN
145, d5tq4A_, 0.9377, 1.72, 0.550, 290, 278, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
146, d3zmmB_, 0.9375, 1.10, 0.559, 274, 270, INHIBITORS OF JAK2 KINASE DOMAIN
147, d3zepC_, 0.9370, 1.21, 0.528, 276, 271, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
148, d4hviA_, 0.9360, 1.20, 0.530, 274, 270, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-1-METHYL-2-OXO-2-PIPERIDIN-1-YL- ETHYL)-AMIDE
149, d4hvdA_, 0.9360, 1.14, 0.530, 276, 270, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-122-TRIMETHYL-PROPYL)-AMIDE
150, d4qt1A_, 0.9342, 1.16, 0.533, 277, 270, JAK3 KINASE DOMAIN IN COMPLEX WITH 1-[(3S)-1-ISOBUTYLSULFONYL-3- PIPERIDYL]-3-(5H-PYRROLO[23-B]PYRAZIN-2-YL)UREA
151, d5tq6A_, 0.9331, 0.99, 0.562, 274, 267, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
152, d3nz0A1, 0.9330, 1.30, 0.594, 283, 271, NON-PHOSPHORYLATED TYK2 KINASE WITH CMP6
153, d4d1sA_, 0.9317, 1.19, 0.567, 280, 270, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
154, d3zepA_, 0.9315, 1.33, 0.535, 274, 271, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
155, d5f1zA1, 0.9313, 1.59, 0.595, 280, 274, STRUCTURE OF TYK2 WITH INHIBITOR 16: 3-AZANYL-5-[(2~{S})-3- METHYLBUTAN-2-YL]-7-[1-METHYL-5-(2-OXIDANYLPROPAN-2-YL)PYRAZOL-3-YL]- 1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
156, d4z16B_, 0.9311, 1.20, 0.533, 276, 270, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
157, d3zmmA_, 0.9305, 1.00, 0.554, 273, 267, INHIBITORS OF JAK2 KINASE DOMAIN
158, d4c62B_, 0.9301, 1.01, 0.558, 271, 267, INHIBITORS OF JAK2 KINASE DOMAIN
159, d4c62A_, 0.9297, 1.02, 0.554, 273, 267, INHIBITORS OF JAK2 KINASE DOMAIN
160, d5tq6B_, 0.9290, 1.02, 0.564, 271, 266, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
161, d5w86D_, 0.9286, 1.46, 0.528, 272, 271, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
162, d3zepD_, 0.9276, 1.28, 0.539, 272, 269, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
163, d5ttuA_, 0.9275, 1.02, 0.530, 271, 266, JAK3 WITH COVALENT INHIBITOR 7
164, d4c61A_, 0.9268, 1.01, 0.556, 272, 266, INHIBITORS OF JAK2 KINASE DOMAIN
165, d5tq7B_, 0.9263, 0.93, 0.558, 269, 265, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
166, d4qpsC_, 0.9241, 1.36, 0.537, 276, 268, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
167, d5f20A_, 0.9226, 1.49, 0.604, 274, 270, STRUCTURE OF TYK2 WITH INHIBITOR 4: 3-AZANYL-5-(2-METHYLPHENYL)-7-(1- METHYLPYRAZOL-3-YL)-1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
168, d5w86C_, 0.9224, 1.66, 0.537, 273, 270, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
169, d3zepB_, 0.9209, 1.06, 0.540, 268, 265, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
170, d4v0gB_, 0.9207, 1.41, 0.528, 272, 269, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
171, d3lxpA_, 0.9171, 1.71, 0.585, 285, 272, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
172, d4qpsA_, 0.9167, 1.53, 0.528, 270, 269, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
173, d4z16A_, 0.9160, 1.15, 0.540, 271, 265, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
174, d4z16C_, 0.9155, 1.16, 0.540, 271, 265, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
175, d5vo6A_, 0.9138, 1.11, 0.536, 271, 263, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR
176, d5w86A_, 0.9133, 1.40, 0.530, 269, 266, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
177, d4z16D_, 0.9126, 1.22, 0.540, 271, 265, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
178, d4gfoA1, 0.9098, 1.46, 0.605, 270, 266, TYK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
179, d5wfjA_, 0.9072, 1.62, 0.534, 265, 264, THE JAK3 KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR
180, d4v0gA_, 0.9072, 1.30, 0.534, 267, 264, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
181, d5w86B_, 0.9035, 1.61, 0.534, 267, 264, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
182, d3nyxA1, 0.9031, 2.07, 0.568, 285, 273, NON-PHOSPHORYLATED TYK2 JH1 DOMAIN WITH QUINOLINE-THIADIAZOLE- THIOPHENE INHIBITOR
183, d3ugcA_, 0.8868, 1.75, 0.557, 274, 262, STRUCTURAL BASIS OF JAK2 INHIBITION BY THE TYPE II INHIBTOR NVP-BBT594
184, d4g5pA_, 0.8843, 2.02, 0.360, 299, 264, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
185, d2jitA_, 0.8811, 2.10, 0.355, 299, 265, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
186, d5xgnA_, 0.8808, 1.90, 0.363, 302, 262, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
187, d5hezD_, 0.8808, 1.92, 0.533, 289, 261, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
188, d5hezC_, 0.8805, 1.95, 0.536, 289, 261, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
189, d2jiuA_, 0.8778, 2.07, 0.360, 303, 264, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
190, d5hezB_, 0.8777, 2.10, 0.534, 289, 262, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
191, d4rixD_, 0.8774, 1.88, 0.360, 297, 261, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
192, d3ikaA_, 0.8772, 2.04, 0.361, 310, 263, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
193, d5hezA_, 0.8768, 2.01, 0.533, 287, 261, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
194, d4riyD_, 0.8768, 2.00, 0.359, 297, 262, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
195, d4riwD_, 0.8723, 2.08, 0.359, 297, 262, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
196, d5cy3A1, 0.8706, 2.17, 0.359, 274, 262, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT AND ORALLY BIOAVAILABLE BENZISOTHIAZOLE INHIBITOR
197, d2ivuA1, 0.8677, 2.02, 0.359, 283, 262, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR ZD6474
198, d4ckjA1, 0.8675, 2.04, 0.359, 287, 262, CRYSTAL STRUCTURE OF RET TYROSINE KINASE DOMAIN BOUND TO ADENOSINE
199, d4li5A1, 0.8660, 2.07, 0.356, 303, 261, EGFR-K IN COMPLEX WITH N-[3-[[5-CHLORO-4-(1H-INDOL-3-YL)PYRIMIDIN-2- YL]AMINO]-4-METHOXY-PHENYL] PROP-2-ENAMIDE
200, d2x2kA1, 0.8639, 2.11, 0.363, 284, 262, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
201, d2ivtA1, 0.8638, 2.11, 0.363, 283, 262, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
202, d3gqiA_, 0.8635, 2.02, 0.387, 304, 261, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
203, d2x2lA1, 0.8632, 2.11, 0.363, 282, 262, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
204, d4ckiA1, 0.8631, 2.19, 0.363, 288, 262, CRYSTAL STRUCTURE OF ONCOGENIC RET TYROSINE KINASE M918T BOUND TO ADENOSINE
205, d4ewhA_, 0.8628, 2.08, 0.360, 274, 261, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
206, d5amnA1, 0.8624, 2.07, 0.360, 282, 261, THE DISCOVERY OF 2-SUBSTITUTED PHENOL QUINAZOLINES AS POTENT AND SELECTIVE RET KINASE INHIBITORS
207, d3pp0B_, 0.8622, 2.23, 0.338, 296, 263, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
208, d4ewhB_, 0.8621, 2.09, 0.360, 273, 261, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
209, d5eg3A_, 0.8620, 1.99, 0.379, 301, 261, CRYSTAL STRUCTURE OF THE ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH THE CSH2 DOMAIN OF PHOSPHOLIPASE C GAMMA (PLCGAMMA)
210, d3bceB_, 0.8616, 2.20, 0.387, 286, 261, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
211, d2ivsA_, 0.8607, 2.05, 0.364, 284, 261, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
212, d4riyB_, 0.8606, 1.96, 0.364, 293, 258, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
213, d4rixB_, 0.8604, 2.00, 0.364, 293, 258, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
214, d4jq8A_, 0.8594, 2.16, 0.356, 303, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4B
215, d3bceC_, 0.8593, 2.26, 0.393, 286, 262, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
216, d5cxzA1, 0.8591, 2.03, 0.364, 267, 258, SYK CATALYTIC DOMAIN COMPLEXED WITH NAPHTHYRIDINE INHIBITOR
217, d2qohB2, 0.8587, 2.07, 0.362, 280, 260, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
218, d1pkgA_, 0.8582, 2.25, 0.355, 290, 262, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
219, d2x2mA1, 0.8577, 2.04, 0.359, 281, 259, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
220, d2ivvA1, 0.8577, 2.03, 0.367, 277, 259, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR PP1
221, d3eqrA_, 0.8576, 2.21, 0.360, 270, 261, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
222, d4wnmA1, 0.8573, 2.11, 0.363, 269, 259, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT TRIAZOLOPYRIDINE INHIBITOR
223, d2z60A1, 0.8573, 2.12, 0.362, 280, 260, CRYSTAL STRUCTURE OF THE T315I MUTANT OF ABL KINASE BOUND WITH PPY-A
224, d5lmbA_, 0.8569, 2.02, 0.366, 264, 257, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
225, d3pp0A_, 0.8568, 2.21, 0.337, 286, 261, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
226, d4jq7A_, 0.8567, 2.21, 0.356, 303, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 2A
227, d4jr3A_, 0.8563, 2.22, 0.356, 303, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 3G
228, d3kulB_, 0.8559, 2.08, 0.335, 271, 260, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
229, d3dqwC_, 0.8559, 1.85, 0.345, 275, 258, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
230, d3dqwD_, 0.8558, 1.97, 0.347, 276, 259, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
231, d3bceA_, 0.8558, 2.30, 0.387, 285, 261, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
232, d2g2hB_, 0.8558, 2.06, 0.362, 272, 260, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
233, d5flfD_, 0.8556, 2.19, 0.385, 290, 262, DISEASE LINKED MUTATION IN FGFR
234, d4riwB_, 0.8554, 2.07, 0.364, 293, 258, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
235, d2qohA2, 0.8552, 2.13, 0.362, 270, 260, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
236, d2j6mA_, 0.8552, 2.31, 0.359, 306, 262, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AEE788
237, d4jrvA_, 0.8549, 2.24, 0.356, 300, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4C
238, d5tr6A1, 0.8548, 2.19, 0.363, 268, 259, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
239, d2itpA_, 0.8548, 2.28, 0.356, 305, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AEE788
240, d3srvB_, 0.8546, 2.12, 0.364, 263, 258, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
241, d5flfA_, 0.8542, 2.24, 0.385, 296, 262, DISEASE LINKED MUTATION IN FGFR
242, d5cxhA1, 0.8542, 2.17, 0.363, 273, 259, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT ORALLY BIOAVAILABLE THIAZOLE INHIBITOR
243, d1m17A_, 0.8541, 2.23, 0.360, 312, 261, EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE DOMAIN WITH 4-ANILINOQUINAZOLINE INHIBITOR ERLOTINIB
244, d4rx7A1, 0.8538, 2.16, 0.363, 270, 259, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR
245, d5ugbA_, 0.8537, 2.25, 0.356, 307, 261, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN IN COMPLEX WITH 4-(4-{[2- {[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9-(PROPAN-2-YL)-9H-PURIN-6- YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
246, d5ui0B_, 0.8536, 2.15, 0.379, 304, 261, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
247, d1u59A1, 0.8535, 2.18, 0.350, 276, 260, CRYSTAL STRUCTURE OF THE ZAP-70 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
248, d4k33A_, 0.8533, 2.14, 0.372, 293, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 3 (FGFR3) KINASE DOMAIN HARBORING THE K650E MUTATION A GAIN-OF-FUNCTION MUTATION RESPONSIBLE FOR THANATOPHORIC DYSPLASIA TYPE II AND SPERMATOCYTIC SEMINOMA
249, d3srvA_, 0.8529, 1.91, 0.365, 262, 255, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
250, d5cavA_, 0.8527, 2.30, 0.356, 306, 261, EGFR KINASE DOMAIN WITH COMPOUND 41A
251, d3vf8A_, 0.8527, 2.18, 0.364, 265, 258, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH PYRAZOLYLBENZIMIDAZOLE INHIBITOR 416
252, d3eqrB_, 0.8525, 2.16, 0.363, 271, 259, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
253, d1m14A_, 0.8525, 2.25, 0.350, 307, 260, TYROSINE KINASE DOMAIN FROM EPIDERMAL GROWTH FACTOR RECEPTOR
254, d4j98B_, 0.8524, 2.17, 0.379, 304, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
255, d4j96B_, 0.8524, 2.16, 0.383, 305, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
256, d4gfgA1, 0.8524, 2.16, 0.363, 273, 259, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R9021
257, d3clyA_, 0.8524, 2.23, 0.369, 289, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAINS TRAPPED IN TRANS-PHOSPHORYLATION REACTION
258, d2f4jA_, 0.8524, 2.30, 0.366, 287, 262, STRUCTURE OF THE KINASE DOMAIN OF AN IMATINIB-RESISTANT ABL MUTANT IN COMPLEX WITH THE AURORA KINASE INHIBITOR VX-680
259, d3r7oA1, 0.8522, 2.16, 0.333, 295, 258, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG
260, d1xbaA1, 0.8520, 2.18, 0.364, 265, 258, CRYSTAL STRUCTURE OF APO SYK TYROSINE KINASE DOMAIN
261, d2j5eA_, 0.8519, 2.22, 0.340, 309, 259, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 13-JAB
262, d1xbcA1, 0.8518, 2.19, 0.364, 267, 258, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH STAUROSPORIN
263, d3eqpB_, 0.8515, 2.27, 0.354, 270, 260, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
264, d4id7A_, 0.8513, 2.09, 0.337, 268, 258, ACK1 KINASE IN COMPLEX WITH THE INHIBITOR CIS-3-[8-AMINO-1-(4- PHENOXYPHENYL)IMIDAZO[15-A]PYRAZIN-3-YL]CYCLOBUTANOL
265, d2itqA_, 0.8513, 2.31, 0.356, 300, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AFN941
266, d2dq7X_, 0.8512, 2.03, 0.337, 262, 258, CRYSTAL STRUCTURE OF FYN KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
267, d5lmaA_, 0.8511, 2.11, 0.366, 267, 257, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
268, d2v7aA_, 0.8509, 2.10, 0.351, 269, 259, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
269, d3q6wA1, 0.8507, 2.20, 0.333, 293, 258, STRUCTURE OF DUALLY-PHOSPHORYLATED MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG WITH SPECIFICITY FOR THE ACTIVATED RECEPTOR
270, d2fo0A3, 0.8506, 2.22, 0.360, 291, 261, ORGANIZATION OF THE SH3-SH2 UNIT IN ACTIVE AND INACTIVE FORMS OF THE C-ABL TYROSINE KINASE
271, d4xg3B_, 0.8505, 2.02, 0.367, 267, 256, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
272, d1m52A_, 0.8505, 2.26, 0.356, 271, 261, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
273, d5c26A1, 0.8503, 2.21, 0.363, 271, 259, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 1
274, d1u4dB_, 0.8503, 2.09, 0.359, 262, 256, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
275, d5ui0A_, 0.8500, 2.18, 0.379, 301, 261, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
276, d1qpjA_, 0.8500, 1.97, 0.364, 265, 258, CRYSTAL STRUCTURE OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH STAUROSPORINE.
277, d5u6bB1, 0.8499, 2.09, 0.314, 289, 258, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
278, d2gs6A2, 0.8498, 2.30, 0.342, 308, 260, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AN ATP ANALOG-PEPTIDE CONJUGATE
279, d4twpB_, 0.8497, 2.19, 0.365, 271, 260, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
280, d3ue4A_, 0.8497, 2.11, 0.369, 270, 260, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
281, d5hg5A_, 0.8495, 2.36, 0.359, 302, 262, EGFR (L858R T790M V948R) IN COMPLEX WITH N-{3-[(2-{[4-(4- METHYLPIPERAZIN-1-YL)PHENYL]AMINO}-7H-PYRROLO[23-D]PYRIMIDIN-4-YL) OXY]PHENYL}PROP-2-ENAMIDE
282, d5u6bD1, 0.8492, 2.11, 0.314, 289, 258, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
283, d3lcdA_, 0.8490, 2.16, 0.332, 290, 259, INHIBITOR BOUND TO A DFG-IN STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
284, d3eqpA_, 0.8490, 2.30, 0.354, 268, 260, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
285, d2gqgB1, 0.8490, 2.13, 0.355, 270, 259, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
286, d5c27A1, 0.8488, 2.26, 0.363, 271, 259, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 2
287, d1oplB2, 0.8484, 2.21, 0.362, 267, 260, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
288, d3hmiA_, 0.8483, 2.09, 0.351, 268, 259, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
289, d4rx8A1, 0.8482, 2.16, 0.370, 266, 257, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR2
290, d3vf9A_, 0.8482, 2.15, 0.366, 265, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 027
291, d4puzB_, 0.8480, 1.97, 0.373, 265, 255, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
292, d2x2mB1, 0.8480, 2.05, 0.359, 274, 256, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
293, d4zogB_, 0.8479, 1.97, 0.358, 268, 257, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
294, d2hziB_, 0.8479, 2.07, 0.364, 264, 258, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
295, d5hg8A_, 0.8478, 2.39, 0.359, 300, 262, EGFR (L858R T790M V948R) IN COMPLEX WITH N-[3-({2-[(1-METHYL-1H- PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- 2-ENAMIDE
296, d5flfB_, 0.8478, 2.32, 0.385, 292, 262, DISEASE LINKED MUTATION IN FGFR
297, d4xg3A_, 0.8478, 1.98, 0.362, 262, 254, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
298, d2pvfA_, 0.8478, 2.17, 0.386, 285, 259, CRYSTAL STRUCTURE OF TYROSINE PHOSPHORYLATED ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH ATP ANALOG AND SUBSTRATE PEPTIDE
299, d5tt7A1, 0.8477, 2.23, 0.362, 270, 257, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
300, d1m52B_, 0.8476, 2.31, 0.356, 272, 261, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
301, d3dk7B_, 0.8475, 2.04, 0.362, 268, 257, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
302, d5xdkA_, 0.8473, 2.38, 0.360, 307, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH CO-1686
303, d2itwA_, 0.8473, 2.36, 0.350, 300, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AFN941
304, d4i23A_, 0.8468, 2.24, 0.357, 304, 258, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH DACOMITINIB (SOAKED)
305, d2xynA_, 0.8466, 2.26, 0.346, 264, 260, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
306, d4xg6A1, 0.8465, 1.96, 0.369, 270, 255, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
307, d3nsvA_, 0.8465, 2.27, 0.338, 264, 260,  
308, d2jitB_, 0.8464, 2.28, 0.309, 312, 262, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
309, d3kulA_, 0.8463, 2.00, 0.336, 267, 256, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
310, d2hz0A_, 0.8463, 2.14, 0.358, 265, 257, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
311, d1opkA3, 0.8463, 2.33, 0.356, 291, 261, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
312, d4rssA_, 0.8462, 2.19, 0.364, 269, 258, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE SYK WITH AN INHIBITOR
313, d3dk3B_, 0.8462, 2.03, 0.362, 269, 257, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
314, d2jiuB_, 0.8461, 2.30, 0.305, 309, 262, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
315, d4xliA_, 0.8460, 2.20, 0.359, 264, 259, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
316, d4j98A_, 0.8458, 2.25, 0.379, 304, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
317, d2ofuA_, 0.8458, 2.20, 0.365, 272, 260, X-RAY CRYSTAL STRUCTURE OF 2-AMINOPYRIMIDINE CARBAMATE 43 BOUND TO LCK
318, d5hibA_, 0.8457, 2.26, 0.364, 314, 258, EGFR KINASE DOMAIN MUTANT TMLR WITH A PYRAZOLOPYRIMIDINE INHIBITOR
319, d4xg9B_, 0.8455, 2.00, 0.369, 265, 255, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
320, d1qpdA_, 0.8455, 2.20, 0.365, 270, 260, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
321, d4pv0A1, 0.8454, 2.31, 0.364, 266, 258, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH AN IMIDAZOPYRAZINE INHIBITOR
322, d4j96A_, 0.8454, 2.25, 0.379, 302, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
323, d1oplA3, 0.8454, 2.32, 0.364, 291, 261, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
324, d2g2hA_, 0.8452, 2.30, 0.350, 272, 260, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
325, d1u54B_, 0.8450, 1.99, 0.354, 261, 254, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
326, d4iwdA1, 0.8449, 2.30, 0.333, 295, 258, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-8033 ANALOG
327, d5lmbB_, 0.8448, 1.96, 0.372, 261, 253, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
328, d4puzA_, 0.8447, 2.13, 0.371, 263, 256, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
329, d5j9yA_, 0.8444, 2.33, 0.377, 300, 260, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1B
330, d4xg4A_, 0.8444, 2.15, 0.371, 264, 256, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
331, d2j0lA_, 0.8441, 2.21, 0.358, 274, 260, CRYSTAL STRUCTURE OF A THE ACTIVE CONFORMATION OF THE KINASE DOMAIN OF FOCAL ADHESION KINASE WITH A PHOSPHORYLATED ACTIVATION LOOP.
332, d3fqhA_, 0.8440, 1.96, 0.364, 262, 253, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
333, d2gs2A_, 0.8439, 2.41, 0.342, 305, 260, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN
334, d3kxzA_, 0.8438, 1.99, 0.370, 263, 257, THE COMPLEX CRYSTAL STRUCTURE OF LCK WITH A PROBE MOLECULE W259
335, d5em8A_, 0.8437, 2.46, 0.356, 303, 261, EGFR KINASE DOMAIN WITH PYRIDONE COMPOUND 13: 4-[(2-METHOXYPHENYL) AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2-OXIDANYLIDENE-1~{H}- PYRIDINE-3-CARBOXAMIDE
336, d3vjnA_, 0.8437, 2.27, 0.353, 297, 258, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH AMPPNP.
337, d3bymA_, 0.8435, 2.23, 0.365, 271, 260, X-RAY CO-CRYSTAL STRUCTURE AMINOBENZIMIDAZOLE TRIAZINE 1 BOUND TO LCK
338, d4twpA_, 0.8432, 2.18, 0.366, 266, 257, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
339, d4dfnA1, 0.8432, 2.36, 0.367, 268, 259, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH AN ADAMANTYLPYRAZINE INHIBITOR
340, d2of4A_, 0.8432, 2.30, 0.360, 271, 261, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 1 BOUND TO LCK
341, d2hziA_, 0.8428, 2.25, 0.362, 268, 260, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
342, d2gqgA1, 0.8428, 2.35, 0.350, 271, 260, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
343, d3fqeA1, 0.8427, 2.21, 0.371, 265, 256, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH YM193306
344, d1qpcA_, 0.8427, 2.24, 0.369, 270, 260, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
345, d5ghvB_, 0.8426, 2.15, 0.367, 265, 256, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
346, d5ghvA_, 0.8426, 2.14, 0.367, 265, 256, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
347, d4xg5B_, 0.8426, 2.15, 0.367, 265, 256,  
348, d4xg5A_, 0.8426, 2.14, 0.367, 265, 256,  
349, d2v7aB_, 0.8425, 2.24, 0.355, 268, 259, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
350, d3kmmA_, 0.8424, 2.25, 0.369, 270, 260, STRUCTURE OF HUMAN LCK KINASE WITH A SMALL MOLECULE INHIBITOR
351, d3dqwA_, 0.8423, 2.19, 0.347, 278, 259, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
352, d1y57A3, 0.8423, 2.24, 0.344, 285, 259, STRUCTURE OF UNPHOSPHORYLATED C-SRC IN COMPLEX WITH AN INHIBITOR
353, d3w2oA1, 0.8422, 2.45, 0.331, 304, 260, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH TAK-285
354, d3ac1A_, 0.8419, 2.25, 0.369, 270, 260, CRYSTAL STRUCTURE OF PYRAZIN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
355, d4xliB_, 0.8416, 2.17, 0.362, 264, 257, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
356, d4j95B_, 0.8416, 2.35, 0.379, 282, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
357, d4px6A1, 0.8415, 2.16, 0.373, 261, 255, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT PYRIDOPYRIMIDINONE INHIBITOR
358, d4zogA_, 0.8414, 2.25, 0.363, 269, 259, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
359, d4wkqA1, 0.8413, 2.28, 0.355, 294, 256, 1.85 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN WITH GEFITINIB
360, d5ugxA_, 0.8412, 2.36, 0.375, 297, 261, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
361, d3ac5A_, 0.8409, 2.27, 0.369, 270, 260, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
362, d2of2A_, 0.8405, 2.34, 0.360, 271, 261, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 8 BOUND TO LCK
363, d4j97C_, 0.8404, 2.20, 0.376, 283, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
364, d4j99D_, 0.8403, 2.20, 0.391, 281, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
365, d3dqwB_, 0.8403, 2.21, 0.347, 278, 259, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
366, d3w2qA1, 0.8401, 2.46, 0.360, 306, 261, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH HKI-272
367, d2zm4A_, 0.8401, 2.28, 0.365, 270, 260, CRYSTAL STRUCTURE OF IMIDAZO QUINOXALINE 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK ACTIVATED FORM (AUTO- PHOSPHORYLATED ON TYR394)
368, d2zm1A_, 0.8401, 2.29, 0.369, 270, 260, CRYSTAL STRUCTURE OF IMIDAZO PYRAZIN 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
369, d4hzrA_, 0.8399, 2.07, 0.354, 261, 254, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
370, d2xynC_, 0.8399, 2.29, 0.351, 262, 259, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
371, d4fl1A_, 0.8398, 2.42, 0.367, 268, 259, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
372, d3ackA_, 0.8398, 2.29, 0.365, 270, 260, CRYSTAL STRUCTURE OF PYRROLO PYRAZINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
373, d3ac3A_, 0.8398, 2.29, 0.365, 270, 260, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
374, d3ac2A_, 0.8398, 2.28, 0.369, 270, 260, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
375, d3ad4A_, 0.8396, 2.29, 0.369, 270, 260, CRYSTAL STRUCTURE OF METHOXY BENZOFURAN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
376, d3acjA_, 0.8396, 2.29, 0.369, 270, 260, CRYSTAL STRUCTURE OF IMIDAZO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
377, d4xeyA_, 0.8395, 2.18, 0.354, 269, 257, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
378, d4j99B_, 0.8394, 2.40, 0.379, 291, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
379, d3nsvC_, 0.8394, 2.30, 0.351, 262, 259,  
380, d3ue4B_, 0.8393, 2.17, 0.372, 268, 258, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
381, d3lckA_, 0.8393, 2.30, 0.365, 270, 260, THE KINASE DOMAIN OF HUMAN LYMPHOCYTE KINASE (LCK) ACTIVATED FORM (AUTO-PHOSPHORYLATED ON TYR394)
382, d3kf4A_, 0.8393, 2.41, 0.363, 281, 259, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
383, d3ad6A_, 0.8392, 2.30, 0.369, 272, 260, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
384, d3ac4A_, 0.8392, 2.29, 0.365, 270, 260, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
385, d1qpeA_, 0.8392, 2.29, 0.369, 270, 260, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
386, d5flfC_, 0.8390, 2.48, 0.368, 283, 261, DISEASE LINKED MUTATION IN FGFR
387, d3vjoA_, 0.8390, 2.43, 0.351, 298, 259, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH AMPPNP.
388, d1u54A_, 0.8390, 2.08, 0.354, 262, 254, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
389, d3b2tA_, 0.8388, 2.35, 0.373, 288, 260, STRUCTURE OF PHOSPHOTRANSFERASE
390, d3ad5A_, 0.8388, 2.30, 0.369, 270, 260, CRYSTAL STRUCTURE OF TRIAZOLONE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
391, d2zybA_, 0.8388, 2.30, 0.369, 270, 260, CRYSTAL STRUCTURE OF PHENYLIMIDAZO PYRAZIN 2 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
392, d4rx9A1, 0.8386, 2.26, 0.369, 264, 255, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT PYRIMIDINE INHIBITOR
393, d3dk7A_, 0.8386, 2.17, 0.362, 265, 257, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
394, d3ac8A_, 0.8386, 2.30, 0.369, 270, 260, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
395, d1u4dA_, 0.8385, 2.11, 0.364, 258, 253, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
396, d4hzrB_, 0.8382, 1.90, 0.351, 258, 251, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
397, d3ug1A_, 0.8382, 2.37, 0.354, 296, 257, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN THE APO FORM
398, d3kf4B_, 0.8381, 2.37, 0.351, 270, 259, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
399, d3dk3A_, 0.8380, 2.18, 0.358, 266, 257, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
400, d4yjoA_, 0.8378, 2.31, 0.366, 267, 257, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222
401, d3ikaB_, 0.8378, 2.40, 0.310, 310, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
402, d3fqsA1, 0.8378, 2.32, 0.371, 264, 256, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R406
403, d4i0sA1, 0.8377, 2.25, 0.369, 263, 255, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(6- CHLORO-1-METHYL-1H-INDAZOL-3-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID ISOPROPYLAMIDE
404, d3w2pA1, 0.8377, 2.48, 0.328, 307, 259, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 2
405, d1oecA_, 0.8377, 2.35, 0.381, 280, 260, FGFR2 KINASE DOMAIN
406, d2eb2A_, 0.8376, 2.35, 0.360, 305, 258, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (G719S)
407, d1xbbA1, 0.8376, 2.32, 0.371, 266, 256, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH GLEEVEC
408, d2xynB_, 0.8375, 2.42, 0.346, 264, 260, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
409, d4j97A_, 0.8374, 2.26, 0.376, 282, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
410, d5gtzA_, 0.8373, 2.30, 0.375, 317, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH JTS-1-39
411, d3nsvB_, 0.8372, 2.43, 0.346, 264, 260,  
412, d4fyoA1, 0.8371, 2.25, 0.369, 263, 255, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH N-{(S)-1- [7-(34-DIMETHOXY-PHENYLAMINO)-THIAZOLO[54-D]PYRIMIDIN-5-YL]- PYRROLIDIN-3-YL}-TEREPHTHALAMIC ACID
413, d4dflA1, 0.8370, 2.25, 0.361, 262, 255, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A SULFONAMIDOPYRAZINE PIPERIDINE INHIBITOR
414, d2itxA_, 0.8369, 2.43, 0.367, 307, 259, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AMP- PNP
415, d1u46B_, 0.8369, 2.06, 0.355, 257, 251, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
416, d4j97B_, 0.8368, 2.27, 0.376, 283, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
417, d4f4pA1, 0.8366, 2.03, 0.375, 260, 253, SYK IN COMPLEX WITH LIGAND LASW836
418, d4xg7A1, 0.8365, 2.09, 0.360, 265, 253, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
419, d4j99C_, 0.8365, 2.53, 0.356, 291, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
420, d3byoA_, 0.8365, 2.33, 0.365, 270, 260, X-RAY CO-CRYSTAL STRUCTURE OF 2-AMINO-6-PHENYLPYRIMIDO[5  4 :56]PYRIMIDO[12-A]BENZIMIDAZOL-5(6H)-ONE 25 BOUND TO LCK
421, d1k9aB3, 0.8364, 1.89, 0.348, 267, 250, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
422, d5uhnA_, 0.8361, 2.40, 0.375, 282, 261, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
423, d2pwlA_, 0.8361, 2.50, 0.381, 284, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
424, d4fynA1, 0.8358, 2.27, 0.369, 263, 255, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 3-(8-{4- [ETHYL-(2-HYDROXY-ETHYL)-AMINO]-PHENYLAMINO}-IMIDAZO[12-A]PYRAZIN-5- YL)-PHENOL
425, d2hz4A_, 0.8358, 2.08, 0.369, 262, 255, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
426, d4xg9A_, 0.8355, 2.20, 0.374, 259, 254, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
427, d2z8cA1, 0.8355, 2.40, 0.324, 297, 259, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN-2- YL]AMINO}PHENYL)ACETIC ACID
428, d4yjuA_, 0.8353, 2.15, 0.370, 262, 254, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249
429, d5tiuA1, 0.8350, 2.16, 0.360, 262, 253, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH INHIBITOR
430, d1gjoA_, 0.8348, 2.39, 0.381, 280, 260, THE FGFR2 TYROSINE KINASE DOMAIN
431, d4j95C_, 0.8344, 2.39, 0.381, 281, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
432, d1iasD_, 0.8342, 2.75, 0.229, 330, 266, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
433, d4lqmA_, 0.8341, 2.36, 0.359, 305, 256, EGFR L858R IN COMPLEX WITH PD168393
434, d4i0tA1, 0.8340, 2.26, 0.370, 262, 254, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(5678- TETRAHYDRO-IMIDAZO[15-A]PYRIDIN-1-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID TERT-BUTYLAMIDE
435, d4yjtA_, 0.8337, 2.36, 0.366, 268, 257, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233
436, d2pwlB_, 0.8337, 2.51, 0.381, 286, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
437, d5t68B_, 0.8332, 2.33, 0.371, 264, 256, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
438, d4j97D_, 0.8330, 2.22, 0.371, 285, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
439, d2r4bA_, 0.8330, 2.44, 0.383, 292, 256, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
440, d3dk6A_, 0.8329, 2.13, 0.361, 262, 255, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
441, d1k9aA3, 0.8328, 1.96, 0.348, 267, 250, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
442, d3fqhB_, 0.8327, 2.16, 0.365, 258, 252, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
443, d3mdyC_, 0.8326, 2.72, 0.245, 320, 261, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
444, d2py3B_, 0.8326, 2.36, 0.371, 284, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
445, d4i0rA1, 0.8324, 2.12, 0.369, 260, 252, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(345- TRIMETHOXY-PHENYL)-5H-PYRROLO[23-B]PYRAZINE-7-CARBOXYLIC ACID ISOPROPYLAMIDE
446, d1iasE_, 0.8324, 2.77, 0.229, 330, 266, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
447, d3kcfE_, 0.8323, 2.77, 0.229, 330, 266, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
448, d1iasA_, 0.8320, 2.77, 0.229, 330, 266, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
449, d5t68A1, 0.8319, 2.35, 0.371, 264, 256, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
450, d3mdyA_, 0.8319, 2.65, 0.246, 320, 260, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
451, d3kcfD_, 0.8319, 2.79, 0.229, 330, 266, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
452, d1iasC_, 0.8319, 2.78, 0.229, 330, 266, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
453, d3kcfC_, 0.8318, 2.77, 0.226, 330, 266, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
454, d2j5fA_, 0.8317, 2.32, 0.369, 308, 255, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 34-JAB
455, d2b4sD_, 0.8313, 2.53, 0.319, 294, 260, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
456, d3ug2A_, 0.8311, 2.49, 0.358, 299, 257, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH GEFITINIB
457, d4xeyB2, 0.8309, 2.22, 0.354, 264, 254, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
458, d2psqA_, 0.8309, 2.64, 0.358, 287, 260, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
459, d4yjpA_, 0.8308, 2.35, 0.367, 263, 256, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223
460, d2r4bB_, 0.8308, 2.40, 0.384, 291, 255, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
461, d2ivsB1, 0.8308, 1.98, 0.378, 272, 251, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
462, d4fz6A1, 0.8304, 2.32, 0.370, 262, 254, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH [6-((S)-2- METHYL-PYRROLIDIN-1-YL)-PYRIDIN-2-YL]-(6-PHENYL-IMIDAZO[12- B]PYRIDAZIN-8-YL)-AMINE
463, d3emgA_, 0.8302, 2.21, 0.368, 255, 253, DISCOVERY AND SAR OF NOVEL 4-THIAZOLYL-2- PHENYLAMINOPYRIMIDINES AS POTENT INHIBITORS OF SPLEEN TYROSINE KINASE (SYK)
464, d3kcfB_, 0.8300, 2.81, 0.226, 324, 265, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
465, d4g5jA_, 0.8298, 2.38, 0.356, 307, 253, CRYSTAL STRUCTURE OF EGFR KINASE IN COMPLEX WITH BIBW2992
466, d2py3A_, 0.8298, 2.52, 0.374, 282, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
467, d3ri1A_, 0.8297, 2.65, 0.358, 285, 260, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
468, d1iasB_, 0.8297, 2.79, 0.223, 324, 265, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
469, d2pvyA_, 0.8296, 2.22, 0.369, 288, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
470, d3bu6A_, 0.8293, 2.49, 0.320, 294, 259, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PHOSPHOPEPTIDE
471, d3zewA_, 0.8291, 2.40, 0.316, 269, 256, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
472, d3d7uC1, 0.8290, 1.74, 0.356, 255, 247, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
473, d3d7uA1, 0.8290, 1.74, 0.356, 255, 247, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
474, d3kcfA_, 0.8288, 2.77, 0.226, 328, 265, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
475, d5uglA_, 0.8287, 2.51, 0.379, 285, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
476, d4hjoA_, 0.8287, 2.24, 0.358, 278, 254, CRYSTAL STRUCTURE OF THE INACTIVE EGFR TYROSINE KINASE DOMAIN WITH ERLOTINIB
477, d5xgnB_, 0.8286, 2.32, 0.323, 308, 257, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
478, d4trlA_, 0.8286, 2.38, 0.323, 268, 257, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
479, d2b4sB_, 0.8286, 2.50, 0.317, 294, 259, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
480, d3w2rA_, 0.8284, 2.16, 0.369, 297, 252, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 4
481, d3lcsA_, 0.8284, 2.62, 0.314, 304, 261, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
482, d3b2tB_, 0.8283, 2.31, 0.371, 287, 256, STRUCTURE OF PHOSPHOTRANSFERASE
483, d4cnhB_, 0.8282, 2.19, 0.321, 293, 252, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
484, d4uxlA_, 0.8281, 2.23, 0.358, 288, 254, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH PF-06463922
485, d5fedA_, 0.8280, 2.40, 0.357, 288, 255, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
486, d3bu3A_, 0.8279, 2.51, 0.320, 294, 259, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE
487, d2hk5A2, 0.8278, 2.21, 0.363, 268, 256, HCK KINASE IN COMPLEX WITH LCK TARGETTED INHIBITOR PG-1009247
488, d4fz7A1, 0.8277, 2.30, 0.368, 261, 253, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 6-((1R2S)- 2-AMINO-CYCLOHEXYLAMINO)-4-(6-ETHYL-PYRIDIN-2-YLAMINO)-PYRIDAZINE-3- CARBOXYLIC ACID AMIDE
489, d5mjbA_, 0.8268, 2.48, 0.307, 276, 257, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
490, d4u5jA_, 0.8265, 1.93, 0.343, 267, 251, C-SRC IN COMPLEX WITH RUXOLITINIB
491, d2pvyD_, 0.8265, 2.27, 0.369, 283, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
492, d1u46A_, 0.8265, 2.14, 0.364, 255, 250, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
493, d2hz4C_, 0.8264, 2.12, 0.368, 259, 253, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
494, d2qu5A_, 0.8263, 2.30, 0.386, 292, 251, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
495, d4j99A_, 0.8262, 2.54, 0.364, 280, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
496, d2pz5B_, 0.8261, 2.37, 0.370, 280, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
497, d3ppzA_, 0.8260, 2.31, 0.328, 264, 256, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
498, d3dk6B_, 0.8260, 1.87, 0.353, 259, 249, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
499, d4g5pB_, 0.8259, 2.25, 0.314, 303, 255, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
500, d2q0bB_, 0.8257, 2.41, 0.369, 282, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
501, d4xg8A_, 0.8252, 2.22, 0.371, 258, 251, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
502, d2pzpB_, 0.8252, 2.38, 0.370, 282, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
503, d2itzA_, 0.8250, 2.35, 0.368, 302, 253, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH IRESSA
504, d2q0bA_, 0.8249, 2.42, 0.369, 280, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
505, d2psqB_, 0.8249, 2.73, 0.358, 286, 260, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
506, d2ittA_, 0.8246, 2.41, 0.366, 302, 254, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AEE788
507, d3sxsA1, 0.8245, 2.30, 0.312, 261, 256, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEXED WITH PP2
508, d3lctA_, 0.8245, 2.72, 0.318, 308, 261, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
509, d4j95A_, 0.8244, 2.58, 0.364, 279, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
510, d1pkgB_, 0.8244, 2.19, 0.359, 277, 251, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
511, d2itnA_, 0.8243, 2.40, 0.366, 304, 254, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AMP-PNP
512, d4bkjB1, 0.8237, 2.61, 0.359, 296, 256, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
513, d4xlvA_, 0.8236, 2.65, 0.319, 307, 260, CRYSTAL STRUCTURE OF THE ACTIVATED INSULIN RECEPTOR TYROSINE KINASE DIMER
514, d4yjqA_, 0.8235, 2.46, 0.362, 264, 254, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000224
515, d3ri1B_, 0.8235, 2.75, 0.358, 283, 260, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
516, d4u5jB_, 0.8234, 1.96, 0.343, 267, 251, C-SRC IN COMPLEX WITH RUXOLITINIB
517, d1k9aE3, 0.8233, 2.15, 0.347, 268, 251, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
518, d3wzeA_, 0.8231, 2.27, 0.382, 298, 251, KDR IN COMPLEX WITH LIGAND SORAFENIB
519, d2pz5A_, 0.8231, 2.42, 0.374, 280, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
520, d1rqqB_, 0.8230, 2.58, 0.324, 294, 259, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
521, d5xp7B_, 0.8225, 1.97, 0.345, 267, 249, C-SRC IN COMPLEX WITH ATP-CHCL
522, d2ityA1, 0.8224, 2.36, 0.372, 299, 253, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH IRESSA
523, d1rqqA_, 0.8224, 2.57, 0.302, 294, 258, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
524, d3geqB1, 0.8223, 1.93, 0.351, 270, 248, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
525, d4xg8C_, 0.8222, 2.13, 0.378, 254, 249, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
526, d1t46A_, 0.8222, 2.26, 0.355, 297, 251, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
527, d4yc8B_, 0.8220, 2.24, 0.366, 264, 254, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
528, d3zosB1, 0.8219, 2.62, 0.355, 301, 256, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
529, d3b2wA_, 0.8219, 2.09, 0.359, 261, 251, CRYSTAL STRUCTURE OF PYRIMIDINE AMIDE 11 BOUND TO LCK
530, d2pzpA_, 0.8219, 2.43, 0.374, 280, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
531, d5gmpA_, 0.8218, 2.33, 0.373, 305, 252, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH XTF-262
532, d4xg2A1, 0.8218, 2.09, 0.361, 258, 249, CRYSTAL STRUCTURE OF LIGAND-FREE SYK
533, d4mkcA_, 0.8218, 2.53, 0.320, 303, 256, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE COMPLEXED WITH LDK378
534, d3q4uD_, 0.8218, 2.93, 0.243, 299, 263, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
535, d5ugxB_, 0.8217, 2.20, 0.389, 282, 252, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
536, d5feeA_, 0.8215, 2.42, 0.360, 287, 253, EGFR KINASE DOMAIN T790M MUTANT IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
537, d4yjvA_, 0.8214, 2.44, 0.360, 263, 253, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000250
538, d5friA1, 0.8213, 2.73, 0.222, 299, 261, ALK5 IN COMPLEX WITHA AN N-(4-ANILINO-2-PYRIDYL)ACETAMIDE INHIBITOR.
539, d4j95D_, 0.8213, 2.08, 0.400, 271, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
540, d3dqxB_, 0.8213, 2.08, 0.341, 268, 252, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
541, d3bu5A_, 0.8211, 2.47, 0.316, 291, 256, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE AND ATP
542, d2pzrB_, 0.8211, 2.43, 0.370, 282, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
543, d2itvA_, 0.8210, 2.47, 0.366, 303, 254, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AMP-PNP
544, d2gs7A_, 0.8208, 2.64, 0.366, 281, 257, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
545, d5e8uA1, 0.8207, 2.71, 0.235, 303, 260, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F)
546, d4wrgA1, 0.8207, 2.30, 0.355, 287, 251, 1.9 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN
547, d4u0iA_, 0.8204, 2.41, 0.357, 297, 252, CRYSTAL STRUCTURE OF KIT IN COMPLEX WITH PONATINIB
548, d2r2pA1, 0.8204, 2.64, 0.320, 276, 259, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 5 (EPHA5)
549, d1yi6B_, 0.8204, 2.46, 0.300, 274, 257, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
550, d1b6cD_, 0.8204, 2.93, 0.233, 326, 266, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
551, d4ag8A_, 0.8203, 2.40, 0.389, 296, 252, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6- YLSULFANYL)-BENZAMIDE)
552, d4zauA_, 0.8202, 2.39, 0.375, 283, 253, AZD9291 COMPLEX WITH WILD TYPE EGFR
553, d4yc8A_, 0.8202, 2.17, 0.361, 259, 252, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
554, d2gs7B_, 0.8202, 2.53, 0.363, 288, 256, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
555, d2pzrA_, 0.8201, 2.44, 0.370, 280, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
556, d5e8tA1, 0.8200, 2.75, 0.226, 300, 261, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
557, d2bdjA_, 0.8200, 2.02, 0.345, 254, 249, SRC KINASE IN COMPLEX WITH INHIBITOR AP23464
558, d5grnA_, 0.8199, 2.40, 0.393, 285, 252, CRYSTAL STRUCTURE OF PDGFRA IN COMPLEX WITH WQ-C-159
559, d2wotA_, 0.8199, 2.83, 0.229, 303, 262, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
560, d5gtyH_, 0.8197, 2.56, 0.374, 300, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
561, d5hcyA_, 0.8196, 2.24, 0.372, 302, 250, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-CARBOXAMIDE AZAINDOLE COMPOUND 13
562, d3zfxH_, 0.8196, 2.18, 0.328, 266, 250, CRYSTAL STRUCTURE OF EPHB1
563, d1b6cH_, 0.8195, 3.02, 0.228, 326, 267, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
564, d6eixA_, 0.8194, 3.05, 0.243, 312, 267, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE Q207E MUTANT OF ACVR1 (ALK2) IN COMPLEX WITH A 2-AMINOPYRIDINE INHIBITOR K02288
565, d5e8wA1, 0.8194, 2.73, 0.231, 302, 260, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
566, d3bbtB_, 0.8192, 2.50, 0.397, 274, 252, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
567, d4zseA_, 0.8190, 2.51, 0.378, 297, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
568, d4i24B_, 0.8189, 2.60, 0.373, 304, 255, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
569, d3w32A_, 0.8189, 2.63, 0.368, 317, 258, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 20A
570, d2pvyB_, 0.8189, 2.12, 0.376, 286, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
571, d4qrcA_, 0.8188, 2.58, 0.391, 297, 256, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 4 IN COMPLEX WITH PONATINIB
572, d3zfxA_, 0.8188, 2.22, 0.328, 267, 250, CRYSTAL STRUCTURE OF EPHB1
573, d5mjbB_, 0.8187, 2.80, 0.312, 278, 260, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
574, d3zfxD_, 0.8187, 2.26, 0.328, 265, 250, CRYSTAL STRUCTURE OF EPHB1
575, d3q4uC_, 0.8187, 2.78, 0.242, 296, 260, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
576, d4yjrA_, 0.8186, 2.50, 0.356, 263, 253, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000225
577, d4bkjA1, 0.8186, 2.58, 0.357, 294, 255, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
578, d3geqA1, 0.8185, 1.94, 0.348, 269, 247, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
579, d5usqA_, 0.8183, 2.74, 0.231, 299, 260, ALK-5 KINASE INHIBITOR COMPLEX
580, d4x2fA1, 0.8183, 2.74, 0.231, 302, 260, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
581, d3c0gB_, 0.8182, 2.36, 0.231, 320, 255, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
582, d5gtyA_, 0.8181, 2.61, 0.373, 300, 255, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
583, d5e8sA1, 0.8180, 2.78, 0.218, 299, 261, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
584, d5d41B_, 0.8180, 2.50, 0.382, 302, 254, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
585, d4zseC_, 0.8178, 2.40, 0.369, 301, 252, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
586, d4yjsA_, 0.8178, 2.34, 0.359, 257, 251, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226
587, d3zfxI_, 0.8178, 2.28, 0.328, 263, 250, CRYSTAL STRUCTURE OF EPHB1
588, d5cnnB_, 0.8177, 2.48, 0.366, 304, 254, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
589, d3fzrA_, 0.8177, 2.06, 0.348, 261, 247, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-431396
590, d2zvaA1, 0.8177, 2.37, 0.345, 260, 255, LYN TYROSINE KINASE DOMAIN-DASATINIB COMPLEX
591, d4zseB_, 0.8176, 2.53, 0.378, 313, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
592, d4x0mA1, 0.8176, 2.73, 0.231, 302, 260, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
593, d5hcxA_, 0.8175, 2.24, 0.378, 298, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH AZABENZIMIDAZOLE COMPOUND 7
594, d3ppzB_, 0.8175, 2.25, 0.321, 264, 252, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
595, d1yi6A_, 0.8174, 2.51, 0.315, 274, 257, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
596, d2wotA1, 0.8173, 2.75, 0.231, 301, 260, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
597, d1xkkA_, 0.8173, 2.55, 0.364, 289, 253, EGFR KINASE DOMAIN COMPLEXED WITH A QUINAZOLINE INHIBITOR- GW572016
598, d1ir3A_, 0.8173, 2.73, 0.319, 300, 260, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH PEPTIDE SUBSTRATE AND ATP ANALOG
599, d1gagA_, 0.8173, 2.75, 0.319, 300, 260, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
600, d5e90A1, 0.8171, 2.73, 0.238, 300, 260, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249F S280T Y282FS287NA350CL352F) IN COMPLEX WITH 3-AMINO-6- [4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2- CARBOXAMIDE
601, d4z55A_, 0.8171, 2.61, 0.322, 294, 255, ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE DERIVATIVE OF LDK378
602, d4rwkA1, 0.8171, 2.56, 0.391, 307, 256, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
603, d3vntA_, 0.8171, 2.33, 0.386, 301, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
604, d2wouA_, 0.8171, 2.80, 0.230, 299, 261, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
605, d2pvyC_, 0.8171, 2.21, 0.375, 285, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
606, d1rw8A_, 0.8171, 2.81, 0.234, 301, 261, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH ATP SITE INHIBITOR
607, d5hczA_, 0.8170, 2.22, 0.355, 300, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-AZETIDINYL AZAINDAZOLE COMPOUND 21
608, d4x2kA1, 0.8170, 2.74, 0.231, 302, 260, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
609, d4x2jA1, 0.8170, 2.74, 0.231, 302, 260, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
610, d4bggA_, 0.8170, 2.83, 0.242, 296, 260, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
611, d3vrzB3, 0.8169, 2.01, 0.347, 269, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
612, d4x2nA1, 0.8168, 2.74, 0.231, 302, 260, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
613, d4x2gA1, 0.8168, 2.81, 0.222, 302, 261, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
614, d3q4uA_, 0.8168, 2.83, 0.235, 298, 260, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
615, d4bggB_, 0.8167, 2.82, 0.242, 293, 260, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
616, d5fm3A_, 0.8166, 2.46, 0.370, 276, 254, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
617, d2ituA_, 0.8166, 2.44, 0.353, 304, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AFN941
618, d5e8zA1, 0.8165, 2.73, 0.235, 300, 260, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3- AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3- YL]PYRAZINE-2-CARBOXAMIDE
619, d4zseD_, 0.8165, 2.60, 0.382, 297, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
620, d4rwiA_, 0.8165, 2.58, 0.391, 305, 256, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
621, d5oxgC1, 0.8164, 2.95, 0.240, 299, 263, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
622, d5hicA_, 0.8164, 2.24, 0.373, 302, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH A IMIDAZOPYRIDINYL- AMINOPYRIMIDINE INHIBITOR
623, d4cd0A_, 0.8164, 2.46, 0.324, 295, 253, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPANE-12-DIOL
624, d1b6cB_, 0.8164, 2.98, 0.233, 326, 266, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
625, d5h0bA3, 0.8163, 2.49, 0.346, 281, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOIC ACID
626, d3l9pA_, 0.8163, 2.62, 0.319, 303, 257, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
627, d3en4B_, 0.8163, 2.09, 0.341, 266, 249, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
628, d5gtyB_, 0.8161, 2.59, 0.374, 299, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
629, d3mtfB_, 0.8161, 2.93, 0.238, 298, 261, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
630, d5h0hA3, 0.8160, 2.49, 0.346, 281, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-NN4-TRIMETHYLPENTANAMIDE
631, d5h09A3, 0.8158, 2.49, 0.346, 281, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-ETHYL2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOATE
632, d4asdA_, 0.8158, 2.35, 0.386, 305, 251, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SORAFENIB (BAY 43-9006)
633, d3vs1A3, 0.8158, 2.10, 0.355, 268, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
634, d2h8hA3, 0.8157, 2.26, 0.324, 280, 253, SRC KINASE IN COMPLEX WITH A QUINAZOLINE INHIBITOR
635, d6aywB_, 0.8155, 2.35, 0.236, 293, 254, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
636, d3c0iA_, 0.8155, 2.43, 0.239, 298, 255, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P212121 FORM
637, d1b6cF_, 0.8155, 2.96, 0.233, 326, 266, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
638, d5casA_, 0.8153, 2.37, 0.380, 299, 250, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41A
639, d3vs3B3, 0.8153, 2.26, 0.355, 271, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
640, d3dqxA_, 0.8152, 2.11, 0.343, 267, 251, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
641, d5vloB_, 0.8151, 2.36, 0.236, 293, 254, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
642, d4p2wB_, 0.8151, 2.24, 0.319, 253, 251,  
643, d3et7A_, 0.8151, 2.04, 0.368, 261, 247, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-2318841
644, d5h0eA3, 0.8150, 2.49, 0.346, 281, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANAMIDE
645, d3vo3A_, 0.8150, 2.38, 0.382, 303, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH IMIDAZO[1 2-B]PYRIDAZINE DERIVATIVE
646, d2hckA3, 0.8150, 2.22, 0.351, 271, 251, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
647, d1qcfA3, 0.8150, 2.29, 0.332, 281, 253, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH A SRC FAMILY- SELECTIVE TYROSINE KINASE INHIBITOR
648, d5cnoA_, 0.8148, 2.52, 0.364, 300, 253, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
649, d5cnnA_, 0.8148, 2.31, 0.367, 300, 251, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
650, d4c02A_, 0.8147, 3.00, 0.246, 313, 264, CRYSTAL STRUCTURE OF HUMAN ACVR1 (ALK2) IN COMPLEX WITH FKBP12.6 AND DORSOMORPHIN
651, d3c0gA_, 0.8146, 2.34, 0.232, 309, 254, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
652, d1py5A_, 0.8146, 2.81, 0.234, 301, 261, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH INHIBITOR
653, d3mfrA_, 0.8144, 2.41, 0.243, 302, 255, CASK-4M CAM KINASE DOMAIN NATIVE
654, d3c0hB_, 0.8144, 2.41, 0.231, 300, 255, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
655, d2wouA1, 0.8144, 2.72, 0.232, 297, 259, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
656, d3f6xD_, 0.8143, 2.12, 0.348, 267, 250, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
657, d5gtyG_, 0.8142, 2.61, 0.375, 299, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
658, d4mxzA_, 0.8142, 2.13, 0.353, 266, 249, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
659, d4mxyA_, 0.8142, 2.13, 0.353, 266, 249, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
660, d4i22A_, 0.8142, 2.45, 0.371, 297, 251, STRUCTURE OF THE MONOMERIC (V948R)GEFITINIB/ERLOTINIB RESISTANT DOUBLE MUTANT (L858R+T790M) EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH GEFITINIB
661, d4aseA_, 0.8142, 2.36, 0.386, 305, 251, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH TIVOZANIB (AV-951)
662, d5e8yA_, 0.8141, 2.86, 0.254, 298, 260, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH STAUROSPORINE
663, d3mfuA_, 0.8140, 2.41, 0.239, 302, 255, CASK-4M CAM KINASE DOMAIN AMPPNP-MN2+
664, d2rgpA_, 0.8140, 2.57, 0.365, 284, 252, STRUCTURE OF EGFR IN COMPLEX WITH HYDRAZONE A POTENT DUAL INHIBITOR
665, d5em6A_, 0.8139, 2.26, 0.359, 301, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 19: 4-[(2- AZANYLPYRIMIDIN-4-YL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]- 2-OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
666, d5cnoB_, 0.8139, 2.54, 0.375, 302, 253, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
667, d3mfsA_, 0.8138, 2.52, 0.250, 303, 256, CASK-4M CAM KINASE DOMAIN AMPPNP
668, d3c0hA_, 0.8137, 2.41, 0.231, 300, 255, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
669, d2c0tA3, 0.8137, 2.01, 0.348, 268, 247, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
670, d3vs4A3, 0.8136, 2.22, 0.356, 270, 250, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
671, d3q4tB1, 0.8136, 2.56, 0.242, 293, 256, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
672, d5gtyE_, 0.8135, 2.47, 0.365, 297, 252, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
673, d4agcA_, 0.8135, 2.36, 0.386, 304, 251, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-( 3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)- BENZAMIDE)
674, d3vs6A3, 0.8135, 2.14, 0.357, 269, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
675, d2p2iA2, 0.8135, 2.25, 0.383, 283, 248, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
676, d2hckB3, 0.8135, 2.25, 0.347, 271, 251, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
677, d1vjyA_, 0.8134, 2.86, 0.224, 299, 259, CRYSTAL STRUCTURE OF A NAPHTHYRIDINE INHIBITOR OF HUMAN TGF- BETA TYPE I RECEPTOR
678, d4d58B_, 0.8133, 2.41, 0.365, 261, 249, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
679, d5ng0B_, 0.8132, 2.44, 0.256, 282, 254, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
680, d5h0gA3, 0.8132, 2.53, 0.346, 281, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-N4-DIMETHYLPENTANAMIDE
681, d5canA_, 0.8132, 2.25, 0.373, 301, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 27
682, d2c0oA3, 0.8132, 2.02, 0.348, 268, 247, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
683, d3g6hA_, 0.8131, 2.04, 0.345, 266, 249, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
684, d2c0iA3, 0.8131, 2.02, 0.348, 268, 247, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
685, d3vryA3, 0.8130, 2.15, 0.357, 269, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
686, d3f6xC_, 0.8129, 2.11, 0.359, 265, 248, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
687, d4k11A3, 0.8128, 2.31, 0.324, 282, 253, THE STRUCTURE OF 1NA IN COMPLEX WITH SRC T338G
688, d5ew3A_, 0.8127, 2.05, 0.386, 274, 246, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
689, d2hz4B1, 0.8127, 1.84, 0.379, 248, 243, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
690, d5e92A_, 0.8126, 2.97, 0.253, 298, 261, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH AMPPNP
691, d5caqA_, 0.8126, 2.29, 0.378, 301, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 33
692, d3vs6B3, 0.8126, 2.16, 0.357, 269, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
693, d1ad5B3, 0.8126, 2.26, 0.347, 271, 251, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
694, d5gnkA_, 0.8125, 2.66, 0.375, 277, 253, CRYSTAL STRUCTURE OF EGFR 696-988 T790M IN COMPLEX WITH LXX-6-34
695, d4asxA1, 0.8125, 2.65, 0.237, 295, 257, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
696, d5cauA_, 0.8124, 2.36, 0.382, 297, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41B
697, d3zosA_, 0.8124, 2.58, 0.358, 301, 254, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
698, d3w2sA_, 0.8124, 2.67, 0.378, 307, 254, EGFR KINASE DOMAIN WITH COMPOUND4
699, d5xy1A1, 0.8123, 1.97, 0.344, 252, 247, CRYSTAL STRUCTURE OF LYN KINASE DOMAIN IN COMPLEX WITH N-(1H-INDAZOL- 6-YL)-8-(PIPERIDIN-4-YLOXY)-6-PROPYLQUINAZOLIN-2-AMINE
700, d3vs1B3, 0.8123, 2.13, 0.359, 268, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
701, d3vs0B3, 0.8123, 2.12, 0.359, 268, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
702, d1ql6A_, 0.8123, 2.50, 0.240, 281, 254, THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES
703, d5gtyD_, 0.8122, 2.58, 0.372, 297, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
704, d3socB1, 0.8122, 2.60, 0.242, 294, 256, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
705, d3sxrA1, 0.8121, 2.29, 0.317, 257, 252, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
706, d4ogrI_, 0.8120, 2.80, 0.243, 318, 259, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
707, d5oxgB_, 0.8119, 2.87, 0.242, 296, 260, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
708, d5gtyF_, 0.8119, 2.38, 0.359, 297, 251, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
709, d5aaaA_, 0.8119, 2.47, 0.325, 294, 252, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
710, d3vryB3, 0.8119, 2.15, 0.353, 269, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
711, d3vs4B3, 0.8118, 2.16, 0.357, 269, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
712, d3pozA_, 0.8118, 2.42, 0.367, 293, 251, EGFR KINASE DOMAIN COMPLEXED WITH TAK-285
713, d1fpuB1, 0.8118, 2.56, 0.367, 266, 251, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
714, d3mtfA_, 0.8117, 2.89, 0.239, 296, 259, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
715, d5em7A_, 0.8116, 2.33, 0.373, 300, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 13: 4-[(2- METHOXYPHENYL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
716, d5e91A_, 0.8116, 2.87, 0.255, 297, 259, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4- (MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE
717, d3vrzA3, 0.8116, 2.16, 0.355, 268, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
718, d3mftA_, 0.8116, 2.43, 0.231, 302, 255, CASK-4M CAM KINASE DOMAIN MN2+
719, d1ad5A3, 0.8116, 2.27, 0.351, 271, 251, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
720, d4ludB3, 0.8115, 2.12, 0.359, 264, 248, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
721, d4fobA_, 0.8115, 2.66, 0.291, 295, 254, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 1
722, d3tzmA_, 0.8115, 2.74, 0.233, 295, 258, TGF-BETA RECEPTOR TYPE 1 IN COMPLEX WITH SB431542
723, d3ky2A1, 0.8115, 2.56, 0.386, 305, 254, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
724, d2c0tB3, 0.8115, 2.09, 0.348, 268, 247, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
725, d4d4sB_, 0.8114, 2.37, 0.363, 260, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN
726, d5c8nA_, 0.8113, 2.31, 0.378, 300, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 23
727, d4d55A_, 0.8113, 2.15, 0.361, 260, 249, FOCAL ADHESION KINASE CATALYTIC DOMAIN
728, d5d41A_, 0.8112, 2.18, 0.367, 300, 248, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
729, d4asxB1, 0.8111, 2.67, 0.237, 296, 257, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
730, d3oomA_, 0.8111, 2.92, 0.238, 297, 260, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00507
731, d2c0iB3, 0.8110, 2.18, 0.355, 268, 248, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
732, d5ut4A_, 0.8109, 2.41, 0.275, 273, 251, JAK2 JH2 IN COMPLEX WITH NVP-BSK805
733, d5oy6B_, 0.8109, 2.84, 0.243, 292, 259, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
734, d3vs7A3, 0.8109, 2.08, 0.356, 267, 247, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
735, d3vs3A3, 0.8109, 2.17, 0.357, 269, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
736, d3bbtD_, 0.8109, 2.28, 0.405, 259, 247, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
737, d5ew8A_, 0.8108, 2.65, 0.391, 291, 256, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
738, d3my0M1, 0.8108, 3.01, 0.254, 297, 264, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
739, d3belA_, 0.8108, 2.59, 0.367, 280, 251, X-RAY STRUCTURE OF EGFR IN COMPLEX WITH OXIME INHIBITOR
740, d4qqtA_, 0.8107, 2.56, 0.391, 283, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 TYROSINE KINASE DOMAIN
741, d2srcA3, 0.8107, 2.36, 0.324, 284, 253, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC IN COMPLEX WITH AMP-PNP
742, d5oxgA_, 0.8106, 2.90, 0.242, 293, 260, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
743, d5i4nA1, 0.8106, 2.43, 0.271, 273, 251, CRYSTAL STRUCTURE OF THE E596A V617F MUTANT JAK2 PSEUDOKINASE DOMAIN BOUND TO MG-ATP
744, d4ogrA_, 0.8106, 2.80, 0.243, 314, 259, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
745, d4fvrA_, 0.8106, 2.41, 0.271, 274, 251, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN MUTANT V617F (MG- ATP-BOUND FORM)
746, d3vs2A3, 0.8106, 2.06, 0.348, 268, 247, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
747, d3f6xA_, 0.8106, 2.06, 0.344, 264, 247, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
748, d2zv8A1, 0.8106, 2.23, 0.343, 256, 251, LYN TYROSINE KINASE DOMAIN-AMP-PNP COMPLEX
749, d5mjaB_, 0.8105, 2.71, 0.277, 274, 256, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
750, d2bdfB_, 0.8105, 2.25, 0.347, 265, 251, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
751, d5j7hA_, 0.8104, 2.24, 0.325, 291, 249, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) BOUND BY BRIGATINIB
752, d3zfxE_, 0.8104, 2.18, 0.328, 262, 247, CRYSTAL STRUCTURE OF EPHB1
753, d3pxkB_, 0.8104, 2.06, 0.376, 258, 245, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
754, d5e8xA_, 0.8103, 2.86, 0.234, 304, 261, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F) IN COMPLEX WITH STAUROSPORINE
755, d4mneB_, 0.8103, 2.36, 0.253, 270, 253, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
756, d4fvqA_, 0.8103, 2.32, 0.276, 274, 250, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (MG-ATP-BOUND FORM)
757, d1opjA1, 0.8103, 2.40, 0.372, 282, 250, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
758, d3socA1, 0.8101, 2.68, 0.237, 296, 257, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
759, d3js2B_, 0.8101, 2.64, 0.391, 291, 256, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
760, d1phkA_, 0.8101, 2.37, 0.238, 277, 252, TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE SUBSTRATE-ANALOGUE AND PRODUCT
761, d1k2pA_, 0.8101, 2.37, 0.324, 258, 253, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
762, d5aa9A_, 0.8100, 2.49, 0.325, 295, 252, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
763, d4uwcB_, 0.8100, 2.66, 0.391, 301, 256, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
764, d4mxzB_, 0.8100, 2.08, 0.351, 264, 248, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
765, d4mxyB_, 0.8100, 2.08, 0.351, 264, 248, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
766, d3vs5A3, 0.8100, 2.15, 0.359, 268, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
767, d3q4tA1, 0.8099, 2.69, 0.237, 294, 257, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
768, d5uhnB_, 0.8098, 2.39, 0.376, 269, 250, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
769, d5calA_, 0.8098, 2.29, 0.375, 300, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 24
770, d3vs0A3, 0.8098, 2.20, 0.355, 268, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
771, d5capA_, 0.8097, 2.24, 0.379, 303, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 30
772, d4rj8A_, 0.8097, 2.38, 0.378, 298, 249, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 8
773, d4rj7A_, 0.8097, 2.34, 0.375, 295, 248, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 1
774, d2c0oB3, 0.8097, 2.19, 0.355, 268, 248, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
775, d1iepB1, 0.8097, 2.39, 0.368, 270, 250, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
776, d3kfaA1, 0.8096, 2.47, 0.371, 283, 251, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
777, d3my0B_, 0.8095, 3.02, 0.250, 295, 264, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
778, d3kfaB1, 0.8095, 2.46, 0.375, 283, 251, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
779, d2rfeD_, 0.8095, 2.64, 0.373, 278, 252, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
780, d5mjaA_, 0.8094, 2.51, 0.317, 271, 252, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
781, d5kz0A_, 0.8094, 2.45, 0.323, 293, 251, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-[(1R)- 1-{[2-AMINO-5-(13-DIMETHYL-1H-PYRAZOL-4-YL)PYRIDIN-3-YL]OXY}ETHYL]- 4-FLUORO-NN-DIMETHYLBENZAMIDE
782, d4wa9B1, 0.8094, 2.10, 0.356, 263, 247, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
783, d3zzeA_, 0.8094, 2.83, 0.331, 286, 254, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH N - ((3Z)-4-CHLORO-7-METHYL-2-OXO-12-DIHYDRO-3H-INDOL-3- YLIDENE)-2-(4-HYDROXYPHENYL)PROPANOHYDRAZIDE
784, d1kswA3, 0.8094, 2.39, 0.320, 284, 253, STRUCTURE OF HUMAN C-SRC TYROSINE KINASE (THR338GLY MUTANT) IN COMPLEX WITH N6-BENZYL ADP
785, d5hu9A1, 0.8093, 2.61, 0.375, 262, 251, CRYSTAL STRUCTURE OF ABL1 IN COMPLEX WITH CHMFL-074
786, d4d4yB_, 0.8093, 2.39, 0.363, 260, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN
787, d4cmoA_, 0.8092, 2.51, 0.321, 295, 252, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 2-((1R)-1-((3-AMINO-6-(2- METHOXYPYRIDIN- -YL)PYRAZIN-2-YL)OXY)ETHYL)-4-FLUORO-N-METHYLBENZAMIDE
788, d4aoiA_, 0.8091, 2.56, 0.335, 289, 251, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( 3-((1H- PYRROLO(23-B)PYRIDIN-3-YL)METHYL)-(124)TRIAZOLO( 43-B)(124) TRIAZIN-6-YL)BENZONITRILE
789, d2eb3A_, 0.8091, 2.33, 0.371, 294, 248, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (L858R) IN COMPLEX WITH AMPPNP
790, d3hmmA_, 0.8090, 2.76, 0.234, 293, 256, STRUCTURE OF ALK5 + GW855857
791, d3my0E1, 0.8089, 2.98, 0.255, 293, 263, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
792, d5oxgD_, 0.8088, 2.91, 0.242, 293, 260, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
793, d5aabA_, 0.8088, 2.46, 0.324, 293, 250, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
794, d4yhfB_, 0.8088, 2.38, 0.311, 269, 251, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
795, d4d5hB_, 0.8088, 2.42, 0.363, 260, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN
796, d3gt8C_, 0.8088, 2.49, 0.373, 296, 252, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
797, d2oiqB_, 0.8088, 2.05, 0.347, 265, 248, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
798, d5e8vA_, 0.8087, 2.87, 0.256, 296, 258, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A)
799, d5c8kA_, 0.8087, 2.30, 0.379, 300, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 1
800, d4ccuA_, 0.8087, 2.40, 0.317, 292, 249, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPAN-2-OL
801, d3vs5B3, 0.8087, 2.17, 0.359, 268, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
802, d3my0L1, 0.8087, 2.98, 0.255, 295, 263, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
803, d2biyA_, 0.8087, 2.72, 0.205, 287, 259, STRUCTURE OF PDK1-S241A MUTANT KINASE DOMAIN
804, d3vs7B3, 0.8086, 2.01, 0.358, 266, 246, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
805, d4focA_, 0.8085, 2.57, 0.290, 296, 252, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 2
806, d3zclA_, 0.8085, 2.57, 0.335, 289, 251, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-3-(1-(1H-PYRROLO(23-B)PYRIDIN-3-YL)ETHYL)-N-ISOPROPYL-( 124)TRIAZOLO(43-B)PYRIDAZIN-6-AMINE
807, d3gvuA1, 0.8085, 2.29, 0.371, 261, 248, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH GLEEVEC
808, d3c4fB_, 0.8085, 2.72, 0.391, 290, 256, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
809, d1opjB1, 0.8085, 2.46, 0.375, 284, 251, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
810, d4cliA_, 0.8084, 2.52, 0.321, 294, 252, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-21016-TRIMETHYL-15 -OXO-10151617-TETRAHYDRO-2H-84-(METHENO)PYRAZOLO(43-H) (2511)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
811, d3w33A_, 0.8084, 2.72, 0.372, 297, 253, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 19B
812, d3my0N1, 0.8084, 2.99, 0.251, 299, 263, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
813, d5c8mA_, 0.8083, 2.32, 0.373, 302, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 17
814, d4i24A_, 0.8083, 2.52, 0.380, 295, 250, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
815, d3my0G1, 0.8083, 2.98, 0.255, 293, 263, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
816, d3kexA_, 0.8083, 2.74, 0.328, 292, 256, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
817, d5t0pA_, 0.8082, 2.10, 0.348, 264, 247, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
818, d4ccbA_, 0.8082, 2.40, 0.325, 287, 249, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 3-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(5-METHYL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE
819, d3my0F1, 0.8082, 3.02, 0.255, 293, 263, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
820, d2zv9A1, 0.8082, 2.20, 0.344, 255, 250, LYN TYROSINE KINASE DOMAIN-PP2 COMPLEX
821, d2hznA2, 0.8082, 2.34, 0.367, 268, 248, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AFG210
822, d5a46B_, 0.8081, 2.62, 0.392, 297, 255, FGFR1 IN COMPLEX WITH DOVITINIB
823, d4mxoA_, 0.8081, 2.20, 0.345, 266, 249, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
824, d4cmuA_, 0.8081, 2.52, 0.321, 294, 252, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (10R)-7-AMINO-12-FLUORO-1310 16-TETRAMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(43- H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
825, d4ap7A_, 0.8081, 2.57, 0.335, 289, 251, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( (6-(4- FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN-3-YL)METHYL) PHENOL
826, d3kexB_, 0.8081, 2.75, 0.328, 283, 256, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
827, d3f6xB_, 0.8081, 2.10, 0.343, 267, 248, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
828, d5oy6A_, 0.8080, 2.85, 0.244, 291, 258, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
829, d4rj4A_, 0.8080, 2.39, 0.373, 299, 249, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 6
830, d3my0A1, 0.8080, 3.00, 0.255, 295, 263, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
831, d4zsaA_, 0.8079, 2.70, 0.391, 289, 256, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
832, d4rwjA1, 0.8079, 2.72, 0.387, 306, 256, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
833, d3my0R1, 0.8079, 3.01, 0.247, 293, 263, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
834, d2x9fA_, 0.8079, 2.46, 0.311, 265, 251, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
835, d1mqbB_, 0.8079, 2.27, 0.337, 265, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
836, d4uwbA_, 0.8078, 2.61, 0.392, 299, 255, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
837, d4tt7A_, 0.8078, 2.55, 0.319, 291, 251, CRYSTAL STRUCTURE OF HUMAN ALK WITH A COVALENT MODIFICATION
838, d3vs2B3, 0.8078, 2.18, 0.359, 268, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
839, d3oy3B1, 0.8078, 2.48, 0.375, 283, 251, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
840, d3h3cA_, 0.8078, 2.15, 0.352, 263, 247, CRYSTAL STRUCTURE OF PYK2 IN COMPLEX WITH SULFOXIMINE- SUBSTITUTED TRIFLUOROMETHYLPYRIMIDINE ANALOG
841, d2wgjA_, 0.8078, 2.58, 0.335, 289, 251, X-RAY STRUCTURE OF PF-02341066 BOUND TO THE KINASE DOMAIN OF C-MET
842, d2j0mB_, 0.8078, 2.02, 0.376, 257, 245, CRYSTAL STRUCTURE A TWO-CHAIN COMPLEX BETWEEN THE FERM AND KINASE DOMAINS OF FOCAL ADHESION KINASE.
843, d3zbxA_, 0.8077, 2.58, 0.335, 282, 251, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR 6- ((6-(4-FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN- 3-YL)METHYL)QUINOLINE.
844, d3tt0A_, 0.8077, 2.66, 0.387, 305, 256, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
845, d3my0U1, 0.8077, 3.04, 0.251, 284, 263, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
846, d5ut5A_, 0.8076, 2.41, 0.276, 272, 250, JAK2 JH2 IN COMPLEX WITH GLPG0634
847, d4qqjA_, 0.8076, 2.57, 0.391, 282, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN HARBORING THE V550L GATE-KEEPER MUTATION
848, d5vndB_, 0.8075, 2.66, 0.391, 295, 256, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
849, d3my1A_, 0.8075, 2.85, 0.246, 314, 260, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
850, d5j9zA_, 0.8074, 2.33, 0.379, 291, 248, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1A
851, d4rj6A_, 0.8074, 2.44, 0.373, 297, 249, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 4
852, d4r7hA_, 0.8074, 2.41, 0.332, 308, 250, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX3397
853, d4fvpA_, 0.8074, 2.36, 0.276, 274, 250, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (APO FORM)
854, d4p2wA_, 0.8073, 2.15, 0.335, 250, 248,  
855, d3qgyB1, 0.8073, 1.69, 0.329, 244, 240, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
856, d3q4uB1, 0.8073, 3.02, 0.246, 298, 260, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
857, d3ik3A1, 0.8073, 2.44, 0.368, 279, 250, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
858, d1k3aA_, 0.8073, 2.83, 0.300, 288, 257, STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR KINASE
859, d3c4fA_, 0.8072, 2.73, 0.391, 290, 256, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
860, d3js2A_, 0.8070, 2.69, 0.391, 295, 256, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
861, d4gu6A_, 0.8069, 2.58, 0.369, 271, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
862, d3k5vA1, 0.8069, 2.48, 0.360, 281, 250, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
863, d1iepA1, 0.8069, 2.49, 0.356, 270, 250, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
864, d5ut1A_, 0.8068, 2.43, 0.276, 272, 250, JAK2 JH2 IN COMPLEX WITH BI-D1870
865, d5ut2A_, 0.8067, 2.43, 0.276, 273, 250, JAK2 JH2 IN COMPLEX WITH PRT062607
866, d3oy3A1, 0.8067, 2.50, 0.375, 283, 251, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
867, d4l7sA1, 0.8066, 1.75, 0.320, 248, 241, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
868, d3gt8D_, 0.8066, 2.51, 0.382, 295, 251, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
869, d4uwcA_, 0.8065, 2.74, 0.391, 300, 256, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
870, d4r5sA_, 0.8065, 2.62, 0.366, 299, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH FIIN-3
871, d4mxoB_, 0.8065, 2.12, 0.343, 264, 248, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
872, d3zxzA_, 0.8065, 2.60, 0.335, 289, 251, X-RAY STRUCTURE OF PF-04217903 BOUND TO THE KINASE DOMAIN OF C-MET
873, d3my0I1, 0.8065, 2.98, 0.256, 292, 262, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
874, d3l8pA_, 0.8065, 2.36, 0.363, 292, 248, CRYSTAL STRUCTURE OF CYTOPLASMIC KINASE DOMAIN OF TIE2 COMPLEXED WITH INHIBITOR CEP11207
875, d4uxqA_, 0.8064, 2.63, 0.395, 286, 253, FGFR4 IN COMPLEX WITH PONATINIB
876, d4cljA_, 0.8064, 2.58, 0.324, 295, 253, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
877, d5uszA_, 0.8063, 2.43, 0.276, 272, 250, JAK2 JH2 IN COMPLEX WITH JNJ-7706621
878, d5am7A_, 0.8063, 2.59, 0.391, 294, 253, FGFR1 MUTANT WITH AN INHIBITOR
879, d3rhxA_, 0.8063, 2.68, 0.391, 289, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
880, d3my0Q1, 0.8063, 3.03, 0.255, 293, 263, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
881, d5ng2B_, 0.8062, 2.26, 0.261, 278, 249, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
882, d5gtyC_, 0.8062, 2.42, 0.372, 295, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
883, d4mxxA_, 0.8062, 2.22, 0.345, 266, 249, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
884, d4fodA_, 0.8060, 2.65, 0.289, 308, 253, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 36
885, d2oiqA_, 0.8060, 2.23, 0.343, 265, 248, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
886, d5ut3A_, 0.8059, 2.45, 0.276, 272, 250, JAK2 JH2 IN COMPLEX WITH IKK-2 INHIBITOR VI
887, d5iuiA_, 0.8058, 2.83, 0.289, 303, 256, CRYSTAL STRUCTURE OF ANAPLASTIC LYPHOMA KINASE (ALK) IN COMPLEX WITH 4
888, d4agdA_, 0.8058, 2.46, 0.386, 303, 251, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SUNITINIB (SU11248) (N-2- DIETHYLAMINOETHYL)-5-((Z)-(5-FLUORO-2-OXO-1H-INDOL-3- YLIDENE)METHYL)-24-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE)
889, d3b8qA1, 0.8058, 2.10, 0.380, 285, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
890, d5am6A1, 0.8057, 2.59, 0.387, 294, 253, NATIVE FGFR1 WITH AN INHIBITOR
891, d4e26A_, 0.8057, 2.53, 0.260, 270, 254, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
892, d4hvsA1, 0.8056, 2.50, 0.363, 323, 251, CRYSTAL STRUCTURE OF KIT KINASE DOMAIN WITH A SMALL MOLECULE INHIBITOR PLX647
893, d3eflA1, 0.8056, 2.00, 0.387, 279, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
894, d2qluA1, 0.8056, 2.77, 0.231, 295, 255, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE II KINASE DOMAIN FROM HUMAN
895, d5ut0A_, 0.8054, 2.45, 0.276, 272, 250, JAK2 JH2 IN COMPLEX WITH AT9283
896, d4d4vA_, 0.8054, 2.01, 0.361, 256, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN
897, d3k5vB1, 0.8054, 2.40, 0.369, 279, 249, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
898, d5xdlA_, 0.8052, 2.38, 0.371, 292, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH CO-1686
899, d2hyyA_, 0.8052, 2.36, 0.363, 263, 248, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
900, d5ut6A_, 0.8051, 2.46, 0.276, 272, 250, JAK2 JH2 IN COMPLEX WITH A DIAMINOPYRIMIDINE
901, d3beaA_, 0.8051, 2.54, 0.327, 310, 251, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH A PYRIMIDINOPYRIDONE INHIBITOR
902, d4bcgA_, 0.8049, 2.87, 0.242, 312, 260, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
903, d3lvpC_, 0.8049, 2.82, 0.302, 293, 258, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
904, d5ng2A_, 0.8048, 2.15, 0.259, 274, 247, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
905, d2hiwA1, 0.8047, 2.59, 0.378, 270, 251, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
906, d4d5kB_, 0.8046, 2.06, 0.369, 256, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN
907, d4ckrA1, 0.8046, 2.65, 0.358, 294, 254, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH DDR1-IN-1
908, d4bkiA1, 0.8046, 2.65, 0.358, 294, 254,  
909, d3my0S1, 0.8046, 3.00, 0.252, 293, 262, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
910, d3my0H1, 0.8046, 3.00, 0.252, 293, 262, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
911, d2xvdA_, 0.8046, 2.79, 0.299, 270, 254, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
912, d6babD_, 0.8045, 2.36, 0.238, 291, 252, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
913, d4anqA_, 0.8045, 2.49, 0.316, 293, 250, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
914, d1k2pB_, 0.8045, 2.47, 0.300, 258, 253, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
915, d4l7sB1, 0.8044, 1.77, 0.320, 248, 241, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
916, d4bcjA_, 0.8044, 2.90, 0.238, 309, 260, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
917, d5oy6C_, 0.8043, 2.90, 0.244, 291, 258, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
918, d5ew8B_, 0.8043, 2.63, 0.394, 290, 254, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
919, d3my0T1, 0.8043, 2.98, 0.257, 291, 261, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
920, d4bggD_, 0.8042, 2.92, 0.243, 286, 259, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
921, d3rwqA_, 0.8042, 2.63, 0.208, 283, 255, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
922, d2pl0A_, 0.8042, 2.36, 0.361, 268, 249, LCK BOUND TO IMATINIB
923, d2i1mA_, 0.8042, 2.55, 0.327, 311, 251, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
924, d1fgiA_, 0.8042, 2.75, 0.387, 283, 256, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
925, d3gt8B_, 0.8041, 2.55, 0.382, 292, 251, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
926, d3gt8A_, 0.8041, 2.57, 0.382, 300, 251, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
927, d1t45A_, 0.8041, 2.43, 0.352, 331, 250, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C- KIT TYROSINE KINASE
928, d1fpuA1, 0.8041, 2.43, 0.365, 271, 249, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
929, d3ik3B1, 0.8040, 2.47, 0.368, 285, 250, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
930, d3cs9A_, 0.8039, 2.44, 0.367, 264, 248, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
931, d5ftoA1, 0.8038, 2.85, 0.286, 297, 255, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH ENTRECTINIB
932, d5a46A_, 0.8038, 2.58, 0.399, 289, 253, FGFR1 IN COMPLEX WITH DOVITINIB
933, d4uwyA_, 0.8038, 2.56, 0.378, 296, 251, FGFR1 APO STRUCTURE
934, d3sxrB1, 0.8038, 2.32, 0.316, 255, 250, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
935, d2xb7A_, 0.8038, 2.19, 0.329, 286, 246, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH NVP- TAE684
936, d5xp7A_, 0.8037, 2.16, 0.347, 265, 248, C-SRC IN COMPLEX WITH ATP-CHCL
937, d5a9uA_, 0.8037, 2.47, 0.317, 292, 249, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
938, d4otwA_, 0.8037, 2.88, 0.329, 272, 255, HER3 PSEUDOKINASE DOMAIN BOUND TO BOSUTINIB
939, d3zc5A_, 0.8037, 2.64, 0.335, 289, 251, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-6-(1-(6-(1-METHYL-1H-PYRAZOL-4-YL)-(124)TRIAZOLO(43- B)PYRIDAZIN-3-YL)ETHYL)QUINOLINE.
940, d4bcfA_, 0.8036, 2.86, 0.239, 307, 259, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
941, d3g0fA_, 0.8036, 2.43, 0.356, 291, 250, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
942, d4qmpA_, 0.8035, 2.64, 0.260, 289, 254, MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
943, d3orxC_, 0.8035, 2.57, 0.205, 283, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
944, d3my0P_, 0.8035, 3.00, 0.256, 290, 262, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
945, d3my0C1, 0.8035, 3.02, 0.252, 298, 262, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
946, d5i9vA_, 0.8034, 2.48, 0.317, 279, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AGS
947, d3lq5A_, 0.8033, 2.77, 0.238, 307, 256, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
948, d4yznA_, 0.8032, 2.61, 0.278, 269, 255, HUMANIZED ROCO4 BOUND TO COMPOUND 19
949, d3uqgA_, 0.8032, 2.01, 0.341, 263, 246, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
950, d3orxA_, 0.8032, 2.58, 0.205, 283, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
951, d3lvpB_, 0.8032, 2.76, 0.309, 295, 256, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
952, d4bggC_, 0.8031, 2.87, 0.250, 279, 256, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
953, d2zv7A1, 0.8031, 2.32, 0.343, 256, 251, LYN TYROSINE KINASE DOMAIN APO FORM
954, d3lmgB_, 0.8030, 2.77, 0.331, 268, 254, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
955, d3cp9B_, 0.8030, 2.26, 0.384, 269, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
956, p4ib5A_, 0.8029, 2.65, 0.227, 331, 256, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
957, d5aa8A_, 0.8028, 2.48, 0.321, 292, 249, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12- FLUORO-21016-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H- 84-(METHENO)PYRAZOLO(43-H)(2511) BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
958, d4kioC1, 0.8028, 1.86, 0.318, 249, 242, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
959, d4bciA_, 0.8028, 2.91, 0.242, 308, 260, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
960, d2jkmA_, 0.8028, 2.29, 0.363, 260, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
961, d4nw6A1, 0.8027, 2.91, 0.256, 296, 258, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 27
962, d4ctcA_, 0.8027, 2.37, 0.320, 288, 247, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 7-AMINO-3-CYCLOPROPYL-12-FLUORO- 11016-TRIMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(4 3-H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
963, d3zbfA_, 0.8027, 2.28, 0.360, 281, 247, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH CRIZOTINIB
964, d3cc6A_, 0.8027, 2.62, 0.374, 269, 254, CRYSTAL STRUCTURE OF KINASE DOMAIN OF PROTEIN TYROSINE KINASE 2 BETA (PTK2B)
965, d6aywA_, 0.8026, 2.52, 0.244, 293, 254, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
966, p5x02A_, 0.8026, 2.48, 0.364, 305, 250, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR FF- 10101
967, d5vndA_, 0.8026, 2.66, 0.392, 302, 255, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
968, d4uwbB_, 0.8026, 2.65, 0.398, 299, 254, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
969, d4ansA_, 0.8026, 2.51, 0.320, 293, 250, STRUCTURE OF L1196MG1269A DOUBLE MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
970, d2auhA1, 0.8026, 2.88, 0.298, 294, 258, CRYSTAL STRUCTURE OF THE GRB14 BPS REGION IN COMPLEX WITH THE INSULIN RECEPTOR TYROSINE KINASE
971, d4d4yA_, 0.8025, 2.01, 0.358, 255, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN
972, d3l8vA_, 0.8025, 2.64, 0.327, 293, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A BIARYLAMINE BASED INHIBITOR
973, d3lzbC_, 0.8024, 2.41, 0.383, 259, 248, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
974, d5k9iB_, 0.8023, 2.04, 0.341, 262, 246, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
975, d4nw5A1, 0.8023, 2.92, 0.256, 296, 258, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 8
976, d4d5kA_, 0.8023, 2.02, 0.358, 255, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN
977, d2yfxA_, 0.8023, 2.52, 0.320, 292, 250, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
978, d2phkA_, 0.8023, 2.50, 0.230, 277, 252, THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION
979, d4ogrE_, 0.8022, 2.77, 0.238, 310, 256, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
980, d4hw7A_, 0.8022, 2.56, 0.336, 289, 250, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX647-OME
981, d3my0D1, 0.8022, 3.00, 0.253, 297, 261, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
982, d2zm3C2, 0.8022, 2.82, 0.304, 295, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
983, d2e2bA1, 0.8022, 2.42, 0.375, 266, 248, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
984, d3lmgA_, 0.8021, 2.96, 0.336, 268, 256, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
985, d2bdfA_, 0.8021, 2.32, 0.337, 261, 249, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
986, d4r7iA_, 0.8020, 2.44, 0.333, 290, 249, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR GLEEVEC
987, d4d4vB_, 0.8020, 2.04, 0.366, 255, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN
988, d2xp2A_, 0.8020, 2.39, 0.324, 285, 247, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB (PF-02341066)
989, d3my0V1, 0.8019, 2.88, 0.252, 281, 258, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
990, d4y95B1, 0.8018, 2.28, 0.329, 265, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
991, d4qmoA_, 0.8018, 2.66, 0.260, 288, 254, MST3 IN COMPLEX WITH IMIDAZOLO-OXINDOLE PKR INHIBITOR C16
992, d2i0yA_, 0.8018, 2.46, 0.329, 289, 249, CFMS TYROSINE KINASE (FGF KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
993, d5t0pB_, 0.8017, 2.15, 0.348, 263, 247, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
994, d5caoA_, 0.8017, 2.33, 0.377, 300, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 29
995, d3plsA_, 0.8017, 2.71, 0.354, 298, 254, RON IN COMPLEX WITH LIGAND AMP-PNP
996, d3krjA_, 0.8017, 2.49, 0.325, 304, 249, CFMS TYROSINE KINASE IN COMPLEX WITH 4-CYANO-1H-IMIDAZOLE-2-CARBOXYLIC ACID (2-CYCLOHEX-1-ENYL-4-PIPERIDIN-4-YL-PHENYL)-AMIDE
997, d3h9rA_, 0.8017, 2.79, 0.246, 312, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TYPE I ACTIVIN RECEPTOR (ACVR1) IN COMPLEX WITH FKBP12 AND DORSOMORPHIN
998, d1lufA_, 0.8017, 2.36, 0.359, 275, 248, CRYSTAL STRUCTURE OF THE MUSK TYROSINE KINASE: INSIGHTS INTO RECEPTOR AUTOREGULATION
999, d5bvkA_, 0.8016, 2.42, 0.372, 278, 250, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
1000, d4y95C1, 0.8016, 2.29, 0.329, 265, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
1001, d4d5hA_, 0.8016, 2.03, 0.358, 255, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1002, d2etmA_, 0.8016, 2.35, 0.365, 262, 249, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
1003, d5uglB_, 0.8015, 2.54, 0.372, 271, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
1004, d4qmqA_, 0.8015, 2.66, 0.260, 289, 254, MST3 IN COMPLEX WITH CP-673451
1005, d4mxcA_, 0.8015, 2.61, 0.328, 290, 250, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
1006, d5hznE_, 0.8014, 2.76, 0.331, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1007, d3eflB_, 0.8014, 2.16, 0.381, 263, 244, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
1008, d2qu6B_, 0.8014, 1.95, 0.373, 260, 241, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
1009, d5hznA_, 0.8013, 2.76, 0.331, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1010, d5fg8A_, 0.8013, 2.59, 0.229, 269, 253, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
1011, d3ms9B1, 0.8013, 2.50, 0.369, 267, 249, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
1012, d4nkaB_, 0.8012, 2.48, 0.392, 287, 250, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
1013, d4bchA_, 0.8012, 2.89, 0.239, 308, 259, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1014, d3orxD_, 0.8011, 2.57, 0.206, 282, 253, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1015, d3lzbB_, 0.8011, 2.57, 0.380, 265, 250, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
1016, d3gxlA_, 0.8011, 2.84, 0.220, 285, 255, ALK-5 KINASE COMPLEX WITH GW857175
1017, d4o2pB_, 0.8010, 2.18, 0.313, 265, 246, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
1018, d4imyE_, 0.8010, 2.76, 0.242, 313, 256, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
1019, d4d58A_, 0.8010, 2.05, 0.362, 255, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
1020, d3u6jA1, 0.8010, 2.53, 0.386, 305, 251, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
1021, d6babA_, 0.8009, 2.36, 0.239, 290, 251, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1022, d5imxA_, 0.8009, 1.99, 0.329, 266, 243, ANAPLASTIC LYMPHOMA KINASE (ALK) CATALYTIC DOMAIN COMPLEXED WITH NOVEL INHIBITOR 3-SULFONYLPYRAZOL-4-AMINO PYRIMIDINE
1023, d5am7B_, 0.8009, 2.50, 0.400, 287, 250, FGFR1 MUTANT WITH AN INHIBITOR
1024, d4l00B_, 0.8009, 2.65, 0.240, 278, 254, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
1025, d5am6B_, 0.8008, 2.57, 0.400, 280, 250, NATIVE FGFR1 WITH AN INHIBITOR
1026, d4kabB_, 0.8008, 2.43, 0.369, 258, 249, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
1027, d3g0fB_, 0.8008, 2.56, 0.355, 293, 251, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
1028, d2ckeA_, 0.8008, 2.79, 0.226, 301, 257, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
1029, d5htiA_, 0.8007, 2.75, 0.331, 290, 251, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH LXM108
1030, d5h9bA_, 0.8007, 2.65, 0.228, 269, 254, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/AMPPN
1031, d4or5A_, 0.8007, 2.96, 0.247, 319, 259, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
1032, d4qmmA_, 0.8006, 2.68, 0.260, 288, 254, MST3 IN COMPLEX WITH AT-9283 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]- 1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
1033, d2wkmA_, 0.8006, 2.88, 0.332, 286, 253, X-RAY STRUCTURE OF PHA-00665752 BOUND TO THE KINASE DOMAIN OF C-MET
1034, d2hiwB1, 0.8006, 2.44, 0.378, 270, 249, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
1035, d4l00A_, 0.8005, 2.42, 0.243, 277, 251, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
1036, d5dg5B_, 0.8004, 2.62, 0.328, 297, 250, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
1037, d4or5F_, 0.8004, 3.08, 0.249, 324, 261, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
1038, d1xo2B_, 0.8004, 2.72, 0.256, 289, 254, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
1039, d5edqA_, 0.8003, 2.33, 0.377, 298, 247, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 15: ~{N}-(7- CHLORANYL-1~{H}-INDAZOL-3-YL)-77-DIMETHYL-2-(1~{H}-PYRAZOL-4-YL)- 5~{H}-FURO[34-D]PYRIMIDIN-4-AMINE
1040, d1h1wA_, 0.8003, 2.67, 0.208, 284, 255, HIGH RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PDK1 CATALYTIC DOMAIN
1041, d4y95D_, 0.8001, 2.43, 0.301, 265, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
1042, d4y95A1, 0.8001, 2.43, 0.301, 265, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
1043, d4w8dA_, 0.8001, 2.69, 0.260, 289, 254, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06454589).
1044, d5hznC_, 0.8000, 2.78, 0.331, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1045, d3b8qB_, 0.8000, 2.16, 0.385, 271, 244, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
1046, d5hznG_, 0.7999, 2.78, 0.331, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1047, d5aacA_, 0.7999, 2.52, 0.317, 292, 249, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
1048, d4u8zA_, 0.7999, 2.68, 0.260, 289, 254, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06447475)
1049, d2etmB_, 0.7999, 2.47, 0.363, 263, 248, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
1050, d4hctA_, 0.7998, 2.46, 0.304, 265, 250, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 52
1051, d3svvA_, 0.7998, 2.05, 0.340, 261, 244, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
1052, d3mvjE_, 0.7998, 2.59, 0.237, 334, 253, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
1053, d5hznF_, 0.7997, 2.79, 0.331, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1054, d5hznB_, 0.7997, 2.79, 0.331, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1055, d5ar2B_, 0.7997, 2.44, 0.264, 285, 250, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
1056, d3lzbD_, 0.7997, 2.58, 0.380, 261, 250, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
1057, d3lzbA_, 0.7997, 2.60, 0.380, 265, 250, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
1058, d1uvrA_, 0.7997, 2.68, 0.208, 284, 255, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-8
1059, d4yhfA_, 0.7996, 2.70, 0.316, 268, 253, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
1060, d4pmmA1, 0.7996, 2.61, 0.380, 281, 250, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N-(3-CYCLOPROPYL- 1-PHENYL-1H-PYRAZOL-5-YL)-2-{4-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1- YL)PHENYL]-1H-123-TRIAZOL-1-YL}ACETAMIDE
1061, d2a2aA_, 0.7996, 2.79, 0.233, 304, 257, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
1062, d4qmvA_, 0.7995, 2.70, 0.260, 288, 254, MST3 IN COMPLEX WITH PF-03814735 N-{2-[(1S4R)-6-{[4- (CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1234- TETRAHYDRO-14-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE
1063, d3tn8A_, 0.7995, 2.99, 0.238, 304, 260, CDK9/CYCLIN T IN COMPLEX WITH CAN508
1064, d4bb4A_, 0.7994, 2.63, 0.300, 265, 250, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1065, d3g6gB_, 0.7994, 2.10, 0.335, 263, 245, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
1066, d3el8A_, 0.7994, 2.07, 0.341, 263, 246, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
1067, d4z3vA_, 0.7993, 2.54, 0.306, 271, 252, FRAGMENT-BASED DISCOVERY OF A SMALL MOLECULE REVERSIBLE INHIBITOR OF BRUTON S TYROSINE KINASE
1068, d4ctbA_, 0.7993, 2.51, 0.321, 292, 249, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (5R)-8-AMINO-3-FLUORO-519-DIMETHYL-20-OXO-5181920- TETRAHYDRO-711-(AZENO)PYRIDO(2 1 :23)IMIDAZO(45-H)(2511) BENZOXADIAZACYCLOTETRADECINE-14-CARBONITRILE
1069, d3my0O1, 0.7993, 2.98, 0.254, 296, 260, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1070, d5ci7A_, 0.7992, 2.63, 0.252, 276, 254, STRUCTURE OF ULK1 BOUND TO A SELECTIVE INHIBITOR
1071, d4pp9B1, 0.7992, 1.81, 0.317, 246, 240, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
1072, d4dglD_, 0.7992, 2.70, 0.227, 328, 256, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
1073, d2zm3D2, 0.7992, 2.92, 0.329, 292, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
1074, d2zm3B2, 0.7992, 2.97, 0.328, 295, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
1075, d5p9kA_, 0.7991, 2.52, 0.295, 271, 251, CRYSTAL STRUCTURE OF BTK WITH CNX 774
1076, d3blrA_, 0.7991, 2.88, 0.233, 300, 257, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
1077, d2zm3A2, 0.7991, 2.90, 0.328, 299, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
1078, d3iw4A_, 0.7990, 2.69, 0.251, 330, 255, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1079, d2xuuA_, 0.7990, 2.82, 0.242, 301, 256, CRYSTAL STRUCTURE OF A DAP-KINASE 1 MUTANT
1080, d3b8rB_, 0.7989, 2.17, 0.381, 267, 244, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
1081, d2ckeC_, 0.7989, 2.84, 0.230, 300, 257, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
1082, d5ng0A_, 0.7988, 2.20, 0.260, 274, 246, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
1083, d4o2pA_, 0.7988, 2.57, 0.343, 265, 251, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
1084, d3oxzA1, 0.7988, 2.19, 0.373, 267, 244, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN BOUND WITH A DFG-OUT INHIBITOR AP24534
1085, d5oy6D_, 0.7987, 2.99, 0.236, 292, 259, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
1086, d5nkeA_, 0.7986, 2.79, 0.328, 292, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3A
1087, d4rqvA_, 0.7986, 2.78, 0.206, 288, 257, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS2
1088, d3orxB_, 0.7986, 2.51, 0.207, 280, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1089, d3my0W1, 0.7986, 2.93, 0.252, 280, 258, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1090, d5dh3B_, 0.7985, 2.95, 0.226, 283, 257, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
1091, d4v05B_, 0.7985, 2.64, 0.397, 286, 252, FGFR1 IN COMPLEX WITH AZD4547.
1092, d4rj5A_, 0.7985, 2.49, 0.377, 296, 247, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 5
1093, d4mneG_, 0.7985, 2.19, 0.252, 259, 246, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1094, d4md7H_, 0.7985, 2.70, 0.223, 330, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1095, d3aglA_, 0.7985, 2.63, 0.237, 338, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
1096, d4rwlB_, 0.7984, 2.57, 0.402, 285, 251, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
1097, d2q0nA_, 0.7984, 2.83, 0.203, 293, 256, STRUCTURE OF HUMAN P21 ACTIVATING KINASE 4 (PAK4) IN COMPLEX WITH A CONSENSUS PEPTIDE
1098, d1re8A_, 0.7984, 2.67, 0.229, 337, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 2
1099, d5i9uA_, 0.7983, 2.57, 0.325, 281, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
1100, d4zlyA_, 0.7983, 2.53, 0.295, 270, 251, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE BOUND TO A CINNOLINE FRAGMENT
1101, d3aglB_, 0.7983, 2.69, 0.233, 335, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
1102, d1k9aF3, 0.7983, 2.44, 0.296, 264, 247, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
1103, d4l01B_, 0.7982, 2.49, 0.243, 274, 251, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
1104, d3byuA_, 0.7982, 2.30, 0.370, 256, 246, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE REVERSE AMIDE 23
1105, d2ckeB_, 0.7982, 2.84, 0.226, 300, 257, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
1106, d3uodA_, 0.7981, 2.70, 0.231, 266, 255, AURORA A IN COMPLEX WITH RPM1693
1107, d1bkxA_, 0.7981, 2.67, 0.233, 337, 253, A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY
1108, d5p9fA_, 0.7980, 2.41, 0.324, 266, 250, BTK IN COMPLEX WITH GDC-0834
1109, d4md7G_, 0.7980, 2.70, 0.223, 332, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1110, d4c7tA_, 0.7980, 2.43, 0.361, 259, 249, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
1111, d3en4A_, 0.7980, 1.90, 0.343, 257, 242, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
1112, d2ckeD_, 0.7980, 2.87, 0.222, 300, 257, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
1113, d1okyA_, 0.7980, 2.61, 0.209, 281, 253, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1114, d5ig1A_, 0.7979, 2.72, 0.247, 300, 255, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
1115, d5ftqA1, 0.7979, 2.62, 0.288, 292, 250, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH CMPD 17
1116, d4zlzA_, 0.7979, 2.52, 0.321, 270, 252, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH A SUBSTITUTED CINNOLINE
1117, d4xx9A_, 0.7979, 2.81, 0.202, 288, 257, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RF4
1118, d4md7F_, 0.7979, 2.70, 0.223, 332, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1119, d4hcuA_, 0.7979, 2.62, 0.280, 263, 250, CRYSTAL STRUCTURE OF ITK IN COMPLEXT WITH COMPOUND 40
1120, d4d4sA_, 0.7979, 2.07, 0.358, 255, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1121, d3lq8A_, 0.7979, 2.64, 0.333, 278, 249, STRUCTURE OF THE KINASE DOMAIN OF C-MET BOUND TO XL880 (GSK1363089)
1122, d2e2bB1, 0.7979, 2.44, 0.362, 258, 246, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
1123, d5ar5A_, 0.7978, 2.32, 0.266, 284, 248, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
1124, d4gg5A_, 0.7978, 2.81, 0.333, 274, 252, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
1125, d3zfxF_, 0.7978, 1.84, 0.333, 254, 240, CRYSTAL STRUCTURE OF EPHB1
1126, d2ijmA_, 0.7978, 2.17, 0.374, 260, 246, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
1127, d2ptkA3, 0.7977, 1.98, 0.354, 259, 243, CHICKEN SRC TYROSINE KINASE
1128, d5p9jA_, 0.7976, 2.66, 0.295, 263, 251, BTK1 COCRYSTALLIZED WITH IBRUTINIB
1129, d5d7vC1, 0.7976, 2.40, 0.333, 262, 249, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1130, d4fnyA_, 0.7976, 2.12, 0.318, 273, 242, CRYSTAL STRUCTURE OF THE R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
1131, d3lvpA_, 0.7976, 2.68, 0.308, 289, 253, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
1132, d5nkhA_, 0.7975, 2.88, 0.327, 295, 257, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3E
1133, d5j87B_, 0.7975, 2.50, 0.315, 274, 251, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1134, d5ia2A_, 0.7975, 2.68, 0.331, 287, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 66
1135, d4ot6A_, 0.7975, 2.46, 0.316, 265, 250, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4- METHANESULFONYL-N-(3-{8-[4-(MORPHOLINE-4-CARBONYL)-PHENYLAMINO]- IMIDAZO[12-A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
1136, d3qgwB_, 0.7975, 1.52, 0.328, 240, 235, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
1137, d2i0vA_, 0.7974, 2.53, 0.325, 303, 249, C-FMS TYROSINE KINASE IN COMPLEX WITH A QUINOLONE INHIBITOR
1138, d4anlA_, 0.7973, 2.58, 0.289, 292, 249, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE
1139, d3dtwA1, 0.7973, 2.14, 0.379, 281, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
1140, d5lvlA_, 0.7972, 2.69, 0.204, 285, 255, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND PS653 BOUND TO THE ATP-BINDING SITE
1141, d5edpA_, 0.7972, 2.44, 0.371, 295, 248, EGFR KINASE (T790M/L858R) APO
1142, d4mxxB_, 0.7972, 2.07, 0.336, 260, 244, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
1143, p4md9H_, 0.7972, 2.73, 0.227, 328, 256, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1144, d4mcvB_, 0.7972, 2.32, 0.315, 265, 248, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
1145, d4brxA_, 0.7972, 2.45, 0.357, 259, 249, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
1146, d4xi2A2, 0.7971, 2.43, 0.304, 274, 250, CRYSTAL STRUCTURE OF AN AUTO-INHIBITED FORM OF BRUTON S TRYROSINE KINASE
1147, d4deeA_, 0.7971, 2.73, 0.231, 271, 255, AURORA A IN COMPLEX WITH ADP
1148, d1uu7A_, 0.7971, 2.55, 0.206, 280, 252, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-2
1149, d1smhA_, 0.7971, 2.70, 0.237, 348, 253, PROTEIN KINASE A VARIANT COMPLEX WITH COMPLETELY ORDERED N- TERMINAL HELIX
1150, d3uo5A_, 0.7970, 2.70, 0.231, 267, 255, AURORA A IN COMPLEX WITH YL1-038-31
1151, d3q9xB_, 0.7970, 2.72, 0.223, 330, 256, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
1152, d2wd1A_, 0.7970, 2.97, 0.331, 289, 254, HUMAN C-MET KINASE IN COMPLEX WITH AZAINDOLE INHIBITOR
1153, d2a2aD_, 0.7970, 2.87, 0.222, 303, 257, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
1154, d4md7E_, 0.7969, 2.72, 0.223, 332, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1155, d4gu9B_, 0.7969, 2.51, 0.340, 255, 247, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
1156, d1rejA_, 0.7969, 2.69, 0.233, 333, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 1
1157, d1bx6A_, 0.7969, 2.68, 0.237, 337, 253, CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1158, d4rx5A1, 0.7968, 2.50, 0.316, 264, 250, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 23
1159, d4k8aB_, 0.7968, 2.39, 0.379, 258, 248, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
1160, d3gxjA_, 0.7968, 2.91, 0.227, 288, 255,  
1161, d2f7xE_, 0.7968, 2.73, 0.236, 336, 254, PROTEIN KINASE A BOUND TO (S)-2-(1H-INDOL-3-YL)-1-[5-((E)-2- PYRIDIN-4-YL-VINYL)-PYRIDIN-3-YLOXYMETHYL]-ETHYLAMINE
1162, d3iw4C_, 0.7967, 2.76, 0.246, 332, 256, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1163, d2ojfE_, 0.7967, 2.75, 0.232, 336, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1164, d2jkkA_, 0.7967, 2.39, 0.359, 258, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
1165, d5osdA_, 0.7966, 2.63, 0.229, 266, 253, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1166, d4zsaB_, 0.7966, 2.60, 0.402, 282, 251, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
1167, d4mcvA_, 0.7966, 2.43, 0.297, 267, 249, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
1168, d4hcvA_, 0.7966, 2.46, 0.305, 263, 249, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 53
1169, d4dgoA_, 0.7966, 2.73, 0.215, 325, 256, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH TYRPHOSTIN AG99
1170, d2f7zE_, 0.7966, 2.75, 0.232, 336, 254, PROTEIN KINASE A BOUND TO (R)-1-(1H-INDOL-3-YLMETHYL)-2-(2- PYRIDIN-4-YL-[17]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
1171, d1unlB_, 0.7966, 2.91, 0.219, 292, 256, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
1172, d1lp4A_, 0.7966, 2.74, 0.215, 327, 256, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 WITH MG-AMPPNP
1173, d5a4cB1, 0.7965, 2.64, 0.401, 284, 252, FGFR1 LIGAND COMPLEX
1174, d4l01A_, 0.7965, 2.47, 0.247, 274, 251, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
1175, d5p9gA_, 0.7964, 2.45, 0.316, 265, 250, STRUCTURE OF BTK WITH RN486
1176, d5d12A_, 0.7964, 2.17, 0.343, 260, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
1177, d4b4lA_, 0.7964, 2.84, 0.245, 299, 257, CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT
1178, d3f82A_, 0.7964, 2.18, 0.333, 278, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH N- (4-(2-AMINO-3-CHLOROPYRIDIN-4-YLOXY)-3-FLUOROPHENYL)-4- ETHOXY-1-(4-FLUOROPHENYL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
1179, d2yabA_, 0.7964, 2.65, 0.236, 299, 254, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
1180, d5hznH_, 0.7963, 2.85, 0.335, 303, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1181, d5hznD_, 0.7963, 2.85, 0.335, 304, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1182, d5d7vB1, 0.7963, 2.42, 0.333, 262, 249, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1183, d4wnoA_, 0.7963, 2.73, 0.247, 272, 255, STRUCTURE OF ULK1 BOUND TO AN INHIBITOR
1184, d4imyA_, 0.7963, 2.96, 0.245, 314, 257, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
1185, d2uztA_, 0.7963, 2.77, 0.232, 336, 254, PKA STRUCTURES OF AKT INDAZOLE-PYRIDINE INHIBITORS
1186, d1dawA_, 0.7963, 2.73, 0.215, 327, 256, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP
1187, d1agwB_, 0.7963, 2.65, 0.398, 272, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
1188, d5dg5A_, 0.7962, 2.60, 0.329, 297, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
1189, p4md9G_, 0.7962, 2.74, 0.227, 329, 256, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1190, p4md8H_, 0.7962, 2.74, 0.223, 331, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1191, d4ludA3, 0.7962, 2.14, 0.366, 261, 243, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
1192, d3idcA_, 0.7962, 2.72, 0.225, 341, 253, CRYSTAL STRUCTURE OF (102-265)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
1193, d2f7eE_, 0.7962, 2.76, 0.232, 336, 254, PKA COMPLEXED WITH (S)-2-(1H-INDOL-3-YL)-1-(5-ISOQUINOLIN-6- YL-PYRIDIN-3-YLOXYMETHYL-ETYLAMINE
1194, d5m56A_, 0.7961, 2.75, 0.215, 331, 256, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1195, d4lueA3, 0.7961, 2.15, 0.365, 261, 244, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
1196, d3wilA_, 0.7961, 2.78, 0.207, 331, 256, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND3 COMPLEX
1197, d3qlgB_, 0.7961, 2.11, 0.332, 260, 244, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
1198, d3ocsA1, 0.7961, 2.48, 0.305, 262, 249, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI1746
1199, d3at4A_, 0.7961, 2.77, 0.219, 331, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVERTIVE
1200, d2a2aC_, 0.7961, 2.88, 0.222, 303, 257, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
1201, d5h8eA_, 0.7960, 2.73, 0.227, 331, 256, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
1202, p4md8F_, 0.7960, 2.74, 0.223, 332, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1203, d4v04B_, 0.7959, 2.52, 0.394, 287, 249, FGFR1 IN COMPLEX WITH PONATINIB.
1204, p4md8G_, 0.7959, 2.74, 0.223, 332, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1205, d4dgnA_, 0.7959, 2.73, 0.215, 325, 256, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR LUTEOLIN
1206, d3qa0B_, 0.7959, 2.74, 0.223, 330, 256, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
1207, d3d4qB_, 0.7959, 2.38, 0.270, 264, 248, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
1208, d2yaaA_, 0.7959, 2.71, 0.235, 300, 255, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
1209, d2uzvA_, 0.7959, 2.77, 0.232, 336, 254, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1210, d2jkqA_, 0.7959, 2.26, 0.370, 258, 246, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
1211, d5ku8B_, 0.7958, 2.78, 0.223, 331, 256, CRYSTAL STRUCTURE OF CK2
1212, p4nh1B_, 0.7958, 2.76, 0.223, 332, 256, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
1213, d4ks8A_, 0.7958, 2.83, 0.238, 286, 256, PAK6 KINASE DOMAIN IN COMPLEX WITH SUNITINIB
1214, d2yhvA_, 0.7958, 2.59, 0.309, 291, 249, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE
1215, d5ew3B_, 0.7957, 2.13, 0.384, 266, 242, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
1216, d5bpyA1, 0.7957, 2.42, 0.306, 262, 248, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
1217, d5ackA_, 0.7957, 2.76, 0.199, 286, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND 7 BOUND TO THE PIF-POCKET
1218, d4otqA_, 0.7957, 2.42, 0.306, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 1-[5-[3-(7-TERT- BUTYL-4-OXO-QUINAZOLIN-3-YL)-2-METHYL-PHENYL]-1-METHYL-2-OXO-3- PYRIDYL]-3-METHYL-UREA
1219, d3zfxB_, 0.7957, 2.02, 0.332, 254, 241, CRYSTAL STRUCTURE OF EPHB1
1220, d3iw4B_, 0.7957, 2.70, 0.248, 325, 254, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1221, d3e8eA_, 0.7957, 2.73, 0.233, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1222, d3d4qA_, 0.7957, 2.39, 0.270, 264, 248, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
1223, p2pvnA_, 0.7957, 2.73, 0.207, 327, 256, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1224, d1q61A_, 0.7957, 2.74, 0.237, 335, 253, PKA TRIPLE MUTANT MODEL OF PKB
1225, d1h1pC1, 0.7957, 2.78, 0.256, 295, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
1226, d5os5A_, 0.7956, 2.64, 0.229, 267, 253, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1227, d4wnpA_, 0.7956, 2.72, 0.247, 273, 255, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
1228, d3oxtA_, 0.7956, 2.74, 0.233, 335, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1229, d3f3tB_, 0.7956, 2.12, 0.337, 259, 243, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
1230, d1xhaA_, 0.7956, 2.71, 0.241, 348, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1231, d1xh8A_, 0.7956, 2.71, 0.237, 337, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1232, d1fvrB_, 0.7956, 2.82, 0.343, 300, 254, TIE2 KINASE DOMAIN
1233, d5i9yA_, 0.7955, 2.92, 0.335, 287, 254, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DASATINIB
1234, d4r1vA_, 0.7955, 3.01, 0.331, 289, 254, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITORS
1235, p4nh1A_, 0.7955, 2.77, 0.223, 330, 256, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
1236, p4md9M_, 0.7955, 2.75, 0.223, 331, 256, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1237, d3fzpA_, 0.7955, 2.13, 0.362, 259, 243, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH ATPGS
1238, d5eycA_, 0.7954, 2.90, 0.333, 288, 252, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH NAPHTHYRIDINONE INHIBITOR 5
1239, d3zfxG_, 0.7954, 1.91, 0.333, 253, 240, CRYSTAL STRUCTURE OF EPHB1
1240, d3warA_, 0.7954, 2.76, 0.227, 334, 256, CRYSTAL STRUCTURE OF HUMAN CK2A
1241, d3up2A_, 0.7954, 2.74, 0.212, 266, 255, AURORA A IN COMPLEX WITH RPM1686
1242, p3u9cB_, 0.7954, 2.76, 0.227, 331, 256, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
1243, d5b7vA_, 0.7953, 2.52, 0.390, 282, 249, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
1244, d4wnpD_, 0.7953, 2.74, 0.247, 272, 255, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
1245, d4rqkA_, 0.7953, 2.71, 0.200, 285, 255, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS1
1246, d4rfyA_, 0.7953, 2.43, 0.306, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(MORPHOLINE-4- CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-34- DIHYDROISOQUINOLIN-1-ONE
1247, d4f1oA1, 0.7953, 2.77, 0.264, 274, 254, CRYSTAL STRUCTURE OF THE L1180T MUTANT ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO APPCP
1248, d4dgmA_, 0.7953, 2.74, 0.215, 326, 256, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR APIGENIN
1249, d4deaA_, 0.7953, 2.74, 0.212, 266, 255, AURORA A IN COMPLEX WITH YL1-038-18
1250, d3wj6A_, 0.7953, 2.52, 0.390, 282, 249,  
1251, d1snuB_, 0.7953, 1.70, 0.321, 241, 237, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1252, d1sm2A_, 0.7953, 1.81, 0.318, 245, 239, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1253, d5u9dA_, 0.7952, 2.56, 0.313, 271, 252, DISCOVERY OF A POTENT BTK INHIBITOR WITH A NOVEL BINDING MODE USING PARALLEL SELECTIONS WITH A DNA-ENCODED CHEMICAL LIBRARY
1254, d5p9iA_, 0.7952, 2.55, 0.303, 271, 251, BTK1 SOAKED WITH IBRUTINIB-REV
1255, p4md9F_, 0.7952, 2.78, 0.219, 327, 256, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1256, d3fhiA_, 0.7952, 2.71, 0.233, 336, 253, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE CATALYTIC AND REGULATORY (RI{ALPHA}) SUBUNITS OF PKA
1257, d2yabB_, 0.7952, 2.63, 0.232, 299, 254, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
1258, d1stcE_, 0.7952, 2.70, 0.245, 334, 253, CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE
1259, d1jwhB_, 0.7952, 2.75, 0.227, 335, 256, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
1260, d1dayA_, 0.7952, 2.75, 0.215, 327, 256, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP
1261, p5n9nA_, 0.7951, 2.76, 0.219, 329, 256, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF85 (4A)
1262, d5hu3A_, 0.7951, 2.61, 0.227, 266, 251, DROSOPHILA CAMKII-D136N IN COMPLEX WITH A PHOSPHORYLATED FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
1263, d4xcuA1, 0.7951, 2.78, 0.387, 287, 253, CRYSTAL STRUCTURE OF FGFR4 WITH AN IRREVERSIBLE INHIBITOR
1264, d4o0vA1, 0.7951, 2.81, 0.215, 289, 256, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1265, p3u9cA_, 0.7951, 2.78, 0.227, 331, 256, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
1266, d3ppkB_, 0.7951, 2.38, 0.270, 264, 248, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
1267, d3ms9A1, 0.7951, 2.46, 0.362, 261, 246, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
1268, d2uzuE_, 0.7951, 2.77, 0.232, 336, 254, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1269, d2helA_, 0.7951, 2.51, 0.312, 256, 247, CRYSTAL STRUCTURE OF A MUTANT EPHA4 KINASE DOMAIN (Y742A)
1270, d1q62A_, 0.7951, 2.74, 0.237, 336, 253, PKA DOUBLE MUTANT MODEL OF PKB
1271, d5d7vA1, 0.7950, 2.43, 0.333, 262, 249, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1272, d3mpmA_, 0.7950, 2.23, 0.354, 257, 246, LCK COMPLEXED WITH A PYRAZOLOPYRIMIDINE
1273, d2xikA_, 0.7950, 2.67, 0.253, 288, 253, STRUCTURE OF HUMAN YSK1 (YEAST SPS1-STE20-RELATED KINASE 1)
1274, d2oh0E_, 0.7950, 2.76, 0.240, 336, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1275, d1u7eA_, 0.7950, 2.72, 0.233, 338, 253,  
1276, p5otyA_, 0.7949, 2.80, 0.227, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712
1277, d5mohA_, 0.7949, 2.79, 0.227, 326, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0583 BOUND.
1278, d5j87A_, 0.7949, 2.43, 0.306, 263, 248, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1279, d4jdiA_, 0.7949, 2.83, 0.215, 289, 256, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
1280, d4cmtA_, 0.7949, 2.45, 0.321, 284, 246, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(3-(METHYLSULFONYL)PHENYL)PYRIDIN-2-AMINE
1281, d3a4pA_, 0.7949, 2.74, 0.332, 285, 250, HUMAN C-MET KINASE DOMAIN COMPLEXED WITH 6-BENZYLOXYQUINOLINE INHIBITOR
1282, d1vebA_, 0.7949, 2.73, 0.237, 338, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 5
1283, d1sm2B_, 0.7949, 1.62, 0.322, 241, 236, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1284, d5nkgA_, 0.7948, 2.85, 0.328, 292, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3D
1285, d5ku8A_, 0.7948, 2.78, 0.223, 328, 256, CRYSTAL STRUCTURE OF CK2
1286, p4md9L_, 0.7948, 2.66, 0.213, 328, 253, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1287, d4f64B_, 0.7948, 2.67, 0.398, 272, 251, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
1288, d3v5lD1, 0.7948, 2.00, 0.317, 244, 240, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
1289, d3uqfA_, 0.7948, 1.99, 0.342, 260, 243, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
1290, d3rhxB_, 0.7948, 2.67, 0.398, 275, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
1291, d3dtwB_, 0.7948, 2.37, 0.380, 269, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
1292, d3at3A_, 0.7948, 2.79, 0.219, 332, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVATIVE
1293, d2uzwE_, 0.7948, 2.78, 0.232, 336, 254, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1294, d2oxdA_, 0.7948, 2.74, 0.215, 325, 256, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE K17 K22 AND K32 INHIBITORS
1295, d2a2aB_, 0.7948, 2.87, 0.226, 303, 257, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
1296, d5bmsA1, 0.7947, 2.87, 0.207, 289, 256, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 4 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
1297, d3thbA_, 0.7947, 2.81, 0.264, 287, 254, STRUCTURE OF PLK1 KINASE DOMAIN IN COMPLEX WITH A BENZOLACTAM-DERIVED INHIBITOR
1298, d2eufB_, 0.7947, 2.84, 0.255, 282, 255, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
1299, d1fgkB_, 0.7947, 2.66, 0.398, 272, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
1300, d5edrA_, 0.7946, 2.41, 0.377, 299, 247, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 27: ~{N}-(1~{H}- INDAZOL-3-YL)-77-DIMETHYL-2-(2-METHYLPYRAZOL-3-YL)-5~{H}-FURO[34- D]PYRIMIDIN-4-AMINE
1301, d5d7vD1, 0.7946, 2.45, 0.333, 262, 249, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1302, d5cu3B_, 0.7946, 2.84, 0.219, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1303, d4yxrA_, 0.7946, 2.74, 0.233, 334, 253, CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH INHIBITOR.
1304, d4pp9A1, 0.7946, 1.84, 0.318, 245, 239, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
1305, p4md8E_, 0.7946, 2.78, 0.223, 332, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1306, d3pxkA_, 0.7946, 2.18, 0.343, 256, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
1307, d3oogA_, 0.7946, 2.74, 0.233, 333, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH A SMALL FRAGMENT
1308, d1jluE_, 0.7946, 2.74, 0.229, 337, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PHOSPHORYLATED SUBSTRATE PEPTIDE AND DETERGENT
1309, d5h8eB_, 0.7945, 2.78, 0.227, 331, 256, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
1310, d4dymA_, 0.7945, 3.00, 0.245, 293, 257, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00135
1311, d3u87A_, 0.7945, 2.79, 0.227, 329, 256, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
1312, d3mssB1, 0.7945, 2.52, 0.358, 260, 246, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
1313, d3e8eP_, 0.7945, 2.73, 0.233, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1314, d3e8cA_, 0.7945, 2.72, 0.233, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1315, d2y7jA_, 0.7945, 2.62, 0.217, 284, 253, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1316, d1zogA_, 0.7945, 2.74, 0.215, 325, 256, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES
1317, d1svgA_, 0.7945, 2.74, 0.237, 338, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 4
1318, p5owlB_, 0.7944, 2.75, 0.227, 332, 256, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
1319, d5motA_, 0.7944, 2.79, 0.223, 328, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0627 BOUND
1320, d5mo8A_, 0.7944, 2.84, 0.219, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1321, d5eydA_, 0.7944, 2.85, 0.339, 289, 251, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH AMG 337
1322, d4riyC_, 0.7944, 2.84, 0.335, 275, 254, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
1323, d4mneC_, 0.7944, 2.34, 0.255, 260, 247, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1324, p4md9P_, 0.7944, 2.79, 0.223, 328, 256, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1325, d4h58A_, 0.7944, 2.42, 0.266, 263, 248, BRAF IN COMPLEX WITH COMPOUND 3
1326, d3e8eL_, 0.7944, 2.73, 0.233, 336, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1327, d3e8cC_, 0.7944, 2.72, 0.233, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1328, d2ijmB_, 0.7944, 2.36, 0.370, 261, 246, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
1329, d1wvxA_, 0.7944, 2.67, 0.249, 275, 253, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
1330, d4ubaA_, 0.7943, 2.78, 0.227, 333, 256, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
1331, d4rixC_, 0.7943, 2.84, 0.335, 275, 254, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
1332, d3wowA_, 0.7943, 2.80, 0.219, 334, 256, CRYSTAL STRUCTURE OF HUMAN CK2A WITH AMPPNP
1333, d3miaA_, 0.7943, 3.05, 0.243, 324, 259, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
1334, d3e8eB_, 0.7943, 2.64, 0.234, 337, 252, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1335, d2p2iB_, 0.7943, 2.18, 0.373, 263, 241, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
1336, d2oxyA_, 0.7943, 2.64, 0.209, 327, 253, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
1337, d1sveA_, 0.7943, 2.74, 0.237, 341, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 1
1338, d5vgoA1, 0.7942, 2.61, 0.304, 264, 250, BRUTON S TYROSINE KINASE (BTK) WITH COMPOUND G-744
1339, d5kupA1, 0.7942, 2.64, 0.296, 264, 250, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 9
1340, d4degA_, 0.7942, 2.89, 0.335, 286, 251, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDAZINE INHIBITOR 2
1341, d3mssD1, 0.7942, 2.51, 0.362, 260, 246, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
1342, d3mssA1, 0.7942, 2.48, 0.358, 260, 246, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
1343, d3e8cF_, 0.7942, 2.73, 0.233, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1344, d3dneA_, 0.7942, 2.73, 0.241, 336, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1345, d2yaaB_, 0.7942, 2.66, 0.236, 299, 254, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
1346, d1svhA_, 0.7942, 2.74, 0.237, 335, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 8
1347, d1snuA_, 0.7942, 1.82, 0.318, 245, 239, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1348, d5mo7A_, 0.7941, 2.82, 0.219, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1349, d5ig1B_, 0.7941, 2.79, 0.247, 304, 255, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
1350, d5bvwA_, 0.7941, 2.40, 0.369, 274, 249, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
1351, d4v05A_, 0.7941, 2.70, 0.397, 287, 252, FGFR1 IN COMPLEX WITH AZD4547.
1352, p4md9K_, 0.7941, 2.77, 0.219, 328, 256, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1353, d4deiA_, 0.7941, 2.87, 0.333, 287, 252, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 24
1354, d3e8cE_, 0.7941, 2.73, 0.233, 336, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1355, d2vx0A_, 0.7941, 2.90, 0.304, 273, 253, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1356, d1jamA_, 0.7941, 2.78, 0.211, 327, 256, CRYSTAL STRUCTURE OF APO-FORM OF Z. MAYS CK2 PROTEIN KINASE ALPHA SUBUNIT
1357, d5tehB_, 0.7940, 2.16, 0.344, 262, 244, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
1358, p5n9kA_, 0.7940, 2.77, 0.219, 329, 256, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF107 (5)
1359, d5mo7B_, 0.7940, 2.81, 0.219, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1360, d5kwhB_, 0.7940, 2.78, 0.227, 331, 256, CRYSTAL STRUCTURE OF CK2
1361, d5h8bB_, 0.7940, 2.80, 0.223, 331, 256, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
1362, d5cu3A_, 0.7940, 2.85, 0.219, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1363, d5cu2A_, 0.7940, 2.84, 0.219, 328, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
1364, d4riwC_, 0.7940, 2.85, 0.327, 275, 254, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
1365, d4o22A1, 0.7940, 2.69, 0.234, 333, 252, BINARY COMPLEX OF METAL-FREE PKAC WITH SP20.
1366, d3v8tB1, 0.7940, 1.82, 0.319, 242, 238, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
1367, d3mssC1, 0.7940, 2.49, 0.358, 260, 246, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
1368, d3e8cD_, 0.7940, 2.73, 0.233, 344, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1369, d2y7jC_, 0.7940, 2.72, 0.197, 284, 254, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1370, d2qu6A1, 0.7940, 2.05, 0.383, 276, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
1371, d2ogvA_, 0.7940, 2.73, 0.331, 317, 251, CRYSTAL STRUCTURE OF THE AUTOINHIBITED HUMAN C-FMS KINASE DOMAIN
1372, d1snxA_, 0.7940, 1.82, 0.318, 245, 239, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1373, d1rekA_, 0.7940, 2.73, 0.229, 336, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 8
1374, d4otrA_, 0.7939, 2.46, 0.306, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-CYCLOPROPYL-2- [3-[5-[[5-(4-ETHYLPIPERAZIN-1-YL)-2-PYRIDYL]AMINO]-1-METHYL-6-OXO-3- PYRIDYL]-2-(HYDROXYMETHYL)PHENYL]-8-FLUORO-ISOQUINOLIN-1-ONE
1375, d4o0yA1, 0.7939, 2.94, 0.214, 289, 257, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1376, p4md9E_, 0.7939, 2.80, 0.215, 329, 256, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1377, d4c3fA_, 0.7939, 2.24, 0.354, 257, 246, STRUCTURE OF LCK IN COMPLEX WITH A COMPOUND DISCOVERED BY VIRTUAL FRAGMENT LINKING
1378, d3e8cB_, 0.7939, 2.73, 0.233, 344, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1379, d2y7jB_, 0.7939, 2.70, 0.213, 281, 253, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1380, d2vx1A_, 0.7939, 2.82, 0.290, 274, 252, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1381, d2rfsA_, 0.7939, 2.66, 0.335, 264, 248, X-RAY STRUCTURE OF SU11274 BOUND TO C-MET
1382, d5mmrA_, 0.7938, 2.82, 0.219, 326, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
1383, d5hngA_, 0.7938, 2.58, 0.211, 280, 251, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1384, d5h2uC1, 0.7938, 2.47, 0.333, 261, 249, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1385, d4wnpC_, 0.7938, 2.71, 0.252, 271, 254, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
1386, d4nksB_, 0.7938, 2.62, 0.396, 271, 250, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
1387, d3u87B_, 0.7938, 2.77, 0.227, 329, 256, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
1388, d3tnpF_, 0.7938, 2.69, 0.230, 334, 252, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1389, d3tnpC_, 0.7938, 2.69, 0.230, 334, 252, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1390, d3kxmA_, 0.7938, 2.75, 0.215, 326, 256, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR K74
1391, d3g0eA1, 0.7938, 2.55, 0.348, 330, 250, KIT KINASE DOMAIN IN COMPLEX WITH SUNITINIB
1392, d3b8rA1, 0.7938, 2.13, 0.384, 282, 242, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
1393, d2vwyA_, 0.7938, 2.83, 0.304, 274, 253, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1394, d1jbpE_, 0.7938, 2.74, 0.229, 339, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE COMPLEXED WITH A SUBSTRATE PEPTIDE ADP AND DETERGENT
1395, d4v01B_, 0.7937, 2.39, 0.390, 275, 246, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
1396, d4f1mA1, 0.7937, 2.84, 0.247, 274, 255, CRYSTAL STRUCTURE OF THE G1179S ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM.
1397, d3wikA_, 0.7937, 2.80, 0.211, 334, 256, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND10 COMPLEX
1398, d3ow3A_, 0.7937, 2.75, 0.233, 334, 253, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1399, d5j87D_, 0.7936, 2.43, 0.306, 263, 248, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1400, d4o0xA1, 0.7936, 2.80, 0.219, 289, 256, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1401, d4jajA_, 0.7936, 2.69, 0.228, 265, 254, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH BENZO[C][1 8]NAPHTHYRIDIN-6(5H)-ONE
1402, d4ii5C_, 0.7936, 2.62, 0.255, 295, 251, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
1403, d3qhwA1, 0.7936, 2.77, 0.256, 295, 254, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1404, d3g5dB_, 0.7936, 2.09, 0.333, 257, 243, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
1405, d3el8B_, 0.7936, 2.12, 0.346, 259, 243, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
1406, d3e8eE_, 0.7936, 2.73, 0.233, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1407, d3cpcB_, 0.7936, 2.15, 0.378, 262, 241, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
1408, d2vo7A_, 0.7936, 2.76, 0.237, 335, 253, STRUCTURE OF PKA COMPLEXED WITH 4-(4-CHLOROBENZYL)-1-(7H- PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN-4-YLAMINE
1409, d2gnfA_, 0.7936, 2.74, 0.241, 339, 253, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH Y- 27632
1410, d5wr7A_, 0.7935, 2.67, 0.382, 301, 249, CRYSTAL STRUCTURE OF TRK-A COMPLEXED WITH A SELECTIVE INHIBITOR CH7057288
1411, d5vedA_, 0.7935, 2.80, 0.215, 289, 256, PAK4 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1412, d5nk5A_, 0.7935, 2.73, 0.328, 287, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1M
1413, d5h8bA_, 0.7935, 2.76, 0.227, 331, 256, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
1414, d5h2uA1, 0.7935, 2.46, 0.333, 261, 249, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1415, d5b7vB_, 0.7935, 2.45, 0.395, 277, 248, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
1416, d4ymjA1, 0.7935, 2.40, 0.401, 267, 247, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
1417, d4nwmB_, 0.7935, 2.34, 0.320, 261, 247, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
1418, d3wj6B_, 0.7935, 2.45, 0.395, 277, 248,  
1419, d3pe1A_, 0.7935, 2.79, 0.219, 327, 256, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-4945
1420, d3mi9A_, 0.7935, 3.04, 0.243, 328, 259, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
1421, d3fjqE_, 0.7935, 2.76, 0.229, 334, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA IN COMPLEX WITH PEPTIDE INHIBITOR PKI ALPHA (6-25)
1422, d3eknA_, 0.7935, 2.96, 0.316, 297, 256, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
1423, d2zjwA_, 0.7935, 2.68, 0.213, 332, 253, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH ELLAGIC ACID
1424, d2vwzA_, 0.7935, 2.83, 0.290, 274, 252, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1425, d5j79A_, 0.7934, 2.36, 0.267, 283, 247, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
1426, d4ot5A_, 0.7934, 2.50, 0.298, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4-TERT-BUTYL-N- (3-{8-[4-(4-METHYL-PIPERAZINE-1-CARBONYL)-PHENYLAMINO]-IMIDAZO[12- A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
1427, d4i3zC_, 0.7934, 2.63, 0.255, 295, 251, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
1428, d4i3zA_, 0.7934, 2.63, 0.255, 295, 251, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
1429, d3qamE_, 0.7934, 2.75, 0.225, 348, 253, CRYSTAL STRUCTURE OF GLU208ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1430, d3mb6A_, 0.7934, 2.82, 0.223, 329, 256, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (CPA)
1431, d3gqlA_, 0.7934, 2.69, 0.393, 287, 252, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
1432, d3axwA_, 0.7934, 2.80, 0.215, 329, 256, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA COMPLEXED WITH A POTENT INHIBITOR
1433, d2vn9B_, 0.7934, 2.59, 0.225, 301, 253, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
1434, d2jdtA_, 0.7934, 2.75, 0.237, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1435, d5h2uB1, 0.7933, 2.48, 0.333, 261, 249, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1436, d5cu4A_, 0.7933, 2.74, 0.213, 327, 253, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1437, d5clpB_, 0.7933, 2.83, 0.219, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
1438, d4x6qC_, 0.7933, 2.69, 0.230, 334, 252, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
1439, d4o21A_, 0.7933, 2.70, 0.234, 333, 252, PRODUCT COMPLEX OF METAL-FREE PKAC ATP-GAMMA-S AND SP20.
1440, p4gubA_, 0.7933, 2.81, 0.219, 329, 256, CASEIN KINASE II BOUND TO INHIBITOR
1441, d3qhwC1, 0.7933, 2.77, 0.256, 295, 254, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1442, d3oezA_, 0.7933, 2.26, 0.335, 261, 245, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
1443, d3at2A_, 0.7933, 2.78, 0.227, 334, 256, CRYSTAL STRUCTURE OF CK2ALPHA
1444, d2gngA_, 0.7933, 2.74, 0.237, 338, 253, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE
1445, d1agwA_, 0.7933, 2.67, 0.378, 278, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
1446, p5n9lA_, 0.7932, 2.81, 0.215, 329, 256, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE DIBENZOFURAN INHIBITOR TF (4B)
1447, d4yo4A1, 0.7932, 2.64, 0.250, 276, 252, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT PHTHALAZINE
1448, d4ymjB1, 0.7932, 2.40, 0.401, 272, 247, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
1449, d2c1aA_, 0.7932, 2.75, 0.237, 335, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
1450, d1snxB_, 0.7932, 1.83, 0.318, 245, 239, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1451, d1m2rA_, 0.7932, 2.77, 0.211, 327, 256, CRYSTAL STRUCTURE OF 58-DI-AMINO-14-DI-HYDROXY- ANTHRAQUINONE/CK2 KINASE COMPLEX
1452, d5nkfA_, 0.7931, 2.80, 0.329, 291, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3B
1453, d5m4cA_, 0.7931, 2.66, 0.217, 329, 253, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER LOW-SALT CONDITIONS
1454, d4xyfA_, 0.7931, 2.82, 0.323, 290, 251, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (S)-5-(8-FLUORO-3-(1-(3-(2- METHOXYETHOXY)QUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43-A]PYRIDIN-6- YL)-3-METHYLISOXAZOLE
1455, d4rwlA_, 0.7931, 2.56, 0.394, 282, 249, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
1456, d4rg0A_, 0.7931, 2.51, 0.298, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[8-FLUORO-2- [2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(4-METHYLPIPERAZIN-1-YL)-2- PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-1-OXO-34-DIHYDROISOQUINOLIN- 6-YL]-2-METHYL-PROPANENITRILE
1457, d3mj2A_, 0.7931, 2.33, 0.309, 259, 246, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR BMS-509744
1458, d2vn9A_, 0.7931, 2.59, 0.225, 301, 253, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
1459, d2uvxA_, 0.7931, 2.76, 0.237, 335, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 7-AZAINDOLE
1460, d2gcdB_, 0.7931, 2.79, 0.241, 308, 253, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1461, d1apmE_, 0.7931, 2.77, 0.229, 338, 253, 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT
1462, d5mmfA_, 0.7930, 2.86, 0.219, 326, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
1463, d5kwhA_, 0.7930, 2.79, 0.227, 331, 256, CRYSTAL STRUCTURE OF CK2
1464, d5b0xA_, 0.7930, 2.80, 0.211, 329, 256, CRYSTAL STRUCTURE OF THE CK2A/BENZOIC ACID DERIVATIVE COMPLEX
1465, d3u4wA_, 0.7930, 2.72, 0.310, 275, 252, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC4B
1466, d3pe2A_, 0.7930, 2.80, 0.215, 327, 256, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR CX-5011
1467, d3idbA_, 0.7930, 2.77, 0.225, 341, 253, CRYSTAL STRUCTURE OF (108-268)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
1468, d1rjbA_, 0.7930, 2.60, 0.367, 298, 248, CRYSTAL STRUCTURE OF FLT3
1469, d1ds5A_, 0.7930, 2.78, 0.211, 328, 256, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1470, d5t1hB_, 0.7929, 2.82, 0.227, 331, 256, CRYSTAL STRUCTURE OF CK2
1471, d4ypdA1, 0.7929, 2.65, 0.250, 276, 252, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT 4-METHYLPYRIDAZINE
1472, d4yhtB_, 0.7929, 2.35, 0.271, 258, 247, BRAF COMPLEXED WITH AN INHIBITOR
1473, d4fnwA_, 0.7929, 2.64, 0.317, 304, 249, CRYSTAL STRUCTURE OF THE APO F1174L ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
1474, d4f63A_, 0.7929, 2.68, 0.378, 278, 251, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
1475, d4dehA_, 0.7929, 2.76, 0.336, 286, 250, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 3
1476, d3q9zB_, 0.7929, 2.78, 0.223, 332, 256, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1477, d2qc6A_, 0.7929, 2.77, 0.211, 326, 256, PROTEIN KINASE CK2 IN COMPLEX WITH DBC
1478, d1fvrA_, 0.7929, 2.80, 0.344, 299, 253, TIE2 KINASE DOMAIN
1479, d5nk7A_, 0.7928, 2.67, 0.332, 284, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2A
1480, d5lpvA_, 0.7928, 2.59, 0.229, 282, 249, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH AMPPNP AND MN FROM ARABIDOPSIS THALIANA
1481, d5h2uD1, 0.7928, 2.49, 0.333, 261, 249, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1482, d5ct0A_, 0.7928, 2.85, 0.219, 326, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
1483, d4rfzA_, 0.7928, 2.51, 0.298, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-8-FLUORO-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5- (MORPHOLINE-4-CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3- PYRIDYL]PHENYL]ISOQUINOLIN-1-ONE
1484, p4ib5C_, 0.7928, 2.82, 0.223, 332, 256, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1485, d4b6lA_, 0.7928, 2.83, 0.248, 281, 254, DISCOVERY OF ORAL POLO-LIKE KINASE (PLK) INHIBITORS WITH ENHANCED SELECTIVITY PROFILE USING RESIDUE TARGETED DRUG DESIGN
1486, d3l9nA_, 0.7928, 2.73, 0.241, 332, 253, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 27
1487, d3kxgA_, 0.7928, 2.77, 0.215, 326, 256, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 34567-PENTABROMO-1H-INDAZOLE (K64)
1488, d2c1bA_, 0.7928, 2.77, 0.237, 335, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ( 4R2S)-5 -(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2- YLMETHANESULFONYL)ISOQUINOLINE
1489, d1rdqE_, 0.7928, 2.77, 0.229, 340, 253, HYDROLYSIS OF ATP IN THE CRYSTAL OF Y204A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
1490, d1m2qA_, 0.7928, 2.79, 0.211, 327, 256, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO-XANTEN-9- ONE/CK2 KINASE COMPLEX
1491, d1ds5C_, 0.7928, 2.79, 0.211, 328, 256, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1492, d5vefA_, 0.7927, 2.81, 0.204, 289, 255, PAK4 KINASE DOMAIN IN COMPLEX WITH FASUDIL
1493, d5cu0A_, 0.7927, 2.85, 0.219, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1494, d3ngaA_, 0.7927, 2.79, 0.227, 331, 256, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
1495, d3bysA_, 0.7927, 2.28, 0.369, 255, 244, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE AMIDE 10B
1496, p2pvhA_, 0.7927, 2.78, 0.211, 327, 256, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1497, d1xh5A_, 0.7927, 2.76, 0.241, 335, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1498, d1fgkA_, 0.7927, 2.68, 0.378, 278, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
1499, d5cx9A_, 0.7926, 2.86, 0.219, 328, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
1500, d4rlkA_, 0.7926, 2.78, 0.211, 327, 256, CRYSTAL STRUCTURE OF Z. MAYS CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
1501, d4aojA_, 0.7926, 2.34, 0.355, 260, 245, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
1502, d3ngaB_, 0.7926, 2.79, 0.227, 331, 256, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
1503, p3be9A_, 0.7926, 2.79, 0.211, 327, 256, STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC PYRAZOLO[15-A] [135]TRIAZINE COMPOUNDS AS POTENT INHIBITORS OF PROTEIN KINASE CK2 AND THEIR ANTICANCER ACTIVITIES
1504, d3agmA_, 0.7926, 2.74, 0.237, 337, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-670
1505, d2uw8A_, 0.7926, 2.72, 0.238, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-CHLORO- PHENYL)-2-PHENYL-ETHYLAMINE
1506, d1ydsE_, 0.7926, 2.76, 0.229, 334, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H8 PROTEIN KINASE INHIBITOR [N-(2-METHYLAMINO)ETHYL]-5- ISOQUINOLINESULFONAMIDE
1507, d1xh9A_, 0.7926, 2.77, 0.245, 336, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1508, d5mo8B_, 0.7925, 2.84, 0.219, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1509, d5mo5A_, 0.7925, 2.86, 0.219, 326, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1510, d3nrmA_, 0.7925, 2.67, 0.229, 263, 253, IMIDAZO[12-A]PYRAZINE-BASED AURORA KINASE INHIBITORS
1511, d1ydrE_, 0.7925, 2.75, 0.229, 334, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5- ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
1512, d1q24A_, 0.7925, 2.78, 0.229, 335, 253, PKA DOUBLE MUTANT MODEL OF PKB IN COMPLEX WITH MGATP
1513, d4tyjA1, 0.7924, 2.59, 0.398, 275, 246, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
1514, d4f64A_, 0.7924, 2.69, 0.378, 278, 251, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
1515, d2vwxA_, 0.7924, 2.84, 0.290, 274, 252, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1516, d2fgiA_, 0.7924, 2.63, 0.380, 274, 250, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
1517, d1ydtE_, 0.7924, 2.78, 0.229, 334, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2- (4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE
1518, d5t1hA_, 0.7923, 2.80, 0.227, 331, 256, CRYSTAL STRUCTURE OF CK2
1519, d4f63B_, 0.7923, 2.67, 0.396, 271, 250, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
1520, d2erzE_, 0.7923, 2.76, 0.229, 334, 253, CRYSTAL STRUCTURE OF C-AMP DEPENDENT KINASE (PKA) BOUND TO HYDROXYFASUDIL
1521, d1h1pA1, 0.7923, 2.82, 0.256, 295, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
1522, d5ek7B_, 0.7922, 2.60, 0.332, 286, 250, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
1523, d5dh3A_, 0.7922, 3.00, 0.223, 287, 256, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
1524, p3e3bX_, 0.7922, 2.86, 0.211, 334, 256, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2ALPHA PRIME WITH A POTENT INDAZOLE-DERIVATIVE INHIBITOR
1525, d2cdzA_, 0.7922, 2.76, 0.206, 289, 253, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A
1526, d1u5qB_, 0.7922, 2.82, 0.241, 308, 253, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1527, p6ehuB_, 0.7921, 2.83, 0.230, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1528, d5oryA_, 0.7921, 2.59, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1529, d5nk1A_, 0.7921, 2.68, 0.332, 284, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1K
1530, d4w9xA_, 0.7921, 2.60, 0.215, 300, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH BARICITINIB
1531, d4rllA_, 0.7921, 2.82, 0.219, 329, 256, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
1532, d3r0tA_, 0.7921, 2.81, 0.219, 327, 256, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-5279
1533, d3q9wA_, 0.7921, 2.82, 0.219, 328, 256, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 8.5
1534, d3pzhA_, 0.7921, 2.79, 0.211, 327, 256, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH EMODIN AT 1.92 A RESOLUTION
1535, d2y7jD_, 0.7921, 2.67, 0.222, 281, 252, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1536, d2oxxA_, 0.7921, 2.78, 0.211, 325, 256, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
1537, d1zohA_, 0.7921, 2.78, 0.215, 326, 256, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
1538, d1fmoE_, 0.7921, 2.80, 0.225, 336, 253, CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE
1539, d1atpE_, 0.7921, 2.78, 0.225, 334, 253, 2.2 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH MNATP AND A PEPTIDE INHIBITOR
1540, d5modA_, 0.7920, 2.86, 0.219, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1541, d4x6rA_, 0.7920, 2.72, 0.230, 347, 252, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
1542, d4mf1A1, 0.7920, 1.80, 0.325, 241, 237, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
1543, d4debA_, 0.7920, 2.73, 0.213, 264, 254, AURORA A IN COMPLEX WITH RK2-17-01
1544, d4bxaB_, 0.7920, 2.80, 0.227, 331, 256,  
1545, d3qalE_, 0.7920, 2.77, 0.225, 339, 253, CRYSTAL STRUCTURE OF ARG280ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1546, d3nunA_, 0.7920, 2.58, 0.212, 278, 250, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH LEAD COMPOUND
1547, d3mvjA_, 0.7920, 2.78, 0.237, 334, 253, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
1548, d3dgkA1, 0.7920, 2.65, 0.250, 276, 252, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN
1549, d3bwjA_, 0.7920, 2.71, 0.234, 338, 252, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR LEAD COMPOUND ARC-1034
1550, d2gnjA_, 0.7920, 2.78, 0.237, 335, 253, PKA THREE FOLD MUTANT MODEL OF RHO-KINASE WITH Y-27632
1551, d2fgiB_, 0.7920, 2.70, 0.398, 272, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
1552, d2cchC2, 0.7920, 2.66, 0.259, 295, 251, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
1553, d1lr4A_, 0.7920, 2.78, 0.211, 327, 256, ROOM TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
1554, d1ds5B_, 0.7920, 2.80, 0.211, 328, 256, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1555, d1cdkA_, 0.7920, 2.77, 0.229, 342, 253, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
1556, d5orpA_, 0.7919, 2.59, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1557, d3sc1A_, 0.7919, 2.56, 0.208, 278, 250, NOVEL ISOQUINOLONE PDK1 INHIBITORS DISCOVERED THROUGH FRAGMENT-BASED LEAD DISCOVERY
1558, d3rp0C_, 0.7919, 2.81, 0.227, 329, 256,  
1559, d3q9xA_, 0.7919, 2.81, 0.223, 330, 256, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
1560, d3kb7A_, 0.7919, 2.85, 0.268, 289, 254, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1561, d2qocA_, 0.7919, 2.71, 0.312, 283, 250, HUMAN EPHA3 KINASE DOMAIN PHOSPHORYLATED AMP-PNP BOUND STRUCTURE
1562, d5cqwB_, 0.7918, 2.80, 0.227, 331, 256, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1563, d3qhrA1, 0.7918, 2.80, 0.256, 295, 254, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1564, d2uw7A_, 0.7918, 2.77, 0.237, 335, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1565, d2uw5A_, 0.7918, 2.74, 0.234, 333, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (R)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1566, d2uw3A_, 0.7918, 2.73, 0.238, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 5-METHYL-4- PHENYL-1H-PYRAZOLE
1567, d1ds5D_, 0.7918, 2.78, 0.211, 328, 256, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1568, d5orvA_, 0.7917, 2.60, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1569, d5orrA_, 0.7917, 2.60, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1570, d4ubaB_, 0.7917, 2.79, 0.223, 333, 256, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
1571, d4otdA_, 0.7917, 2.82, 0.267, 334, 255, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN
1572, d4h1jA_, 0.7917, 2.56, 0.376, 263, 250, CRYSTAL STRUCTURE OF PYK2 WITH THE PYRAZOLE 13A
1573, d3pwdA_, 0.7917, 2.79, 0.211, 327, 256, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH NBC (Z1)
1574, d3c13A_, 0.7917, 2.82, 0.223, 328, 256, LOW PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1575, d3bqcA_, 0.7917, 2.83, 0.219, 328, 256, HIGH PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1576, d1xh7A_, 0.7917, 2.73, 0.238, 337, 252, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1577, d1cdkB_, 0.7917, 2.78, 0.229, 342, 253, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
1578, d5veeA_, 0.7916, 2.93, 0.206, 289, 257, PAK4 KINASE DOMAIN IN COMPLEX WITH FRAX486
1579, d5oseA_, 0.7916, 2.60, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1580, d5orzA_, 0.7916, 2.60, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1581, d5nk2A_, 0.7916, 2.69, 0.332, 290, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2B
1582, d4eonA1, 0.7916, 2.67, 0.259, 297, 251, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1583, d3t9tA_, 0.7916, 2.64, 0.289, 263, 249, CRYSTAL STRUCTURE OF BTK MUTANT (F435TK596R) COMPLEXED WITH IMIDAZO[15-A]QUINOXALINE
1584, d3qlfB_, 0.7916, 2.18, 0.332, 258, 244, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
1585, d5osfA_, 0.7915, 2.61, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1586, d5i0bA_, 0.7915, 2.88, 0.215, 288, 256, STRUCTURE OF PAK4
1587, d5cspA_, 0.7915, 2.83, 0.223, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
1588, d4pmpA1, 0.7915, 2.54, 0.385, 276, 247, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 1-CYCLOPROPYL-1- [3-(13-THIAZOL-2-YL)BENZYL]-3-[4-(TRIFLUOROMETHOXY)PHENYL]UREA
1589, d3v5lC1, 0.7915, 1.84, 0.315, 242, 238, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
1590, d3qhrC1, 0.7915, 2.81, 0.256, 295, 254, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1591, d3mb7A_, 0.7915, 2.85, 0.215, 330, 256, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (AMR)
1592, d2w4kA_, 0.7915, 2.87, 0.246, 301, 256, X-RAY STRUCTURE OF A DAP-KINASE 2-302
1593, d2cpkE_, 0.7915, 2.74, 0.230, 333, 252, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE
1594, d1q8tA_, 0.7915, 2.77, 0.233, 338, 253, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH RHO-KINASE INHIBITOR Y-27632
1595, d5p9hA_, 0.7914, 2.47, 0.317, 264, 249, BTK1 COCRYSTALLIZED WITH RN983
1596, d5os4A_, 0.7914, 2.60, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1597, d5ornA_, 0.7914, 2.61, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1598, d5iugA_, 0.7914, 2.37, 0.324, 285, 244, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5A
1599, d5ho7A_, 0.7914, 2.62, 0.211, 280, 251, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1600, d5cu2B_, 0.7914, 2.86, 0.223, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
1601, d5ctpB_, 0.7914, 2.88, 0.219, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1602, d4rixA_, 0.7914, 2.74, 0.335, 269, 251, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
1603, p4ib5B_, 0.7914, 2.84, 0.211, 329, 256, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1604, d4f1tA1, 0.7914, 2.90, 0.255, 267, 255, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO THE ROCK INHIBITOR H1152
1605, d4a06A_, 0.7914, 2.69, 0.202, 282, 253, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS114 BOUND TO THE PIF-POCKET
1606, d3vw8A_, 0.7914, 2.55, 0.335, 303, 245, CRYSTAL STRUCTURE OF HUMAN C-MET KINASE DOMAIN WITH ITS INHIBITOR
1607, d3rp0A_, 0.7914, 2.86, 0.227, 329, 256,  
1608, d3pvgA_, 0.7914, 2.80, 0.211, 326, 256, CRYSTAL STRUCTURE OF Z. MAYS CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMO-1-CARBOXYMETHYLBENZIMIDAZOLE (K68)
1609, d3pooA_, 0.7914, 2.78, 0.233, 331, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1610, d3l9lB_, 0.7914, 2.77, 0.237, 337, 253, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
1611, d3gu8A1, 0.7914, 2.65, 0.250, 276, 252, CRYSTAL STRUCTURE OF DAPKL93G WITH N6-CYCLOPENTYLADENOSINE
1612, d2vz6A1, 0.7914, 2.27, 0.244, 285, 246, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
1613, d2fb8A_, 0.7914, 2.33, 0.272, 259, 246, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
1614, d1lpuA_, 0.7914, 2.80, 0.211, 327, 256, LOW TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
1615, d5os6A_, 0.7913, 2.60, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1616, d5os1A_, 0.7913, 2.61, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1617, d5orxA_, 0.7913, 2.61, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1618, d5orwA_, 0.7913, 2.60, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1619, d4p2kA_, 0.7913, 2.42, 0.312, 259, 247, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
1620, p4lfiB_, 0.7913, 2.83, 0.207, 371, 256, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1621, d4ii5A_, 0.7913, 2.80, 0.256, 295, 254, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
1622, d4fihA_, 0.7913, 2.86, 0.215, 291, 256, CATALYTIC DOMAIN OF HUMAN PAK4 WITH QKFTGLPRQW PEPTIDE
1623, d4f0fA1, 0.7913, 2.88, 0.251, 274, 255, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM
1624, d3rp0B_, 0.7913, 2.83, 0.223, 329, 256,  
1625, d3qa0A_, 0.7913, 2.83, 0.223, 330, 256, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
1626, d3dkcA1, 0.7913, 2.82, 0.320, 310, 253, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH ATP
1627, d3amaA_, 0.7913, 2.77, 0.233, 342, 253, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR JNJ- 7706621
1628, d2w4jA_, 0.7913, 2.65, 0.250, 276, 252, X-RAY STRUCTURE OF A DAP-KINASE 2-277
1629, d1uu8A_, 0.7913, 2.62, 0.211, 277, 251, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-1
1630, d5os0A_, 0.7912, 2.61, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1631, d5i9xA_, 0.7912, 2.71, 0.332, 284, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH BOSUTINIB (SKI-606)
1632, d4riyA_, 0.7912, 2.74, 0.335, 269, 251, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
1633, d4m0yA_, 0.7912, 2.77, 0.288, 263, 250, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 1 [4- (CARBAMOYLAMINO)-1-(NAPHTHALEN-1-YL)-1H-PYRAZOLE-3-CARBOXAMIDE]
1634, d3uo4A_, 0.7912, 2.74, 0.197, 266, 254, AURORA A IN COMPLEX WITH RPM1680
1635, d3q9yA_, 0.7912, 2.83, 0.223, 327, 256, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 8.5
1636, d3kxjA_, 0.7912, 2.80, 0.211, 326, 256,  
1637, d2gnhA_, 0.7912, 2.77, 0.237, 338, 253, PKA FIVE FOLD MUTANT MODEL OF RHO-KINASE WITH H1152P
1638, d5lvoA_, 0.7911, 2.76, 0.192, 285, 255, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PSE10 BOUND TO THE PIF-POCKET
1639, d5eobA_, 0.7911, 3.00, 0.328, 288, 253, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
1640, d5cu0B_, 0.7911, 2.87, 0.223, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1641, d4yhtA_, 0.7911, 2.33, 0.272, 256, 246, BRAF COMPLEXED WITH AN INHIBITOR
1642, p4lfiA_, 0.7911, 2.83, 0.207, 370, 256, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1643, d4eolC1, 0.7911, 2.67, 0.259, 296, 251, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1644, d3tl8D_, 0.7911, 2.69, 0.258, 306, 252, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
1645, d2qcsA_, 0.7911, 2.74, 0.230, 335, 252, A COMPLEX STRUCTURE BETWEEN THE CATALYTIC AND REGULATORY SUBUNIT OF PROTEIN KINASE A THAT REPRESENTS THE INHIBITED STATE
1646, d5mpjA_, 0.7910, 2.84, 0.223, 326, 256, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
1647, d5mo6A_, 0.7910, 2.88, 0.219, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1648, d4gk3A_, 0.7910, 2.65, 0.327, 275, 248, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 87
1649, d3qd3A_, 0.7910, 2.59, 0.212, 278, 250, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL {(3R6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE
1650, d3gu6A1, 0.7910, 2.67, 0.250, 276, 252, CRYSTAL STRUCTURE OF DAPKQ23V-ADP
1651, d3aoxA_, 0.7910, 2.66, 0.309, 298, 249, X-RAY CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CH5424802
1652, p2pvlA_, 0.7910, 2.80, 0.211, 327, 256, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1653, d1xh6A_, 0.7910, 2.80, 0.237, 331, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1654, d1xh4A_, 0.7910, 2.73, 0.234, 334, 252, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1655, p6ehuA_, 0.7909, 2.84, 0.230, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1656, d5vloA_, 0.7909, 2.56, 0.239, 290, 251, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1657, d5p9mA_, 0.7909, 2.79, 0.310, 271, 252, BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059
1658, d5os3A_, 0.7909, 2.61, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1659, d5nk6A_, 0.7909, 2.59, 0.333, 284, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2D
1660, d5cu6A_, 0.7909, 2.84, 0.223, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA
1661, d5csvA_, 0.7909, 2.84, 0.223, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 6 BOUND
1662, d4xmoA_, 0.7909, 2.79, 0.324, 289, 250, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (R)-5-(8-FLUORO-3-(1- FLUORO-1-(3-METHOXYQUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43- A]PYRIDIN-6-YL)-3-METHYLISOXAZOLE
1663, d4oa9A_, 0.7909, 2.70, 0.224, 280, 250,  
1664, d4gk4A_, 0.7909, 2.69, 0.325, 275, 249, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 90
1665, d3qlgA_, 0.7909, 2.12, 0.337, 259, 243, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
1666, d3l9mB_, 0.7909, 2.77, 0.241, 336, 253, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
1667, d3e8eI_, 0.7909, 2.77, 0.233, 345, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1668, d5jrsA1, 0.7908, 2.24, 0.324, 257, 244, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
1669, d4o0sA_, 0.7908, 2.65, 0.230, 265, 252, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
1670, d4nk9A_, 0.7908, 2.66, 0.392, 281, 250, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
1671, d4mf1B1, 0.7908, 1.99, 0.321, 244, 240, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
1672, d4m15A_, 0.7908, 2.71, 0.288, 263, 250, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE] AND ADP
1673, d4jdhA_, 0.7908, 2.78, 0.197, 289, 254, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
1674, d4j8nC_, 0.7908, 2.72, 0.198, 266, 253, AURORA A KINASE APO
1675, d4bxaA_, 0.7908, 2.81, 0.227, 331, 256,  
1676, d3w8lB_, 0.7908, 2.85, 0.223, 326, 256, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
1677, d3v8wB1, 0.7908, 1.75, 0.318, 240, 236, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
1678, d5oroA_, 0.7907, 2.61, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1679, d5cqwA_, 0.7907, 2.82, 0.227, 331, 256, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1680, d4anmA1, 0.7907, 2.80, 0.211, 327, 256, COMPLEX OF CK2 WITH A CDC7 INHIBITOR
1681, d3rp0D_, 0.7907, 2.82, 0.227, 329, 256,  
1682, d3kxnA_, 0.7907, 2.80, 0.215, 327, 256, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR TETRAIODOBENZIMIDAZOLE (K88)
1683, d2uw4A_, 0.7907, 2.75, 0.234, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-(5-METHYL- 1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1684, d2pvrA_, 0.7907, 2.84, 0.223, 328, 256, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (C- TERMINAL DELETION MUTANT 1-335) IN COMPLEX WITH TWO SULFATE IONS
1685, d2hy81_, 0.7907, 2.90, 0.218, 293, 257, PAK1 COMPLEX WITH ST2001
1686, d2gfcA_, 0.7907, 2.81, 0.237, 335, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1687, d1u5qA_, 0.7907, 2.83, 0.241, 308, 253, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1688, d1qmzC1, 0.7907, 2.67, 0.255, 295, 251, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
1689, d4imyC_, 0.7906, 2.82, 0.241, 310, 253, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
1690, d3up7A_, 0.7906, 2.79, 0.197, 264, 254, AURORA A IN COMPLEX WITH YL1-038-09
1691, d3qcqA_, 0.7906, 2.54, 0.209, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-(3- AMINO-1H-INDAZOL-6-YL)-N4-ETHYL-24-PYRIMIDINEDIAMINE
1692, d3ofmA_, 0.7906, 2.85, 0.215, 325, 256, STRUCTURE OF A HUMAN CK2ALPHA PRIME THE PARALOG ISOFORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM HOMO SAPIENS
1693, d3l9lA_, 0.7906, 2.77, 0.245, 338, 253, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
1694, d3gu5A1, 0.7906, 2.66, 0.250, 276, 252, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP-MG2+
1695, d2og8A_, 0.7906, 2.09, 0.368, 246, 242, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
1696, d1m2pA_, 0.7906, 2.81, 0.211, 325, 256, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO- ANTHRAQUINONE/CK2 KINASE COMPLEX
1697, d5orsA_, 0.7905, 2.62, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1698, d5mowA1, 0.7905, 2.88, 0.223, 326, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1699, d4j8nB_, 0.7905, 2.73, 0.198, 266, 253, AURORA A KINASE APO
1700, d4fx3A_, 0.7905, 2.72, 0.250, 298, 252, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
1701, d4a4oA_, 0.7905, 2.85, 0.264, 290, 254, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2- (2-AMINO-PYRIMIDIN-4-YL)-1567-TETRAHYDRO-PYRROLOPYRIDIN- 4-ONE INHIBITOR
1702, d2gniA_, 0.7905, 2.79, 0.237, 338, 253, PKA FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR FASUDIL (HA1077)
1703, d2a27B_, 0.7905, 2.77, 0.217, 303, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1704, d5ho8A_, 0.7904, 2.59, 0.212, 278, 250, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1705, d4otfA1, 0.7904, 2.46, 0.308, 261, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH GDC0834
1706, d4nk9B_, 0.7904, 2.71, 0.396, 282, 250, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
1707, d4j8nA_, 0.7904, 2.73, 0.198, 266, 253, AURORA A KINASE APO
1708, d3qcsA_, 0.7904, 2.54, 0.209, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-[2- AMINO-6-(4-MORPHOLINYL)-4-PYRIMIDINYL]-1H-INDAZOL-3-AMINE
1709, d2gu8A_, 0.7904, 2.79, 0.229, 335, 253, DISCOVERY OF 2-PYRIMIDYL-5-AMIDOTHIOPHENES AS NOVEL AND POTENT INHIBITORS FOR AKT: SYNTHESIS AND SAR STUDIES
1710, d2a27G_, 0.7904, 2.77, 0.217, 303, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1711, d1om1A_, 0.7904, 2.81, 0.211, 325, 256, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH IQA
1712, p5ooiA_, 0.7903, 2.82, 0.219, 329, 256, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
1713, d5nkcA_, 0.7903, 2.70, 0.332, 286, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2H
1714, d5moeA_, 0.7903, 2.87, 0.219, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1715, d4knbC_, 0.7903, 2.81, 0.335, 271, 248, C-MET IN COMPLEX WITH OSI LIGAND
1716, d4gg7A_, 0.7903, 2.95, 0.324, 278, 253, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
1717, d4a4lA_, 0.7903, 2.85, 0.264, 290, 254, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO-PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR
1718, d3v8wA1, 0.7903, 1.74, 0.318, 241, 236, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
1719, d2vo6A_, 0.7903, 2.76, 0.234, 335, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4- CHLOROBENZYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YLAMINE
1720, d2gcdA_, 0.7903, 2.83, 0.241, 308, 253, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1721, d1qmzA1, 0.7903, 2.68, 0.255, 295, 251, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
1722, d1fgiB_, 0.7903, 2.75, 0.398, 272, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
1723, d5f9eA1, 0.7902, 2.72, 0.233, 331, 253, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1724, d3qriA1, 0.7902, 2.51, 0.379, 270, 248, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
1725, d3kxhA_, 0.7902, 2.81, 0.215, 326, 256, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR (2-DYMETHYLAMMINO-4567-TETRABROMOBENZOIMIDAZOL-1YL- ACETIC ACID (K66)
1726, d3hrfA_, 0.7902, 2.76, 0.201, 284, 254, CRYSTAL STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN ALLOSTERIC ACTIVATOR BOUND TO THE PIF-POCKET
1727, d3gubA1, 0.7902, 2.68, 0.250, 276, 252, CRYSTAL STRUCTURE OF DAPKL93G COMPLEXED WITH N6-(2- PHENYLETHYL)ADENOSINE
1728, d3g5dA_, 0.7902, 2.07, 0.332, 256, 241, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
1729, d2vz6B1, 0.7902, 2.37, 0.250, 288, 248, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
1730, d2vnyA_, 0.7902, 2.75, 0.234, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)AMINE
1731, d5dr2A1, 0.7901, 2.62, 0.231, 263, 251, AURORA A KINASE IN COMPLEX WITH AA30 AND ATP IN SPACE GROUP P6122
1732, d5cx9B_, 0.7901, 2.88, 0.223, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
1733, d5cvhA_, 0.7901, 2.85, 0.219, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA
1734, d4ks7A_, 0.7901, 2.97, 0.207, 286, 256, PAK6 KINASE DOMAIN IN COMPLEX WITH PF-3758309
1735, d4fx3C_, 0.7901, 2.72, 0.250, 298, 252, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
1736, d3bhhB1, 0.7901, 2.46, 0.221, 288, 249, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
1737, d2uw6A_, 0.7901, 2.74, 0.238, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (S)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1738, d5fbnC_, 0.7900, 2.66, 0.308, 256, 250, BTK KINASE DOMAIN WITH INHIBITOR 1
1739, d5ct0B_, 0.7900, 2.88, 0.223, 326, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
1740, d4cegA_, 0.7900, 2.62, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA A 122-403 C290A C393A BOUND TO ADP
1741, d3p0mA_, 0.7900, 2.79, 0.233, 335, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1742, d2xchA_, 0.7900, 2.57, 0.208, 278, 250, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1743, d2oxyB_, 0.7900, 2.84, 0.215, 327, 256, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
1744, d2a27E_, 0.7900, 2.78, 0.231, 303, 255, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1745, d4jdjA_, 0.7899, 2.83, 0.216, 288, 255, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
1746, d4fijA_, 0.7899, 2.89, 0.215, 291, 256, CATALYTIC DOMAIN OF HUMAN PAK4
1747, d3cp9A1, 0.7899, 2.11, 0.379, 281, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
1748, d2a27D_, 0.7899, 2.77, 0.217, 304, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1749, d2a27C_, 0.7899, 2.82, 0.216, 303, 255, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1750, d5a4cA_, 0.7898, 2.60, 0.402, 294, 249, FGFR1 LIGAND COMPLEX
1751, d4nwmA_, 0.7898, 2.45, 0.304, 261, 247, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
1752, d4jboA_, 0.7898, 2.70, 0.233, 266, 253, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
1753, d4eolA1, 0.7898, 2.71, 0.259, 293, 251, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1754, d4eokC1, 0.7898, 2.66, 0.255, 296, 251, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
1755, d4eokA1, 0.7898, 2.69, 0.255, 292, 251, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
1756, d4dggA_, 0.7898, 2.12, 0.337, 261, 243, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
1757, d3owkA_, 0.7898, 2.89, 0.219, 330, 256, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
1758, d2x39A_, 0.7898, 2.68, 0.246, 316, 252, STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB
1759, d1zwsD_, 0.7898, 2.77, 0.227, 278, 255, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1760, d1o6kA_, 0.7898, 2.71, 0.238, 317, 252, STRUCTURE OF ACTIVATED FORM OF PKB KINASE DOMAIN S474D WITH GSK3 PEPTIDE AND AMP-PNP
1761, d5w5oO_, 0.7897, 2.19, 0.267, 276, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1762, d5nk9A_, 0.7897, 2.62, 0.333, 285, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2E
1763, d4wbbB_, 0.7897, 2.73, 0.230, 334, 252, SINGLE TURNOVER AUTOPHOSPHORYLATION CYCLE OF THE PKA RIIB HOLOENZYME
1764, d4txcA_, 0.7897, 2.76, 0.244, 276, 254, CRYSTAL STRUCTURE OF DAPK1 KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
1765, d4riwA_, 0.7897, 2.78, 0.335, 269, 251, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
1766, d4bxbA_, 0.7897, 2.87, 0.223, 328, 256,  
1767, d3genA_, 0.7897, 2.59, 0.305, 264, 249, THE 1.6 A CRYSTAL STRUCTURE OF HUMAN BRUTON S TYROSINE KINASE BOUND TO A PYRROLOPYRIMIDINE-CONTAINING COMPOUND
1768, d2vo0A_, 0.7897, 2.80, 0.237, 340, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
1769, p2pvmA_, 0.7897, 2.82, 0.211, 327, 256, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1770, d2jdsA_, 0.7897, 2.75, 0.238, 334, 252, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A- 443654
1771, d2a27A_, 0.7897, 2.82, 0.216, 304, 255, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1772, d1jklA_, 0.7897, 2.71, 0.250, 280, 252, 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE
1773, d5dn3A_, 0.7896, 2.73, 0.229, 264, 253, AURORA A IN COMPLEX WITH ATP AND AA35.
1774, d5cquA_, 0.7896, 2.87, 0.223, 328, 256, MONOCLINIC COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1775, p4jqeA_, 0.7896, 2.85, 0.207, 369, 256, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH AMPPN
1776, d3lvpD_, 0.7896, 2.69, 0.308, 282, 250, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
1777, d3d7tB_, 0.7896, 2.45, 0.290, 265, 248, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
1778, d2uvzA_, 0.7896, 2.75, 0.238, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH C-PHENYL-C-(4-( 9H-PURIN-6-YL)-PHENYL)-METHYLAMINE
1779, d1yrpB_, 0.7896, 2.76, 0.241, 275, 253, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
1780, d1yrpA_, 0.7896, 2.76, 0.241, 275, 253, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
1781, d5orlA_, 0.7895, 2.59, 0.235, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1782, d5iuhA_, 0.7895, 2.32, 0.321, 285, 243, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5D
1783, d4utdA_, 0.7895, 2.62, 0.231, 266, 251, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION
1784, d4njdA1, 0.7895, 2.92, 0.215, 289, 256, STRUCTURE OF P21-ACTIVATED KINASE 4 WITH A NOVEL INHIBITOR KY-04031
1785, d4m13A_, 0.7895, 2.74, 0.288, 264, 250, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 8 [4- (CARBAMOYLAMINO)-1-(7-PROPOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
1786, d3uqgB_, 0.7895, 2.08, 0.340, 257, 241, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
1787, d5nk4A_, 0.7894, 2.77, 0.332, 290, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2C
1788, d5mmfB_, 0.7894, 2.87, 0.223, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
1789, d4krcA_, 0.7894, 2.89, 0.247, 297, 255, CRYSTAL STRUCTURE OF PHO85-PCL10-ATP-GAMMA-S COMPLEX
1790, d4j8nD_, 0.7894, 2.70, 0.198, 265, 252, AURORA A KINASE APO
1791, d2ya9A_, 0.7894, 2.78, 0.235, 299, 255, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
1792, d5mmrB_, 0.7893, 2.87, 0.219, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
1793, d5j87C_, 0.7893, 2.53, 0.306, 261, 248, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1794, d4l67A_, 0.7893, 2.91, 0.211, 289, 256, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF PAK4
1795, d4kioD1, 0.7893, 1.80, 0.325, 240, 237, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
1796, d3qcxA_, 0.7893, 2.55, 0.209, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-{2- AMINO-6-[(3R)-3-METHYL-4-MORPHOLINYL]-4-PYRIMIDINYL}-1H-INDAZOL-3- AMINE
1797, d3dndA_, 0.7893, 2.80, 0.237, 334, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1798, p2pvkA_, 0.7893, 2.82, 0.211, 327, 256, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1799, d2a27H_, 0.7893, 2.79, 0.231, 304, 255, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1800, d1fvvA_, 0.7893, 2.71, 0.254, 298, 252, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
1801, d5n1vA_, 0.7892, 2.74, 0.217, 331, 253, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
1802, d5mo6B_, 0.7892, 2.90, 0.219, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1803, d5dt3A_, 0.7892, 2.63, 0.231, 263, 251, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
1804, d4oacA_, 0.7892, 2.63, 0.225, 280, 249,  
1805, d4m0zA_, 0.7892, 2.73, 0.288, 264, 250, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 5 {4- (CARBAMOYLAMINO)-1-(7-METHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE}
1806, d4kwpA_, 0.7892, 2.84, 0.219, 329, 256, CRYSTAL STRUCTURE OF HUMAN CK2-ALPHA IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR (K164) AT 1.25 A RESOLUTION
1807, d3ppkA_, 0.7892, 2.39, 0.272, 262, 246, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
1808, d3l9mA_, 0.7892, 2.78, 0.245, 338, 253, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
1809, d5mpjB_, 0.7891, 2.88, 0.223, 324, 256, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
1810, d4wsqA_, 0.7891, 2.79, 0.225, 317, 249, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1811, d4rwkB_, 0.7891, 2.63, 0.382, 282, 249, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
1812, d3f5pT1, 0.7891, 3.18, 0.298, 294, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1813, d3ewhA1, 0.7891, 2.73, 0.382, 295, 251, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDYL-PYRIMIDINE BENZIMIDAZOLE INHIBITOR
1814, d3cjgA_, 0.7891, 2.42, 0.378, 280, 246, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
1815, d2uvyA_, 0.7891, 2.76, 0.238, 333, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH METHYL-(4-(9H- PURIN-6-YL)-BENZYL)-AMINE
1816, d1q8wA_, 0.7891, 2.73, 0.234, 334, 252, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR FASUDIL (HA-1077)
1817, d1l3rE_, 0.7891, 2.77, 0.226, 338, 252, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
1818, d5ortA_, 0.7890, 2.63, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1819, d3u51A_, 0.7890, 1.94, 0.342, 256, 240, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
1820, d2vo3A_, 0.7890, 2.76, 0.234, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
1821, d1zwsB_, 0.7890, 2.78, 0.224, 278, 255, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1822, d1o6lA_, 0.7890, 2.70, 0.238, 316, 252, CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B (PKB-PIF CHIMERA) TERNARY COMPLEX WITH AMP-PNP AND GSK3 PEPTIDE
1823, d5swhB_, 0.7889, 2.14, 0.343, 261, 242, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
1824, d5nkdA_, 0.7889, 2.67, 0.333, 287, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2I
1825, d5ek7A_, 0.7889, 2.64, 0.332, 286, 250, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
1826, d5cs6A_, 0.7889, 2.88, 0.219, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
1827, d4tl0A_, 0.7889, 2.89, 0.246, 300, 256, CRYSTAL STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 WITH A CRUCIAL PHOSPHOMIMICKING MUTATION
1828, d4otgA_, 0.7889, 2.85, 0.267, 322, 255, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH LESTAURTINIB
1829, d4oa2A_, 0.7889, 2.59, 0.230, 280, 248,  
1830, d3qgyA1, 0.7889, 1.90, 0.322, 244, 239, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
1831, d3owlA_, 0.7889, 2.91, 0.219, 330, 256, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
1832, d3nusA_, 0.7889, 2.57, 0.209, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT8
1833, d3cpbA1, 0.7889, 2.06, 0.372, 278, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
1834, d2g15A_, 0.7889, 3.03, 0.304, 301, 253, STRUCTURAL CHARACTERIZATION OF AUTOINHIBITED C-MET KINASE
1835, d2a27F_, 0.7889, 2.83, 0.216, 303, 255, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1836, p5os8A_, 0.7888, 2.89, 0.227, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 11
1837, d5dnrA_, 0.7888, 2.68, 0.230, 264, 252, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P41212
1838, d2vnwA_, 0.7888, 2.77, 0.234, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)METHANAMINE
1839, d1j91A_, 0.7888, 2.89, 0.207, 327, 256, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
1840, d5movA_, 0.7887, 2.87, 0.223, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0633 BOUND
1841, d5ia3A_, 0.7887, 2.47, 0.337, 275, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH PD173955
1842, d4rwiB_, 0.7887, 2.54, 0.395, 280, 248, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
1843, d4m12A_, 0.7887, 2.75, 0.288, 264, 250, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 7 [4- (CARBAMOYLAMINO)-1-(7-ETHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
1844, d4aojC_, 0.7887, 2.43, 0.385, 261, 247, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
1845, d3v5jA1, 0.7887, 1.77, 0.318, 239, 236, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
1846, d3gu7A1, 0.7887, 2.72, 0.250, 276, 252, CRYSTAL STRUCTURE OF DAPKQ23V-ADP-MG2+
1847, d3blhA1, 0.7887, 3.06, 0.238, 291, 256, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
1848, p5oulA_, 0.7886, 2.87, 0.223, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 9
1849, d5l2wA1, 0.7886, 2.71, 0.255, 296, 251, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
1850, d4figB_, 0.7886, 2.94, 0.203, 292, 256, CATALYTIC DOMAIN OF HUMAN PAK4
1851, d3mv5A_, 0.7886, 2.72, 0.242, 315, 252, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1852, d3gu4A1, 0.7886, 2.69, 0.250, 276, 252, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP
1853, d2gnlA_, 0.7886, 2.80, 0.233, 338, 253, PKA THREEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR H- 1152P
1854, d1na7A_, 0.7886, 2.87, 0.223, 326, 256, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2
1855, d5tobA_, 0.7885, 2.10, 0.389, 245, 239, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
1856, d4eopC1, 0.7885, 2.73, 0.255, 295, 251, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1857, d4eonC1, 0.7885, 2.74, 0.259, 296, 251, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1858, d4ebvA1, 0.7885, 2.59, 0.370, 261, 246, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
1859, d3d94A_, 0.7885, 2.69, 0.341, 288, 249, CRYSTAL STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE IN COMPLEX WITH PQIP
1860, d3ambA_, 0.7885, 2.80, 0.237, 340, 253, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR VX- 680
1861, d2yjrA_, 0.7885, 2.30, 0.336, 278, 244, STRUCTURE OF F1174L MUTANT ANAPLASTIC LYMPHOMA KINASE
1862, d2uzdA_, 0.7885, 2.85, 0.256, 295, 254, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
1863, d2uzbC_, 0.7885, 2.71, 0.255, 292, 251, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
1864, d1zwsC_, 0.7885, 2.84, 0.223, 278, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1865, d4ybkA_, 0.7884, 2.51, 0.339, 266, 248, C-HELIX-OUT DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
1866, d4k8aA_, 0.7884, 2.37, 0.350, 251, 243, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
1867, d4aw1A_, 0.7884, 2.64, 0.200, 283, 250, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS210 BOUND TO THE PIF-POCKET
1868, d3juhB_, 0.7884, 2.72, 0.221, 334, 253, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
1869, d3bz3A_, 0.7884, 2.44, 0.370, 259, 246, CRYSTAL STRUCTURE ANALYSIS OF FOCAL ADHESION KINASE WITH A METHANESULFONAMIDE DIAMINOPYRIMIDINE INHIBITOR
1870, d2yacA_, 0.7884, 2.88, 0.264, 290, 254, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH NMS-P937
1871, d1fq1B_, 0.7884, 2.67, 0.256, 295, 250, CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
1872, d4pf4A1, 0.7883, 2.68, 0.250, 277, 252, 1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1 AA 1-277
1873, d4jdkA_, 0.7883, 2.86, 0.212, 288, 255, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
1874, d4f0iB_, 0.7883, 2.68, 0.378, 294, 249, CRYSTAL STRUCTURE OF APO TRKA
1875, d3rwpA_, 0.7883, 2.56, 0.209, 277, 249, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
1876, d3qgwA_, 0.7883, 1.91, 0.322, 244, 239, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
1877, d3q9zA_, 0.7883, 2.87, 0.227, 332, 256, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1878, d3q04A_, 0.7883, 2.86, 0.223, 328, 256, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 8.5
1879, p5otzA_, 0.7882, 2.90, 0.227, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 1
1880, d4fnxA_, 0.7882, 2.59, 0.308, 292, 247, CRYSTAL STRUCTURE OF THE APO R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
1881, d4at5A1, 0.7882, 2.78, 0.386, 291, 249, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580
1882, d3of0A_, 0.7882, 2.27, 0.340, 260, 244, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
1883, d3nuyA_, 0.7882, 2.57, 0.209, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT17
1884, d3cthA_, 0.7882, 2.73, 0.317, 295, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
1885, d3bw5A_, 0.7882, 2.72, 0.221, 334, 253,  
1886, d2yakA_, 0.7882, 2.79, 0.248, 277, 254, STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OSV)
1887, d1ymiA_, 0.7882, 2.72, 0.221, 334, 253,  
1888, d1u5rB_, 0.7882, 2.87, 0.241, 308, 253, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1889, d1q8uA_, 0.7882, 2.80, 0.233, 341, 253, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR H-1152P
1890, d5em5A_, 0.7881, 2.61, 0.372, 298, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 2: 4-[2-(4- CHLOROPHENYL)ETHYLAMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
1891, p4mwhA_, 0.7881, 2.87, 0.207, 371, 256, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1892, d3zh8C_, 0.7881, 2.74, 0.194, 312, 253, A NOVEL SMALL MOLECULE APKC INHIBITOR
1893, p3o17B_, 0.7881, 2.84, 0.198, 357, 253, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
1894, d2j0iA_, 0.7881, 2.94, 0.219, 289, 256, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
1895, d5njzA_, 0.7880, 2.54, 0.336, 273, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1G
1896, d5mp8A_, 0.7880, 2.90, 0.219, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1897, d5ikwA_, 0.7880, 2.53, 0.215, 297, 246, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
1898, d5cvhB_, 0.7880, 2.89, 0.219, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA
1899, d4mnfB_, 0.7880, 2.28, 0.270, 257, 244, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
1900, d4m14A_, 0.7880, 2.76, 0.288, 263, 250, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE]
1901, d4figA_, 0.7880, 2.95, 0.203, 292, 256, CATALYTIC DOMAIN OF HUMAN PAK4
1902, p4fi1A_, 0.7880, 2.87, 0.207, 371, 256, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1903, d4dedA_, 0.7880, 2.88, 0.212, 265, 255, AURORA A IN COMPLEX WITH YL1-038-21
1904, d3rcjA_, 0.7880, 2.70, 0.202, 281, 252, RAPID PREPARATION OF TRIAZOLYL SUBSTITUTED NH-HETEROCYCLIC KINASE INHIBITORS VIA ONE-POT SONOGASHIRA COUPLING TMS-DEPROTECTION CUAAC SEQUENCE
1905, d3owjA_, 0.7880, 2.92, 0.223, 328, 256, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A PYRIDOCARBAZOLE DERIVATIVE INHIBITOR
1906, d3d0eB_, 0.7880, 2.70, 0.238, 322, 252, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1907, d3cpbB_, 0.7880, 2.22, 0.369, 263, 241, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
1908, d3bhtC1, 0.7880, 2.71, 0.255, 269, 251, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
1909, d2uw0A_, 0.7880, 2.77, 0.234, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  6-(4-(4-(4- CHLORO-PHENYL)-PIPERIDIN-4-YL)-PHENYL)-9H-PURINE
1910, d1xjdA_, 0.7880, 2.63, 0.257, 280, 249, CRYSTAL STRUCTURE OF PKC-THETA COMPLEXED WITH STAUROSPORINE AT 2A RESOLUTION
1911, d4gv1A1, 0.7879, 2.71, 0.242, 328, 252, PKB ALPHA IN COMPLEX WITH AZD5363
1912, d4fzaB1, 0.7879, 2.65, 0.255, 280, 251, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX
1913, d3prfA_, 0.7879, 2.41, 0.268, 262, 246, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
1914, d3cquA_, 0.7879, 2.69, 0.246, 318, 252, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1915, d2yjsA_, 0.7879, 2.51, 0.314, 286, 245, STRUCTURE OF C1156Y MUTANT ANAPLASTIC LYMPHOMA KINASE
1916, d1ig1A_, 0.7879, 2.72, 0.250, 280, 252, 1.8A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MN.
1917, p6gihA_, 0.7878, 2.76, 0.225, 324, 253, CRYSTAL STRUCTURE OF CK2ALPHA WITH CAM187 BOUND 
1918, d4wnpB_, 0.7878, 2.85, 0.247, 272, 255, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
1919, d4w9wA_, 0.7878, 2.65, 0.211, 306, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH SMALL MOLECULE AZD-7762
1920, d3zh8A_, 0.7878, 2.76, 0.190, 318, 253, A NOVEL SMALL MOLECULE APKC INHIBITOR
1921, d3fc2A_, 0.7878, 2.98, 0.267, 293, 255, PLK1 IN COMPLEX WITH BI6727
1922, d3f3uB_, 0.7878, 2.29, 0.340, 259, 244, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
1923, d3d0eA_, 0.7878, 2.70, 0.238, 322, 252, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1924, p2pvjA_, 0.7878, 2.84, 0.211, 326, 256, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1925, d2hz0B_, 0.7878, 1.94, 0.373, 243, 236, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
1926, d2fb8B_, 0.7878, 2.41, 0.272, 259, 246, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
1927, d1uu9A_, 0.7878, 2.62, 0.212, 276, 250, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-3
1928, d1jksA_, 0.7878, 2.74, 0.250, 280, 252, 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
1929, d5w5oK_, 0.7877, 2.19, 0.264, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1930, d5k9iA_, 0.7877, 2.10, 0.343, 258, 242, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
1931, d5da3A1, 0.7877, 2.61, 0.341, 261, 249, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN WITH INHIBITOR
1932, d4ct2A_, 0.7877, 2.76, 0.209, 277, 253, HUMAN PDK1-PKCZETA KINASE CHIMERA
1933, d3tz8B_, 0.7877, 2.31, 0.339, 263, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
1934, d2jdrA_, 0.7877, 2.71, 0.242, 316, 252, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A- 443654
1935, d5w5oM_, 0.7876, 2.23, 0.267, 276, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1936, d5li1A1, 0.7876, 2.60, 0.200, 329, 250, STRUCTURE OF A PAR3-INHIBITORY PEPTIDE BOUND TO PKCIOTA CORE KINASE DOMAIN
1937, d5cvgA_, 0.7876, 2.67, 0.211, 326, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH A NOVEL CLOSED CONFORMATION OF THE AD LOOP
1938, d4j52A_, 0.7876, 2.90, 0.268, 293, 254, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A PYRIMIDODIAZEPINONE INHIBITOR
1939, d4h58B_, 0.7876, 2.46, 0.271, 262, 247, BRAF IN COMPLEX WITH COMPOUND 3
1940, d4eoiC1, 0.7876, 2.74, 0.255, 295, 251, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1941, d3svvB_, 0.7876, 2.07, 0.346, 257, 240, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
1942, d1ol7A_, 0.7876, 2.62, 0.232, 261, 250, STRUCTURE OF HUMAN AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288
1943, d1mq4A_, 0.7876, 2.65, 0.231, 261, 251, CRYSTAL STRUCTURE OF AURORA-A PROTEIN KINASE
1944, d5w5oJ_, 0.7875, 2.19, 0.264, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1945, d5n1vB_, 0.7875, 2.85, 0.223, 331, 256, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
1946, d5m56B_, 0.7875, 2.87, 0.219, 328, 256, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1947, d5av1A_, 0.7875, 2.65, 0.251, 275, 251, CRYSTAL STRUCTURE OF DAPK1 IN THE PRESENCE OF BROMIDE IONS.
1948, d5av0A_, 0.7875, 2.65, 0.251, 275, 251, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH 73 4 - TRIHYDROXYISOFLAVONE.
1949, d2ya9B_, 0.7875, 2.77, 0.232, 299, 254, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
1950, d1zoeA_, 0.7875, 2.85, 0.211, 325, 256, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
1951, d1okzA_, 0.7875, 2.57, 0.209, 276, 249, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH UCN-01
1952, d5w5oD_, 0.7874, 2.18, 0.264, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1953, d5nkbA_, 0.7874, 2.65, 0.333, 285, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4A
1954, d5mowB_, 0.7874, 2.93, 0.223, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1955, d5moeB_, 0.7874, 2.84, 0.220, 323, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1956, d5lvnA_, 0.7874, 2.75, 0.202, 283, 253, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENOSINE BOUND TO THE ATP- BINDING SITE
1957, d5h8gA_, 0.7874, 2.79, 0.209, 324, 254, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7B
1958, d4w8eA_, 0.7874, 2.82, 0.261, 290, 253, STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF-06645342)
1959, d4qmyA_, 0.7874, 2.84, 0.265, 287, 253, MST3 IN COMPLEX WITH STAUROSPORINE
1960, d4fbxA_, 0.7874, 2.83, 0.227, 333, 256, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT CRYSTALLIZED IN THE PRESENCE OF A BISUBSTRATE INHIBITOR
1961, d3u4uA_, 0.7874, 2.91, 0.223, 327, 256, CASEIN KINASE 2 IN COMPLEX WITH AZ-INHIBITOR
1962, d2uw9A_, 0.7874, 2.69, 0.242, 316, 252, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1963, d2pe0A_, 0.7874, 2.47, 0.211, 275, 247, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-HYDROXY-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-13-DIHYDRO- INDOL-2-ONE COMPLEX
1964, d5fbnD_, 0.7873, 2.63, 0.305, 255, 249, BTK KINASE DOMAIN WITH INHIBITOR 1
1965, d4eklA_, 0.7873, 2.69, 0.242, 329, 252, AKT1 WITH GDC0068
1966, d4cxaA_, 0.7873, 2.87, 0.239, 329, 255, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
1967, d3zh8B_, 0.7873, 2.77, 0.190, 317, 253, A NOVEL SMALL MOLECULE APKC INHIBITOR
1968, d3nx8A_, 0.7873, 2.85, 0.237, 333, 253, HUMAN CAMP DEPENDENT PROTEIN KINASE IN COMPLEX WITH PHENOL
1969, d3e88B_, 0.7873, 2.71, 0.242, 319, 252, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1970, d3e88A_, 0.7873, 2.71, 0.242, 319, 252, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1971, d2uzbA_, 0.7873, 2.72, 0.255, 295, 251, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
1972, d2jdoA_, 0.7873, 2.70, 0.246, 314, 252, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1973, d1zwsG_, 0.7873, 2.79, 0.224, 278, 255, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1974, d1jkkA_, 0.7873, 2.79, 0.249, 277, 253, 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.
1975, d1j91B_, 0.7873, 2.90, 0.207, 327, 256, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
1976, d1bygA_, 0.7873, 2.07, 0.361, 246, 241, KINASE DOMAIN OF HUMAN C-TERMINAL SRC KINASE (CSK) IN COMPLEX WITH INHIBITOR STAUROSPORINE
1977, d5uoxA_, 0.7872, 2.65, 0.291, 263, 247, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
1978, d4bn1A_, 0.7872, 2.66, 0.231, 261, 251, CRYSTAL STRUCTURE OF V174M MUTANT OF AURORA-A KINASE
1979, d3tnqB_, 0.7872, 2.67, 0.231, 331, 251, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1980, d3f5pA1, 0.7872, 3.20, 0.298, 298, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1981, d3cpcA1, 0.7872, 2.10, 0.372, 277, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
1982, d1zwsH_, 0.7872, 2.86, 0.227, 278, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1983, p5v62A_, 0.7871, 2.85, 0.233, 349, 253, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP3
1984, d5mo5B_, 0.7871, 2.93, 0.219, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1985, d4g2fA_, 0.7871, 2.66, 0.328, 275, 247, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 7
1986, d3prfB_, 0.7871, 2.41, 0.272, 262, 246, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
1987, d3g6gA_, 0.7871, 2.31, 0.337, 264, 246, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
1988, d3dfcB1, 0.7871, 2.73, 0.250, 276, 252, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH AMPPNP
1989, d2v7oA1, 0.7871, 2.78, 0.217, 297, 254, CRYSTAL STRUCTURE OF HUMAN CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II GAMMA
1990, d1zwsF_, 0.7871, 2.80, 0.227, 278, 255, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1991, d5cshA_, 0.7870, 2.92, 0.223, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
1992, d4appA1, 0.7870, 2.86, 0.185, 290, 254, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH (S)-N-(5-(3-BENZYL-1-METHYLPIPERAZINE-4- CARBONYL)-66-DIMETHYL-1456-TETRAHYDROPYRROLO(34-C) PYRAZOL-3-YL)-3-PHENOXYBENZAMIDE
1993, d3f5gA1, 0.7870, 2.66, 0.251, 275, 251, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH ADP AND MG2+
1994, d3f3uA_, 0.7870, 2.23, 0.340, 261, 244, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
1995, d2x4fB_, 0.7870, 2.80, 0.213, 288, 254, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
1996, d5i9zA_, 0.7869, 2.59, 0.332, 273, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DANUSERTIB (PHA739358)
1997, d4kabA_, 0.7869, 2.35, 0.343, 255, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
1998, d2owbA_, 0.7869, 2.89, 0.268, 294, 254, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1999, d4q9zA1, 0.7868, 2.71, 0.234, 330, 252, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
2000, d4mneF_, 0.7868, 2.26, 0.254, 258, 244, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
2001, d4eosC1, 0.7868, 2.75, 0.255, 295, 251, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2002, d3zewB_, 0.7868, 2.25, 0.324, 252, 241, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
2003, d3q6uA1, 0.7868, 2.44, 0.332, 281, 244, STRUCTURE OF THE APO MET RECEPTOR KINASE IN THE DUALLY-PHOSPHORYLATED ACTIVATED STATE
2004, d3o2mB_, 0.7868, 2.89, 0.198, 358, 253, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
2005, d3f5pI1, 0.7868, 3.19, 0.298, 293, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2006, d2jedA_, 0.7868, 2.73, 0.254, 324, 252, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
2007, d5ta6A_, 0.7867, 3.02, 0.255, 294, 255, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR.
2008, d5nk3A_, 0.7867, 2.89, 0.329, 281, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1L
2009, d5ia4A_, 0.7867, 2.77, 0.309, 269, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH FORETINIB (XL880)
2010, d4ra4A_, 0.7867, 2.74, 0.217, 317, 253, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE C ALPHA IN COMPLEX WITH COMPOUND 28 ((R)-6-((3S4S)-13-DIMETHYL-PIPERIDIN-4-YL)-7-(2-FLUORO- PHENYL)-4-METHYL-210-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
2011, d4oabA_, 0.7867, 2.73, 0.233, 279, 249,  
2012, d3juhA_, 0.7867, 2.76, 0.221, 334, 253, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
2013, d2qo9A_, 0.7867, 2.70, 0.310, 277, 248, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION PHOSPHORYLATED AMP-PNP BOUND
2014, d2cchA2, 0.7867, 2.73, 0.263, 295, 251, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
2015, d5w5oG_, 0.7866, 2.20, 0.264, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2016, d5ta8A_, 0.7866, 2.93, 0.252, 294, 254, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR
2017, p5owlA_, 0.7866, 2.90, 0.227, 331, 256, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
2018, d5nqcA_, 0.7866, 2.76, 0.213, 331, 253, CK2ALPHA IN COMPLEX WITH NMR154
2019, d3e87B_, 0.7866, 2.72, 0.242, 321, 252, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2020, d3e87A_, 0.7866, 2.72, 0.242, 321, 252, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2021, d1pjkA_, 0.7866, 2.93, 0.219, 331, 256, CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
2022, d1fmkA3, 0.7866, 2.37, 0.336, 270, 247, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC
2023, d5xvuA_, 0.7865, 2.82, 0.229, 321, 253, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
2024, d5u6bC_, 0.7865, 2.56, 0.332, 270, 247, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
2025, d5sysA_, 0.7865, 2.05, 0.332, 258, 241, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
2026, d5i3oA_, 0.7865, 2.75, 0.214, 302, 248, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2027, d5hq0A1, 0.7865, 2.90, 0.258, 289, 252, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
2028, d4y72A1, 0.7865, 2.90, 0.258, 289, 252, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
2029, d4gu9A_, 0.7865, 2.37, 0.343, 252, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
2030, d3orzD_, 0.7865, 2.64, 0.208, 278, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2031, d3h9oA_, 0.7865, 2.49, 0.211, 275, 247, PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK-1) IN COMPLEX WITH COMPOUND 9
2032, d3f5pK1, 0.7865, 3.16, 0.300, 292, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2033, d3f5pB1, 0.7865, 3.21, 0.298, 297, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2034, d3eh9A1, 0.7865, 2.67, 0.251, 274, 251, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH ADP
2035, d2ofvA2, 0.7865, 2.11, 0.374, 243, 238, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 1 BOUND TO LCK
2036, d2g9xC2, 0.7865, 2.76, 0.259, 273, 251, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
2037, d4oa6A_, 0.7864, 2.73, 0.229, 279, 249,  
2038, d4krdA_, 0.7864, 2.82, 0.246, 294, 252, CRYSTAL STRUCTURE OF PHO85-PCL10 COMPLEX
2039, d4j53A_, 0.7864, 2.90, 0.260, 293, 254, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH TAK-960
2040, d4dceB_, 0.7864, 2.27, 0.314, 284, 242, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
2041, d3v5lA1, 0.7864, 1.80, 0.322, 238, 236, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
2042, d3orzB_, 0.7864, 2.64, 0.208, 278, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2043, d3f5pD1, 0.7864, 3.22, 0.298, 296, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2044, d3blqA_, 0.7864, 2.94, 0.236, 295, 254, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
2045, d2uzlA_, 0.7864, 2.73, 0.255, 295, 251, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2046, d2qurA_, 0.7864, 2.83, 0.233, 338, 253, CRYSTAL STRUCTURE OF F327A/K285P MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
2047, d2c6tA_, 0.7864, 2.87, 0.256, 295, 254, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2048, d1z5mA_, 0.7864, 2.48, 0.211, 275, 247, CRYSTAL STRUCTURE OF N1-[3-[[5-BROMO-2-[[3-[(1-PYRROLIDINYLCARBONYL) AMINO]PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PROPYL]-22- DIMETHYLPROPANEDIAMIDE COMPLEXED WITH HUMAN PDK1
2049, d5xgmA_, 0.7863, 2.55, 0.378, 288, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH GO6976
2050, d5auwA_, 0.7863, 2.61, 0.256, 274, 250, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH QUERCETIN.
2051, d4ct1A_, 0.7863, 2.74, 0.209, 283, 253, HUMAN PDK1-PKCZETA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS315 BOUND TO THE PIF-POCKET
2052, d3fl5A_, 0.7863, 2.89, 0.207, 324, 256, PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR QUINALIZARIN
2053, d3dpkA_, 0.7863, 2.34, 0.333, 279, 243, CFMS TYROSINE KINASE IN COMPLEX WITH A PYRIDOPYRIMIDINONE INHIBITOR
2054, d5v24B_, 0.7862, 2.54, 0.289, 263, 246, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2055, d5modB_, 0.7862, 2.93, 0.219, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2056, d4qmsA_, 0.7862, 3.01, 0.260, 283, 254, MST3 IN COMPLEX WITH DASATINIB
2057, d4gu6B_, 0.7862, 2.47, 0.374, 258, 246, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
2058, d4f65A_, 0.7862, 2.82, 0.382, 279, 249, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
2059, d3f5pG1, 0.7862, 3.22, 0.298, 298, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2060, d3f5pC1, 0.7862, 3.21, 0.298, 300, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2061, d2rkuA_, 0.7862, 3.02, 0.255, 294, 255, STRUCTURE OF PLK1 IN COMPLEX WITH BI2536
2062, p2h96B_, 0.7862, 2.90, 0.198, 357, 253, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
2063, d1ol5A_, 0.7862, 2.88, 0.209, 263, 253, STRUCTURE OF AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288 AND BOUND TO TPX2 1-43
2064, d5xvuB_, 0.7861, 2.83, 0.229, 321, 253, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
2065, d4wsqB_, 0.7861, 2.75, 0.226, 310, 248, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2066, d4ra5A1, 0.7861, 2.79, 0.237, 331, 253, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
2067, d4r1yA_, 0.7861, 2.53, 0.317, 265, 243, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITOR
2068, d3u51B_, 0.7861, 1.93, 0.343, 255, 239, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
2069, d3tl8G_, 0.7861, 2.81, 0.257, 301, 253, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
2070, d3nuuA_, 0.7861, 2.59, 0.209, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT11
2071, d1f0qA_, 0.7861, 2.89, 0.211, 329, 256, CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN
2072, d5i3rA_, 0.7860, 2.77, 0.214, 302, 248, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2073, d5av3A_, 0.7860, 2.66, 0.251, 275, 251, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF IODIDE IONS.
2074, d3qd4A_, 0.7860, 2.58, 0.214, 276, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL{(3R5R)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-5-METHYL-3-PIPERIDINYL}CARBAMATE
2075, d3o2mA_, 0.7860, 2.79, 0.198, 358, 252, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
2076, d2jdvA_, 0.7860, 2.84, 0.237, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH A-443654
2077, d1yomA_, 0.7860, 2.08, 0.336, 260, 241, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
2078, d5auvA_, 0.7859, 2.68, 0.251, 275, 251, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH APIGENIN.
2079, d3a7fA_, 0.7859, 2.66, 0.265, 283, 249, HUMAN MST3 KINASE
2080, d5j79B_, 0.7858, 2.34, 0.270, 277, 244, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
2081, d5auxA_, 0.7858, 2.70, 0.255, 275, 251, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH KAEMPFEROL.
2082, d4qmxA_, 0.7858, 2.88, 0.257, 287, 253, MST3 IN COMPLEX WITH SARACATINIB
2083, d3oezB_, 0.7858, 2.22, 0.342, 261, 243, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
2084, d3f5pS1, 0.7858, 3.20, 0.298, 294, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2085, d5xvuC_, 0.7857, 2.83, 0.229, 321, 253, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
2086, p5omyA_, 0.7857, 2.87, 0.227, 332, 256, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
2087, d5m4fA_, 0.7857, 2.94, 0.227, 330, 256, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER LOW-SALT CONDITIONS
2088, d4yneA1, 0.7857, 2.39, 0.388, 276, 245, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
2089, d4qmzA_, 0.7857, 2.88, 0.257, 286, 253, MST3 IN COMPLEX WITH SUNITINIB
2090, d3f5pM1, 0.7857, 3.11, 0.300, 294, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2091, d3e8dB_, 0.7857, 2.72, 0.242, 317, 252, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2092, d3e8dA_, 0.7857, 2.72, 0.242, 315, 252, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2093, d1jktA_, 0.7857, 2.87, 0.249, 276, 253, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2094, d5cyiC1, 0.7856, 2.74, 0.255, 295, 251, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
2095, d5ctpA_, 0.7856, 2.95, 0.219, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
2096, d2pe1A_, 0.7856, 2.48, 0.211, 275, 247, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-OXO-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-23-DIHYDRO-1H- INDOL-5-YL}-UREA {BX-517} COMPLEX
2097, d5w5oE_, 0.7855, 2.21, 0.264, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2098, d5u6bA_, 0.7855, 2.58, 0.332, 270, 247, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
2099, d5av4A_, 0.7855, 2.63, 0.252, 274, 250, CRYSTAL STRUCTURE OF DAPK1-GENISTEIN COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2100, d4uv0A_, 0.7855, 2.87, 0.243, 300, 255, STRUCTURE OF A SEMISYNTHETIC PHOSPHORYLATED DAPK
2101, d3f5pH1, 0.7855, 3.24, 0.298, 298, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2102, d2ou7A_, 0.7855, 2.99, 0.263, 292, 255, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
2103, d5av2A_, 0.7854, 2.68, 0.251, 275, 251, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2104, d4qnaA_, 0.7854, 3.03, 0.260, 284, 254, MST3 IN COMPLEX WITH 2-(46-DIAMINO-135-TRIAZIN-2-YL)PHENOL
2105, d3qkmA_, 0.7854, 2.71, 0.242, 329, 252, SPIROCYCLIC SULFONAMIDES AS AKT INHIBITORS
2106, d3f5pL1, 0.7854, 3.17, 0.300, 292, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2107, d3a7iA_, 0.7854, 2.88, 0.253, 286, 253, HUMAN MST3 KINASE IN COMPLEX WITH ADENINE
2108, d2uzlC_, 0.7854, 2.75, 0.255, 295, 251, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2109, d5auyA_, 0.7853, 2.68, 0.251, 275, 251, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH MORIN.
2110, d4qmuA_, 0.7853, 2.90, 0.253, 286, 253, MST3 IN COMPLEX WITH JNJ-7706621 4-({5-AMINO-1-[(26-DIFLUOROPHENYL) CARBONYL]-1H-124-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE
2111, d4mnfA_, 0.7853, 2.33, 0.270, 257, 244, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
2112, d4e26B_, 0.7853, 2.52, 0.262, 264, 248, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
2113, d3wzdA_, 0.7853, 2.35, 0.385, 278, 244, KDR IN COMPLEX WITH LIGAND LENVATINIB
2114, d5w5oA_, 0.7852, 2.22, 0.264, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2115, d5swhA_, 0.7852, 2.05, 0.336, 258, 241, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
2116, d5ia0C_, 0.7852, 2.44, 0.339, 269, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
2117, d4nusA_, 0.7852, 3.03, 0.262, 301, 256, RSK2 N-TERMINAL KINASE IN COMPLEX WITH LJH685
2118, d4at3A1, 0.7852, 2.93, 0.364, 286, 250, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N
2119, d3q53A_, 0.7852, 3.06, 0.210, 291, 257, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN IN COMPLEX WITH ATP
2120, d3ocbB_, 0.7852, 2.73, 0.250, 319, 252, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
2121, d3ehaA1, 0.7852, 2.69, 0.251, 275, 251, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH AMPPNP
2122, d3cd8A_, 0.7852, 2.76, 0.339, 278, 248, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
2123, d3bhuC1, 0.7852, 2.78, 0.255, 269, 251, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
2124, d5i3oB_, 0.7851, 2.89, 0.217, 302, 249, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2125, p3o17A_, 0.7851, 2.86, 0.198, 357, 253, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
2126, d1wvyA_, 0.7851, 2.93, 0.248, 273, 254, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2127, d1jwhA_, 0.7851, 2.74, 0.217, 336, 253, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
2128, d5w5oH_, 0.7850, 2.23, 0.264, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2129, d3v5lB1, 0.7850, 1.77, 0.315, 239, 235, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
2130, d3qcyA_, 0.7850, 2.57, 0.210, 275, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 4-[2- AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-N-PHENYL-2- MORPHOLINECARBOXAMIDE
2131, d1zwsA_, 0.7850, 2.86, 0.227, 278, 255, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2132, d4o0tA_, 0.7849, 2.91, 0.208, 292, 255, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2133, d3en5B_, 0.7849, 2.26, 0.350, 261, 243, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
2134, d3ddpC1, 0.7849, 2.75, 0.255, 297, 251, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
2135, d3e5aA_, 0.7848, 2.85, 0.198, 264, 253, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH VX-680 AND TPX2
2136, d3cqwA_, 0.7848, 2.77, 0.246, 318, 252, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
2137, d2nruA_, 0.7848, 2.95, 0.239, 293, 251, CRYSTAL STRUCTURE OF IRAK-4
2138, d5lpbA_, 0.7847, 2.65, 0.231, 280, 247, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
2139, d4f0iA_, 0.7847, 2.70, 0.379, 284, 248, CRYSTAL STRUCTURE OF APO TRKA
2140, d3g6hB_, 0.7847, 2.13, 0.339, 259, 242, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
2141, d3f5pF1, 0.7847, 3.23, 0.298, 298, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2142, d3ckxA_, 0.7847, 2.64, 0.264, 276, 250, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24) IN COMPLEX WITH STAUROSPORINE
2143, d2ofvB2, 0.7847, 1.97, 0.379, 243, 235, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 1 BOUND TO LCK
2144, d1h1sC1, 0.7847, 2.74, 0.255, 295, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
2145, d4qmnA_, 0.7846, 3.03, 0.260, 283, 254, MST3 IN COMPLEX WITH BOSUTINIB
2146, d3rhkA_, 0.7846, 2.91, 0.304, 298, 250, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
2147, d3iopA_, 0.7846, 2.52, 0.211, 275, 247, PDK-1 IN COMPLEX WITH THE INHIBITOR COMPOUND-8I
2148, d2uzeA_, 0.7846, 2.76, 0.255, 295, 251, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2149, d2r7iB_, 0.7846, 2.77, 0.221, 322, 253, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2150, d5ar5B_, 0.7845, 2.27, 0.272, 279, 243, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
2151, d4v01A_, 0.7845, 2.52, 0.388, 273, 245, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
2152, d3v5jB1, 0.7845, 1.72, 0.321, 239, 234, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
2153, d2uzeC_, 0.7845, 2.75, 0.255, 295, 251, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2154, d1oiyC1, 0.7845, 2.76, 0.255, 295, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2155, d1gy3C_, 0.7845, 2.75, 0.255, 295, 251, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
2156, d5v60A_, 0.7844, 2.94, 0.232, 347, 254, PHOSPHO-ERK2 BOUND TO AMP-PCP
2157, d5nhjA_, 0.7844, 3.11, 0.230, 345, 256, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2158, d4bcnC1, 0.7844, 2.75, 0.255, 293, 251, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2159, d3bhvC1, 0.7844, 2.75, 0.255, 269, 251, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
2160, d3bhhA1, 0.7844, 2.49, 0.222, 287, 248, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2161, d5jkgA_, 0.7843, 2.54, 0.393, 266, 247, THE CRYSTAL STRUCTURE OF FGFR4 KINASE DOMAIN IN COMPLEX WITH LY2874455
2162, d5ia0B_, 0.7843, 2.63, 0.333, 266, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
2163, d5auuA_, 0.7843, 2.65, 0.252, 274, 250, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH LUTEOLIN.
2164, d2rkpA_, 0.7843, 2.79, 0.213, 334, 253,  
2165, d1oguC1, 0.7843, 2.78, 0.255, 269, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
2166, d1jstC_, 0.7843, 2.75, 0.255, 297, 251, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
2167, d6babB_, 0.7842, 2.33, 0.241, 285, 245, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2168, d5efqA_, 0.7842, 2.97, 0.258, 321, 256, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
2169, d4qmtA_, 0.7842, 2.91, 0.257, 284, 253, MST3 IN COMPLEX WITH HESPERADIN
2170, d4q9zB_, 0.7842, 2.88, 0.213, 308, 254, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
2171, d4knbA_, 0.7842, 2.99, 0.336, 273, 250, C-MET IN COMPLEX WITH OSI LIGAND
2172, d4eomC1, 0.7842, 2.78, 0.259, 271, 251, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2173, d4eojC1, 0.7842, 2.80, 0.259, 278, 251, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
2174, d3tudA1, 0.7842, 2.42, 0.361, 255, 244, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH N-(4-METHYL-3-(8-METHYL-7- OXO-2-(PHENYLAMINO)-78-DIHYDROPYRIDO[23-D]PYRIMIDIN-6-YL)PHENYL)-3- (TRIFLUOROMETHYL)BENZAMIDE
2175, d3ky2B_, 0.7842, 2.68, 0.395, 280, 248, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
2176, d3gqlB_, 0.7842, 2.60, 0.399, 276, 248, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
2177, d4uwyB_, 0.7841, 2.53, 0.394, 273, 246, FGFR1 APO STRUCTURE
2178, d4dceA_, 0.7841, 2.51, 0.314, 288, 245, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
2179, d4aw0A_, 0.7841, 2.79, 0.202, 283, 253, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS182 BOUND TO THE PIF-POCKET
2180, d3qklA_, 0.7841, 2.76, 0.242, 317, 252, SPIROCHROMANE AKT INHIBITORS
2181, d3mvhA_, 0.7841, 2.71, 0.247, 311, 251, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
2182, d3fzoA_, 0.7841, 2.75, 0.378, 262, 249, CRYSTAL STRUCTURE OF PYK2-APO PROLINE-RICH TYROSINE KINASE
2183, d2wmbC1, 0.7841, 2.65, 0.257, 265, 249, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2184, d2r7iD_, 0.7841, 2.81, 0.221, 322, 253, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2185, d2pe2A_, 0.7841, 2.52, 0.211, 275, 247, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-OXO-5-UREIDO-12-DIHYDRO-INDOL-(3Z)-YLIDENEMETHYL]-1H- PYRROL-3-YL}-N-(2-PIPERIDIN-1-YL-ETHYL)-BENZAMIDE COMPLEX
2186, d2c5nA_, 0.7841, 2.79, 0.250, 296, 252, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2187, d1gy3A_, 0.7841, 2.76, 0.255, 295, 251, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
2188, d5jfsA_, 0.7840, 2.45, 0.389, 277, 244, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-00593174
2189, d4dggB_, 0.7840, 2.34, 0.354, 259, 243, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
2190, d3rpsA_, 0.7840, 2.76, 0.202, 334, 252, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
2191, d3h30A_, 0.7840, 2.79, 0.213, 333, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
2192, d3f5pR1, 0.7840, 3.25, 0.298, 293, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2193, d3f5pJ1, 0.7840, 3.18, 0.300, 292, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2194, d2clqA_, 0.7840, 2.70, 0.285, 263, 249, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2195, d1oi9C1, 0.7840, 2.78, 0.255, 295, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2196, d5jfxA_, 0.7839, 2.44, 0.389, 277, 244, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-06273340
2197, d5auzA_, 0.7839, 2.66, 0.252, 274, 250, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH GENISTEIN.
2198, d4grbA_, 0.7839, 2.95, 0.223, 327, 256, CASEIN KINASE 2 (CK2) BOUND TO INHIBITOR
2199, d4dawA_, 0.7839, 3.09, 0.206, 293, 257, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH THE RUTHENIUM PHTHALIMIDE COMPLEX
2200, d4au8B_, 0.7839, 2.56, 0.229, 277, 245, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
2201, d3rpsB_, 0.7839, 2.84, 0.212, 334, 255, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
2202, d3f66B_, 0.7839, 2.75, 0.335, 269, 248, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
2203, d3f5uA1, 0.7839, 2.74, 0.251, 275, 251, CRYSTAL STRUCTURE OF THE DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH AMPPNP AND MG2+
2204, d2wxvA1, 0.7839, 2.80, 0.250, 298, 252, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
2205, d1ol1C_, 0.7839, 2.82, 0.250, 296, 252, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
2206, d6bqpA1, 0.7838, 2.77, 0.225, 262, 249, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CRENOLANIB
2207, d5i3rB_, 0.7838, 2.90, 0.217, 302, 249, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2208, d4qmlA_, 0.7838, 2.74, 0.255, 280, 251, MST3 IN COMPLEX WITH AMP-PNP
2209, d2jedB1, 0.7838, 2.77, 0.226, 315, 252, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
2210, d1h1rC1, 0.7838, 2.78, 0.255, 295, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
2211, d1h1qC1, 0.7838, 2.76, 0.255, 295, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
2212, d5lpzA_, 0.7837, 2.64, 0.235, 283, 247, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1196) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
2213, d5kmnA1, 0.7837, 2.83, 0.376, 290, 250, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
2214, d4u45A_, 0.7837, 2.78, 0.225, 289, 249, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
2215, d3zfxC_, 0.7837, 1.95, 0.343, 248, 236, CRYSTAL STRUCTURE OF EPHB1
2216, d3f5pE1, 0.7837, 3.25, 0.298, 298, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2217, d2c5xC_, 0.7837, 2.81, 0.254, 296, 252, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2218, d5w5oL_, 0.7836, 2.33, 0.259, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2219, d3qriB_, 0.7836, 2.58, 0.382, 262, 246, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
2220, d3qkkA_, 0.7836, 2.75, 0.242, 326, 252, SPIROCHROMANE AKT INHIBITORS
2221, d3ha6A1, 0.7836, 2.76, 0.210, 262, 252, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH TPX2 AND COMPOUND 10
2222, p2gmxB_, 0.7836, 2.90, 0.198, 357, 253, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
2223, d6babC_, 0.7835, 2.32, 0.241, 284, 245, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2224, d5t18A1, 0.7835, 2.45, 0.299, 259, 244, CRYSTAL STRUCTURE OF BRUTON AGAMMABULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-986142 AKA (2S)-6-FLUORO-5-[3-(8-FLUORO-1-METHYL-24-DIOXO- 1234-TETRAHYDROQUINAZOLIN-3-YL)-2-METHYLPHENYL]-2-(2- HYDROXYPROPAN-2-YL)-2349-TETRAHYDRO-1H-CARBAZOLE-8-CARBOXAMIDE
2225, d2b9iA_, 0.7835, 2.59, 0.235, 338, 247, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM MSG5
2226, d4wunA_, 0.7834, 2.60, 0.402, 282, 246, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
2227, d4bcoC1, 0.7834, 2.81, 0.259, 268, 251, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2228, d3a7jA_, 0.7834, 2.91, 0.253, 286, 253, HUMAN MST3 KINASE IN COMPLEX WITH MNADP
2229, d2reiA1, 0.7834, 2.48, 0.344, 274, 244, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7)
2230, d5uq0A_, 0.7833, 2.37, 0.403, 266, 243, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
2231, d5i9wA_, 0.7833, 2.25, 0.343, 267, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ANP
2232, d3tt0B_, 0.7833, 2.45, 0.400, 272, 245, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
2233, d3miyA1, 0.7833, 1.69, 0.326, 237, 233, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
2234, d3ccnA_, 0.7833, 2.79, 0.340, 275, 247, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
2235, d5w5oF_, 0.7832, 2.28, 0.264, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2236, d5uorB_, 0.7832, 2.53, 0.294, 262, 245, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2237, d5lvmA_, 0.7832, 2.78, 0.202, 283, 253, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENINE BOUND TO THE ATP- BINDING SITE
2238, d5cvfA_, 0.7832, 2.89, 0.220, 325, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
2239, p4fmqA_, 0.7832, 2.84, 0.226, 350, 252, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
2240, d3tl8A_, 0.7832, 2.80, 0.258, 300, 252, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
2241, d3ionA_, 0.7832, 2.49, 0.211, 274, 246, PDK1 IN COMPLEX WITH COMPOUND 8H
2242, d2iw8A1, 0.7832, 2.76, 0.247, 296, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
2243, d1urcC_, 0.7832, 2.83, 0.250, 296, 252, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
2244, d5m4uA_, 0.7831, 2.91, 0.215, 332, 256, ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
2245, d4ybjB_, 0.7831, 2.01, 0.335, 253, 239, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
2246, d4nstA_, 0.7831, 2.95, 0.242, 322, 256, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
2247, d4eopA1, 0.7831, 2.75, 0.255, 294, 251, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2248, d4cfwC1, 0.7831, 2.77, 0.255, 295, 251, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2249, d3rhkB_, 0.7831, 2.81, 0.305, 299, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
2250, d3lm0A1, 0.7831, 2.50, 0.224, 271, 246, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B)
2251, d3gqlC_, 0.7831, 2.56, 0.399, 275, 248, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
2252, d3f3vA_, 0.7831, 2.41, 0.335, 261, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
2253, p2h96A_, 0.7831, 2.89, 0.198, 358, 253, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
2254, d5w5oP_, 0.7830, 2.28, 0.260, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2255, d4qmwA_, 0.7830, 2.91, 0.253, 286, 253, MST3 IN COMPLEX WITH PP-121 1-CYCLOPENTYL-3-(1H-PYRROLO[23- B]PYRIDIN-5-YL)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
2256, d3f3wA_, 0.7830, 2.30, 0.340, 261, 244, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
2257, d2cciC2, 0.7830, 2.94, 0.256, 295, 254, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
2258, d5w5oC_, 0.7829, 2.29, 0.260, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2259, d4kaoB_, 0.7829, 2.49, 0.346, 254, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
2260, d4eooC1, 0.7829, 2.78, 0.255, 295, 251, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2261, d4cfuC1, 0.7829, 2.78, 0.255, 269, 251, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2262, d3f3vB_, 0.7829, 2.31, 0.336, 262, 244, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
2263, d1okuC_, 0.7829, 2.82, 0.254, 296, 252,  
2264, d5w5oB_, 0.7828, 2.29, 0.264, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2265, d4v04A_, 0.7828, 2.57, 0.390, 290, 246, FGFR1 IN COMPLEX WITH PONATINIB.
2266, d3h30B_, 0.7828, 2.81, 0.213, 333, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
2267, d2iw9C2, 0.7828, 2.71, 0.257, 267, 249, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2268, d1h26C1, 0.7828, 2.71, 0.257, 266, 249, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
2269, d2oh4A1, 0.7827, 2.67, 0.383, 296, 248, CRYSTAL STRUCTURE OF VEGFR2 WITH A BENZIMIDAZOLE-UREA INHIBITOR
2270, d5nhoA_, 0.7826, 3.10, 0.220, 343, 255, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2271, d5bvnA_, 0.7826, 2.72, 0.332, 278, 250, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
2272, d3u6iA_, 0.7826, 2.70, 0.314, 281, 245, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 58A
2273, d3orzA_, 0.7826, 2.57, 0.210, 276, 248, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2274, d2y0aA_, 0.7826, 2.94, 0.239, 300, 255, STRUCTURE OF DAPK1 CONSTRUCT RESIDUES 1-304
2275, p2g01B_, 0.7826, 2.92, 0.198, 356, 253, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
2276, d5mrdA_, 0.7825, 2.79, 0.206, 283, 253, HUMAN PDK1-PKCIOTA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS267 BOUND TO THE PIF-POCKET
2277, d4nkaA_, 0.7825, 2.56, 0.390, 279, 246, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
2278, d4bcmC1, 0.7825, 2.78, 0.255, 293, 251, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2279, d3orzC_, 0.7825, 2.57, 0.210, 276, 248, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2280, d2c5vA_, 0.7825, 2.82, 0.250, 296, 252, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2281, d5mp8B_, 0.7824, 2.90, 0.220, 323, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
2282, d5jfwA_, 0.7824, 2.48, 0.389, 277, 244, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05247452
2283, d4ra5B_, 0.7824, 2.80, 0.210, 310, 252, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
2284, d4pmsA1, 0.7824, 2.66, 0.379, 279, 248, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 4-NAPHTHALEN-1-YL- 1-[(5-PHENYL-124-OXADIAZOL-3-YL)METHYL]-1H-PYRROLO[32-C]PYRIDINE- 2-CARBOXYLIC ACID
2285, d2x0gA_, 0.7824, 2.94, 0.224, 318, 254, X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX
2286, d2c5vC_, 0.7824, 2.82, 0.254, 296, 252, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2287, d5w5oI_, 0.7823, 2.34, 0.259, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2288, d5uyjA1, 0.7823, 2.90, 0.224, 279, 250, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2289, d4uy9A_, 0.7823, 2.84, 0.312, 313, 250, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
2290, d3tz8A_, 0.7823, 2.41, 0.335, 261, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
2291, d3o7lB_, 0.7823, 2.78, 0.220, 326, 250, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
2292, d1okuA_, 0.7823, 2.82, 0.250, 296, 252,  
2293, p5v61A_, 0.7822, 3.07, 0.231, 348, 255, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP2
2294, d4cfnC1, 0.7822, 2.78, 0.255, 293, 251, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2295, d2oibD_, 0.7822, 3.09, 0.238, 288, 252, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
2296, d5te0A_, 0.7821, 2.73, 0.227, 316, 247, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH BIBF 1120
2297, d3ddpA1, 0.7821, 2.78, 0.255, 296, 251, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
2298, d2xzsA_, 0.7821, 3.11, 0.226, 301, 257, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
2299, d5fboA_, 0.7820, 2.45, 0.309, 255, 246, BTK-INHIBITOR CO-STRUCTURE
2300, d2c4gA2, 0.7820, 2.82, 0.250, 297, 252, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
2301, d5bpyB1, 0.7819, 2.45, 0.311, 246, 244, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
2302, d4eqcA1, 0.7819, 3.11, 0.210, 292, 257, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN IN COMPLEX WITH FRAX597 INHIBITOR
2303, d4a07A_, 0.7819, 2.79, 0.202, 282, 252, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS171 BOUND TO THE PIF-POCKET
2304, p2no3B_, 0.7819, 2.86, 0.198, 357, 252, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
2305, d3qd0A_, 0.7818, 2.56, 0.211, 274, 247, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH (2R5S)- 1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-N- PHENYL-3-PIPERIDINECARBOXAMIDE
2306, d3my5C1, 0.7818, 2.71, 0.257, 265, 249, CDK2/CYCLINA IN COMPLEX WITH DRB
2307, d3i5nA_, 0.7818, 2.99, 0.333, 280, 249, CRYSTAL STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR 13
2308, d2iw6C2, 0.7818, 2.81, 0.255, 294, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2309, d2dwbA_, 0.7818, 2.62, 0.234, 259, 248, AURORA-A KINASE COMPLEXED WITH AMPPNP
2310, d1vywA1, 0.7818, 2.82, 0.250, 298, 252, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
2311, d4rwjB_, 0.7817, 2.74, 0.379, 282, 248, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
2312, d4nifB_, 0.7817, 2.86, 0.226, 349, 252, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
2313, d3hrcA_, 0.7817, 2.73, 0.203, 279, 251, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ATP
2314, d3f66A_, 0.7817, 2.87, 0.333, 288, 249, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
2315, d2og8B2, 0.7817, 2.25, 0.368, 247, 242, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
2316, d2c5oC_, 0.7817, 2.84, 0.250, 296, 252, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2317, d1zwsE_, 0.7817, 2.83, 0.213, 278, 254, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2318, d1uu3A_, 0.7817, 2.61, 0.210, 276, 248, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH LY333531
2319, d5os2A_, 0.7816, 2.61, 0.234, 261, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2320, d5kmlA1, 0.7816, 2.86, 0.376, 290, 250, TRKA JM-KINASE WITH 1-(5-METHYL-3-PHENYL-12-OXAZOL-4-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
2321, d4pdoB_, 0.7816, 2.22, 0.337, 261, 240, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
2322, d4pdoA_, 0.7816, 2.22, 0.337, 261, 240, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
2323, d4nstC_, 0.7816, 3.01, 0.250, 317, 256, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
2324, d4kioA1, 0.7816, 1.79, 0.321, 238, 234, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
2325, p4jr7A_, 0.7816, 2.75, 0.203, 367, 251, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
2326, d3tz9A_, 0.7816, 2.43, 0.335, 261, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
2327, d3bhuA1, 0.7816, 2.79, 0.255, 295, 251, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
2328, p2no3A_, 0.7816, 2.83, 0.198, 357, 252, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
2329, d1uv5A_, 0.7816, 3.16, 0.230, 348, 256, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3 -OXIME
2330, d6bleA1, 0.7815, 2.87, 0.224, 263, 250, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CP673451
2331, d5nhhA_, 0.7815, 3.18, 0.234, 348, 256, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2332, d5autA_, 0.7815, 2.74, 0.247, 274, 251, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH ANS.
2333, d4ztmA_, 0.7815, 3.00, 0.237, 287, 249, IRAK4-INHIBITOR CO-STRUCTURE
2334, d4twoA_, 0.7815, 2.69, 0.313, 278, 246, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 164
2335, d4nifE_, 0.7815, 2.86, 0.226, 348, 252, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
2336, d4eoiA1, 0.7815, 2.77, 0.255, 293, 251, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2337, d3ulzA_, 0.7815, 2.87, 0.257, 291, 249, CRYSTAL STRUCTURE OF APO BAK1
2338, d3be2A1, 0.7815, 2.41, 0.376, 285, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZAMIDE INHIBITOR
2339, d2x6dA_, 0.7815, 2.65, 0.233, 255, 249, AURORA-A BOUND TO AN INHIBITOR
2340, d2v22C_, 0.7815, 2.86, 0.250, 296, 252, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2341, d2fysA_, 0.7815, 2.96, 0.217, 348, 254, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
2342, d2c5oA_, 0.7815, 2.85, 0.250, 296, 252, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2343, d2bdwB_, 0.7815, 2.75, 0.218, 309, 252, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
2344, d1h28C1, 0.7815, 2.80, 0.255, 295, 251, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
2345, d5lmkC1, 0.7814, 2.70, 0.258, 264, 248, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
2346, d5dfpA_, 0.7814, 3.06, 0.211, 292, 256, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND FRAX1036
2347, d5ar2A_, 0.7814, 2.41, 0.267, 277, 243, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
2348, d4eosA1, 0.7814, 2.77, 0.263, 293, 251, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2349, d3qrkA1, 0.7814, 2.57, 0.382, 268, 246, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DP- 987
2350, d3ocbA_, 0.7814, 2.81, 0.242, 315, 252, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
2351, d3f3tA_, 0.7814, 2.41, 0.339, 261, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
2352, d2zoqB_, 0.7814, 3.09, 0.216, 351, 255, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
2353, d2c4gC2, 0.7814, 2.83, 0.250, 298, 252, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
2354, d5lpyA_, 0.7813, 2.67, 0.231, 282, 247, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ATP FROM ARABIDOPSIS THALIANA
2355, d2c5pA_, 0.7813, 2.85, 0.250, 296, 252,  
2356, d1u5rA_, 0.7813, 2.85, 0.242, 308, 252, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2357, d5cshB_, 0.7812, 2.82, 0.222, 323, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
2358, p3nieA_, 0.7812, 3.28, 0.187, 369, 257, CRYSTAL STRUCTURE OF PF11_0147
2359, d1yolB_, 0.7812, 1.91, 0.333, 253, 237, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
2360, d1yhwA_, 0.7812, 3.15, 0.202, 293, 257, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH ONE POINT MUTATIONS (K299R)
2361, d5kmoA1, 0.7811, 2.80, 0.378, 290, 249, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(2- PYRIDYL)UREA
2362, d2yn8B_, 0.7811, 2.36, 0.326, 260, 242, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2363, d1yomB_, 0.7811, 2.26, 0.339, 261, 242, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
2364, d4ybjA_, 0.7810, 2.05, 0.343, 255, 239, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
2365, d4qteA_, 0.7810, 3.08, 0.231, 348, 255, STRUCTURE OF ERK2 IN COMPLEX WITH VTX-11E 4-{2-[(2-CHLORO-4- FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3- CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
2366, d2wevA_, 0.7810, 2.85, 0.250, 296, 252, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2367, d1w98A2, 0.7810, 2.78, 0.259, 296, 251, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
2368, d1h1sA1, 0.7810, 2.79, 0.255, 295, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
2369, d5ur1A_, 0.7809, 2.53, 0.404, 278, 245, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
2370, d4eoqC1, 0.7809, 2.82, 0.259, 271, 251, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
2371, d3ow4B_, 0.7809, 2.79, 0.246, 317, 252, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
2372, d3el7A_, 0.7809, 2.13, 0.347, 254, 239, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 3
2373, d1jktB_, 0.7809, 2.80, 0.254, 276, 252, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2374, d5clpA_, 0.7808, 2.79, 0.223, 322, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
2375, d4tygA1, 0.7808, 2.86, 0.373, 290, 252, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
2376, d4iz5D_, 0.7808, 3.01, 0.220, 347, 254, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
2377, d3w8lA_, 0.7808, 2.89, 0.213, 326, 253, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
2378, d3nayB_, 0.7808, 2.59, 0.215, 278, 247, PDK1 IN COMPLEX WITH INHIBITOR MP6
2379, d3lm5A1, 0.7808, 2.50, 0.224, 267, 245, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) IN COMPLEX WITH QUERCETIN
2380, d2xzsB_, 0.7808, 3.08, 0.223, 293, 256, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
2381, d1h1rA1, 0.7808, 2.80, 0.255, 295, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
2382, d5f9eB_, 0.7807, 2.88, 0.213, 293, 253, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
2383, d4qnyA_, 0.7807, 2.93, 0.237, 333, 253, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
2384, d4iz5C_, 0.7807, 3.01, 0.220, 347, 254, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
2385, d4iz5A_, 0.7807, 3.01, 0.220, 347, 254, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
2386, d3ow4A_, 0.7807, 2.80, 0.246, 317, 252, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
2387, d2c5tC_, 0.7807, 2.86, 0.250, 296, 252,  
2388, d5ia5A_, 0.7806, 2.89, 0.320, 273, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH GOLVATINIB (E7050)
2389, d5ia1A_, 0.7806, 2.31, 0.342, 261, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH MLN8054
2390, d5hkmA_, 0.7806, 2.47, 0.212, 272, 245, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2391, d5efqC_, 0.7806, 2.92, 0.256, 325, 254, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
2392, d4iz5B_, 0.7806, 3.01, 0.220, 347, 254, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
2393, d4gt5A_, 0.7806, 2.76, 0.378, 290, 249, CRYSTAL STRUCTURE OF THE INACTIVE TRKA KINASE DOMAIN
2394, d4au8A1, 0.7806, 2.54, 0.234, 274, 244, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
2395, d3nayA_, 0.7806, 2.59, 0.215, 278, 247, PDK1 IN COMPLEX WITH INHIBITOR MP6
2396, d2xckA_, 0.7806, 2.56, 0.206, 275, 247, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2397, d2whaC_, 0.7806, 2.86, 0.250, 296, 252,  
2398, d2r7bA_, 0.7806, 2.52, 0.211, 274, 246, CRYSTAL STRUCTURE OF THE PHOSPHOINOSITIDE-DEPENDENT KINASE- 1 (PDK-1)CATALYTIC DOMAIN BOUND TO A DIBENZONAPHTHYRIDINE INHIBITOR
2399, d2c5xA_, 0.7806, 2.85, 0.250, 296, 252, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2400, d1fvvC_, 0.7806, 2.86, 0.254, 298, 252, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
2401, d1e9hC1, 0.7806, 2.83, 0.259, 295, 251, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
2402, d2x4zA1, 0.7805, 3.07, 0.195, 289, 256, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH PF-03758309
2403, d2iw8C2, 0.7805, 2.69, 0.250, 264, 248, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
2404, d2c5pC_, 0.7805, 2.87, 0.258, 296, 252,  
2405, d1yhvA_, 0.7805, 3.15, 0.202, 293, 257, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH TWO POINT MUTATIONS (K299R T423E)
2406, d1unlA_, 0.7805, 2.98, 0.217, 292, 253, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
2407, d1p5eC1, 0.7805, 2.82, 0.255, 295, 251, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
2408, d5jfvA_, 0.7804, 2.48, 0.385, 277, 244, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05206283
2409, p4h3qA_, 0.7804, 2.88, 0.226, 352, 252, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
2410, d3fwqB_, 0.7804, 3.01, 0.207, 334, 256, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
2411, d3dogC1, 0.7804, 2.70, 0.258, 266, 248, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
2412, d3bhtA2, 0.7804, 2.81, 0.255, 295, 251, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
2413, d2uueC_, 0.7804, 2.87, 0.250, 296, 252, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2414, d1wvwA_, 0.7804, 2.88, 0.252, 275, 254, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2415, d1oiuC1, 0.7804, 2.71, 0.258, 264, 248, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2416, d4fnzA_, 0.7803, 2.47, 0.316, 287, 244, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PIPERIDINE-CARBOXAMIDE INHIBITOR 2
2417, d3ce3A_, 0.7803, 2.89, 0.313, 293, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOPYRIDINEPYRIDONE BASED INHIBITOR
2418, d2iw6A1, 0.7803, 2.80, 0.255, 291, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2419, d3dogA1, 0.7802, 2.82, 0.255, 296, 251, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
2420, d2x1nC_, 0.7802, 2.87, 0.250, 296, 252, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2421, d2qobA_, 0.7802, 2.80, 0.312, 279, 247, HUMAN EPHA3 KINASE DOMAIN BASE STRUCTURE
2422, p2g01A_, 0.7802, 2.94, 0.202, 355, 253, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
2423, d5uq2A_, 0.7801, 2.88, 0.254, 296, 252, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
2424, d5u94A_, 0.7801, 2.47, 0.205, 263, 244, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PASTA KINASE PKNB IN COMPLEX WITH THE POTENTIAL THERAPUTIC KINASE INHIBITOR GSK690693.
2425, d5nkaA_, 0.7801, 2.59, 0.324, 271, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2G
2426, d5cyiA1, 0.7801, 2.80, 0.255, 297, 251, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
2427, d4bicA_, 0.7801, 2.62, 0.293, 260, 246, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2428, d3krlA_, 0.7801, 2.63, 0.329, 281, 246, CFMS TYROSINE KINASE IN COMPLEX WITH 5-CYANO-FURAN-2-CARBOXYLIC ACID [4-(4-METHYL-PIPERAZIN-1-YL)-2-PIPERIDIN-1-YL-PHENYL]-AMIDE
2429, d2wihA1, 0.7801, 2.83, 0.250, 298, 252, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
2430, d2wevC_, 0.7801, 2.87, 0.258, 296, 252, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2431, d2jgzA_, 0.7801, 2.77, 0.259, 288, 251, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
2432, d5j5sA_, 0.7800, 2.11, 0.312, 258, 240, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
2433, d5bvoA_, 0.7800, 2.67, 0.339, 276, 248, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
2434, d3nszA_, 0.7800, 2.99, 0.219, 327, 256, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH AMPPN
2435, d3cs9B_, 0.7800, 2.45, 0.360, 247, 242, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
2436, d2qi8A_, 0.7800, 2.22, 0.317, 255, 240, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
2437, d2rl5A1, 0.7799, 2.74, 0.385, 290, 247, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A 23-DIHYDRO-14-BENZOXAZINE INHIBITOR
2438, d2c6tC_, 0.7799, 2.83, 0.255, 295, 251, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2439, d5v19B_, 0.7798, 2.71, 0.287, 260, 247, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2440, d5ke0A_, 0.7798, 3.11, 0.231, 340, 255, DISCOVERY OF 1-1H-PYRAZOLO 43-C PYRIDINE-6-YL UREA INHIBITORS OF EXTRACELLULAR SIGNAL REGULATED KINASE ERK FOR THE TREATMENT OF CANCERS
2441, d2oicD_, 0.7798, 2.61, 0.242, 284, 244, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
2442, d2cciA2, 0.7798, 2.82, 0.255, 295, 251, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
2443, d5if1A_, 0.7797, 2.86, 0.250, 298, 252, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
2444, d3eidA_, 0.7797, 2.77, 0.252, 292, 250, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
2445, d1ol2C_, 0.7797, 2.86, 0.250, 296, 252, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
2446, d1oi9A1, 0.7797, 2.80, 0.255, 294, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2447, d5fd2A_, 0.7796, 2.85, 0.276, 264, 250, B-RAF WILD-TYPE KINASE DOMAIN IN COMPLEX WITH A PURINYLPYRIDINYLAMINO- BASED INHIBITOR
2448, d2uzdC_, 0.7796, 2.83, 0.255, 295, 251, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2449, d1k9aD3, 0.7796, 2.77, 0.320, 268, 247, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
2450, d2nruB_, 0.7795, 2.99, 0.240, 294, 250, CRYSTAL STRUCTURE OF IRAK-4
2451, d2g9xA2, 0.7795, 2.83, 0.259, 297, 251, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
2452, d2bkzA2, 0.7795, 2.85, 0.250, 298, 252, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
2453, d2b9jA_, 0.7795, 2.61, 0.236, 337, 246, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM FAR1
2454, d1urcA_, 0.7795, 2.86, 0.250, 296, 252, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
2455, d1pkdC1, 0.7795, 2.82, 0.255, 295, 251, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
2456, d5kmjA_, 0.7794, 2.83, 0.378, 300, 249, TRKA JM-KINASE WITH {N}-(2-PYRIDYLMETHYL)-2-[2-(2-THIENYL)INDOL-1- YL]ACETAMIDE
2457, d4yo6A_, 0.7794, 3.01, 0.237, 286, 249, IRAK4-INHIBITOR CO-STRUCTURE
2458, d4qnyB_, 0.7794, 3.13, 0.238, 339, 256, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
2459, d4eorC1, 0.7794, 2.82, 0.260, 269, 250, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
2460, d4aw5A_, 0.7794, 2.57, 0.296, 261, 243, COMPLEX OF THE EPHB4 KINASE DOMAIN WITH AN OXINDOLE INHIBITOR
2461, d2b9hA_, 0.7794, 2.62, 0.244, 337, 246, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM STE7
2462, d1szmA_, 0.7794, 2.85, 0.238, 317, 252, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
2463, p6g97A_, 0.7793, 3.08, 0.232, 344, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2464, d5sysB_, 0.7793, 2.15, 0.328, 258, 241, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
2465, d4xs2A_, 0.7793, 3.05, 0.237, 283, 249, IRAK4-INHIBITOR CO-STRUCTURE
2466, d4agwA_, 0.7793, 2.23, 0.336, 258, 241, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
2467, d3uimA_, 0.7793, 2.91, 0.257, 291, 249, STRUCTURAL BASIS FOR THE IMPACT OF PHOSPHORYLATION ON PLANT RECEPTOR- LIKE KINASE BAK1 ACTIVATION
2468, d3tl8H_, 0.7793, 2.67, 0.261, 303, 249, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
2469, d3q52A_, 0.7793, 3.18, 0.210, 292, 257, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN
2470, d3ddqC1, 0.7793, 2.71, 0.258, 265, 248, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
2471, d1tkiB_, 0.7793, 2.90, 0.165, 321, 254, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
2472, d1tkiA_, 0.7793, 2.90, 0.165, 321, 254, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
2473, d1h28A1, 0.7793, 2.82, 0.255, 295, 251, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
2474, d1h1qA1, 0.7793, 2.81, 0.255, 295, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
2475, d5t1sA_, 0.7792, 3.02, 0.237, 280, 249, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
2476, d3tnwC_, 0.7792, 2.75, 0.257, 291, 249, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
2477, d3cjfA_, 0.7792, 2.52, 0.374, 276, 246, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
2478, d2bujA1, 0.7792, 3.04, 0.228, 283, 254, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
2479, d1pyxA_, 0.7792, 3.18, 0.227, 343, 256, GSK-3 BETA COMPLEXED WITH AMP-PNP
2480, d1oiyA1, 0.7792, 2.81, 0.255, 292, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2481, d1ckjA_, 0.7792, 3.23, 0.208, 296, 259, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
2482, d5uy6A1, 0.7790, 2.96, 0.224, 280, 250, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2483, d5lpwA_, 0.7790, 2.75, 0.236, 280, 246, CRYSTAL STRUCTURE OF THE APO-BRI1 KINASE DOMAIN (865-1160)
2484, d5ax9C_, 0.7790, 2.69, 0.228, 282, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2485, d4o0rA_, 0.7790, 3.09, 0.191, 293, 256, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2486, d4ebwA_, 0.7790, 2.63, 0.367, 259, 245, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
2487, d3fztA_, 0.7790, 2.58, 0.382, 259, 246, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-4618433
2488, d3ag9B_, 0.7790, 2.80, 0.227, 317, 251, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
2489, d2iw9A2, 0.7790, 2.82, 0.255, 292, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2490, d5nevA1, 0.7789, 2.83, 0.259, 294, 251, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
2491, d4lueB3, 0.7789, 2.17, 0.372, 256, 239, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
2492, p4f9bA_, 0.7789, 3.18, 0.230, 318, 256, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
2493, d2c5nC_, 0.7789, 2.89, 0.254, 296, 252, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2494, d1oiuA1, 0.7789, 2.82, 0.255, 293, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2495, d1eh4A_, 0.7789, 3.18, 0.174, 293, 259, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
2496, d4p5qA_, 0.7788, 2.73, 0.329, 275, 246, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
2497, d4f65B_, 0.7788, 2.76, 0.386, 279, 249, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
2498, d3eqgA_, 0.7788, 3.15, 0.238, 314, 256, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH PD ADP AND MG2P
2499, d2whaA_, 0.7788, 2.89, 0.250, 296, 252,  
2500, p2gmxA_, 0.7788, 2.91, 0.202, 357, 252, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
2501, d1yolA_, 0.7788, 2.10, 0.336, 256, 238, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
2502, d4cnhA_, 0.7787, 2.60, 0.316, 285, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
2503, d2r7iA_, 0.7787, 2.77, 0.219, 322, 251, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2504, d5mo4A3, 0.7786, 2.44, 0.366, 271, 243, ABL1 KINASE (T334I_D382N) IN COMPLEX WITH ASCIMINIB AND NILOTINIB
2505, d2xh5A_, 0.7786, 2.81, 0.242, 316, 252, STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB
2506, d1oguA1, 0.7786, 2.83, 0.255, 293, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
2507, d4pqnA_, 0.7785, 1.99, 0.314, 240, 236, ITK KINASE DOMAIN WITH COMPOUND GNE-9822
2508, d4i4fA_, 0.7785, 2.53, 0.366, 255, 243, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH AN ALLOSTERIC BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
2509, d4bcoA1, 0.7785, 2.83, 0.259, 297, 251, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2510, d3u6hA_, 0.7785, 2.72, 0.316, 280, 244, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 26
2511, p3n9xB_, 0.7785, 3.23, 0.203, 362, 256, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
2512, d3d5uA_, 0.7785, 3.05, 0.244, 288, 254, CRYSTAL STRUCTURE OF A WILDTYPE POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
2513, d2x1nA_, 0.7785, 2.90, 0.250, 296, 252, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2514, d2wpaA1, 0.7785, 2.86, 0.250, 298, 252, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
2515, d2whbC_, 0.7785, 2.88, 0.250, 296, 252, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2516, d1finA_, 0.7785, 2.87, 0.258, 298, 252, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
2517, d5tehA_, 0.7784, 2.28, 0.333, 261, 243, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
2518, d4cfmA1, 0.7784, 2.83, 0.255, 295, 251, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2519, d4bcpA1, 0.7784, 2.84, 0.263, 297, 251, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2520, d3lw0B_, 0.7784, 2.92, 0.333, 292, 249, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
2521, d2nruD_, 0.7784, 2.96, 0.240, 293, 250, CRYSTAL STRUCTURE OF IRAK-4
2522, d1h27C1, 0.7784, 2.84, 0.255, 290, 251, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
2523, d5u6iA_, 0.7783, 3.15, 0.231, 339, 255, DISCOVERY OF MLI-2 AN ORALLY AVAILABLE AND SELECTIVE LRRK2 INHIBITOR THAT REDUCES BRAIN KINASE ACTIVITY
2524, d5kmkA1, 0.7783, 2.84, 0.378, 302, 249, TRKA JM-KINASE WITH 2-FLUORO-{N}-[2-(4-FLUOROPHENYL)-6-METHYL-3- PYRIDYL]-4-(TRIFLUOROMETHYL)BENZAMIDE
2525, d3miyB1, 0.7783, 1.83, 0.325, 238, 234, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
2526, d1okwC_, 0.7783, 2.89, 0.250, 296, 252, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
2527, d5lmkA1, 0.7782, 2.85, 0.255, 295, 251, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
2528, d4eojA1, 0.7782, 2.85, 0.259, 293, 251, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
2529, d4bcnA1, 0.7782, 2.82, 0.255, 295, 251, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2530, d3lw0C_, 0.7782, 2.92, 0.333, 292, 249, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
2531, d3lw0A_, 0.7782, 2.92, 0.333, 292, 249, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
2532, d2xbaA_, 0.7782, 2.55, 0.313, 283, 243, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PHA-E429
2533, d2f57B1, 0.7782, 3.12, 0.211, 293, 256, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
2534, d3o0gA_, 0.7781, 2.95, 0.218, 289, 252, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
2535, d3lw0D_, 0.7781, 2.92, 0.333, 292, 249, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
2536, d2bkzC2, 0.7781, 2.88, 0.250, 297, 252, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
2537, d4u44A_, 0.7780, 2.69, 0.227, 286, 247, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
2538, d4i4eA_, 0.7780, 2.43, 0.339, 254, 242, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH HINGE BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
2539, d1h26A1, 0.7780, 2.83, 0.255, 295, 251, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
2540, d4ub7A_, 0.7779, 3.09, 0.207, 334, 256, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26) SHOWING AN EXTREME DISTORTION OF THE ATP-BINDING LOOP COMBINED WITH A PI-HALOGEN BOND
2541, d4eorA1, 0.7779, 2.86, 0.263, 292, 251, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
2542, p3nieB_, 0.7779, 3.27, 0.187, 367, 256, CRYSTAL STRUCTURE OF PF11_0147
2543, d2wmbA1, 0.7779, 2.84, 0.259, 295, 251, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2544, d5uafA_, 0.7778, 2.81, 0.343, 291, 245, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
2545, d5uadA_, 0.7778, 2.81, 0.343, 291, 245, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
2546, d5nevC1, 0.7778, 2.85, 0.259, 295, 251, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
2547, d5kx7B_, 0.7778, 2.91, 0.239, 286, 247, IRAK4-INHIBITOR CO-STRUCTURE
2548, d4eomA1, 0.7778, 2.85, 0.259, 294, 251, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2549, d3f3wB_, 0.7778, 2.40, 0.336, 260, 244, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
2550, d2whbA_, 0.7778, 2.89, 0.250, 296, 252, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2551, d5j7bB_, 0.7777, 2.42, 0.258, 281, 244, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
2552, d4uy9B_, 0.7777, 2.88, 0.316, 315, 250, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
2553, d5d11B_, 0.7776, 2.20, 0.314, 255, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
2554, d2qokA_, 0.7775, 2.67, 0.314, 281, 245, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:S768A TRIPLE MUTANT
2555, d5p9lA_, 0.7774, 2.67, 0.316, 252, 247, BTK1 IN COMPLEX WITH CC 292
2556, d5kmiA_, 0.7774, 2.90, 0.378, 300, 249, TRKA JM-KINASE WITH 1-(9{H}-FLUOREN-9-YL)-3-(2-METHYL-4-PHENYL- PYRIMIDIN-5-YL)UREA
2557, d5dt4A_, 0.7774, 2.62, 0.235, 259, 247, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
2558, d4bcmA1, 0.7774, 2.83, 0.263, 292, 251, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2559, d3ddqA1, 0.7774, 2.85, 0.259, 295, 251, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
2560, d3bhvA1, 0.7774, 2.84, 0.255, 295, 251, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
2561, d1uwhA_, 0.7774, 2.75, 0.267, 264, 247, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
2562, d4eevA_, 0.7773, 2.71, 0.333, 283, 246, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH LY2801653
2563, d4crsA1, 0.7773, 2.71, 0.262, 329, 248, HUMAN PROTEIN KINASE N2 (PKN2 PRKCL2) IN COMPLEX WITH ATPGAMMAS
2564, d3d5wA_, 0.7773, 2.99, 0.241, 284, 253, CRYSTAL STRUCTURE OF A PHOSPHORYLATED POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH ADP.
2565, d2jkoA_, 0.7773, 2.44, 0.369, 256, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
2566, d5objA_, 0.7772, 2.67, 0.234, 260, 248, AURORA A KINASE IN COMPLEX WITH 2-(3-FLUOROPHENYL)QUINOLINE-4- CARBOXYLIC ACID AND ATP
2567, d3a7gA_, 0.7772, 2.98, 0.249, 289, 253, HUMAN MST3 KINASE
2568, d6bkuA1, 0.7771, 2.89, 0.225, 264, 249, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO GSK650394
2569, d4eooA1, 0.7770, 2.87, 0.255, 292, 251, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2570, d1h25C1, 0.7770, 2.77, 0.261, 277, 249, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
2571, d1gngB_, 0.7770, 3.22, 0.226, 355, 257, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
2572, d1ckjB_, 0.7770, 3.32, 0.193, 293, 259, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
2573, d5nk0A_, 0.7769, 2.59, 0.340, 273, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1J
2574, d4bhnB_, 0.7769, 2.63, 0.291, 257, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2575, d4agwB_, 0.7769, 2.23, 0.336, 257, 241, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
2576, d2wxvC1, 0.7769, 2.90, 0.250, 298, 252, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
2577, d2f2cB_, 0.7769, 2.79, 0.258, 280, 248, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
2578, d4zs0A_, 0.7768, 2.63, 0.235, 257, 247, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO SB-6-OH
2579, d4y73C_, 0.7768, 2.94, 0.238, 290, 248, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
2580, d2wmaA1, 0.7768, 2.84, 0.255, 295, 251, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2581, d4ztnA_, 0.7767, 3.00, 0.238, 286, 248, IRAK4-INHIBITOR CO-STRUCTURE
2582, d2nryB_, 0.7767, 2.99, 0.238, 286, 248, CRYSTAL STRUCTURE OF IRAK-4
2583, d2nruC_, 0.7767, 3.02, 0.240, 293, 250, CRYSTAL STRUCTURE OF IRAK-4
2584, d5nhlA_, 0.7766, 3.25, 0.223, 345, 256, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2585, d5kmmA1, 0.7766, 2.88, 0.378, 300, 249, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(1- NAPHTHYL)UREA
2586, d4kioB1, 0.7766, 1.80, 0.322, 237, 233, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
2587, d3my5A1, 0.7766, 2.87, 0.255, 294, 251, CDK2/CYCLINA IN COMPLEX WITH DRB
2588, d3cs9D_, 0.7766, 2.75, 0.371, 263, 245, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
2589, d5opbA_, 0.7765, 2.98, 0.249, 262, 249, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH INDAZOLE LRRK2 INHIBITOR
2590, d5nhpA_, 0.7765, 3.17, 0.220, 338, 255, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2591, d4ypsA1, 0.7765, 2.60, 0.366, 275, 243, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
2592, d1j1bB_, 0.7765, 3.22, 0.227, 364, 256, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
2593, d5up3A_, 0.7764, 2.55, 0.291, 258, 244, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2594, d5drdA_, 0.7764, 2.63, 0.235, 259, 247, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
2595, d4qo9B_, 0.7764, 3.00, 0.253, 285, 253, MST3 IN COMPLEX WITH DANUSERTIB
2596, d4gk2A_, 0.7764, 2.64, 0.333, 265, 243, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 66
2597, d3a7gB_, 0.7764, 3.05, 0.248, 290, 254, HUMAN MST3 KINASE
2598, d2wfyC_, 0.7764, 2.91, 0.254, 296, 252, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2599, d1eh4B_, 0.7764, 3.35, 0.176, 293, 261, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
2600, d6brcA1, 0.7763, 2.95, 0.224, 263, 250, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
2601, d5hhwA_, 0.7763, 2.91, 0.323, 306, 251, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH CIS-(R)-7-(3-(AZETIDIN-1-YLMETHYL)CYCLOBUTYL)-5-(3-((TETRAHYDRO-2H- PYRAN-2-YL)METHOXY)PHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE.
2602, d3bhyA1, 0.7763, 2.47, 0.246, 267, 244, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH A BETA-CARBOLINE LIGAND
2603, d2i0eA_, 0.7763, 2.76, 0.245, 326, 249, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
2604, d5kbqA_, 0.7762, 3.04, 0.188, 289, 255, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
2605, d5if1C_, 0.7762, 2.92, 0.254, 296, 252, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
2606, d5d12B_, 0.7762, 2.16, 0.347, 253, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
2607, d5d11A_, 0.7762, 2.18, 0.346, 254, 240, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
2608, d4ztlD_, 0.7762, 2.92, 0.240, 285, 246, IRAK4-INHIBITOR CO-STRUCTURE
2609, d5j5sB_, 0.7761, 2.24, 0.329, 258, 240, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
2610, d4qtbB_, 0.7761, 3.23, 0.219, 348, 256, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
2611, d4bcpC1, 0.7761, 2.77, 0.258, 266, 248, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2612, d2welA_, 0.7761, 2.93, 0.209, 304, 253, CRYSTAL STRUCTURE OF SU6656-BOUND CALCIUM/CALMODULIN- DEPENDENT PROTEIN KINASE II DELTA IN COMPLEX WITH CALMODULIN
2613, d2i40A_, 0.7761, 2.77, 0.257, 291, 249, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
2614, d2bpmA2, 0.7761, 2.89, 0.250, 298, 252, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
2615, d1q41A_, 0.7761, 3.23, 0.223, 339, 256, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
2616, d5kx8A_, 0.7760, 3.03, 0.238, 285, 248, IRAK4-INHIBITOR CO-STRUCTURE
2617, d4izaA_, 0.7760, 3.07, 0.228, 346, 254, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
2618, d4cfvA1, 0.7760, 2.86, 0.255, 297, 251, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2619, d4bidB_, 0.7760, 2.69, 0.298, 258, 245, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2620, d3uzpA_, 0.7760, 3.35, 0.193, 292, 259, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
2621, d3otuA_, 0.7760, 2.65, 0.206, 276, 248, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR JS30
2622, d5op2A_, 0.7759, 3.06, 0.248, 263, 250, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2623, d5i8aA1, 0.7759, 2.45, 0.379, 265, 240, TRKA WITH (6~{R})-3-METHYLSULFANYL-6-PHENYL-1-(1~{H}-PYRAZOL-3-YL)-6 7-DIHYDRO-5~{H}-THIENO[34-C]PYRIDIN-4-ONE
2624, d5dosA_, 0.7759, 2.64, 0.235, 259, 247, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
2625, d5deyA_, 0.7759, 3.07, 0.208, 295, 255, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
2626, d5d7aA_, 0.7759, 2.69, 0.228, 289, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2627, d2gphA_, 0.7759, 3.13, 0.224, 345, 255, DOCKING MOTIF INTERACTIONS IN THE MAP KINASE ERK2
2628, d4u43A_, 0.7758, 2.74, 0.224, 287, 246, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
2629, d3d7tA_, 0.7758, 2.19, 0.335, 249, 239, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
2630, d2clqB_, 0.7758, 2.70, 0.289, 259, 246, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2631, d5t1sB_, 0.7757, 2.99, 0.239, 282, 247, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
2632, d4ptgB_, 0.7757, 3.22, 0.223, 332, 256, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
2633, d3f5xC_, 0.7757, 2.91, 0.258, 298, 252, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
2634, d3efkA_, 0.7757, 2.47, 0.312, 276, 240, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
2635, d2x4fA_, 0.7757, 2.98, 0.209, 289, 253, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
2636, d2v22A_, 0.7757, 2.92, 0.250, 296, 252, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2637, d2i40C_, 0.7757, 2.92, 0.250, 296, 252, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
2638, d1q5kB_, 0.7757, 3.22, 0.219, 344, 256, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
2639, d1ol1A_, 0.7757, 2.91, 0.250, 296, 252, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
2640, d4cfuA1, 0.7756, 2.86, 0.255, 295, 251, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2641, d2r7iC_, 0.7756, 2.77, 0.224, 321, 250, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2642, d5f94B_, 0.7755, 3.24, 0.227, 349, 256, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
2643, d3zduA_, 0.7755, 2.76, 0.233, 297, 245, CRYSTAL STRUCTURE OF THE HUMAN CDKL3 KINASE DOMAIN
2644, d3v5qB1, 0.7755, 2.51, 0.387, 262, 243, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
2645, d2zoqA_, 0.7755, 3.03, 0.209, 351, 253, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
2646, d4yo6D_, 0.7754, 2.97, 0.239, 285, 247, IRAK4-INHIBITOR CO-STRUCTURE
2647, d4pteB_, 0.7754, 3.24, 0.227, 347, 256, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
2648, d4bicB_, 0.7754, 2.73, 0.297, 259, 246, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2649, d2erkA_, 0.7754, 2.88, 0.228, 351, 250, PHOSPHORYLATED MAP KINASE ERK2
2650, d2b9fA_, 0.7754, 2.79, 0.237, 337, 249, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED FUS3
2651, d5lqfA1, 0.7753, 2.94, 0.257, 284, 249, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
2652, d4wunB_, 0.7753, 2.65, 0.384, 268, 245, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
2653, d4twcA_, 0.7753, 3.44, 0.195, 293, 261, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
2654, d4ic7A_, 0.7753, 3.02, 0.241, 355, 253, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
2655, d3tz9B_, 0.7753, 2.34, 0.331, 259, 242, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
2656, d5ia0A_, 0.7752, 2.57, 0.336, 263, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
2657, d2hyyB1, 0.7752, 2.24, 0.380, 252, 237, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
2658, d5kx8C_, 0.7751, 2.92, 0.239, 287, 247, IRAK4-INHIBITOR CO-STRUCTURE
2659, d4ztnD_, 0.7751, 2.97, 0.239, 285, 247, IRAK4-INHIBITOR CO-STRUCTURE
2660, d1q5kA_, 0.7751, 3.26, 0.223, 345, 256, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
2661, d1pkdA1, 0.7751, 2.87, 0.255, 295, 251, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
2662, d1h24C1, 0.7751, 2.88, 0.259, 292, 251, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
2663, d4dhfB_, 0.7750, 2.66, 0.235, 258, 247, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
2664, d1pyxB_, 0.7750, 3.26, 0.227, 338, 256, GSK-3 BETA COMPLEXED WITH AMP-PNP
2665, d5dt0A_, 0.7749, 2.64, 0.235, 259, 247, AURORA A KINASE IN COMPLEX WITH JNJ-7706621 IN SPACE GROUP P6122
2666, d4bhnA_, 0.7749, 2.66, 0.292, 256, 243, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2667, d3eqhA_, 0.7749, 3.16, 0.239, 314, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH U0126 ADP AND MG2P
2668, d1vywC1, 0.7749, 2.93, 0.254, 298, 252, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
2669, d1p5eA1, 0.7749, 2.89, 0.259, 295, 251, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
2670, d4zk5A_, 0.7748, 2.91, 0.225, 286, 249, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
2671, d3fxzA_, 0.7748, 3.24, 0.206, 292, 257, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX LAMBDA-FL172
2672, d3a7hB_, 0.7748, 3.08, 0.256, 290, 254, HUMAN MST3 KINASE IN COMPLEX WITH ATP
2673, d5to8A_, 0.7747, 2.22, 0.381, 250, 239, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
2674, d5j7bA_, 0.7747, 2.46, 0.263, 277, 243, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
2675, d4bibB_, 0.7747, 2.70, 0.294, 258, 245, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2676, d3d14A1, 0.7747, 2.65, 0.231, 257, 247, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-{5-[2-(THIENO[32-D]PYRIMIDIN-4-YLAMINO)- ETHYL]- THIAZOL-2-YL}-3-(3-TRIFLUOROMETHYL-PHENYL)-UREA
2677, d3a8xA1, 0.7747, 2.90, 0.198, 331, 253, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
2678, d3a7hA_, 0.7747, 3.00, 0.233, 289, 253, HUMAN MST3 KINASE IN COMPLEX WITH ATP
2679, d2yn8A_, 0.7747, 2.17, 0.332, 253, 238, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2680, d2vwvA_, 0.7747, 2.76, 0.303, 255, 244, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2681, d1okvC_, 0.7747, 2.93, 0.254, 296, 252, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
2682, d4nksA_, 0.7746, 2.59, 0.392, 265, 245, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
2683, d4dhfA_, 0.7746, 2.66, 0.235, 258, 247, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
2684, d3l1sA_, 0.7746, 3.24, 0.227, 336, 256, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
2685, d2wfyA_, 0.7746, 2.93, 0.246, 295, 252, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2686, d2henB1, 0.7746, 2.54, 0.303, 258, 241, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
2687, d4h1mA_, 0.7745, 2.57, 0.389, 256, 244, CRYSTAL STRUCTURE OF PYK2 WITH THE INDOLE 10C
2688, d3octA_, 0.7745, 2.30, 0.310, 244, 242, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE MUTANT V555R IN COMPLEX WITH DASATINIB
2689, d1koaA2, 0.7745, 3.19, 0.214, 350, 257, TWITCHIN KINASE FRAGMENT (C.ELEGANS) AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
2690, d4yp8C_, 0.7744, 2.94, 0.238, 287, 248, IRAK4-INHIBITOR CO-STRUCTURE
2691, d4eoqA1, 0.7744, 2.89, 0.259, 293, 251, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
2692, d2uueA_, 0.7744, 2.93, 0.250, 296, 252, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2693, d2gsfA_, 0.7744, 2.77, 0.314, 281, 245, THE HUMAN EPHA3 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
2694, d2cjmC_, 0.7744, 2.83, 0.256, 294, 250, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
2695, d1j1cB_, 0.7744, 3.24, 0.227, 364, 256, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
2696, d6bqqA1, 0.7743, 2.95, 0.224, 269, 250, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH BI2526
2697, d5x17A_, 0.7743, 3.35, 0.208, 290, 259, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
2698, d4pmtA1, 0.7743, 2.57, 0.349, 269, 241, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N~4~-(4-MORPHOLIN- 4-YLPHENYL)-N~6~-(PYRIDIN-3-YLMETHYL)PYRIDO[32-D]PYRIMIDINE-46- DIAMINE
2699, d4fv7A_, 0.7743, 3.08, 0.221, 342, 253, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E94
2700, d4obpA_, 0.7742, 2.92, 0.225, 285, 249, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
2701, d4cfwA1, 0.7742, 2.87, 0.259, 297, 251, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2702, d5uitB_, 0.7741, 2.95, 0.240, 283, 246, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
2703, d3vw6A_, 0.7741, 2.62, 0.306, 255, 242, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
2704, d3v8tA1, 0.7741, 1.73, 0.325, 236, 231, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
2705, d3fwqA_, 0.7741, 3.09, 0.203, 334, 256, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
2706, d2henD1, 0.7741, 2.54, 0.303, 258, 241, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
2707, d1ol2A_, 0.7741, 2.94, 0.258, 296, 252, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
2708, d1p4fA_, 0.7740, 2.62, 0.248, 269, 246, DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT
2709, d1kobB_, 0.7740, 3.19, 0.206, 352, 257, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
2710, d5f94A_, 0.7739, 3.27, 0.227, 346, 256, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
2711, d3sayA_, 0.7739, 3.23, 0.227, 347, 255, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
2712, d3i4bA_, 0.7739, 3.24, 0.223, 359, 256, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
2713, d3eqcA_, 0.7739, 3.16, 0.239, 312, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH COMPOUND 1 ATP-GS AND MG2P
2714, d2fumB_, 0.7739, 2.52, 0.206, 262, 243, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2715, d1k9aC3, 0.7739, 2.89, 0.317, 266, 246, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
2716, d1csnA_, 0.7739, 3.29, 0.178, 293, 259, BINARY COMPLEX OF CASEIN KINASE-1 WITH MGATP
2717, d5uiqC_, 0.7738, 2.90, 0.239, 280, 247, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
2718, d4ptgA_, 0.7738, 3.26, 0.227, 333, 256, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
2719, d2c5tA_, 0.7738, 2.94, 0.250, 296, 252,  
2720, d4ztnB_, 0.7737, 2.95, 0.244, 282, 246, IRAK4-INHIBITOR CO-STRUCTURE
2721, d4rfmA1, 0.7737, 2.56, 0.300, 248, 243, ITK KINASE DOMAIN IN COMPLEX WITH COMPOUND 1 N-{1-[(11-DIOXO-1-THIAN- 2-YL)(PHENYL)METHYL]-1H- PYRAZOL-4-YL}-55-DIFLUORO-5A-METHYL-1H4H 4AH5H5AH6H-CYCLOPROPA[F]INDAZOLE-3-CARBOXAMIDE
2722, d3dkfA1, 0.7737, 2.87, 0.332, 293, 247, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
2723, d2wpaC1, 0.7737, 2.95, 0.254, 298, 252, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
2724, d1s9iA_, 0.7737, 3.27, 0.247, 303, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
2725, d5c03B_, 0.7736, 2.49, 0.221, 260, 244, CRYSTAL STRUCTURE OF KINASE
2726, d4cfnA1, 0.7736, 2.88, 0.255, 293, 251, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2727, d3tubA_, 0.7736, 2.58, 0.373, 253, 244, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-3-((1R2S)-2- PHENYLCYCLOPROPYL)UREA
2728, d3db6A_, 0.7736, 3.11, 0.244, 287, 254, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 902
2729, d1kobA_, 0.7736, 3.26, 0.209, 352, 258, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
2730, d5ax9A_, 0.7735, 2.68, 0.230, 282, 244, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2731, d5ng3A_, 0.7734, 2.86, 0.257, 283, 249, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
2732, d2fumA_, 0.7734, 2.61, 0.205, 263, 244, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2733, d4cfmC1, 0.7733, 2.73, 0.255, 265, 247, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2734, d4bieA_, 0.7733, 2.60, 0.288, 257, 243, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2735, d4aojB_, 0.7733, 2.44, 0.387, 258, 243, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
2736, p3n9xA_, 0.7733, 3.26, 0.196, 374, 255, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
2737, d2o5kA1, 0.7733, 3.29, 0.230, 350, 256, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A BENZOIMIDAZOL INHIBITOR
2738, d1vr2A_, 0.7733, 2.66, 0.382, 275, 246, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN
2739, d1q41B_, 0.7733, 3.28, 0.227, 343, 256, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
2740, d5nkiA_, 0.7732, 2.47, 0.339, 268, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4B
2741, d3piyA_, 0.7732, 2.65, 0.325, 262, 246, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH R406
2742, d3dlsD_, 0.7732, 2.72, 0.228, 284, 246, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2743, d2wmaC1, 0.7732, 2.67, 0.259, 264, 247, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2744, d2qonA_, 0.7732, 2.74, 0.311, 281, 244, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742A TRIPLE MUTANT
2745, d1mruB_, 0.7732, 2.46, 0.207, 271, 242, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
2746, d5t1sD_, 0.7731, 3.02, 0.240, 281, 246, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
2747, d5kx8D_, 0.7731, 3.00, 0.240, 283, 246, IRAK4-INHIBITOR CO-STRUCTURE
2748, d5hesA_, 0.7731, 2.75, 0.294, 287, 245, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
2749, d4knbB_, 0.7731, 2.77, 0.337, 256, 243, C-MET IN COMPLEX WITH OSI LIGAND
2750, d3orxG_, 0.7731, 2.62, 0.215, 274, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2751, d3efjA_, 0.7731, 2.50, 0.308, 276, 240, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
2752, d1mqbA_, 0.7731, 2.65, 0.311, 263, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
2753, d5t1tD_, 0.7730, 2.92, 0.240, 283, 246, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
2754, d4ptcB_, 0.7730, 3.27, 0.227, 347, 256, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
2755, d3i4bB_, 0.7730, 3.25, 0.223, 347, 256, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
2756, d1okwA_, 0.7730, 2.96, 0.242, 296, 252, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
2757, d1j1bA_, 0.7730, 3.27, 0.227, 354, 256, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
2758, d5oq8A_, 0.7728, 3.07, 0.253, 261, 249, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2759, d5lqfD1, 0.7728, 2.85, 0.259, 282, 247, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
2760, d4ztmC_, 0.7728, 3.04, 0.239, 282, 247, IRAK4-INHIBITOR CO-STRUCTURE
2761, d4dglC_, 0.7728, 2.97, 0.213, 334, 253, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
2762, d3f5xA_, 0.7728, 2.91, 0.259, 297, 251, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
2763, d3d15A_, 0.7728, 2.63, 0.232, 256, 246, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-(3-CHLORO-PHENYL)-3-{5-[2-(THIENO[32- D]PYRIMIDIN-4-YLAMINO)- ETHYL]-THIAZOL-2-YL}-UREA [SNS-314]
2764, d5w5oN_, 0.7727, 2.34, 0.258, 272, 240, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2765, d5t1tC_, 0.7727, 3.02, 0.238, 286, 248, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
2766, d4mwiA_, 0.7727, 2.48, 0.217, 266, 244, CRYSTAL STRUCTURE OF THE HUMAN MLKL PSEUDOKINASE DOMAIN
2767, d3iecB_, 0.7727, 2.78, 0.249, 313, 249, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2768, d5m4iA_, 0.7726, 3.07, 0.208, 331, 255, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
2769, d5fqdF_, 0.7726, 3.35, 0.178, 294, 259, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
2770, d3mblA_, 0.7726, 3.17, 0.240, 290, 254, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGADP
2771, d3eqfA_, 0.7726, 3.27, 0.243, 314, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH K252A AND MG2P
2772, d5acbC_, 0.7725, 3.16, 0.241, 324, 257, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
2773, d4kbkB_, 0.7725, 3.31, 0.198, 289, 258, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
2774, d3tnwA1, 0.7725, 2.90, 0.255, 294, 251, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
2775, d3pixA_, 0.7725, 2.86, 0.301, 268, 249, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-ISOPROPYL-7- (4-METHYL-PIPERAZIN-1-YL)-4-(5-METHYL-2H-PYRAZOL-3-YLAMINO)-2H- PHTHALAZIN-1-ONE
2776, d3eqiA_, 0.7725, 3.26, 0.243, 315, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ADP AND MG2P
2777, d3dj7A_, 0.7725, 2.68, 0.231, 257, 247, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 130.
2778, d5uabA_, 0.7724, 2.76, 0.342, 288, 243, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
2779, d4nm7A1, 0.7724, 3.26, 0.227, 354, 256, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 E-MOTIF
2780, d4nm5A1, 0.7724, 3.27, 0.223, 360, 256, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 C-MOTIF
2781, d4pteA_, 0.7723, 3.19, 0.228, 341, 254, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
2782, d4hnfB_, 0.7723, 3.33, 0.205, 290, 259, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
2783, d4cfvC1, 0.7723, 2.71, 0.256, 263, 246, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2784, d1zrzA_, 0.7723, 2.86, 0.207, 310, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF ATYPICAL PROTEIN KINASE C-IOTA
2785, d1h25A1, 0.7723, 2.91, 0.255, 292, 251, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
2786, d5x17B_, 0.7722, 3.33, 0.194, 289, 258, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
2787, d5hlnB_, 0.7722, 3.32, 0.229, 346, 258, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
2788, d5f95B_, 0.7722, 3.27, 0.227, 338, 256, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
2789, d5d7aB_, 0.7722, 2.85, 0.231, 286, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2790, d4zy4A_, 0.7722, 3.05, 0.209, 288, 253, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
2791, d4ztlC_, 0.7722, 3.08, 0.235, 282, 247, IRAK4-INHIBITOR CO-STRUCTURE
2792, d4c2vA_, 0.7722, 2.88, 0.200, 270, 250, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
2793, d3of0B_, 0.7722, 2.17, 0.333, 251, 237, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
2794, d3cs9C_, 0.7722, 2.46, 0.387, 243, 240, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
2795, d5nhvA_, 0.7721, 3.23, 0.224, 345, 255, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2796, d4tyeA_, 0.7721, 2.92, 0.386, 292, 251, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
2797, d4qp8B_, 0.7721, 2.82, 0.229, 337, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
2798, d4qp3B_, 0.7721, 3.14, 0.209, 331, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
2799, p3vugA_, 0.7721, 2.85, 0.205, 356, 249, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
2800, d3nizA1, 0.7721, 2.93, 0.248, 284, 250, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH ADP BOUND.
2801, d3my0X_, 0.7721, 2.68, 0.265, 257, 245, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2802, d3dlsF_, 0.7721, 2.77, 0.228, 281, 246, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2803, d3c1xA_, 0.7721, 2.61, 0.325, 290, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOTRIAZINE BASED INHIBITOR
2804, d1e9hA_, 0.7721, 2.92, 0.255, 295, 251, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
2805, p3zuvA_, 0.7720, 3.09, 0.217, 357, 253, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
2806, d3iecD_, 0.7720, 2.70, 0.247, 311, 247, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2807, d2xyuA_, 0.7720, 2.64, 0.342, 260, 243, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH VUF 12058
2808, d2i0eB_, 0.7720, 2.82, 0.245, 300, 249, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
2809, d2hyyD1, 0.7720, 2.35, 0.380, 251, 237, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
2810, d3iecC_, 0.7719, 2.70, 0.251, 311, 247, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2811, d3amyA_, 0.7719, 2.81, 0.202, 318, 248, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH APIGENIN
2812, d5w84A_, 0.7718, 2.91, 0.242, 279, 244, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 4)
2813, d4yp8A_, 0.7718, 3.03, 0.243, 284, 247, IRAK4-INHIBITOR CO-STRUCTURE
2814, d4ptcA_, 0.7718, 3.30, 0.223, 342, 256, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
2815, p3zuvC_, 0.7718, 3.16, 0.217, 357, 254, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
2816, d3orxH_, 0.7718, 2.64, 0.215, 274, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2817, d3orxE_, 0.7718, 2.64, 0.215, 274, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2818, d2wihC1, 0.7718, 2.97, 0.254, 298, 252, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
2819, d1o6yA_, 0.7718, 2.44, 0.207, 260, 241, CATALYTIC DOMAIN OF PKNB KINASE FROM MYCOBACTERIUM TUBERCULOSIS
2820, d5dpvA_, 0.7717, 2.64, 0.236, 257, 246, AURORA A KINASE IN COMPLEX WITH AA35 AND JNJ-7706621 IN SPACE GROUP P6122
2821, d4zy5A_, 0.7717, 3.11, 0.213, 283, 253, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
2822, d3ii5A_, 0.7717, 2.82, 0.266, 262, 248, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
2823, d3dlsE_, 0.7717, 2.89, 0.235, 282, 247, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2824, d1h27A1, 0.7717, 2.91, 0.255, 295, 251, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
2825, d5t3qA1, 0.7716, 2.65, 0.315, 277, 241, CRYSTAL STRUCTURE OF THE C-MET KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
2826, d4y73A_, 0.7716, 2.95, 0.240, 289, 246, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
2827, p3vudA_, 0.7716, 2.84, 0.209, 355, 249, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
2828, d5hd7A_, 0.7715, 3.30, 0.230, 347, 256, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT MUTANT SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
2829, d3zlsA_, 0.7715, 3.22, 0.243, 315, 255, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 6
2830, d3uytC_, 0.7715, 3.40, 0.204, 286, 260, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2831, d3uysC_, 0.7715, 3.34, 0.194, 286, 258, CRYSTAL STRUCTURE OF APO HUMAN CK1D
2832, d3m1sA_, 0.7715, 3.28, 0.227, 348, 256, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
2833, d2csnA_, 0.7715, 3.33, 0.174, 293, 259, BINARY COMPLEX OF CASEIN KINASE-1 WITH CKI7
2834, d1cmkE_, 0.7715, 3.01, 0.214, 348, 252, CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
2835, d5vamA_, 0.7714, 2.84, 0.264, 269, 250, BRAF IN COMPLEX WITH RAF709
2836, d5m44A_, 0.7714, 2.88, 0.211, 329, 251, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
2837, d5kziA_, 0.7714, 2.64, 0.192, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN IMIDAZOPYRIDAZINE INHIBITOR.
2838, d4i6fA_, 0.7714, 3.26, 0.213, 285, 254, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2839, d3q3bA_, 0.7714, 3.29, 0.223, 344, 256, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
2840, d3eqdA_, 0.7714, 3.32, 0.238, 315, 256, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ATP-GS AND MG2P
2841, d3dlsA_, 0.7714, 2.84, 0.235, 285, 247, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2842, d2vgoB_, 0.7714, 3.14, 0.197, 277, 254, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
2843, d5l6oA_, 0.7713, 2.39, 0.324, 267, 238, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 3)
2844, d3zrkB_, 0.7713, 3.37, 0.229, 348, 258, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
2845, d3orxF_, 0.7713, 2.65, 0.215, 274, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2846, d3l1sB_, 0.7713, 3.30, 0.227, 330, 256, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
2847, d5fqdC_, 0.7712, 3.38, 0.178, 294, 259, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
2848, d4l44A_, 0.7712, 2.93, 0.261, 321, 249, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM II)
2849, d3zrkA_, 0.7712, 3.39, 0.229, 345, 258, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
2850, d2oibC_, 0.7712, 2.81, 0.238, 278, 244, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
2851, d5k76B_, 0.7711, 2.95, 0.241, 281, 245, IRAK4 IN COMPLEX WITH COMPOUND 28
2852, d4yfiC_, 0.7711, 2.72, 0.266, 269, 241, TNNI3K COMPLEXED WITH INHIBITOR 1
2853, d2qq7A_, 0.7711, 2.14, 0.352, 251, 236, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN WITH IRREVERSIBLE INHIBITOR
2854, d2jd5A_, 0.7711, 2.86, 0.222, 353, 248, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
2855, d5t1sC_, 0.7710, 3.04, 0.239, 284, 247, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
2856, d4qtbA_, 0.7710, 3.34, 0.202, 351, 257, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
2857, d4i6hA_, 0.7710, 3.28, 0.213, 285, 254, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE ALPHA-SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2858, p3vuhA_, 0.7710, 2.86, 0.205, 355, 249, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M3 IN MAP KINASE JNK1
2859, d3e8nA1, 0.7710, 3.18, 0.236, 290, 254, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) COMPLEXED WITH A POTENT INHIBITOR RDEA119 AND MGATP
2860, d1q8zB_, 0.7710, 3.20, 0.203, 364, 256, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
2861, d1h4lA_, 0.7710, 2.76, 0.215, 278, 246, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
2862, d4qo9A_, 0.7709, 2.91, 0.267, 280, 251, MST3 IN COMPLEX WITH DANUSERTIB
2863, d3ztxA_, 0.7709, 2.99, 0.199, 269, 251, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
2864, d2nryC_, 0.7709, 2.93, 0.241, 280, 245, CRYSTAL STRUCTURE OF IRAK-4
2865, d1ctpE_, 0.7709, 3.02, 0.214, 332, 252, STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
2866, d5jznA_, 0.7708, 2.74, 0.219, 268, 247, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
2867, d5cs6B_, 0.7708, 2.79, 0.222, 316, 248, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
2868, d4ztmD_, 0.7708, 2.94, 0.241, 282, 245, IRAK4-INHIBITOR CO-STRUCTURE
2869, d3zrmB_, 0.7708, 3.39, 0.229, 347, 258, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
2870, d3sayB_, 0.7708, 3.28, 0.227, 347, 255, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
2871, d2zv2A_, 0.7708, 2.79, 0.224, 256, 245, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2 BETA CAMKK2 KINASE DOMAIN IN COMPLEX WITH STO-609
2872, d5w4wC_, 0.7707, 3.37, 0.186, 284, 258, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2873, d5f95A_, 0.7707, 3.30, 0.227, 345, 256, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
2874, d5c01B_, 0.7707, 2.49, 0.214, 260, 243, CRYSTAL STRUCTURE OF KINASE
2875, d4nm0A1, 0.7707, 3.31, 0.227, 355, 256, CRYSTAL STRUCTURE OF PEPTIDE INHIBITOR-FREE GSK-3/AXIN COMPLEX
2876, d3tucA_, 0.7707, 2.67, 0.359, 257, 245, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-BENZYL-N-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
2877, d3fzsA_, 0.7707, 2.50, 0.388, 254, 242, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH BIRB796
2878, d3etaB_, 0.7707, 2.87, 0.309, 292, 246, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
2879, d2y6oA_, 0.7707, 2.65, 0.342, 263, 243, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH DASATINIB.
2880, d5jsmA1, 0.7706, 2.89, 0.275, 262, 247, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
2881, d3fy0A_, 0.7706, 3.23, 0.207, 292, 256, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX DW1
2882, d2nryD_, 0.7706, 3.03, 0.244, 282, 246, CRYSTAL STRUCTURE OF IRAK-4
2883, d1unhB_, 0.7706, 2.67, 0.209, 276, 244, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
2884, d5jrsB1, 0.7705, 2.31, 0.339, 239, 239, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
2885, d4btjB_, 0.7705, 3.21, 0.188, 293, 255, TTBK1 IN COMPLEX WITH ATP
2886, d3qupA_, 0.7705, 2.25, 0.343, 241, 236, INHIBITOR BOUND STRUCTURE OF THE KINASE DOMAIN OF THE MURINE RECEPTOR TYROSINE KINASE TYRO3 (SKY)
2887, d3efjB_, 0.7705, 2.50, 0.310, 275, 239, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
2888, d5w4wB_, 0.7704, 3.41, 0.190, 291, 258, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2889, d4o0wA_, 0.7704, 2.66, 0.232, 259, 246, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2890, d4mygB_, 0.7704, 2.86, 0.217, 335, 249, MAPK13 ACTIVE FORM
2891, d4i6bA_, 0.7704, 3.31, 0.213, 285, 254, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2892, d4i5pA_, 0.7704, 3.29, 0.213, 284, 254, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2893, d2bfxA_, 0.7704, 3.03, 0.198, 269, 252, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
2894, d4xj0B_, 0.7703, 3.17, 0.236, 338, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
2895, d3qyiA_, 0.7703, 3.17, 0.220, 346, 254,  
2896, d1j1cA_, 0.7703, 3.31, 0.227, 354, 256, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
2897, d5c03A_, 0.7702, 2.50, 0.222, 260, 243, CRYSTAL STRUCTURE OF KINASE
2898, d3zrlB_, 0.7702, 3.40, 0.229, 347, 258, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
2899, d3du8B_, 0.7702, 3.30, 0.227, 339, 256, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
2900, d2hyyC1, 0.7702, 2.41, 0.380, 249, 237, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
2901, d1q3wA_, 0.7702, 3.31, 0.227, 344, 256, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
2902, p6g9aA_, 0.7701, 3.21, 0.224, 341, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2903, d3zrmA_, 0.7701, 3.41, 0.229, 344, 258, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
2904, d3du8A_, 0.7701, 3.31, 0.227, 336, 256, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
2905, d1h4lB_, 0.7701, 2.77, 0.215, 278, 246, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
2906, d5vamB_, 0.7700, 2.62, 0.265, 260, 245, BRAF IN COMPLEX WITH RAF709
2907, d5mqvC_, 0.7700, 3.25, 0.199, 288, 256, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
2908, d5ar4B_, 0.7700, 2.66, 0.258, 279, 244, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
2909, d3efkB_, 0.7700, 2.47, 0.315, 272, 238, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
2910, d1q3wB_, 0.7700, 3.34, 0.227, 341, 256, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
2911, d4yfiA_, 0.7699, 2.70, 0.267, 268, 240, TNNI3K COMPLEXED WITH INHIBITOR 1
2912, d4xj0A_, 0.7699, 3.07, 0.239, 345, 251, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
2913, d3uytB_, 0.7699, 3.29, 0.207, 286, 256, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2914, d1mp8A_, 0.7699, 2.54, 0.336, 252, 241, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE (FAK)
2915, d5hd4A_, 0.7698, 3.27, 0.212, 347, 255, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT WILD TYPE SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
2916, d5dr9A_, 0.7698, 2.63, 0.237, 257, 245, AURORA A KINASE IN COMPLEX WITH AA29 AND JNJ-7706621 IN SPACE GROUP P6122
2917, d5cenA_, 0.7698, 2.57, 0.316, 281, 244, CRYSTAL STRUCTURE OF DLK (KINASE DOMAIN)
2918, d4ibmA_, 0.7698, 3.04, 0.323, 301, 251, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
2919, d2bfyA_, 0.7698, 3.05, 0.198, 270, 252, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
2920, d5k3yB_, 0.7697, 3.15, 0.197, 277, 254, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
2921, d4ztmB_, 0.7697, 2.80, 0.239, 280, 243, IRAK4-INHIBITOR CO-STRUCTURE
2922, d4u7zA1, 0.7697, 3.20, 0.240, 290, 254, MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK1) BOUND TO G805
2923, d4acgA_, 0.7697, 3.31, 0.223, 350, 256, GSK3B IN COMPLEX WITH INHIBITOR
2924, d2wqbA_, 0.7697, 2.73, 0.333, 289, 246, STRUCTURE OF THE TIE2 KINASE DOMAIN IN COMPLEX WITH A THIAZOLOPYRIMIDINE INHIBITOR
2925, d1howA_, 0.7697, 2.91, 0.209, 346, 249, THE X-RAY CRYSTAL STRUCTURE OF SKY1P AN SR PROTEIN KINASE IN YEAST
2926, d6brcB_, 0.7696, 3.00, 0.225, 260, 249, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
2927, d5k5nA_, 0.7696, 3.18, 0.233, 331, 253, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
2928, d5d7aC_, 0.7696, 2.83, 0.228, 286, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2929, d3uqfB_, 0.7696, 2.23, 0.342, 253, 237, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
2930, d2qi8B_, 0.7696, 2.09, 0.336, 249, 235, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
2931, d2oibB_, 0.7696, 2.97, 0.232, 278, 246, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
2932, d1q97B_, 0.7696, 3.30, 0.187, 361, 256, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
2933, d5w85B_, 0.7695, 2.95, 0.233, 279, 245, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)
2934, d5hlwA_, 0.7695, 3.14, 0.329, 284, 249, CRYSTAL STRUCTURE OF C-MET MUTANT Y1230H IN COMPLEX WITH COMPOUND 14
2935, p3vuiA_, 0.7695, 2.89, 0.205, 355, 249, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
2936, d1okvA_, 0.7695, 3.02, 0.242, 295, 252, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
2937, d5l8lA_, 0.7694, 2.92, 0.191, 263, 251, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 1)
2938, d5dr6A_, 0.7694, 2.63, 0.237, 257, 245, AURORA A KINASE IN COMPLEX WITH AA30 AND JNJ-7706621 IN SPACE GROUP P6122
2939, d2jd5B_, 0.7694, 3.30, 0.203, 360, 256, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
2940, d4qp7A_, 0.7693, 2.81, 0.218, 337, 248, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
2941, d4gt4B_, 0.7693, 2.78, 0.324, 273, 247, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
2942, d4cxaC_, 0.7693, 3.17, 0.250, 330, 256, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
2943, d3zrlA_, 0.7693, 3.43, 0.229, 345, 258, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
2944, d3m1sB_, 0.7693, 3.32, 0.227, 349, 256, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
2945, d5ng3D_, 0.7692, 2.87, 0.258, 278, 248, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
2946, d4qqcA1, 0.7692, 2.73, 0.367, 271, 245, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
2947, d4qq5A1, 0.7692, 2.79, 0.366, 272, 246, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
2948, p3v3vA_, 0.7692, 2.91, 0.209, 351, 249, STRUCTURAL AND FUNCTIONAL ANALYSIS OF QUERCETAGETIN A NATURAL JNK1 INHIBITOR
2949, d2bpmC2, 0.7692, 3.00, 0.254, 298, 252, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
2950, d6b16A_, 0.7691, 3.08, 0.209, 285, 253, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
2951, d4tw9A_, 0.7691, 3.36, 0.202, 290, 257, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
2952, d3qlfA_, 0.7691, 1.94, 0.342, 249, 234, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
2953, d3pp1A1, 0.7691, 3.17, 0.237, 290, 253, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGATP
2954, d5dewA_, 0.7690, 3.18, 0.208, 295, 255, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
2955, d4xs2D_, 0.7690, 2.89, 0.241, 277, 245, IRAK4-INHIBITOR CO-STRUCTURE
2956, d1q99B_, 0.7690, 3.13, 0.204, 364, 255, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
2957, d1h24A1, 0.7690, 2.96, 0.259, 292, 251, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
2958, p6g93A_, 0.7689, 3.24, 0.236, 343, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2959, d5t1tA_, 0.7689, 3.00, 0.240, 283, 246, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
2960, d5cwzA_, 0.7689, 2.78, 0.229, 284, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
2961, d4yo6C_, 0.7689, 2.99, 0.243, 286, 247, IRAK4-INHIBITOR CO-STRUCTURE
2962, d4bieB_, 0.7689, 2.75, 0.299, 257, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2963, d5ct7A_, 0.7688, 2.59, 0.276, 257, 243, BRAF IN COMPLEX WITH RAF265
2964, p3vukA_, 0.7688, 2.89, 0.205, 355, 249, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M5 IN MAP KINASE JNK1
2965, d1uwhB_, 0.7688, 2.79, 0.272, 264, 246, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
2966, d4ztnC_, 0.7687, 3.07, 0.235, 284, 247, IRAK4-INHIBITOR CO-STRUCTURE
2967, d4lmnA1, 0.7687, 3.24, 0.240, 291, 254, CRYSTAL STRUCTURE OF MEK1 KINASE BOUND TO GDC0973
2968, d4j1rD_, 0.7687, 3.44, 0.229, 345, 258, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
2969, d4j1rB_, 0.7687, 3.45, 0.229, 346, 258, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
2970, d3zlyA_, 0.7687, 3.25, 0.244, 310, 254, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 8
2971, d3zlxA_, 0.7687, 3.29, 0.243, 312, 255, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 18
2972, d3my0K_, 0.7687, 2.88, 0.252, 261, 246, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2973, d3iecA_, 0.7687, 2.75, 0.251, 311, 247, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2974, d3f7zB1, 0.7687, 3.40, 0.229, 338, 258, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
2975, d3etaA_, 0.7687, 2.80, 0.310, 293, 245, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
2976, d3d2iA_, 0.7687, 2.64, 0.233, 255, 245, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH 1-{5-[2-(1-METHYL-1H- PYRAZOLO[43-D]PYRIMIDIN-7-YLAMINO)-ETHYL]-THIAZOL-2-YL}-3- (3-TRIFLUOROMETHYL-PHENYL)-UREA
2977, d2bfyB_, 0.7687, 3.17, 0.201, 278, 254, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
2978, d1o9uA_, 0.7687, 3.30, 0.231, 349, 255, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE
2979, d1finC_, 0.7687, 3.02, 0.250, 298, 252, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
2980, d4j1rA_, 0.7686, 3.44, 0.229, 343, 258, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
2981, d5uitA_, 0.7685, 2.79, 0.242, 284, 244, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
2982, d4kspA_, 0.7685, 2.53, 0.269, 257, 242, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
2983, d2wipA1, 0.7685, 2.81, 0.243, 293, 247, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
2984, d1yxtA_, 0.7685, 2.68, 0.188, 274, 245, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMPPNP
2985, p6gdqA_, 0.7684, 3.23, 0.236, 339, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2986, d5hlnA_, 0.7684, 3.35, 0.229, 346, 258, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
2987, d5ar7B_, 0.7684, 2.49, 0.264, 278, 242, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
2988, d4qpaA_, 0.7684, 3.18, 0.202, 331, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
2989, d4qp1B_, 0.7684, 3.20, 0.205, 343, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
2990, d4q9sA_, 0.7684, 2.44, 0.368, 252, 242, CRYSTAL STRUCTURE OF HUMAN FOCAL ADHESION KINASE (FAK) BOUND TO COMPOUND1 (35-DIHYDRO[124]TRIAZINO[34-C][14]BENZOXAZIN-2(1H)- ONE)
2991, d4j1rC_, 0.7684, 3.45, 0.229, 344, 258, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
2992, d4c2vB_, 0.7684, 3.22, 0.197, 280, 254, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
2993, d4btmB_, 0.7684, 3.24, 0.180, 293, 255, TTBK1 IN COMPLEX WITH INHIBITOR
2994, d4b8mB_, 0.7684, 3.22, 0.197, 279, 254, AURORA B KINASE IN COMPLEX WITH VX-680
2995, d3dv3A_, 0.7684, 3.14, 0.242, 288, 252, MEK1 WITH PF-04622664 BOUND
2996, d3a8xB1, 0.7684, 2.90, 0.187, 325, 251, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
2997, d2p2hA1, 0.7684, 2.66, 0.380, 289, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDINYL-TRIAZINE INHIBITOR
2998, d2aypA_, 0.7684, 3.13, 0.248, 268, 250, CRYSTAL STRUCTURE OF CHK1 WITH AN INDOL INHIBITOR
2999, d5k7gD_, 0.7683, 3.00, 0.241, 283, 245, IRAK4 IN COMPLEX WITH AZ3862
3000, d4at4A1, 0.7683, 3.05, 0.382, 289, 249, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429
3001, d4achA_, 0.7683, 3.34, 0.227, 350, 256, GSK3B IN COMPLEX WITH INHIBITOR
3002, d3dlsC_, 0.7683, 2.93, 0.235, 281, 247, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3003, d1wzyA_, 0.7683, 3.02, 0.231, 350, 251, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A PYRAZOLOPYRIDAZINE DERIVATIVE
3004, d5k5nB_, 0.7682, 3.19, 0.233, 334, 253, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
3005, d4u80A_, 0.7682, 3.21, 0.240, 286, 254, MEK 1 KINASE BOUND TO G799
3006, d4qp6B_, 0.7682, 3.21, 0.213, 334, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
3007, d4qp2B_, 0.7682, 3.21, 0.206, 329, 253, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
3008, d4itjB_, 0.7682, 2.91, 0.269, 276, 245, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
3009, d4b8mA_, 0.7682, 3.03, 0.199, 270, 251, AURORA B KINASE IN COMPLEX WITH VX-680
3010, d3o7lD_, 0.7682, 3.01, 0.210, 333, 252, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
3011, d3f69B_, 0.7682, 2.98, 0.198, 282, 252, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
3012, d2yerA_, 0.7682, 3.19, 0.247, 268, 251, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
3013, d2vrxA_, 0.7682, 3.03, 0.199, 268, 251, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
3014, d1unhA_, 0.7682, 2.86, 0.206, 276, 247, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
3015, d1ungA_, 0.7682, 2.96, 0.209, 288, 249, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
3016, d1i09B_, 0.7682, 3.35, 0.223, 341, 256, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
3017, d5bx0A_, 0.7681, 3.30, 0.239, 315, 255, AN AUTOMATED MICROSCALE THERMOPHORESIS SCREENING APPROACH FOR FRAGMENT-BASED LEAD DISCOVERY
3018, d4j71A_, 0.7681, 3.43, 0.229, 347, 258, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
3019, d3f3zA_, 0.7681, 2.97, 0.211, 271, 251, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840 IN PRESENCE OF INDIRUBIN E804
3020, d2jldA_, 0.7681, 3.33, 0.227, 349, 256, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
3021, d1h8fB_, 0.7681, 3.36, 0.227, 350, 256, GLYCOGEN SYNTHASE KINASE 3 BETA.
3022, d5w4wA_, 0.7680, 3.46, 0.201, 291, 259, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
3023, d5fdxA_, 0.7680, 3.02, 0.333, 280, 249, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
3024, d4ty1A_, 0.7680, 2.67, 0.188, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AMINOOXADIAZOLE-INDOLE INHIBITOR.
3025, d5h3qA_, 0.7679, 2.97, 0.364, 302, 247, CRYSTAL STRUCTURE OF TRKA KINASE WITH LIGAND
3026, d4mtaA_, 0.7679, 2.69, 0.192, 273, 245, CRYSTAL STRUCTURE OF PIM-1 KINASE DOMAIN IN COMPLEX WITH 2-METHYL-5- PHENYLFURAN-3-CARBOXYLIC ACID
3027, d4byiA_, 0.7679, 2.61, 0.238, 254, 244, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
3028, d4alwA_, 0.7679, 2.62, 0.189, 273, 244, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
3029, p3zu7A_, 0.7679, 3.10, 0.230, 344, 252, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE MAP KINASE ERK2
3030, d1h8fA_, 0.7679, 3.36, 0.223, 352, 256, GLYCOGEN SYNTHASE KINASE 3 BETA.
3031, d5cwzB_, 0.7678, 2.80, 0.229, 284, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
3032, d5aafA_, 0.7678, 2.61, 0.238, 254, 244, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14A)
3033, d4qp9A_, 0.7678, 2.84, 0.231, 335, 247, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-PROPYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
3034, p4h3pA_, 0.7678, 3.08, 0.226, 342, 252, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
3035, d3qc4A_, 0.7678, 2.87, 0.214, 276, 248, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
3036, d5e1sA_, 0.7677, 2.68, 0.322, 284, 245, THE CRYSTAL STRUCTURE OF INSR TYROSINE KINASE IN COMPLEX WITH THE INHIBITOR BI 885578
3037, d4ntsB_, 0.7677, 3.02, 0.210, 341, 252, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
3038, d4iq6A_, 0.7677, 3.37, 0.227, 324, 256, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
3039, d4arkA1, 0.7677, 3.20, 0.241, 290, 253, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH  A SMALL MOLECULE INHIBITOR AND ADP
3040, d4afjA_, 0.7677, 3.28, 0.231, 342, 255, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
3041, d2e9vA_, 0.7677, 3.25, 0.255, 268, 251, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
3042, d5eykB_, 0.7676, 3.17, 0.202, 275, 253, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
3043, d4y73B_, 0.7676, 2.99, 0.237, 289, 245, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
3044, d2vgoA_, 0.7676, 3.04, 0.199, 268, 251, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
3045, d1q99A_, 0.7676, 2.94, 0.213, 354, 249, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
3046, d5l8kA_, 0.7675, 3.04, 0.183, 266, 252, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 2)
3047, d5buiA_, 0.7675, 2.90, 0.234, 338, 248, ERK2 COMPLEXED WITH 2-PYRIDIYL TETRAHYDROAZAINDAZOLE
3048, d4l46A_, 0.7675, 2.97, 0.261, 317, 249, CRYSTAL STRUCTURES OF HUMAN P70S6K1-WT
3049, d1i44A_, 0.7675, 2.70, 0.333, 282, 246, CRYSTALLOGRAPHIC STUDIES OF AN ACTIVATION LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
3050, d5hlpA_, 0.7674, 3.45, 0.229, 337, 258, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
3051, d4ic7D_, 0.7674, 3.35, 0.207, 353, 256, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
3052, d3sd0B_, 0.7674, 3.39, 0.227, 349, 256, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
3053, d4yp8D_, 0.7673, 2.99, 0.243, 285, 247, IRAK4-INHIBITOR CO-STRUCTURE
3054, d4xs2C_, 0.7673, 2.96, 0.241, 281, 245, IRAK4-INHIBITOR CO-STRUCTURE
3055, p4ux9D_, 0.7673, 2.82, 0.191, 344, 246, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
3056, d4rmzA_, 0.7673, 3.00, 0.240, 284, 246, CRYSTAL STRUCTURE OF IRAK-4
3057, d4qyyA_, 0.7673, 3.32, 0.212, 337, 255, DISCOVERY OF NOVEL DUAL MECHANISM ERK INHIBITORS BY AFFINITY SELECTION SCREENING OF AN INACTIVE KINASE STATE
3058, d4ixpA_, 0.7673, 3.02, 0.255, 334, 251, CRYSTAL STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK)
3059, d4afjB_, 0.7673, 3.23, 0.232, 346, 254, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
3060, d3zlwA_, 0.7673, 3.36, 0.234, 312, 256, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 3
3061, d3og7B_, 0.7673, 2.54, 0.270, 254, 244, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
3062, d3gb2A_, 0.7673, 3.42, 0.229, 340, 258, GSK3BETA INHIBITOR COMPLEX
3063, d5ar8B_, 0.7672, 2.43, 0.261, 274, 241, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
3064, d5aadA_, 0.7672, 2.54, 0.240, 252, 242, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (7A)
3065, d3q3bB_, 0.7672, 3.37, 0.227, 341, 256, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
3066, d2yexA_, 0.7672, 3.30, 0.246, 269, 252, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
3067, d1gngA_, 0.7672, 3.36, 0.230, 348, 257, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
3068, d5uiuB_, 0.7671, 2.93, 0.245, 287, 245, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 30
3069, d5k72A_, 0.7671, 2.86, 0.243, 277, 243, IRAK4 IN COMPLEX WITH COMPOUND 21
3070, d4ztlA_, 0.7671, 2.98, 0.239, 280, 243, IRAK4-INHIBITOR CO-STRUCTURE
3071, d3sv0A_, 0.7671, 3.38, 0.186, 294, 258, CRYSTAL STRUCTURE OF CASEIN KINASE-1 LIKE PROTEIN IN PLANT
3072, d1mruA_, 0.7671, 2.57, 0.207, 269, 242, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
3073, d1j3hB_, 0.7671, 2.98, 0.211, 327, 251, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
3074, d5li9A1, 0.7670, 2.77, 0.198, 328, 248, STRUCTURE OF A NUCLEOTIDE-BOUND FORM OF PKCIOTA CORE KINASE DOMAIN
3075, d4apcB1, 0.7670, 2.97, 0.215, 291, 247, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
3076, d4acdB_, 0.7670, 3.35, 0.227, 350, 256, GSK3B IN COMPLEX WITH INHIBITOR
3077, d3v5qA1, 0.7670, 2.55, 0.382, 260, 241, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
3078, d1i09A_, 0.7670, 3.38, 0.227, 338, 256, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
3079, d4un0C_, 0.7669, 3.17, 0.243, 308, 255, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
3080, d4qp4A_, 0.7669, 2.85, 0.222, 337, 248, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
3081, d4iq6B_, 0.7669, 3.38, 0.227, 332, 256, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
3082, d4alvA_, 0.7669, 2.68, 0.188, 274, 245, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
3083, d2cguA_, 0.7669, 3.10, 0.249, 263, 249, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3084, d5uisB_, 0.7668, 3.00, 0.241, 274, 245, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
3085, d4c2wB_, 0.7668, 3.24, 0.197, 277, 254, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
3086, d3c7qA_, 0.7668, 2.70, 0.373, 286, 244, STRUCTURE OF VEGFR2 KINASE DOMAIN IN COMPLEX WITH BIBF1120
3087, p2y4iC_, 0.7668, 3.17, 0.242, 313, 252, KSR2-MEK1 HETERODIMER
3088, d2np8A_, 0.7668, 2.72, 0.236, 256, 246, STRUCTURAL BASIS FOR THE INHIBITION OF AURORA A KINASE BY A NOVEL CLASS OF HIGH AFFINITY DISUBSTITUTED PYRIMIDINE INHIBITORS
3089, d2jldB_, 0.7668, 3.35, 0.227, 349, 256, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
3090, d2cgxA_, 0.7668, 3.07, 0.254, 265, 248, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3091, d1q4lA_, 0.7668, 3.38, 0.215, 342, 256, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
3092, d4y73D_, 0.7667, 2.98, 0.240, 288, 246, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
3093, d4aszA1, 0.7667, 3.01, 0.381, 286, 247, CRYSTAL STRUCTURE OF APO TRKB KINASE DOMAIN
3094, d3vvhC1, 0.7667, 3.16, 0.237, 282, 253, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
3095, d2qoqA_, 0.7667, 2.72, 0.314, 284, 242, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BASE AMP-PNP BOUND STRUCTURE
3096, d1p4oA_, 0.7667, 3.12, 0.313, 308, 249, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
3097, d4n70A_, 0.7666, 2.70, 0.188, 274, 245, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
3098, d4k0yA_, 0.7666, 2.70, 0.192, 274, 245, STRUCTURE OF PIM-1 KINASE BOUND TO N-(4-FLUOROPHENYL)-7-HYDROXY-5- (PIPERIDIN-4-YL)PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
3099, d3zonA_, 0.7666, 2.43, 0.228, 261, 241, HUMAN TYK2 PSEUDOKINASE DOMAIN BOUND TO A KINASE INHIBITOR
3100, d2vwuA_, 0.7666, 2.64, 0.292, 253, 240, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3101, d2cgvA_, 0.7666, 3.06, 0.254, 264, 248, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3102, d3r22A_, 0.7665, 2.60, 0.230, 255, 244, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
3103, d1p4oB_, 0.7665, 3.13, 0.313, 314, 249, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
3104, d1jpaA_, 0.7665, 2.51, 0.328, 273, 241, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
3105, d5diaA_, 0.7664, 2.70, 0.192, 273, 245, PIM1 IN COMPLEX WITH CPD36 ((1S3S)-N1-(6-(5-(PYRIDIN-3-YL)-1H- PYRAZOLO[34-C]PYRIDIN-3-YL)PYRIDIN-2-YL)CYCLOHEXANE-13-DIAMINE)
3106, d5dhjA_, 0.7664, 2.69, 0.188, 273, 245, PIM1 IN COMPLEX WITH CPD4 (3-METHYL-5-(PYRIDIN-3-YL)-1H-PYRAZOLO[34- C]PYRIDINE)
3107, d5dgzA_, 0.7664, 2.69, 0.184, 273, 245, DISCOVERY OF 35-SUBSTITUTED 6-AZAINDAZOLES AS POTENT PAN-PIM INHIBITORS
3108, d5c01A_, 0.7664, 2.49, 0.211, 258, 242, CRYSTAL STRUCTURE OF KINASE
3109, d1q8yA_, 0.7664, 2.78, 0.224, 351, 246, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
3110, d1jpaB_, 0.7664, 2.44, 0.331, 269, 239, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
3111, d4twcB_, 0.7663, 3.42, 0.202, 292, 258, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
3112, d4gt4A_, 0.7663, 2.80, 0.324, 274, 247, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
3113, d4bidA_, 0.7663, 2.54, 0.300, 254, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3114, d3pupB_, 0.7663, 3.37, 0.227, 347, 256, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
3115, d2a1aB1, 0.7663, 2.84, 0.256, 266, 246, PKR KINASE DOMAIN-EIF2ALPHA COMPLEX
3116, d5k7gC_, 0.7662, 2.99, 0.241, 283, 245, IRAK4 IN COMPLEX WITH AZ3862
3117, d5aagA_, 0.7662, 2.59, 0.239, 253, 243, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14B)
3118, d3r00A_, 0.7662, 2.70, 0.188, 274, 245, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
3119, d2vgpB_, 0.7662, 3.26, 0.197, 277, 254, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
3120, d2bujB1, 0.7662, 3.15, 0.228, 277, 254, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
3121, d1jowB_, 0.7662, 2.62, 0.252, 277, 242, CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
3122, d5kgdA_, 0.7661, 2.70, 0.192, 273, 245, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-PYRIDIN-3-YL-1~{H}- BENZIMIDAZOLE
3123, d4fc0A_, 0.7661, 2.56, 0.269, 254, 242, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
3124, d4bibA_, 0.7661, 2.54, 0.296, 254, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3125, d4bckC1, 0.7661, 2.93, 0.257, 291, 249, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3126, d4achB_, 0.7661, 3.37, 0.227, 350, 256, GSK3B IN COMPLEX WITH INHIBITOR
3127, d1q97A_, 0.7661, 2.79, 0.224, 351, 246, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
3128, d5uiqB_, 0.7660, 2.84, 0.243, 272, 243, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
3129, d5jznB_, 0.7660, 2.88, 0.238, 266, 248, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
3130, d5hlpB_, 0.7660, 3.48, 0.229, 335, 258, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
3131, d4wt6A_, 0.7660, 2.70, 0.188, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIADIAZOLAMINE-INDOLE INHIBITOR.
3132, d4wrsA_, 0.7660, 2.70, 0.188, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AZASPIRO PYRAZINYL-INDAZOLE INHIBITOR.
3133, d4tn6A_, 0.7660, 3.31, 0.191, 292, 257, CK1D IN COMPLEX WITH INHIBITOR
3134, d2y6mA_, 0.7660, 2.67, 0.343, 262, 242, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN
3135, d2vwwA_, 0.7660, 2.66, 0.307, 253, 241, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3136, d2c3kA_, 0.7660, 3.11, 0.250, 262, 248, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
3137, d2xj2A_, 0.7659, 2.66, 0.189, 273, 244, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3138, d5nk8A_, 0.7658, 2.50, 0.324, 266, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2F
3139, d4wovA_, 0.7658, 2.48, 0.227, 258, 242, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH BMS-066 AKA 2-METHOXY-N-({6-[3-METHYL-7-(METHYLAMINO)- 35810-TETRAAZATRICYCLO[7.3.0.0 6]DODECA-1(9)2(6)4711-PENTAEN- 11-YL]PYRIDIN-2-YL}METHY L)ACETAMIDE
3140, d4j71B_, 0.7658, 3.47, 0.229, 347, 258, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
3141, d3pupA_, 0.7658, 3.38, 0.227, 346, 256, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
3142, d3eqbA1, 0.7658, 3.19, 0.241, 288, 253, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3143, d1q8zA_, 0.7658, 2.96, 0.209, 354, 249, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
3144, d5v82A_, 0.7657, 2.66, 0.193, 273, 244, PIM1 KINASE IN COMPLEX WITH CPD17 (1-(6-(44-DIFLUOROPIPERIDIN-3-YL) PYRIDIN-2-YL)-6-(6-METHYLPYRAZIN-2-YL)-1H-PYRAZOLO[43-C]PYRIDINE)
3145, d5jrqA1, 0.7657, 2.94, 0.274, 257, 248, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
3146, d3slsB1, 0.7657, 3.06, 0.243, 291, 251, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
3147, d2e9oA_, 0.7657, 3.21, 0.252, 269, 250, STRUCTURE OF H-CHK1 COMPLEXED WITH AA582939
3148, d2cjmA_, 0.7657, 3.01, 0.260, 285, 250, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
3149, d4c8bA_, 0.7656, 2.27, 0.262, 279, 237, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
3150, d4bckA1, 0.7656, 3.00, 0.259, 296, 251, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3151, d4accB_, 0.7656, 3.37, 0.227, 350, 256, GSK3B IN COMPLEX WITH INHIBITOR
3152, d3vc4A_, 0.7656, 2.70, 0.184, 274, 245, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3153, d3mygA_, 0.7656, 2.55, 0.244, 252, 242, AURORA A KINASE COMPLEXED WITH SCH 1473759
3154, d3eidC_, 0.7656, 2.98, 0.256, 290, 250, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
3155, d3dlsB_, 0.7656, 2.93, 0.236, 280, 246, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3156, d4dtkA_, 0.7655, 2.71, 0.188, 273, 245, NOVEL AND SELECTIVE PAN-PIM KINASE INHIBITOR
3157, d4acdA_, 0.7655, 3.38, 0.227, 350, 256, GSK3B IN COMPLEX WITH INHIBITOR
3158, d2o64A_, 0.7655, 2.71, 0.188, 274, 245, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETAGETIN
3159, d2e9vB_, 0.7655, 3.18, 0.256, 268, 250, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
3160, d2chlA_, 0.7655, 3.50, 0.169, 298, 260, STRUCTURE OF CASEIN KINASE 1 GAMMA 3
3161, d5op7A_, 0.7654, 3.10, 0.246, 261, 248, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
3162, d5jzjA_, 0.7654, 2.81, 0.215, 271, 246, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
3163, d4bcqC1, 0.7654, 2.93, 0.261, 291, 249, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3164, d2xj1A_, 0.7654, 2.68, 0.189, 273, 244, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INIBITOR
3165, d2bfxB_, 0.7654, 3.11, 0.199, 275, 251, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
3166, d1r0pA_, 0.7654, 3.07, 0.312, 301, 247, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH THE MICROBIAL ALKALOID K-252A
3167, d5ipjA_, 0.7653, 2.71, 0.188, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A QUINAZOLINONE-PYRROLOPYRROLONE INHIBITOR.
3168, d5eolA_, 0.7653, 2.71, 0.188, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A MACROCYCLIC QUINOXALINE-PYRROLODIHYDROPIPERIDINONE INHIBITOR
3169, d3f2aA_, 0.7653, 2.73, 0.192, 276, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 IN COMPLEX WITH DAPPA
3170, d5uoxB_, 0.7652, 2.69, 0.303, 252, 241, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3171, d4n6zA_, 0.7652, 2.67, 0.184, 272, 244, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
3172, d4dbnA_, 0.7652, 2.65, 0.272, 257, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
3173, d4c8bB_, 0.7652, 2.45, 0.258, 281, 240, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
3174, d4acgB_, 0.7652, 3.37, 0.223, 350, 256, GSK3B IN COMPLEX WITH INHIBITOR
3175, d2xj0A_, 0.7652, 2.71, 0.188, 274, 245, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-4 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3176, d5w4wD_, 0.7651, 3.30, 0.188, 287, 255, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
3177, d5hieC_, 0.7651, 2.68, 0.280, 253, 243, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3178, d4mblA_, 0.7651, 2.71, 0.184, 274, 245, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
3179, d3f88A_, 0.7651, 3.46, 0.229, 340, 258, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
3180, d2rfnA_, 0.7651, 2.41, 0.314, 268, 236, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
3181, d5uiuA_, 0.7650, 2.92, 0.242, 286, 244, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 30
3182, d5ar4A_, 0.7650, 2.47, 0.262, 274, 240, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
3183, d4mygA_, 0.7650, 2.89, 0.218, 335, 248, MAPK13 ACTIVE FORM
3184, d3vbqA_, 0.7650, 2.63, 0.189, 271, 243, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3185, d3qtiA_, 0.7650, 3.00, 0.331, 292, 245, C-MET KINASE IN COMPLEX WITH NVP-BVU972
3186, d3f88B_, 0.7650, 3.45, 0.229, 340, 258, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
3187, d2ywpA_, 0.7650, 3.17, 0.253, 269, 249, CRYSTAL STRUCTURE OF CHK1 WITH A UREA INHIBITOR
3188, d2wipC1, 0.7650, 2.86, 0.243, 291, 247, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
3189, d4r6vA1, 0.7649, 2.83, 0.367, 271, 245, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-3 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
3190, d4cjyC_, 0.7649, 3.22, 0.243, 303, 255,  
3191, d4wsyA_, 0.7648, 2.72, 0.188, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIAZOLAMINE-INDAZOLE INHIBITOR.
3192, d4prjA_, 0.7648, 2.53, 0.232, 251, 241, AURORA A KINASE DOMAIN WITH COMPOUND 2 (N-[1-(3-CYANOBENZYL)-1H- PYRAZOL-4-YL]-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
3193, d4hyhA_, 0.7648, 3.10, 0.246, 263, 248, X-RAY CRYSTAL STRUCTURE OF COMPOUND 39 BOUND TO HUMAN CHK1 KINASE DOMAIN
3194, d2objA_, 0.7648, 2.67, 0.184, 272, 244, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH INHIBITOR
3195, d4p5zA_, 0.7647, 2.72, 0.324, 267, 241, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
3196, d4jx7A_, 0.7647, 2.71, 0.188, 274, 245, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR 2-[(TRANS- 4-AMINOCYCLOHEXYL)AMINO]-4-{[3-(TRIFLUOROMETHYL) PHENYL]AMINO}PYRIDO[43-D]PYRIMIDIN-5(6H)-ONE
3197, d4aluA_, 0.7647, 2.71, 0.184, 274, 245, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
3198, d3c4eD_, 0.7647, 2.72, 0.192, 273, 245, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3199, d2rfnB_, 0.7647, 2.49, 0.316, 269, 237, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
3200, d5iisA_, 0.7646, 2.72, 0.188, 273, 245, DESIGN SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIP OF POTENT PAN- PIM KINASE INHIBITORS DERIVED FROM THE PYRIDYL-AMIDE SCAFFOLD
3201, d4accA_, 0.7646, 3.39, 0.227, 350, 256, GSK3B IN COMPLEX WITH INHIBITOR
3202, d3zm4A_, 0.7646, 3.29, 0.245, 309, 253, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 1
3203, d3vvhB1, 0.7646, 3.20, 0.238, 289, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
3204, d1yxxA_, 0.7646, 2.72, 0.188, 274, 245, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH (3E)-3-[(4- HYDROXYPHENYL)IMINO]-1H-INDOL-2(3H)-ONE
3205, d1q4lB_, 0.7646, 3.42, 0.219, 337, 256, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
3206, d5fdpA_, 0.7645, 3.21, 0.319, 285, 251, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2099 INHIBITOR AT 2.25 ANGSTROMS RESOLUTION.
3207, d4k1bA_, 0.7645, 2.70, 0.184, 273, 245, STRUCTURE OF PIM-1 KINASE BOUND TO N-(5-(2-FLUOROPHENYL)-1H-PYRROLO[2 3-B]PYRIDIN-3-YL)-5-((((3R4R)-3-FLUOROPIPERIDIN-4-YL)METHYL)AMINO) PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
3208, d2fgaA_, 0.7645, 3.17, 0.257, 269, 249,  
3209, d3vw6B_, 0.7644, 2.63, 0.304, 253, 240, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
3210, d1uwjA_, 0.7644, 2.76, 0.275, 264, 244, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
3211, d3jxwA_, 0.7643, 2.71, 0.188, 274, 245, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
3212, d2oi4X_, 0.7643, 2.77, 0.183, 275, 246, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH FLUORINATED RUTHENIUM PYRIDOCARBAZOLE
3213, d2hwoA_, 0.7643, 2.19, 0.345, 251, 235, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR
3214, d2f57A1, 0.7643, 3.26, 0.181, 290, 254, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
3215, d1zysA_, 0.7643, 3.25, 0.260, 271, 250, CO-CRYSTAL STRUCTURE OF CHECKPOINT KINASE CHK1 WITH A PYRROLO-PYRIDINE INHIBITOR
3216, d1jstA_, 0.7643, 3.00, 0.259, 297, 251, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
3217, d5w85A_, 0.7642, 2.99, 0.243, 278, 243, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)
3218, d5uiqA_, 0.7642, 2.90, 0.244, 268, 242, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
3219, d4u81A1, 0.7642, 3.23, 0.241, 288, 253, MEK1 KINASE BOUND TO SMALL MOLECULE INHIBITOR G659
3220, d3w55A_, 0.7642, 2.88, 0.232, 335, 246, THE STRUCTURE OF ERK2 IN COMPLEX WITH FR148083
3221, d3f7zA1, 0.7642, 3.35, 0.227, 338, 255, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
3222, d2e14A_, 0.7642, 2.88, 0.232, 335, 246,  
3223, d5ng3B_, 0.7641, 2.80, 0.261, 275, 245, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
3224, d5mqvA_, 0.7641, 3.24, 0.201, 286, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3225, d5jsmB1, 0.7641, 2.99, 0.275, 259, 247, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
3226, d4rmzB_, 0.7641, 3.01, 0.246, 282, 244, CRYSTAL STRUCTURE OF IRAK-4
3227, d4k18A_, 0.7641, 2.76, 0.187, 277, 246, STRUCTURE OF PIM-1 KINASE BOUND TO 5-(4-CYANOBENZYL)-N-(4- FLUOROPHENYL)-7-HYDROXYPYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
3228, d2pk9A_, 0.7641, 3.11, 0.247, 287, 251, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
3229, d2p55A2, 0.7641, 3.23, 0.241, 288, 253, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3230, d2gdoA_, 0.7641, 3.40, 0.250, 269, 252, 4-(AMINOALKYLAMINO)-3-BENZIMIDAZOLE-QUINOLINONES AS POTENT CHK1 INHIBITORS
3231, d5kgiA_, 0.7640, 2.72, 0.188, 273, 245, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR 2-[34-BIS(CHLORANYL) PHENOXY]ETHANAMINE
3232, d5k3yA_, 0.7640, 2.98, 0.197, 267, 249, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
3233, d4zy6A_, 0.7640, 3.12, 0.210, 284, 252, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
3234, d4xhkB_, 0.7640, 2.73, 0.188, 269, 245, PIM1 KINASE IN COMPLEX WITH COMPOUND 1S
3235, d4k9yA_, 0.7640, 3.14, 0.332, 271, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-[4-(6-AMINO- PURIN-9-YL)-PHENYL]-3-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-UREA
3236, d3pj2A_, 0.7640, 2.31, 0.322, 248, 239, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[4-(2- DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-6-(4-FLUORO-PHENOXY)-8-METHYL-8H- PYRIDO[23-D]PYRIMIDIN-7-ONE
3237, d3o71A_, 0.7640, 3.16, 0.217, 340, 253, CRYSTAL STRUCTURE OF ERK2/DCC PEPTIDE COMPLEX
3238, d3cqeA_, 0.7640, 2.81, 0.200, 258, 245, WEE1 KINASE COMPLEX WITH INHIBITOR PD074291
3239, d2xruA_, 0.7640, 2.62, 0.247, 253, 243, AURORA-A T288E COMPLEXED WITH PHA-828300
3240, d5oq7A_, 0.7639, 3.04, 0.260, 259, 246, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3241, d5hieA_, 0.7639, 3.06, 0.278, 258, 248, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3242, d4b9dB1, 0.7639, 3.01, 0.227, 291, 247, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
3243, d3v01A1, 0.7639, 3.22, 0.241, 288, 253, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
3244, d1ckiA_, 0.7639, 3.20, 0.213, 292, 253, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
3245, d5ur1B_, 0.7638, 2.74, 0.400, 265, 245, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
3246, d5ih5A_, 0.7638, 3.34, 0.208, 286, 255, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A
3247, d5dwrA_, 0.7638, 2.68, 0.184, 273, 244, IDENTIFICATION OF N-(4-((1R3S5S)-3-AMINO-5-METHYLCYCLOHEXYL)PYRIDIN- 3-YL)-6-(26-DIFLUOROPHENYL)-5-FLUOROPICOLINAMIDE (PIM447) A POTENT AND SELECTIVE PROVIRAL INSERTION SITE OF MOLONEY MURINE LEUKEMIA (PIM) 12 AND 3 KINASE INHIBITOR IN CLINICAL TRIALS FOR HEMATOLOGICAL MALIGNANCIES
3248, d4c2wA_, 0.7638, 3.04, 0.200, 268, 250, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
3249, d3v04A1, 0.7638, 3.23, 0.241, 288, 253, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
3250, d5o21A_, 0.7637, 3.10, 0.261, 272, 249, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
3251, d5kggA_, 0.7637, 2.73, 0.188, 273, 245, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-(5-CHLORANYL-1~{H}-INDOL- 3-YL)ETHANAMINE
3252, d5itaA_, 0.7637, 2.53, 0.282, 250, 241, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
3253, d4hgsA1, 0.7637, 3.54, 0.169, 301, 260, CRYSTAL STRUCTURE OF CK1GS WITH COMPOUND 13
3254, d3r01A_, 0.7637, 2.73, 0.188, 274, 245, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
3255, d2xngA_, 0.7637, 2.59, 0.240, 253, 242, STRUCTURE OF AURORA-A BOUND TO A SELECTIVE IMIDAZOPYRAZINE INHIBITOR
3256, d5k7gA_, 0.7636, 2.90, 0.244, 277, 242, IRAK4 IN COMPLEX WITH AZ3862
3257, d5k75B_, 0.7636, 3.08, 0.240, 274, 246, IRAK4 IN COMPLEX WITH COMPOUND 1
3258, d5hieB_, 0.7636, 2.99, 0.274, 259, 248, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3259, d4g17A1, 0.7636, 3.53, 0.169, 301, 260, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-TERT-BUTYLPHENYL)AMINO]-1H- BENZIMIDAZOLE-6-CARBONITRILE
3260, d4ae6A_, 0.7636, 3.06, 0.218, 319, 252, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
3261, d1s9jA1, 0.7636, 3.20, 0.241, 288, 253, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3262, d5t1tB_, 0.7635, 2.90, 0.243, 280, 243, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3263, d4yc3A1, 0.7635, 2.99, 0.261, 294, 249, CDK1/CYCLINB1/CKS2 APO
3264, d4g16A1, 0.7635, 3.53, 0.169, 301, 260, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2- YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE
3265, d5kgeA_, 0.7634, 2.73, 0.188, 273, 245, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 5-(34-DICHLOROPHENYL)- 1~{H}-PYRAZOL-3-AMINE
3266, d4n6yA_, 0.7634, 2.74, 0.184, 273, 245, PIM1 COMPLEXED WITH A PHENYLCARBOXAMIDE
3267, d4bznA_, 0.7634, 2.70, 0.189, 272, 244, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO(12-A) PYRAZINONE INHIBITOR
3268, d3naxA_, 0.7634, 2.89, 0.214, 278, 248, PDK1 IN COMPLEX WITH INHIBITOR MP7
3269, d2hxlA_, 0.7634, 3.24, 0.248, 272, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1
3270, d2f9gA_, 0.7634, 2.74, 0.242, 332, 244, CRYSTAL STRUCTURE OF FUS3 PHOSPHORYLATED ON TYR182
3271, d1ywnA_, 0.7634, 2.83, 0.371, 279, 245, VEGFR2 IN COMPLEX WITH A NOVEL 4-AMINO-FURO[23-D]PYRIMIDINE
3272, d2ojgA_, 0.7633, 3.29, 0.213, 337, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH NN-DIMETHYL-4-(4- PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
3273, d2e9uA_, 0.7633, 3.20, 0.253, 269, 249, STRUCTURE OF H-CHK1 COMPLEXED WITH A780125
3274, d4ditA_, 0.7632, 3.25, 0.231, 328, 251, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A IMIDAZOPYRIDINE INHIBITOR
3275, d3sd0A_, 0.7632, 3.43, 0.227, 350, 256, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
3276, d3qtwA_, 0.7632, 3.05, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-13
3277, d2oibA_, 0.7632, 3.07, 0.230, 280, 243, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
3278, d1yxuD_, 0.7632, 2.75, 0.188, 273, 245, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3279, d1p14A_, 0.7632, 2.74, 0.324, 287, 244, CRYSTAL STRUCTURE OF A CATALYTIC-LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
3280, d1m7nB_, 0.7632, 3.13, 0.302, 299, 248, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
3281, d5ih6A_, 0.7631, 3.37, 0.208, 286, 255, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A DERIVATIVE
3282, d3kk8A_, 0.7631, 3.22, 0.213, 283, 253, CAMKII SUBSTRATE COMPLEX A
3283, d4jbpA_, 0.7630, 2.63, 0.239, 255, 243, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3284, d3rk5A_, 0.7630, 3.05, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-72
3285, d3p08A_, 0.7630, 2.93, 0.317, 252, 243, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
3286, d2ydiA_, 0.7630, 3.24, 0.256, 279, 250, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
3287, d2x8dA_, 0.7630, 3.24, 0.252, 279, 250, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
3288, d2w1gA1, 0.7630, 2.65, 0.218, 254, 243, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3289, d1tvoA_, 0.7630, 3.33, 0.227, 350, 255, THE STRUCTURE OF ERK2 IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
3290, d1pxpA_, 0.7630, 3.08, 0.257, 294, 249, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- N N -DIMETHYL-BENZENE-14-DIAMINE
3291, d5l4qB_, 0.7629, 2.42, 0.237, 287, 236, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
3292, d5k75C_, 0.7629, 3.06, 0.240, 282, 246, IRAK4 IN COMPLEX WITH COMPOUND 1
3293, d5ar7A_, 0.7629, 2.67, 0.263, 278, 243, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
3294, d3slsA1, 0.7629, 3.00, 0.237, 289, 249, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
3295, d3jpvA_, 0.7629, 2.75, 0.192, 273, 245, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A PYRROLO[23- A]CARBAZOLE LIGAND
3296, d2bzhB_, 0.7629, 2.79, 0.183, 275, 246, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
3297, d1xqzA_, 0.7629, 2.78, 0.183, 277, 246, CRYSTAL STRUCTURE OF HPIM-1 KINASE AT 2.1 A RESOLUTION
3298, d5l4qA_, 0.7628, 2.43, 0.237, 293, 236, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
3299, d3bgqA_, 0.7628, 2.70, 0.189, 272, 244, HUMAN PIM-1 KINASE IN COMPLEX WITH AN TRIAZOLO PYRIDAZINE INHIBITOR VX2
3300, d2henA1, 0.7628, 2.69, 0.303, 258, 241, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
3301, d5jsmC1, 0.7627, 2.79, 0.280, 259, 243, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
3302, d3r21A_, 0.7627, 2.64, 0.239, 254, 243, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
3303, d2ojiA_, 0.7627, 3.32, 0.201, 344, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
3304, d6bqlA1, 0.7626, 3.14, 0.212, 276, 250, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH TAE-226
3305, d5ax9B_, 0.7626, 2.67, 0.232, 274, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
3306, d4qp1A_, 0.7626, 3.22, 0.209, 342, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
3307, d4gcjA1, 0.7626, 2.84, 0.254, 298, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
3308, d3dzqA_, 0.7626, 2.87, 0.317, 268, 243, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH INHIBITOR AWL-II- 38.3
3309, d3bhhD1, 0.7626, 2.67, 0.209, 285, 244, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
3310, d2xizA_, 0.7626, 2.71, 0.184, 273, 244, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-3 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3311, d5o21B_, 0.7625, 3.12, 0.269, 273, 249, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
3312, d3unjA_, 0.7625, 3.04, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR YL1-038-31
3313, d1s9iB_, 0.7625, 3.21, 0.247, 291, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
3314, d3bgpA_, 0.7624, 2.71, 0.184, 272, 244, HUMAN PIM-1 COMPLEXED WITH A BENZOISOXAZOLE INHIBITOR VX1
3315, d5telA_, 0.7623, 2.74, 0.188, 273, 245, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
3316, d5k4iA_, 0.7623, 2.72, 0.230, 336, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH COMPOUND 22
3317, d5j95A_, 0.7623, 2.99, 0.224, 284, 246, MAP4K4 IN COMPLEX WITH INHIBITOR
3318, d5ih4A_, 0.7623, 3.34, 0.197, 286, 254, HUMAN CASEIN KINASE 1 ISOFORM DELTA APO (KINASE DOMAIN)
3319, d4xh6A_, 0.7623, 2.74, 0.188, 273, 245, CRYSTAL STRUCTURE OF PROTO-ONCOGENE KINASE PIM1 BOUND TO HISPIDULIN
3320, d4ficA_, 0.7623, 2.17, 0.350, 251, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH A HINGE REGION-BINDING FRAGMENT
3321, d4bf2A_, 0.7623, 2.54, 0.301, 253, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3322, d3r02A_, 0.7623, 2.67, 0.189, 271, 243, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
3323, d3ctjA_, 0.7623, 2.86, 0.324, 289, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
3324, d1zltA_, 0.7623, 3.27, 0.252, 272, 250, CRYSTAL STRUCTURE OF CHK1 COMPLEXED WITH A HYMENALDISINE ANALOG
3325, d1pxnA_, 0.7623, 3.05, 0.261, 294, 249, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL
3326, d3qc4B1, 0.7622, 2.86, 0.220, 268, 246, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
3327, d4lghB_, 0.7621, 1.97, 0.352, 247, 233, CRYSTAL STRUCTURE OF 1NM-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
3328, d1yxvA_, 0.7621, 2.74, 0.188, 274, 245, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH 34-DIHYDROXY-1- METHYLQUINOLIN-2(1H)-ONE
3329, d5oq5A_, 0.7620, 3.20, 0.256, 265, 250, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
3330, d5nguA_, 0.7620, 3.38, 0.224, 339, 255, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3331, d4qpaB_, 0.7620, 3.24, 0.209, 345, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
3332, d4m67A_, 0.7620, 2.47, 0.220, 264, 241, CRYSTAL STRUCTURE OF THE HUMAN MLKL KINASE-LIKE DOMAIN
3333, d3qu0A_, 0.7620, 3.08, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-38
3334, d2xmyA_, 0.7620, 3.08, 0.253, 295, 249, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
3335, d2vrxB_, 0.7620, 3.12, 0.200, 274, 250, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
3336, d2e9nA_, 0.7620, 3.24, 0.248, 269, 250, STRUCTURE OF H-CHK1 COMPLEXED WITH A767085
3337, d6b8uA_, 0.7619, 2.68, 0.276, 253, 243, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
3338, d5uiqD_, 0.7619, 2.68, 0.243, 271, 239, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
3339, d5mqvF_, 0.7619, 3.27, 0.201, 286, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3340, d5aaeA_, 0.7619, 2.60, 0.240, 252, 242, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14D)
3341, d4o0uA_, 0.7619, 2.73, 0.196, 259, 245, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3342, d4bzoA_, 0.7619, 2.70, 0.184, 272, 244, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO- PYRAZINONE INHIBITOR
3343, d3dcvA_, 0.7619, 2.78, 0.188, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM1 KINASE COMPLEXED WITH 4-(4- HYDROXY-3-METHYL-PHENYL)-6-PHENYLPYRIMIDIN-2(1H)-ONE
3344, d3bgzA_, 0.7619, 2.72, 0.189, 267, 244, HUMAN PIM-1 KINASE IN COMPLEX WITH DIPHENYL INDOLE INHIBITOR VX3
3345, d5uq0B_, 0.7618, 2.57, 0.404, 256, 240, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
3346, d5hzeA_, 0.7618, 3.32, 0.241, 305, 253, MEK1 ADOPTS DFG-OUT CONFORMATION WHEN BOUND TO AN ANALOG OF E6201.
3347, d5ct7B_, 0.7618, 2.45, 0.267, 254, 240, BRAF IN COMPLEX WITH RAF265
3348, d4hglA1, 0.7618, 3.55, 0.165, 301, 260, CRYSTAL STRUCTURE OF CK1G3 WITH COMPOUND 1
3349, d2j2iB_, 0.7618, 2.73, 0.184, 273, 245, CRYSTAL STRUCTURE OF THE HUMAB PIM1 IN COMPLEX WITH LY333531
3350, d2hxqA_, 0.7618, 3.21, 0.253, 272, 249, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2
3351, d1q8yB_, 0.7618, 3.28, 0.194, 357, 253, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
3352, d5ko1A_, 0.7617, 2.63, 0.218, 265, 243, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 4.
3353, d4kbcA_, 0.7617, 3.38, 0.195, 288, 256, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
3354, d2ojjA_, 0.7617, 3.39, 0.212, 344, 255, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-N-(1-(3- CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
3355, d5vt1A1, 0.7616, 3.06, 0.213, 264, 249, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO A BENZAMIDE INHIBITOR
3356, d5c1qB_, 0.7616, 2.73, 0.188, 273, 245, SERINE/THREONINE-PROTEIN KINASE PIM-1
3357, p4ux9A_, 0.7616, 2.87, 0.215, 343, 246, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
3358, d3od6X_, 0.7616, 3.18, 0.219, 344, 251, CRYSTAL STRUCTURE OF P38ALPHA Y323T ACTIVE MUTANT
3359, d1yi3A_, 0.7616, 2.67, 0.185, 267, 243, CRYSTAL STRUCTURE OF PIM-1 BOUND TO LY294002
3360, d1x8bA_, 0.7616, 2.76, 0.197, 259, 244, STRUCTURE OF HUMAN WEE1A KINASE: KINASE DOMAIN COMPLEXED WITH INHIBITOR PD0407824
3361, p6g9hA_, 0.7615, 3.35, 0.213, 343, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3362, d4s33A_, 0.7615, 3.33, 0.201, 347, 254, ERK2 R65S MUTANT COMPLEXED WITH AMP-PNP
3363, d3qtuA_, 0.7615, 3.11, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-132
3364, d3py0A_, 0.7615, 3.06, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR SU9516
3365, d3pizA_, 0.7615, 2.44, 0.315, 245, 238, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH (5-AMINO-1-O- TOLYL-1H-PYRAZOL-4-YL)-[3-(1-METHANESULFONYL-PIPERIDIN-4-YL)-PHENYL]- METHANONE
3366, d3jyaA_, 0.7615, 2.76, 0.188, 274, 245, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
3367, d2o3pA_, 0.7615, 2.76, 0.188, 274, 245, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETIN
3368, d2henC1, 0.7615, 2.62, 0.304, 258, 240, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
3369, d5uirB_, 0.7614, 2.80, 0.244, 273, 242, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 11
3370, d5kcxA_, 0.7614, 2.73, 0.184, 272, 244, PIM-1 KINASE IN COMPLEX WITH A SELECTIVE N-SUBSTITUTED 7-AZAINDOLE INHIBITOR
3371, d5imeA1, 0.7614, 2.80, 0.208, 279, 245, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
3372, d1m7nA_, 0.7614, 2.96, 0.305, 299, 246, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
3373, d4hgtA_, 0.7613, 3.24, 0.198, 283, 252, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
3374, d3fdnA_, 0.7613, 2.72, 0.233, 261, 245, STRUCTURE-BASED DRUG DESIGN OF NOVEL AURORA KINASE A INHIBITORS: STRUCTURE BASIS FOR POTENCY AND SPECIFICITY
3375, d4wovB_, 0.7612, 2.41, 0.234, 256, 239, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH BMS-066 AKA 2-METHOXY-N-({6-[3-METHYL-7-(METHYLAMINO)- 35810-TETRAAZATRICYCLO[7.3.0.0 6]DODECA-1(9)2(6)4711-PENTAEN- 11-YL]PYRIDIN-2-YL}METHY L)ACETAMIDE
3376, d4fv1A_, 0.7612, 3.27, 0.213, 342, 253, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK4
3377, d4btjA_, 0.7612, 3.22, 0.178, 292, 253, TTBK1 IN COMPLEX WITH ATP
3378, d3uytA_, 0.7612, 3.42, 0.202, 287, 258, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
3379, d3rk7A_, 0.7612, 3.09, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-71
3380, d3qtzA_, 0.7612, 3.09, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-36
3381, d3k5uA_, 0.7612, 2.68, 0.202, 260, 243, IDENTIFICATION SAR STUDIES AND X-RAY COCRYSTAL ANALYSIS OF A NOVEL FURANO-PYRIMIDINE AURORA KINASE A INHIBITOR
3382, d2x7fB_, 0.7612, 2.77, 0.230, 288, 244, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
3383, d1v0oA_, 0.7612, 3.00, 0.236, 276, 246, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
3384, d5obrA_, 0.7611, 2.66, 0.235, 255, 243, AURORA A KINASE IN COMPLEX WITH 2-(3-CHLORO-5-FLUOROPHENYL)QUINOLINE- 4-CARBOXYLIC ACID AND JNJ-7706621
3385, p3teiA_, 0.7611, 2.77, 0.229, 339, 245, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
3386, d3r9dA_, 0.7611, 3.10, 0.253, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-135
3387, d3krxA2, 0.7611, 3.14, 0.182, 349, 253, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (CO-CRYSTAL)
3388, d4xs2B_, 0.7610, 3.01, 0.239, 278, 243, IRAK4-INHIBITOR CO-STRUCTURE
3389, d4pnkA2, 0.7610, 3.16, 0.177, 350, 254, G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GSK180736A
3390, d3krwA2, 0.7610, 3.13, 0.205, 349, 254, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (SOAK)
3391, d2xiyA_, 0.7610, 2.73, 0.189, 273, 244, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-2 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3392, d4u40A_, 0.7609, 3.22, 0.227, 295, 251, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
3393, d2ow3B_, 0.7609, 3.45, 0.227, 351, 255, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
3394, d2in6A_, 0.7609, 2.77, 0.197, 256, 244, WEE1 KINASE COMPLEX WITH INHIBITOR PD311839
3395, d2a0cX_, 0.7609, 3.11, 0.261, 294, 249, HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II A NOVEL 269- TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
3396, d5vuaB_, 0.7608, 2.63, 0.190, 270, 242, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
3397, d3qtiB_, 0.7608, 2.84, 0.335, 280, 242, C-MET KINASE IN COMPLEX WITH NVP-BVU972
3398, d4kbkC_, 0.7607, 3.37, 0.188, 280, 255, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3399, d4kbaB_, 0.7607, 3.36, 0.197, 285, 254, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
3400, d3rpvA_, 0.7607, 3.09, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-88
3401, d1uwjB_, 0.7607, 2.95, 0.264, 263, 246, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
3402, d5k7iA_, 0.7606, 2.83, 0.246, 272, 240, IRAK4 IN COMPLEX WITH AZ3864
3403, d4jbqA_, 0.7606, 2.69, 0.234, 257, 244, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3404, d4btmA_, 0.7606, 3.22, 0.182, 292, 253, TTBK1 IN COMPLEX WITH INHIBITOR
3405, d4as0A_, 0.7606, 2.75, 0.184, 273, 245, CYCLOMETALATED PHTHALIMIDES AS PROTEIN KINASE INHIBITORS
3406, d2z2wA_, 0.7606, 2.78, 0.193, 260, 244, HUMAND WEE1 KINASE COMPLEXED WITH INHIBITOR PF0335770
3407, d1ia8A_, 0.7606, 3.27, 0.248, 272, 250, THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1
3408, d5jsmD1, 0.7605, 3.05, 0.272, 255, 246, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
3409, d5di1A_, 0.7605, 3.02, 0.224, 285, 246, MAP4K4 IN COMPLEX WITH AN INHIBITOR
3410, d3ti1A_, 0.7605, 3.13, 0.261, 294, 249, CDK2 IN COMPLEX WITH SUNITINIB
3411, d1r0eB_, 0.7605, 3.44, 0.227, 344, 256, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
3412, d1cm8B_, 0.7605, 2.74, 0.201, 327, 244, PHOSPHORYLATED MAP KINASE P38-GAMMA
3413, d1cm8A_, 0.7605, 2.74, 0.201, 327, 244, PHOSPHORYLATED MAP KINASE P38-GAMMA
3414, d1ckiB_, 0.7605, 3.34, 0.209, 286, 254, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
3415, d5mqvB_, 0.7604, 3.32, 0.201, 287, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3416, d5kgkA_, 0.7604, 2.75, 0.184, 273, 245, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 3-(4-METHOXYPHENYL)-1~{H}- PYRAZOL-5-AMINE
3417, d4yffA_, 0.7604, 2.76, 0.267, 264, 240, TNNI3K COMPLEXED WITH INHIBITOR 2
3418, d4tthB_, 0.7604, 2.75, 0.260, 256, 242, CRYSTAL STRUCTURE OF A CDK6/VCYCLIN COMPLEX WITH INHIBITOR BOUND
3419, d4rpvA_, 0.7604, 2.76, 0.184, 273, 245, CO-CRYSTAL STRUCTURE OF PIM1 WITH COMPOUND 3
3420, d3qzfA_, 0.7604, 3.08, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52
3421, d3qtxA_, 0.7604, 3.09, 0.249, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-35
3422, d3qqkA_, 0.7604, 3.12, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR L4
3423, d2ydkA_, 0.7604, 3.26, 0.248, 263, 250, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
3424, d2fysB_, 0.7604, 2.85, 0.224, 338, 246, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
3425, d5he1A2, 0.7603, 3.17, 0.177, 342, 254, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224062
3426, d3qruA_, 0.7603, 3.10, 0.257, 295, 249, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12
3427, d3d5xA_, 0.7603, 3.09, 0.250, 279, 248, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH WORTMANNIN.
3428, d2iztA_, 0.7603, 3.41, 0.171, 296, 257, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3429, d5jzjB_, 0.7602, 2.83, 0.241, 261, 245, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
3430, d4jx3A_, 0.7602, 2.77, 0.184, 274, 245, CRYSTAL STRUCTURE OF PIM1 KINASE
3431, d3qxpA_, 0.7602, 3.05, 0.247, 294, 247, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
3432, d2wtkC1, 0.7602, 2.97, 0.219, 261, 247, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
3433, d2bzjA_, 0.7602, 2.77, 0.188, 273, 245, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3
3434, p6cpwA_, 0.7601, 3.16, 0.204, 328, 250, DISCOVERY OF 3(S)-THIOMETHYL PYRROLIDINE ERK INHIBITORS FOR ONCOLOGY 
3435, d5mqvD_, 0.7601, 3.36, 0.200, 287, 255, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3436, d5k75D_, 0.7601, 3.03, 0.238, 280, 244, IRAK4 IN COMPLEX WITH COMPOUND 1
3437, d4mbiA_, 0.7601, 2.78, 0.188, 274, 245, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
3438, d4l43A_, 0.7601, 2.99, 0.264, 316, 246, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM I)
3439, d4a7cA_, 0.7601, 2.81, 0.188, 273, 245, CRYSTAL STRUCTURE OF PIM1 KINASE WITH ETP46546
3440, d2xnbA_, 0.7601, 3.14, 0.261, 296, 249, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
3441, d1yxuC_, 0.7601, 2.72, 0.184, 272, 244, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3442, d5turA_, 0.7600, 2.74, 0.189, 270, 244, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
3443, d5k72D_, 0.7600, 2.96, 0.244, 276, 242, IRAK4 IN COMPLEX WITH COMPOUND 21
3444, d5he2A2, 0.7600, 3.19, 0.173, 353, 254, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224406
3445, d4rc4A_, 0.7600, 2.72, 0.189, 272, 244, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3446, d4ll5A_, 0.7600, 2.72, 0.184, 268, 244, CRYSTAL STRUCTURE OF PIM-1 IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
3447, d4ae9A_, 0.7600, 3.06, 0.219, 321, 251, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
3448, d3vbvA_, 0.7600, 2.70, 0.189, 268, 243, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3449, d3q4zA1, 0.7600, 2.92, 0.206, 281, 247, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
3450, d3o23A_, 0.7600, 3.09, 0.331, 293, 248, HUMAN UNPHOSPHORYLATED IGF1-R KINASE DOMAIN IN COMPLEX WITH AN HYDANTOIN INHIBITOR
3451, d3m11A_, 0.7600, 2.64, 0.207, 256, 242, CRYSTAL STRUCTURE OF AURORA A KINASE COMPLEXED WITH INHIBITOR
3452, d2w1fA1, 0.7600, 2.65, 0.219, 253, 242, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3453, d2qo7A_, 0.7600, 2.63, 0.318, 278, 239, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED AMP-PNP BOUND
3454, d2ow3A_, 0.7600, 3.58, 0.229, 346, 258, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
3455, d5vucB_, 0.7599, 2.60, 0.187, 269, 241, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
3456, d5ng3C_, 0.7599, 3.02, 0.261, 272, 245, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
3457, d5he0A2, 0.7599, 3.20, 0.193, 346, 254, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG215022
3458, d4erkA_, 0.7599, 3.36, 0.209, 350, 254, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE
3459, d4d4rB_, 0.7599, 3.28, 0.337, 270, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3460, d3a8wA1, 0.7599, 2.93, 0.197, 323, 249, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
3461, d2ghgA1, 0.7599, 3.27, 0.248, 269, 250, H-CHK1 COMPLEXED WITH A431994
3462, p6g9mA_, 0.7598, 3.31, 0.236, 341, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3463, d5toeA_, 0.7598, 2.74, 0.189, 272, 244, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
3464, d5l6pA_, 0.7598, 2.65, 0.328, 274, 241, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 6)
3465, d3rk9A_, 0.7598, 3.12, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-74
3466, d3lokA_, 0.7598, 2.17, 0.348, 248, 233, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
3467, d3erkA_, 0.7598, 3.25, 0.231, 350, 251, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025
3468, d1xr1A_, 0.7598, 2.88, 0.183, 277, 246, CRYSTAL STRUCTURE OF HPIM-1 KINASE IN COMPLEX WITH AMP-PNP AT 2.1 A RESOLUTION
3469, d1r0eA_, 0.7598, 3.45, 0.227, 344, 256, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
3470, d4l3lA_, 0.7597, 3.09, 0.258, 291, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN (ZINC ANOMALOUS)
3471, d4i41A_, 0.7597, 2.73, 0.189, 272, 244, CRYSTAL STRUCTURE OF HUMAN SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE
3472, d4fv3A_, 0.7597, 3.28, 0.213, 346, 253, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK6
3473, d4fv2A_, 0.7597, 3.29, 0.213, 344, 253, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK5
3474, d3vbtA_, 0.7597, 2.71, 0.189, 267, 243, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3475, d2x8iA_, 0.7597, 3.17, 0.250, 261, 248, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
3476, d2broA_, 0.7597, 3.44, 0.222, 272, 252, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3477, d1jqhA_, 0.7597, 3.26, 0.296, 291, 253, IGF-1 RECEPTOR KINASE DOMAIN
3478, d4s32A_, 0.7596, 3.36, 0.220, 346, 255, CRYSTAL STRUCTURE OF ERK2 AMP-PNP COMPLEX
3479, d4rvtA_, 0.7596, 2.94, 0.224, 281, 245, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
3480, d3rniA_, 0.7596, 3.11, 0.265, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-3-86
3481, d3r04A_, 0.7596, 2.70, 0.189, 271, 243, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
3482, d3ekkA_, 0.7596, 2.82, 0.322, 285, 245, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
3483, d3dkoA1, 0.7596, 2.69, 0.312, 272, 240, COMPLEX BETWEEN THE KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7) AND INHIBITOR ALW-II-49-7
3484, d1yxuB_, 0.7596, 2.79, 0.188, 273, 245, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3485, p6g9dA_, 0.7595, 3.32, 0.202, 345, 253, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3486, p6g8xA_, 0.7595, 3.33, 0.202, 338, 253, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3487, d4ez3A_, 0.7595, 3.04, 0.255, 294, 247, CDK2 IN COMPLEX WITH NSC 134199
3488, d3pyyA1, 0.7595, 2.46, 0.383, 251, 235, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
3489, d3bwfA_, 0.7595, 2.78, 0.188, 273, 245, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AN OSMIUM COMPOUND
3490, d5v5yA_, 0.7594, 2.89, 0.203, 259, 246, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH MK1775
3491, d4zp5A_, 0.7594, 3.04, 0.224, 284, 246, MAP4K4 IN COMPLEX WITH INHIBITOR
3492, d4rc2A_, 0.7594, 2.74, 0.189, 272, 244, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3493, d4j7bA_, 0.7594, 3.02, 0.244, 284, 246, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
3494, d4apcA1, 0.7594, 3.12, 0.215, 289, 247, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
3495, d1q3dA_, 0.7594, 3.48, 0.227, 339, 256, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
3496, d5mqvE_, 0.7593, 3.31, 0.201, 287, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3497, d4qyhB_, 0.7593, 3.19, 0.255, 264, 247, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
3498, d4b9dA1, 0.7593, 3.12, 0.215, 286, 247, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
3499, d3r8zA_, 0.7593, 3.20, 0.261, 290, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-1-136
3500, d3qrjB1, 0.7593, 2.32, 0.389, 252, 234, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
3501, d3q96A_, 0.7593, 2.64, 0.274, 253, 241, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
3502, d3jy0A_, 0.7593, 2.75, 0.184, 275, 244, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
3503, d1q3dB_, 0.7593, 3.47, 0.227, 339, 256, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
3504, p6g91A_, 0.7592, 3.33, 0.217, 344, 253, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3505, d4nt4A1, 0.7592, 3.36, 0.184, 299, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF GILGAMESH ISOFORM I FROM DROSOPHILA MELANOGASTER
3506, d2izsA_, 0.7592, 3.59, 0.165, 298, 260, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3507, p6c3eA_, 0.7591, 2.86, 0.257, 258, 241, CRYSTAL STRUCTURE OF RIP1 KINASE BOUND TO INHIBITOR
3508, d5vubB_, 0.7591, 2.62, 0.187, 269, 241, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
3509, d5jt2B1, 0.7591, 2.61, 0.292, 250, 240, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
3510, d3uysD_, 0.7591, 3.30, 0.186, 284, 253, CRYSTAL STRUCTURE OF APO HUMAN CK1D
3511, d3unkA_, 0.7591, 3.10, 0.253, 295, 249, CDK2 IN COMPLEX WITH INHIBITOR YL5-083
3512, d5k72C_, 0.7590, 2.99, 0.244, 277, 242, IRAK4 IN COMPLEX WITH COMPOUND 21
3513, d2qo2A_, 0.7590, 2.72, 0.317, 282, 240, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED APO STRUCTURE
3514, d1yxuA_, 0.7590, 2.80, 0.184, 273, 245, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3515, d1jqhC_, 0.7590, 3.27, 0.296, 291, 253, IGF-1 RECEPTOR KINASE DOMAIN
3516, d4fuxA_, 0.7589, 3.34, 0.213, 342, 253, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E75
3517, d4aguA_, 0.7589, 2.62, 0.213, 277, 239, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
3518, d2vgpA_, 0.7589, 2.99, 0.206, 265, 247, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
3519, d2oidD_, 0.7589, 2.89, 0.246, 274, 240, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
3520, d3uokB_, 0.7588, 2.80, 0.239, 265, 243, AURORA A IN COMPLEX WITH YL5-81-1
3521, d3umwA_, 0.7588, 2.62, 0.191, 264, 241, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDAZOL-3-YL)METHYLENE]-6-METHOXY-7-(PIPERAZIN-1-YLMETHYL)BENZOFURAN- 3(2H)-ONE
3522, d5nhfA_, 0.7587, 3.34, 0.209, 339, 254, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3523, d4nfnA_, 0.7587, 3.36, 0.180, 293, 255, HUMAN TAU TUBULIN KINASE 1 (TTBK1) COMPLEXED WITH 3-({5-[(4-AMINO-4- METHYLPIPERIDIN-1-YL)METHYL]PYRROLO[21-F][124]TRIAZIN-4-YL}AMINO)- 5-BROMOPHENOL
3524, d4mneE_, 0.7587, 3.28, 0.237, 286, 253, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3525, d3ztxB_, 0.7587, 3.13, 0.201, 272, 249, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
3526, d2f49A_, 0.7587, 2.93, 0.199, 335, 246, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
3527, d2cgwA_, 0.7587, 3.19, 0.254, 262, 248, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3528, d4fkuA_, 0.7586, 3.13, 0.266, 293, 248, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3529, d3idpA_, 0.7586, 2.82, 0.275, 255, 244, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
3530, d3cr0A_, 0.7586, 2.86, 0.188, 257, 245, WEE1 KINASE COMPLEX WITH INHIBITOR PD259_809
3531, d3c4dA1, 0.7586, 2.70, 0.280, 257, 243,  
3532, d5x18A_, 0.7585, 3.62, 0.131, 294, 260, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
3533, d5opuA_, 0.7585, 3.11, 0.252, 261, 246, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
3534, d5flfE_, 0.7585, 2.77, 0.388, 258, 242, DISEASE LINKED MUTATION IN FGFR
3535, d4l45A_, 0.7585, 2.99, 0.264, 317, 246, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389E
3536, d3rjcA_, 0.7585, 3.14, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR L4-12
3537, d3qqjA_, 0.7585, 3.10, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR L2
3538, d2qvsE_, 0.7585, 3.16, 0.218, 323, 252, CRYSTAL STRUCTURE OF TYPE IIA HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
3539, d1j3hA_, 0.7585, 3.09, 0.200, 329, 250, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
3540, d4xp2A_, 0.7584, 3.34, 0.220, 337, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3541, d4hyiA_, 0.7584, 3.31, 0.260, 269, 250, X-RAY CRYSTAL STRUCTURE OF COMPOUND 40 BOUND TO HUMAN CHK1 KINASE DOMAIN
3542, d3qqgA_, 0.7584, 3.07, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR L2-5
3543, d3mvjB_, 0.7584, 3.15, 0.195, 320, 251, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
3544, d2izuA_, 0.7584, 3.47, 0.171, 297, 257, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3545, d5uirA_, 0.7583, 2.63, 0.248, 270, 238, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 11
3546, d5o13A_, 0.7583, 2.68, 0.190, 270, 242, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
3547, d4p4cA_, 0.7583, 2.79, 0.328, 266, 241, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
3548, d3r8lA_, 0.7583, 3.12, 0.253, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR L3-4
3549, d3c4eB_, 0.7583, 2.80, 0.184, 273, 245, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3550, d3bi6A_, 0.7583, 2.88, 0.200, 258, 245, WEE1 KINASE COMPLEX WITH INHIBITOR PD352396
3551, d2brnA_, 0.7583, 3.24, 0.217, 268, 249, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3552, d1yhsA_, 0.7583, 2.72, 0.189, 267, 243, CRYSTAL STRUCTURE OF PIM-1 BOUND TO STAUROSPORINE
3553, d4u9aA_, 0.7582, 2.97, 0.237, 272, 241, SULPHUR ANOMALOUS CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
3554, d5oq7B_, 0.7581, 3.03, 0.262, 256, 244, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3555, d4twnA1, 0.7581, 3.08, 0.333, 275, 246, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH BIRB796
3556, d3vbxA_, 0.7581, 2.73, 0.189, 268, 243, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3557, p6g92A_, 0.7580, 3.35, 0.220, 343, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3558, d4enxA_, 0.7580, 2.64, 0.195, 266, 241, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH INHIBITOR (2E5Z)-2- (2-CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-NITROBENZYLIDENE)THIAZOLIDIN-4- ONE
3559, d3qxoA_, 0.7580, 3.10, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84
3560, d3ql8A_, 0.7580, 3.11, 0.249, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260
3561, d3nlbA_, 0.7580, 3.29, 0.250, 261, 248, NOVEL KINASE PROFILE HIGHLIGHTS THE TEMPORAL BASIS OF CONTEXT DEPENDENT CHECKPOINT PATHWAYS TO CELL DEATH
3562, d2xixA_, 0.7580, 2.72, 0.185, 272, 243, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-1 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3563, d2b54A_, 0.7580, 3.08, 0.254, 298, 248, HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN- 232305
3564, d4zzmA_, 0.7579, 3.34, 0.225, 344, 253, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
3565, d4qygA_, 0.7579, 3.36, 0.249, 264, 249, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
3566, d4iz7A_, 0.7579, 3.10, 0.208, 344, 250, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
3567, d3vbyA_, 0.7579, 2.73, 0.189, 267, 243, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3568, d3c9wA2, 0.7579, 2.88, 0.234, 335, 244, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
3569, d2a19B1, 0.7579, 2.97, 0.244, 261, 246, PKR KINASE DOMAIN- EIF2ALPHA- AMP-PNP COMPLEX.
3570, d5lcjA_, 0.7578, 3.35, 0.220, 345, 254, IN-GEL ACTIVITY-BASED PROTEIN PROFILING OF A CLICKABLE COVALENT ERK 1/2 INHIBITOR
3571, d4xrlA_, 0.7578, 3.40, 0.205, 337, 254, CRYSTAL STRUCTURE AT ROOM TEMPERATURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3572, d4j7bD_, 0.7578, 2.99, 0.241, 281, 245, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
3573, d3uokA_, 0.7578, 2.82, 0.239, 265, 243, AURORA A IN COMPLEX WITH YL5-81-1
3574, p6gdmA_, 0.7577, 3.27, 0.214, 341, 252, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3575, d4s34A_, 0.7577, 3.38, 0.220, 343, 255, ERK2 (I84A) IN COMPLEX WITH AMP-PNP
3576, d2x8eA_, 0.7577, 3.04, 0.253, 259, 245, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
3577, d2qg5A1, 0.7577, 3.24, 0.215, 268, 251, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
3578, d1irkA_, 0.7577, 3.07, 0.325, 303, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN RECEPTOR
3579, d6bu6A_, 0.7576, 3.52, 0.154, 322, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3580, d5acbD_, 0.7576, 3.23, 0.244, 319, 254, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
3581, d4lmuA_, 0.7576, 2.68, 0.186, 265, 242, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH THE INHIBITOR QUERCETIN (RESULTING FROM DISPLACEMENT OF SKF86002)
3582, d3pxyA_, 0.7576, 3.09, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR JWS648
3583, d3pvuA2, 0.7576, 3.24, 0.185, 340, 254, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD101)
3584, d5es1A_, 0.7575, 2.43, 0.273, 304, 238, CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
3585, d4u97A_, 0.7575, 2.66, 0.239, 272, 238, CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
3586, d4bgqA_, 0.7575, 2.83, 0.234, 276, 244, CRYSTAL STRUCTURE OF THE HUMAN CDKL5 KINASE DOMAIN
3587, d3tizA_, 0.7575, 3.08, 0.258, 293, 248, CDK2 IN COMPLEX WITH NSC 111848
3588, d3qtqA_, 0.7575, 3.15, 0.253, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-1-137
3589, d3c4eC_, 0.7575, 2.77, 0.180, 272, 244, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3590, d2oidB_, 0.7575, 3.03, 0.236, 272, 242, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
3591, p6g9nA_, 0.7574, 3.33, 0.213, 344, 253, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3592, d4xp3A_, 0.7574, 3.45, 0.220, 339, 255, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3593, d3c4eA_, 0.7574, 2.82, 0.180, 273, 245, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3594, d2exmA_, 0.7574, 3.11, 0.265, 298, 249, HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
3595, d1pxoA_, 0.7574, 3.18, 0.257, 294, 249, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YL]-(3-NITRO-PHENYL)-AMINE
3596, d5umoA_, 0.7573, 3.28, 0.203, 347, 251, STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE
3597, d4qygB_, 0.7573, 3.22, 0.255, 264, 247, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
3598, d3qqhA_, 0.7573, 3.09, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR L2-2
3599, d2c6oA_, 0.7573, 3.09, 0.254, 290, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3600, d5vc4A_, 0.7572, 2.92, 0.198, 261, 247, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB-ISOMER
3601, d4zzoA_, 0.7572, 3.46, 0.220, 339, 255, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
3602, d4yo6B_, 0.7572, 2.94, 0.241, 277, 241, IRAK4-INHIBITOR CO-STRUCTURE
3603, d2clxA_, 0.7572, 3.13, 0.257, 293, 249, 4-ARYLAZO-35-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY CRYSTAL STRUCTURE IN COMPLEX WITH CDK2 SELECTIVITY AND CELLULAR EFFECTS
3604, d1ykrA_, 0.7572, 3.17, 0.257, 298, 249, CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR
3605, d1hckA_, 0.7572, 3.18, 0.261, 294, 249, HUMAN CYCLIN-DEPENDENT KINASE 2
3606, d5fdxB_, 0.7571, 2.96, 0.328, 274, 244, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
3607, d4yffB_, 0.7571, 2.77, 0.268, 264, 239, TNNI3K COMPLEXED WITH INHIBITOR 2
3608, d4lg4C_, 0.7571, 3.21, 0.223, 288, 251, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3609, d4aguC_, 0.7571, 2.65, 0.218, 278, 239, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
3610, d3uliA_, 0.7571, 3.19, 0.258, 286, 248, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE
3611, d3dy7A_, 0.7571, 3.21, 0.236, 260, 250, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3612, d2br1A_, 0.7571, 3.32, 0.220, 272, 250, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3613, d1xwsA_, 0.7571, 2.79, 0.184, 273, 245, CRYSTAL STRUCTURE OF THE HUMAN PIM1 KINASE DOMAIN
3614, d5hesB_, 0.7570, 2.65, 0.298, 278, 238, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
3615, d4tn6B_, 0.7570, 3.37, 0.189, 285, 254, CK1D IN COMPLEX WITH INHIBITOR
3616, d4p41B_, 0.7570, 2.93, 0.258, 256, 244,  
3617, d4kb8B_, 0.7570, 3.44, 0.208, 285, 255, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
3618, d3rkbA_, 0.7570, 3.23, 0.253, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-73
3619, d2uzoA_, 0.7570, 3.09, 0.262, 290, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
3620, d2bziB_, 0.7570, 2.77, 0.189, 272, 244, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2
3621, d6bruA_, 0.7569, 3.52, 0.158, 322, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3622, d4qyhA_, 0.7569, 3.31, 0.250, 264, 248, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
3623, d3p86A_, 0.7569, 2.47, 0.314, 250, 239, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
3624, d5ootA_, 0.7568, 3.18, 0.247, 260, 247, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
3625, d4mneA_, 0.7568, 3.38, 0.245, 286, 253, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3626, d3tiyA_, 0.7568, 3.13, 0.262, 293, 248, CDK2 IN COMPLEX WITH NSC 35676
3627, d3r9hA_, 0.7568, 3.16, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-142
3628, d1golA_, 0.7568, 3.40, 0.209, 357, 254, COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52
3629, p6ge0A_, 0.7567, 3.27, 0.214, 343, 252, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3630, d5uisA_, 0.7567, 2.58, 0.246, 269, 236, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
3631, d5iexA_, 0.7567, 3.02, 0.260, 285, 246, CRYSTAL STRUCTURE OF (RS)-S-{4-[(5-BROMO-4-{[(2R3R)-2-HYDROXY-1- METHYLPROPYL]OXY}- PYRIMIDIN-2-YL)AMINO]PHENYL}-S- CYCLOPROPYLSULFOXIMIDE BOUND TO CDK2
3632, d4s31A_, 0.7567, 3.41, 0.201, 347, 254, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 1 WTERK2 AT 1.45A
3633, d3pyyB1, 0.7567, 2.01, 0.384, 244, 229, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
3634, d5itaB_, 0.7566, 2.49, 0.272, 252, 239, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
3635, d4lm5A_, 0.7566, 2.69, 0.190, 264, 242, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH 2-{4-[(3-AMINOPROPYL) AMINO]QUINAZOLIN-2-YL}PHENOL (RESULTING FROM DISPLACEMENT OF SKF86002)
3636, d3r1qA_, 0.7566, 3.10, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102
3637, d3i60A_, 0.7566, 2.83, 0.230, 335, 243, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-4-(2-(2-CHLOROPHENYLAMINO)-5- METHYLPYRIMIDIN-4-YL)-N-(2-HYDROXY-1-PHENYLETHYL)-1H-PYRROLE-2- CARBOXAMIDE
3638, d3c9wB2, 0.7566, 2.90, 0.230, 335, 244, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
3639, d3c4cA1, 0.7566, 2.76, 0.272, 257, 243, B-RAF KINASE IN COMPLEX WITH PLX4720
3640, d2qoiA_, 0.7566, 2.70, 0.314, 274, 239, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F DOUBLE MUTANT
3641, d5texA_, 0.7565, 2.83, 0.184, 274, 245, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
3642, d5hieD_, 0.7565, 2.80, 0.280, 253, 243, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3643, d3vvhA1, 0.7565, 3.25, 0.243, 286, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
3644, d3rm7A_, 0.7565, 3.13, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91
3645, d3qzgA_, 0.7565, 3.12, 0.253, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76
3646, d2xneA_, 0.7565, 2.69, 0.236, 246, 242, STRUCTURE OF AURORA-A BOUND TO AN IMIDAZOPYRAZINE INHIBITOR
3647, d2x7fC_, 0.7565, 2.73, 0.236, 285, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
3648, d2qlqB_, 0.7565, 2.14, 0.348, 248, 233, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN WITH COVALENT INHIBITOR RL3
3649, d2brbA_, 0.7565, 3.29, 0.257, 272, 249, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3650, d1yxsA_, 0.7565, 2.83, 0.180, 274, 245, CRYSTAL STRUCTURE OF KINASE PIM1 WITH P123M MUTATION
3651, d6bu6D_, 0.7564, 3.46, 0.163, 318, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3652, d5uorA_, 0.7564, 2.45, 0.306, 249, 235, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3653, d4hokM_, 0.7564, 3.54, 0.181, 291, 259, CRYSTAL STRUCTURE OF APO CK1E
3654, d3qzhA_, 0.7564, 3.11, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124
3655, d2qodA_, 0.7564, 2.84, 0.328, 274, 241, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y602F MUTANT
3656, p5nzzE_, 0.7563, 3.24, 0.217, 343, 249, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
3657, d4gt3A_, 0.7563, 3.27, 0.227, 347, 251, ATP-BOUND FORM OF THE ERK2 KINASE
3658, d5kx8B_, 0.7562, 3.02, 0.241, 278, 241, IRAK4-INHIBITOR CO-STRUCTURE
3659, d3c4dB1, 0.7562, 2.66, 0.269, 256, 242,  
3660, d2izrA_, 0.7562, 3.60, 0.162, 298, 259, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3661, d1erkA_, 0.7562, 3.42, 0.201, 357, 254, STRUCTURE OF SIGNAL-REGULATED KINASE
3662, d4qp8A_, 0.7561, 2.79, 0.226, 335, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
3663, d4nfmA_, 0.7561, 3.40, 0.180, 293, 255, HUMAN TAU TUBULIN KINASE 1 (TTBK1)
3664, d4hnfA_, 0.7561, 3.49, 0.187, 289, 257, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
3665, d4l42A_, 0.7560, 3.12, 0.258, 299, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1-PIF
3666, d4kb8C_, 0.7560, 3.32, 0.198, 277, 252, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
3667, d3ii5B_, 0.7560, 2.76, 0.272, 257, 243, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
3668, d3a99A_, 0.7560, 2.87, 0.188, 273, 245, STRUCTURE OF PIM-1 KINASE CRYSTALLIZED IN THE PRESENCE OF P27KIP1 CARBOXY-TERMINAL PEPTIDE
3669, d5k76A_, 0.7559, 2.93, 0.233, 270, 240, IRAK4 IN COMPLEX WITH COMPOUND 28
3670, d5csxA_, 0.7559, 3.00, 0.280, 261, 246, CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370
3671, d3s00A_, 0.7559, 3.15, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR L4-14
3672, d3r28A_, 0.7559, 3.09, 0.265, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140
3673, d3pvwA2, 0.7559, 3.24, 0.177, 343, 254, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD103A)
3674, d4hniA_, 0.7558, 3.30, 0.194, 284, 253, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
3675, d4aguB_, 0.7558, 2.62, 0.214, 276, 238, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
3676, d3vn9A_, 0.7558, 3.21, 0.249, 291, 253, RIFINED CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED MAP2K6 IN A PUTATIVE AUTO-INHIBITION STATE
3677, d3r1sA_, 0.7558, 3.15, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127
3678, d3bhhC1, 0.7558, 2.77, 0.217, 284, 244, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
3679, d2i6lA_, 0.7558, 2.75, 0.212, 292, 241, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
3680, d1pxlA_, 0.7558, 3.02, 0.264, 290, 246, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- (4-TRIFLUOROMETHYL-PHENYL)-AMINE
3681, d5oopA_, 0.7557, 3.23, 0.226, 261, 248, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMP-PNP
3682, d4kbaC_, 0.7557, 3.36, 0.209, 277, 253, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
3683, d3an0A_, 0.7557, 3.21, 0.249, 291, 253,  
3684, d2qlqA_, 0.7557, 2.05, 0.343, 245, 230, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN WITH COVALENT INHIBITOR RL3
3685, d2c6iA_, 0.7557, 3.13, 0.262, 292, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3686, d1ywvA_, 0.7557, 2.83, 0.180, 274, 245, CRYSTAL STRUCTURES OF PROTO-ONCOGENE KINASE PIM1: A TARGET OF ABERRANT SOMATIC HYPERMUTATIONS IN DIFFUSE LARGE CELL LYMPHOMA
3687, d5ieyA_, 0.7556, 3.06, 0.260, 286, 246, CRYSTAL STRUCTURE OF A CDK INHIBITOR BOUND TO CDK2
3688, d4zznA_, 0.7556, 3.37, 0.220, 338, 254, HUMAN ERK2 IN COMPLEX WITH AN INHIBITOR
3689, d4medA_, 0.7556, 2.79, 0.189, 272, 244, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE DERIVATIVES
3690, d4kspB_, 0.7556, 2.73, 0.273, 256, 242, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
3691, d4fv6A_, 0.7556, 2.85, 0.236, 332, 242, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E57
3692, d3we8A_, 0.7556, 2.83, 0.188, 273, 245, PIM-1 KINASE IN COMPLEX WITH RUTHENIUM-BASED INHIBITOR
3693, d3a8wB1, 0.7556, 2.89, 0.194, 324, 247, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
3694, d2qofA_, 0.7556, 2.72, 0.314, 280, 239, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F MUTANT
3695, d1jqhB_, 0.7556, 3.38, 0.296, 287, 253, IGF-1 RECEPTOR KINASE DOMAIN
3696, d5op4A_, 0.7555, 3.11, 0.249, 259, 245, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDINE LRRK2 INHIBITOR
3697, d4ntsA_, 0.7555, 3.12, 0.192, 341, 250, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
3698, d3royA_, 0.7555, 3.13, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154
3699, d3r6xA_, 0.7555, 3.14, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158
3700, d2brmA_, 0.7555, 3.17, 0.219, 263, 247, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3701, d4xneA_, 0.7554, 3.37, 0.202, 344, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3702, d4bf2B_, 0.7553, 2.71, 0.305, 252, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3703, d3p08B_, 0.7553, 2.98, 0.318, 258, 242, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
3704, d5v24A_, 0.7552, 2.67, 0.307, 249, 238, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3705, d5v19A_, 0.7552, 2.58, 0.300, 250, 237, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3706, d5he3A2, 0.7552, 3.24, 0.173, 346, 254, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224411
3707, d4rc3A_, 0.7552, 2.75, 0.189, 271, 243, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3708, d4l3jA_, 0.7552, 3.00, 0.260, 291, 246, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN
3709, d4kd1A_, 0.7552, 3.16, 0.261, 298, 249, CDK2 IN COMPLEX WITH DINACICLIB
3710, d3v5wA2, 0.7552, 3.27, 0.177, 355, 254, HUMAN G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH SOLUBLE GBETAGAMMA SUBUNITS AND PAROXETINE
3711, d3r73A_, 0.7552, 3.15, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164
3712, d3qyzA_, 0.7552, 3.39, 0.220, 339, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3713, d3qywA_, 0.7552, 3.40, 0.220, 340, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3714, d3my0J_, 0.7552, 2.27, 0.274, 252, 234, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3715, d2qooA_, 0.7552, 2.86, 0.324, 273, 241, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742F TRIPLE MUTANT
3716, d4fv8A_, 0.7551, 2.74, 0.232, 333, 241, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E63
3717, d3r8uA_, 0.7551, 3.18, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-1-132
3718, d3r7vA_, 0.7551, 3.15, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9
3719, d3pj1A_, 0.7551, 2.30, 0.331, 241, 236, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 3-(26-DICHLORO- PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-1-METHYL-34- DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
3720, d5vc6A_, 0.7549, 2.92, 0.199, 259, 246, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
3721, d4tw9B_, 0.7549, 3.44, 0.204, 289, 255, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
3722, d3uohB_, 0.7549, 2.81, 0.240, 264, 242, AURORA A IN COMPLEX WITH RPM1722
3723, d3uohA_, 0.7549, 2.81, 0.240, 264, 242, AURORA A IN COMPLEX WITH RPM1722
3724, d2qg5D1, 0.7549, 3.32, 0.211, 267, 251, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
3725, d4fsuA_, 0.7548, 3.22, 0.256, 260, 246, CRYSTAL STRUCTURE OF THE CHK1
3726, d4erwA_, 0.7548, 3.18, 0.262, 292, 248, CDK2 IN COMPLEX WITH STAUROSPORINE
3727, d4enyA_, 0.7548, 2.64, 0.196, 261, 240, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH (2E5Z)-2-(2- CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-METHOXYBENZYLIDENE)THIAZOLIDIN-4- ONE
3728, d5ukmA2, 0.7547, 3.28, 0.177, 353, 254, BOVINE GRK2 IN COMPLEX WITH HUMAN GBETAGAMMA SUBUNITS AND CCG258208 (14AS)
3729, d5ukfA_, 0.7547, 3.63, 0.149, 322, 262, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
3730, d4lggB_, 0.7547, 2.01, 0.326, 245, 230, STRUCTURE OF 3MB-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
3731, p4h3pD_, 0.7547, 2.98, 0.220, 338, 246, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
3732, d4g6nA_, 0.7547, 3.39, 0.220, 341, 254, CRYSTAL STRUCTURE OF THE ERK2
3733, d3r63A_, 0.7547, 3.46, 0.220, 347, 255, STRUCTURE OF ERK2 (SPE) MUTANT (S246E)
3734, d1y8yA_, 0.7547, 3.11, 0.258, 292, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
3735, d5lckA_, 0.7546, 3.35, 0.221, 345, 253, A CLICKABLE COVALENT ERK 1/2 INHIBITOR
3736, d4yp8B_, 0.7546, 2.97, 0.245, 278, 241, IRAK4-INHIBITOR CO-STRUCTURE
3737, d3r1yA_, 0.7546, 3.18, 0.253, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134
3738, d3dtcA_, 0.7546, 2.36, 0.342, 245, 234, CRYSTAL STRUCTURE OF MIXED-LINEAGE KINASE MLK1 COMPLEXED WITH COMPOUND 16
3739, d2o63A_, 0.7546, 2.85, 0.184, 274, 245, CRYSTAL STRUCTURE OF PIM1 WITH MYRICETIN
3740, d2j4zA_, 0.7546, 2.88, 0.221, 263, 244, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
3741, d1pxmA_, 0.7546, 3.05, 0.260, 290, 246, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL
3742, d1pxjA_, 0.7546, 3.17, 0.257, 294, 249, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
3743, d5c9cA_, 0.7545, 2.83, 0.272, 254, 243, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
3744, d4ficB_, 0.7545, 1.97, 0.348, 245, 230, KINASE DOMAIN OF CSRC IN COMPLEX WITH A HINGE REGION-BINDING FRAGMENT
3745, d3uo6A_, 0.7545, 2.73, 0.241, 264, 241, AURORA A IN COMPLEX WITH YL5-083
3746, d3r8vA_, 0.7545, 3.16, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-1-135
3747, d3r7eA_, 0.7545, 3.16, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67
3748, d3qx4A_, 0.7545, 3.16, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78
3749, d3qqfA_, 0.7545, 3.16, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR L1
3750, d3comB_, 0.7545, 3.40, 0.193, 279, 254, CRYSTAL STRUCTURE OF MST1 KINASE
3751, d2z7lA_, 0.7545, 3.31, 0.211, 329, 251, UNPHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE ERK2 IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN 2-YL]AMINO}PHENYL)ACETIC ACID
3752, d2w1eA1, 0.7545, 2.68, 0.220, 252, 241, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3753, d2c3jA_, 0.7545, 3.08, 0.250, 257, 244, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
3754, d1yi4A_, 0.7545, 2.77, 0.185, 267, 243, STRUCTURE OF PIM-1 BOUND TO ADENOSINE
3755, d3uo6B_, 0.7544, 2.73, 0.241, 264, 241, AURORA A IN COMPLEX WITH YL5-083
3756, d3s0oA_, 0.7544, 3.08, 0.247, 293, 247, CDK2 IN COMPLEX WITH INHIBITOR RC-1-138
3757, d4rvkA_, 0.7543, 3.26, 0.263, 264, 247, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 8: N-[3-(6-CYANO-9H- PYRROLO[23-B:54-C ]DIPYRIDIN-3-YL)PHENYL]ACETAMIDE
3758, d4ftiA_, 0.7543, 3.26, 0.259, 270, 247, CRYSTAL STRUCTURE OF THE CHK1
3759, d3nw6A_, 0.7543, 3.14, 0.302, 301, 248, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11A)
3760, d3h0zA_, 0.7543, 2.50, 0.244, 248, 238, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3761, d4qp3A_, 0.7542, 3.13, 0.206, 339, 248, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
3762, d3tkiA_, 0.7542, 3.25, 0.255, 272, 247, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S25
3763, d3en7A_, 0.7542, 2.15, 0.351, 247, 231, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH S1 A MULTITARGETED KINASE INHIBITOR
3764, d3cikA2, 0.7542, 3.25, 0.186, 347, 253, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
3765, d5oorA_, 0.7541, 3.16, 0.252, 273, 246, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH STAUROSPORINE
3766, d4rvmA_, 0.7541, 3.26, 0.255, 264, 247, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 19
3767, d3r8mA_, 0.7541, 2.99, 0.256, 286, 246, CDK2 IN COMPLEX WITH INHIBITOR L3-3
3768, d4ibmB_, 0.7540, 3.07, 0.325, 294, 249, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
3769, d4c3rA_, 0.7540, 2.69, 0.199, 252, 241, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP
3770, d3rpoA_, 0.7540, 3.17, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156
3771, d3qwjA_, 0.7540, 3.16, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142
3772, d3py3A1, 0.7540, 3.43, 0.213, 352, 254, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38ALPHA MAP KINASE
3773, d2bcjA3, 0.7540, 3.28, 0.189, 348, 254, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GALPHA-Q AND GBETAGAMMA SUBUNITS
3774, p4ux9C_, 0.7538, 2.86, 0.213, 333, 244, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
3775, d3raiA_, 0.7538, 3.17, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160
3776, p6g9jA_, 0.7537, 3.30, 0.227, 347, 251, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3777, d5uisC_, 0.7537, 2.78, 0.244, 270, 238, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
3778, d5oprA_, 0.7537, 3.08, 0.254, 258, 244, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIDINE LRRK2 INHIBITOR
3779, d4ithB_, 0.7537, 2.77, 0.252, 270, 238, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
3780, d4fsnA_, 0.7537, 3.23, 0.256, 270, 246, CRYSTAL STRUCTURE OF THE CHK1
3781, d3uixA_, 0.7537, 2.70, 0.187, 266, 241, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3782, d1pf8A_, 0.7537, 3.07, 0.253, 298, 245, CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR
3783, d3k54A_, 0.7536, 2.46, 0.312, 243, 237, STRUCTURES OF HUMAN BRUTON S TYROSINE KINASE IN ACTIVE AND INACTIVE CONFORMATIONS SUGGESTS A MECHANISM OF ACTIVATION FOR TEC FAMILY KINASES.
3784, d4yffD_, 0.7535, 2.71, 0.256, 257, 238, TNNI3K COMPLEXED WITH INHIBITOR 2
3785, d4yffC_, 0.7535, 2.71, 0.256, 258, 238, TNNI3K COMPLEXED WITH INHIBITOR 2
3786, d4x7qB_, 0.7535, 2.43, 0.208, 243, 236, PIM2 KINASE IN COMPLEX WITH COMPOUND 1S
3787, d4kaoA_, 0.7535, 2.71, 0.342, 252, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
3788, d4h58C_, 0.7535, 2.86, 0.262, 272, 244, BRAF IN COMPLEX WITH COMPOUND 3
3789, d3qx2A_, 0.7535, 3.17, 0.253, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190
3790, d3c4cB1, 0.7535, 2.64, 0.274, 256, 241, B-RAF KINASE IN COMPLEX WITH PLX4720
3791, d2c6mA_, 0.7535, 3.15, 0.262, 290, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3792, d5op5A_, 0.7534, 3.18, 0.248, 259, 246, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
3793, d5o26A_, 0.7534, 3.26, 0.255, 271, 251, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN COMPLEX WITH AMP-PNP/MG2+
3794, d5o11A_, 0.7534, 2.66, 0.183, 268, 240, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
3795, d4qp7B_, 0.7534, 2.78, 0.215, 335, 242, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
3796, d3q96B_, 0.7534, 2.76, 0.277, 262, 242, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
3797, d2e9pA_, 0.7534, 3.34, 0.225, 269, 249, STRUCTURE OF H-CHK1 COMPLEXED WITH A771129
3798, d2c6kA_, 0.7534, 3.13, 0.262, 292, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3799, d4g6oA_, 0.7533, 3.40, 0.218, 339, 252, CRYSTAL STRUCTURE OF THE ERK2
3800, d3qwkA_, 0.7533, 3.20, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150
3801, d2x7fA_, 0.7533, 2.70, 0.237, 276, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
3802, d2v0dA_, 0.7533, 3.14, 0.262, 292, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
3803, d5ukkA2, 0.7532, 3.27, 0.181, 348, 254, HUMAN GRK2 IN COMPLEX WITH HUMAN G-BETA-GAMMA SUBUNITS AND CCG211998 (14AK)
3804, d3repA_, 0.7532, 3.10, 0.265, 268, 249, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MNATP)
3805, d3pj3A_, 0.7532, 2.19, 0.322, 240, 233, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-METHYL-5-[(E)- (3-PHENYL-ACRYLOYL)AMINO]-N-(2-PHENYL-3H-IMIDAZO[45-B]PYRIDIN-6-YL)- BENZAMIDE
3806, d2o65A_, 0.7532, 2.88, 0.184, 274, 245, CRYSTAL STRUCTURE OF PIM1 WITH PENTAHYDROXYFLAVONE
3807, d2bikB_, 0.7532, 2.80, 0.184, 272, 244, HUMAN PIM1 PHOSPHORYLATED ON SER261
3808, d5vc5A_, 0.7531, 2.97, 0.198, 261, 247, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PD- 166285
3809, d5valB_, 0.7531, 2.77, 0.260, 254, 242, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
3810, d5ievA_, 0.7531, 3.05, 0.261, 284, 245, CRYSTAL STRUCTURE OF BAY 1000394 (RONICICLIB) BOUND TO CDK2
3811, d5byyA_, 0.7531, 3.20, 0.239, 338, 251, ERK5 IN COMPLEX WITH SMALL MOLECULE
3812, d3pxrA_, 0.7531, 3.17, 0.261, 294, 249, APO CDK2 CRYSTALLIZED FROM JEFFAMINE
3813, d5uklA2, 0.7530, 3.24, 0.166, 353, 253, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG222886 (14BD)
3814, d4kbkA_, 0.7530, 3.46, 0.206, 283, 253, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3815, d4iaaA_, 0.7530, 2.81, 0.189, 272, 244, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE
3816, d4fuyA_, 0.7530, 3.19, 0.226, 329, 248, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK2
3817, d2w1dA1, 0.7530, 2.66, 0.221, 251, 240, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3818, d1v0oB_, 0.7530, 2.94, 0.243, 274, 243, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
3819, d4xrjA_, 0.7529, 3.25, 0.197, 344, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3820, d4s2zA_, 0.7529, 3.55, 0.219, 346, 256, ERK2 INTRINSICALLY ACTIVE MUTANT R65S
3821, d3we4A_, 0.7529, 3.06, 0.260, 286, 246, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRIMIDINE DERIVATIVE PF-4708671 2-{[4-(5-ETHYLPYRIMIDIN-4-YL)PIPERAZIN-1- YL]METHYL}-5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOLE
3822, d3nw7A_, 0.7529, 3.15, 0.304, 297, 247, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (34)
3823, d4aotA1, 0.7528, 3.04, 0.260, 276, 242, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
3824, d3r7yA_, 0.7528, 3.21, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88
3825, d3qrtA_, 0.7528, 3.19, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55
3826, d3pscA2, 0.7528, 3.25, 0.186, 344, 253, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
3827, d3kmwA_, 0.7528, 3.11, 0.265, 268, 249, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MGATP)
3828, d2oj9A_, 0.7528, 3.30, 0.293, 295, 249, STRUCTURE OF IGF-1R KINASE DOMAIN COMPLEXED WITH A BENZIMIDAZOLE INHIBITOR
3829, p5nzzF_, 0.7527, 2.99, 0.216, 341, 245, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
3830, d4ft3A_, 0.7527, 2.97, 0.263, 269, 243, CRYSTAL STRUCTURE OF THE CHK1
3831, d3ag9A_, 0.7527, 3.19, 0.196, 323, 250, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
3832, d4iz7C_, 0.7526, 2.99, 0.212, 340, 245, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
3833, d3dkgA_, 0.7526, 2.98, 0.315, 281, 241, STRUCTURE OF MUTANT(Y1248L) MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
3834, d1hclA_, 0.7526, 3.23, 0.261, 294, 249, HUMAN CYCLIN-DEPENDENT KINASE 2
3835, d4rblA_, 0.7525, 2.78, 0.189, 271, 243, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3836, d4itiB_, 0.7525, 2.78, 0.252, 270, 238, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
3837, d3op5A_, 0.7525, 3.55, 0.158, 320, 259, HUMAN VACCINIA-RELATED KINASE 1
3838, d2hwpA_, 0.7525, 2.13, 0.313, 245, 230, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
3839, d1ym7D3, 0.7525, 3.27, 0.173, 340, 254, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3840, d3qziA_, 0.7524, 3.16, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-126
3841, d2wmrA_, 0.7524, 3.06, 0.255, 254, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3842, d2fumD_, 0.7524, 2.75, 0.197, 258, 239, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3843, d1ym7C3, 0.7524, 3.27, 0.173, 346, 254, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3844, d1ym7A3, 0.7524, 3.27, 0.173, 347, 254, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3845, d4ft0A_, 0.7523, 3.25, 0.256, 266, 246, CRYSTAL STRUCTURE OF THE CHK1
3846, d3zhpC1, 0.7523, 2.91, 0.245, 267, 245, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3847, d3r71A_, 0.7523, 3.21, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-162
3848, d2hy0A_, 0.7523, 3.24, 0.256, 272, 246, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 22
3849, d4joaA_, 0.7522, 2.57, 0.308, 250, 234, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 7-AZAINDOLE BASED INHIBITOR
3850, d4itjA_, 0.7522, 2.85, 0.259, 261, 239, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
3851, d2b53A_, 0.7522, 3.15, 0.246, 294, 248, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN- 234325
3852, d1ym7B3, 0.7522, 3.27, 0.173, 347, 254, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3853, d1b39A_, 0.7522, 3.08, 0.268, 290, 246, HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
3854, d4dbnB_, 0.7521, 2.86, 0.263, 263, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
3855, d3r8pA_, 0.7521, 3.19, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-6
3856, d1sykA_, 0.7521, 3.16, 0.188, 348, 250, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
3857, d1pxkA_, 0.7521, 3.10, 0.260, 290, 246, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]- N -HYDROXYIMINOFORMAMIDE
3858, d5opvA_, 0.7520, 3.27, 0.259, 261, 247, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
3859, p4ux9B_, 0.7520, 2.80, 0.202, 327, 242, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
3860, d4fc0B_, 0.7520, 2.84, 0.263, 263, 243, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
3861, d2f49B_, 0.7520, 3.05, 0.215, 337, 247, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
3862, d2c69A_, 0.7520, 3.16, 0.262, 292, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3863, d2c68A_, 0.7520, 3.14, 0.262, 290, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3864, d1sykB_, 0.7520, 3.16, 0.188, 323, 250, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
3865, d5d9kB_, 0.7519, 2.87, 0.250, 280, 244, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
3866, d4xp0A_, 0.7519, 3.35, 0.203, 336, 251, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3867, d2hogA_, 0.7519, 3.24, 0.256, 272, 246, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 20
3868, d1h0vA_, 0.7519, 3.12, 0.263, 288, 247, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5 -YL]METHOXYPURINE
3869, d4s30A_, 0.7518, 3.52, 0.220, 342, 255, ERK2 INTRINSICALLY ACTIVE MUTANT (I84A)
3870, d4qp6A_, 0.7518, 3.17, 0.206, 339, 248, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
3871, d4hokU_, 0.7518, 3.51, 0.188, 289, 255, CRYSTAL STRUCTURE OF APO CK1E
3872, d4hniB_, 0.7518, 3.28, 0.195, 284, 251, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
3873, d3rm6A_, 0.7518, 3.14, 0.259, 293, 247, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-80
3874, d2c5yA_, 0.7518, 3.12, 0.263, 290, 247, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
3875, d4btkA_, 0.7517, 3.34, 0.175, 287, 252, TTBK1 IN COMPLEX WITH INHIBITOR
3876, d3idpB_, 0.7517, 2.83, 0.276, 256, 243, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
3877, d2fa2A_, 0.7517, 3.18, 0.201, 333, 249, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
3878, d5aneA_, 0.7516, 3.22, 0.257, 294, 249, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-METHOXY-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
3879, d4qp4B_, 0.7516, 2.81, 0.219, 335, 242, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
3880, d3unzB_, 0.7516, 2.83, 0.241, 263, 241, AURORA A IN COMPLEX WITH RPM1679
3881, d3unzA_, 0.7516, 2.83, 0.241, 263, 241, AURORA A IN COMPLEX WITH RPM1679
3882, d3t9iA_, 0.7516, 2.85, 0.177, 273, 243, PIM1 COMPLEXED WITH A NOVEL 36-DISUBSTITUTED INDOLE AT 2.6 ANG RESOLUTION
3883, d4qyeA_, 0.7515, 3.28, 0.259, 271, 247, CHK1 KINASE DOMAIN IN COMPLEX WITH DIARYLPYRAZINE COMPOUND 1
3884, d4jjrA_, 0.7515, 3.16, 0.206, 284, 248, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
3885, d3r9oA_, 0.7515, 3.01, 0.266, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-2-143
3886, d4xozA_, 0.7514, 3.38, 0.198, 341, 252, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3887, d4lg4A_, 0.7514, 3.40, 0.211, 289, 251, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3888, d2c30A_, 0.7514, 3.44, 0.206, 289, 253, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 6
3889, d1y91A_, 0.7514, 3.08, 0.261, 286, 245, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
3890, d1pw2A_, 0.7514, 3.23, 0.261, 294, 249, APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
3891, d4ftuA_, 0.7513, 3.26, 0.256, 270, 246, CRYSTAL STRUCTURE OF THE CHK1
3892, d2r3oA_, 0.7513, 3.09, 0.264, 289, 246, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3893, d1b38A_, 0.7513, 3.09, 0.268, 290, 246, HUMAN CYCLIN-DEPENDENT KINASE 2
3894, d5oq6A_, 0.7512, 3.17, 0.257, 257, 245, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
3895, d4hokI_, 0.7512, 3.48, 0.188, 291, 255, CRYSTAL STRUCTURE OF APO CK1E
3896, d5jt2A1, 0.7511, 3.08, 0.275, 253, 244, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
3897, d5eykA_, 0.7511, 2.97, 0.200, 263, 245, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
3898, d4zjiB_, 0.7511, 3.19, 0.224, 276, 250, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
3899, d3zfyA_, 0.7511, 2.62, 0.326, 260, 236, CRYSTAL STRUCTURE OF EPHB3
3900, d3qqlA_, 0.7511, 3.21, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR L3
3901, d2c6lA_, 0.7511, 3.14, 0.263, 291, 247, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3902, d2c47D1, 0.7511, 3.32, 0.190, 289, 252, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
3903, d1pxiA_, 0.7511, 3.21, 0.261, 294, 249, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(25-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN-2- YLAMINE
3904, d4qp2A_, 0.7510, 3.18, 0.206, 336, 248, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
3905, d4f0gA1, 0.7510, 2.82, 0.267, 260, 240, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM
3906, d3zhpD_, 0.7510, 2.88, 0.246, 264, 244, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3907, d1nvqA_, 0.7510, 3.30, 0.255, 264, 247, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/UCN-01
3908, d3umxA_, 0.7509, 2.62, 0.192, 261, 239, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDOL-3-YL)METHYLENE]-7-(AZEPAN-1-YLMETHYL)-6-HYDROXYBENZOFURAN- 3(2H)-ONE
3909, d3qrjA1, 0.7509, 2.23, 0.391, 246, 230, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
3910, d3oz6B_, 0.7509, 2.84, 0.267, 341, 243, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
3911, d3h0yA_, 0.7509, 2.66, 0.237, 250, 240, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3912, d4qyfA_, 0.7508, 3.30, 0.255, 269, 247, CHK1 KINASE DOMAIN IN COMPLEX WITH AMINOPYRAZINE COMPOUND 13
3913, d3rzbA_, 0.7508, 3.02, 0.258, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-2-23
3914, d2w1hA_, 0.7508, 3.00, 0.262, 283, 244, FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA (AT9283) A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY
3915, d1nvsA_, 0.7508, 3.30, 0.255, 264, 247, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/SB218078
3916, d2brgA_, 0.7507, 3.20, 0.220, 257, 246, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3917, d5opsA_, 0.7506, 3.13, 0.250, 258, 244, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
3918, d5o26B_, 0.7505, 3.25, 0.256, 265, 250, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN COMPLEX WITH AMP-PNP/MG2+
3919, d5bueA_, 0.7505, 2.80, 0.233, 329, 240, ERK2 COMPLEXED WITH N-BENZYLPYRIDONE TETRAHYDROAZAINDAZOLE
3920, d2qq7B_, 0.7505, 2.09, 0.352, 244, 230, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN WITH IRREVERSIBLE INHIBITOR
3921, d4mneD_, 0.7504, 3.26, 0.245, 285, 249, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3922, d4fv9A_, 0.7504, 2.72, 0.234, 331, 239, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E71
3923, d3oriB_, 0.7504, 2.60, 0.188, 267, 239, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3924, d1e1xA_, 0.7504, 3.10, 0.264, 290, 246, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
3925, d4hokE_, 0.7503, 3.47, 0.188, 291, 255, CRYSTAL STRUCTURE OF APO CK1E
3926, d3uojB_, 0.7502, 2.83, 0.241, 263, 241, AURORA A IN COMPLEX WITH RPM1715
3927, d3uojA_, 0.7502, 2.83, 0.241, 263, 241, AURORA A IN COMPLEX WITH RPM1715
3928, d5vdkA_, 0.7501, 3.01, 0.196, 260, 245, CRYSTAL STRUCTURE OF HUMAN WEE2 KINASE DOMAIN IN COMPLEX WITH MK1775
3929, d4qtaA_, 0.7501, 2.84, 0.232, 335, 241, STRUCTURE OF HUMAN ERK2 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
3930, d1h0uA_, 0.7501, 3.14, 0.263, 291, 247,  
3931, d1fotA_, 0.7501, 3.14, 0.213, 299, 249, STRUCTURE OF THE UNLIGANDED CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT FROM SACCHAROMYCES CEREVISIAE
3932, d5k75A_, 0.7500, 2.93, 0.238, 271, 239, IRAK4 IN COMPLEX WITH COMPOUND 1
3933, d4zjiA_, 0.7500, 3.15, 0.221, 278, 249, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
3934, d4lynA_, 0.7500, 2.99, 0.266, 287, 244, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH (2S)-N-(5-(((5-TERT-BUTYL-13-OXAZOL-2-YL)METHYL)SULFANYL)-13- THIAZOL-2-YL)-2-PHENYLPROPANAMIDE
3935, d4fv5A_, 0.7500, 2.64, 0.236, 330, 237, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK9
3936, d4bcqA1, 0.7500, 3.05, 0.248, 289, 246, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3937, d3py1A1, 0.7500, 3.21, 0.249, 298, 245, CDK2 TERNARY COMPLEX WITH SU9516 AND ANS
3938, d4o6eA_, 0.7499, 3.02, 0.233, 328, 245, DISCOVERY OF 5678-TETRAHYDROPYRIDO[34-D]PYRIMIDINE INHIBITORS OF ERK2
3939, d4ft9A_, 0.7499, 3.22, 0.257, 270, 245, CRYSTAL STRUCTURE OF THE CHK1
3940, d5valA_, 0.7498, 2.75, 0.261, 254, 241, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
3941, d4fkoA_, 0.7498, 3.28, 0.256, 291, 246, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
3942, d3qquA_, 0.7498, 3.20, 0.316, 285, 247, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
3943, d2c3lA_, 0.7497, 3.30, 0.251, 265, 247, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
3944, d5k7gB_, 0.7496, 2.87, 0.245, 275, 237, IRAK4 IN COMPLEX WITH AZ3862
3945, d5c9cB_, 0.7496, 2.77, 0.266, 251, 241, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
3946, d4yfiB_, 0.7496, 2.89, 0.267, 262, 240, TNNI3K COMPLEXED WITH INHIBITOR 1
3947, d3uolA_, 0.7495, 2.88, 0.241, 263, 241, AURORA A IN COMPLEX WITH SO2-162
3948, d3ot3A_, 0.7495, 3.28, 0.256, 259, 246, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22K BOUND TO HUMAN CHK1 KINASE DOMAIN
3949, d5eakA_, 0.7494, 2.81, 0.270, 305, 241, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
3950, d3uzpB_, 0.7494, 3.43, 0.198, 284, 253, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
3951, d3uolB_, 0.7494, 2.88, 0.241, 263, 241, AURORA A IN COMPLEX WITH SO2-162
3952, d3iggA_, 0.7494, 3.13, 0.260, 290, 246, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFQ WITH CDK-2
3953, d2oicC_, 0.7494, 3.04, 0.237, 277, 240, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
3954, p5nzzG_, 0.7493, 3.14, 0.190, 342, 247, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
3955, d5k00A_, 0.7493, 2.61, 0.269, 311, 238, MELK IN COMPLEX WITH NVS-MELK5
3956, d4zjjA_, 0.7493, 3.24, 0.220, 280, 250, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
3957, d5vd2A_, 0.7492, 2.94, 0.204, 258, 245, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PF- 03814735
3958, d5k4jA1, 0.7492, 3.02, 0.267, 281, 243, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH COMPOUND 22
3959, d4n0sA_, 0.7492, 3.41, 0.221, 348, 253, COMPLEX OF ERK2 WITH CAFFEIC ACID
3960, d4fkqA_, 0.7492, 3.07, 0.265, 283, 245, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3961, d3sa0A_, 0.7492, 3.42, 0.221, 354, 253, COMPLEX OF ERK2 WITH NORATHYRIOL
3962, d3oriA_, 0.7492, 2.62, 0.188, 267, 239, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3963, d2vtrA_, 0.7492, 3.11, 0.268, 290, 246, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3964, d2r3rA_, 0.7492, 3.12, 0.268, 290, 246, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3965, d5ajqA_, 0.7491, 3.23, 0.256, 280, 246, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
3966, d3r83A_, 0.7491, 3.24, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-92
3967, d4n4sA_, 0.7490, 3.19, 0.208, 342, 250, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
3968, d4ft7A_, 0.7490, 3.27, 0.264, 270, 246, CRYSTAL STRUCTURE OF THE CHK1
3969, d2r3hA_, 0.7490, 3.07, 0.257, 289, 245, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3970, d2qolA_, 0.7490, 2.87, 0.311, 271, 238, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596:Y602:S768G TRIPLE MUTANT
3971, d5d9kA_, 0.7489, 2.86, 0.255, 280, 243, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
3972, d5byzA_, 0.7489, 3.41, 0.221, 348, 253, ERK5 IN COMPLEX WITH SMALL MOLECULE
3973, d4ae6B_, 0.7489, 3.20, 0.205, 321, 249, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
3974, d3qtrA_, 0.7489, 3.06, 0.258, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-1-148
3975, p5lw1H_, 0.7488, 3.06, 0.206, 355, 247, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
3976, d1r1wA_, 0.7488, 3.01, 0.320, 287, 241, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET
3977, d1h0wA_, 0.7488, 3.02, 0.262, 283, 244, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL]METHOXYPURINE
3978, d4p90A_, 0.7487, 2.73, 0.204, 272, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
3979, d2vtmA_, 0.7487, 3.14, 0.264, 290, 246, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3980, d2c47B_, 0.7487, 3.38, 0.194, 289, 252, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
3981, d5ih9A_, 0.7486, 2.69, 0.275, 308, 240, MELK IN COMPLEX WITH NVS-MELK8A
3982, d3sqqA_, 0.7486, 3.11, 0.254, 288, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-3-96
3983, d2z7rA_, 0.7486, 2.89, 0.266, 265, 241, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO STAUROSPORINE
3984, d1w8cA_, 0.7485, 3.17, 0.263, 290, 247, CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H- PURIN-2-YLAMINE AND MONOMERIC CDK2
3985, d5anjA_, 0.7484, 3.18, 0.263, 291, 247, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH N-(9H-PURIN-6-YL) THIOPHENE-2-CARBOXAMIDE  PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
3986, d2r3pA_, 0.7484, 3.13, 0.256, 289, 246, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3987, d4u42A_, 0.7483, 2.93, 0.222, 282, 243, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
3988, d3lfnA_, 0.7483, 3.17, 0.269, 285, 245, CRYSTAL STRUCTURE OF CDK2 WITH SAR57 AN AMINOINDAZOLE TYPE INHIBITOR
3989, d5bvdA_, 0.7482, 2.71, 0.235, 330, 238, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
3990, d4zxtA_, 0.7482, 3.41, 0.214, 348, 252, COMPLEX OF ERK2 WITH CATECHOL
3991, d4itiA_, 0.7482, 2.93, 0.238, 272, 239, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
3992, d3pj8A1, 0.7482, 3.22, 0.259, 287, 247, STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[43-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE.
3993, d1nvrA_, 0.7482, 3.33, 0.255, 264, 247, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/STAUROSPORINE
3994, d5ceoA_, 0.7481, 2.60, 0.321, 269, 237, DLK IN COMPLEX WITH INHIBITOR 2-((6-(33-DIFLUOROPYRROLIDIN-1-YL)-4- (1-(OXETAN-3-YL)PIPERIDIN-4-YL)PYRIDIN-2-YL)AMINO)ISONICOTINONITRILE
3995, d4fv0A_, 0.7481, 3.42, 0.206, 341, 252, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK3
3996, d2vv9A_, 0.7481, 2.86, 0.257, 279, 241, CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE
3997, d2vtlA_, 0.7481, 3.14, 0.264, 290, 246, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3998, d2o8yB_, 0.7481, 2.68, 0.247, 266, 235, APO IRAK4 KINASE DOMAIN
3999, d5vc3A_, 0.7480, 2.99, 0.207, 260, 246, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
4000, d4yfiD_, 0.7480, 2.88, 0.268, 261, 239, TNNI3K COMPLEXED WITH INHIBITOR 1
4001, d4hokS_, 0.7480, 3.55, 0.184, 286, 255, CRYSTAL STRUCTURE OF APO CK1E
4002, d3v6rA_, 0.7480, 2.93, 0.201, 349, 244, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
4003, d3i5zA_, 0.7480, 2.87, 0.237, 331, 240, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-N-(2-HYDROXY-1-PHENYLETHYL)-4- (5-METHYL-2-(PHENYLAMINO)PYRIMIDIN-4-YL)-1H-PYRROLE-2-CARBOXAMIDE
4004, d2cmwA_, 0.7480, 3.44, 0.190, 294, 252, STRUCTURE OF HUMAN CASEIN KINASE 1 GAMMA-1 IN COMPLEX WITH 2-(2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9- ISOPROPYLPURINE (CASP TARGET)
4005, d5cwzC_, 0.7479, 2.71, 0.236, 271, 237, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
4006, d4kbkD_, 0.7479, 3.45, 0.199, 281, 251, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
4007, d1h08A_, 0.7479, 3.02, 0.263, 283, 243, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4008, d1e1vA_, 0.7479, 3.13, 0.260, 290, 246, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
4009, d5d10A_, 0.7478, 2.19, 0.328, 248, 232, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL236
4010, d5ci6B_, 0.7477, 3.06, 0.246, 350, 244, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
4011, d4lggA_, 0.7476, 2.02, 0.338, 241, 228, STRUCTURE OF 3MB-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
4012, d3p86B_, 0.7476, 2.35, 0.335, 239, 233, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
4013, d1omwA3, 0.7476, 3.33, 0.169, 344, 254, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN G PROTEIN-COUPLED RECEPTOR KINASE 2 AND HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNITS
4014, d5d10B_, 0.7475, 2.28, 0.353, 247, 232, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL236
4015, d4rj3A_, 0.7475, 3.12, 0.260, 287, 246, CDK2 WITH EGFR INHIBITOR COMPOUND 8
4016, d4jjrB_, 0.7475, 3.31, 0.188, 283, 250, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
4017, d4d2rA_, 0.7475, 3.41, 0.301, 300, 249, HUMAN IGF IN COMPLEX WITH A DYRK1B INHIBITOR
4018, d5bveA_, 0.7474, 2.84, 0.238, 330, 239, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
4019, d4kbcB_, 0.7474, 3.26, 0.210, 277, 248, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
4020, d4fszA_, 0.7474, 3.25, 0.258, 268, 244, CRYSTAL STRUCTURE OF THE CHK1
4021, d2vtoA_, 0.7474, 3.09, 0.270, 283, 244, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4022, d1ke8A_, 0.7474, 3.08, 0.266, 282, 244, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO- 12-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(13- THIAZOL-2-YL)BENZENESULFONAMIDE
4023, d1h07A_, 0.7474, 3.02, 0.266, 285, 244, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4024, d5bujA_, 0.7473, 2.83, 0.233, 331, 240, ERK2 COMPLEXED WITH A N-H TETRAHYDROAZAINDAZOLE
4025, d4ztrA_, 0.7473, 2.68, 0.213, 249, 239, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1141
4026, d4hgtB_, 0.7473, 3.38, 0.196, 280, 250, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
4027, d3ns9A_, 0.7473, 3.09, 0.265, 289, 245, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194
4028, d3f69A_, 0.7473, 2.92, 0.202, 270, 243, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
4029, d1fvtA_, 0.7473, 3.08, 0.266, 282, 244, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR
4030, d4ztsA_, 0.7472, 2.67, 0.213, 249, 239, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1142
4031, d4hokW_, 0.7472, 3.41, 0.186, 289, 253, CRYSTAL STRUCTURE OF APO CK1E
4032, d4fsrA_, 0.7472, 3.28, 0.257, 269, 245, CRYSTAL STRUCTURE OF THE CHK1
4033, d2b52A_, 0.7472, 3.08, 0.259, 283, 243, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH- 042562
4034, d4fkrA_, 0.7471, 3.08, 0.266, 282, 244, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4035, d3ggfA_, 0.7471, 2.97, 0.261, 275, 245, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
4036, d1pmeA_, 0.7471, 3.46, 0.218, 333, 252, STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE
4037, d1gz8A_, 0.7471, 3.17, 0.259, 290, 247, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3 -METHYL-2 -OXO)BUTOXYPURINE
4038, d2r3fA_, 0.7470, 3.14, 0.264, 290, 246, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4039, d3tkhA_, 0.7469, 3.22, 0.258, 269, 244, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S01
4040, d2r3iA_, 0.7469, 3.13, 0.260, 289, 246, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4041, d2fa2B_, 0.7469, 3.04, 0.204, 332, 245, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
4042, d1di8A_, 0.7469, 3.17, 0.261, 283, 245, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-67-DIMETHOXYQUINAZOLINE
4043, d5tkdB_, 0.7468, 2.48, 0.209, 247, 235, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH 6-[(35-DIMETHYLPHE NYL)AMINO]-8- (METHYLAMINO) IMIDAZO[12-B]PYRIDAZINE-3-CARBO XAMIDE
4044, d4wa9A1, 0.7468, 2.14, 0.368, 236, 228, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
4045, d3vapA_, 0.7468, 2.70, 0.243, 249, 239, SYNTHESIS AND SAR STUDIES OF IMIDAZO-[12-A]-PYRAZINE AURORA KINASE INHIBITORS WITH IMPROVED OFF TARGET KINASE SELECTIVITY
4046, d3e7oA_, 0.7468, 3.10, 0.218, 342, 248, CRYSTAL STRUCTURE OF JNK2
4047, p5lw1B_, 0.7467, 3.14, 0.210, 355, 248, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
4048, d4zjjB_, 0.7467, 3.16, 0.226, 277, 248, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4049, d4fkvA_, 0.7467, 2.92, 0.264, 282, 242, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4050, d4ez7A1, 0.7467, 3.25, 0.259, 298, 247, CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1- NAPHTHALENE SULFONIC ACID
4051, d2ds1A_, 0.7467, 3.18, 0.260, 290, 246, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
4052, p5lw1E_, 0.7466, 3.09, 0.206, 355, 247, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
4053, d5x18B_, 0.7465, 3.68, 0.128, 294, 258, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
4054, d4kb8D_, 0.7465, 3.42, 0.187, 278, 251, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4055, d3d2kA_, 0.7464, 2.53, 0.243, 245, 235, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH [7-(2-{2-[3-(3-CHLORO- PHENYL)-UREIDO]-THIAZOL-5-YL}-ETHYLAMINO)-PYRAZOLO[43- D]PYRIMIDIN-1-YL]-ACETIC ACID
4056, d2io6A_, 0.7464, 2.80, 0.187, 252, 240, WEE1 KINASE COMPLEXED WITH INHIBITOR PD330961
4057, p5oatF_, 0.7463, 3.09, 0.198, 359, 247, PINK1 STRUCTURE
4058, d3zfyB_, 0.7463, 2.71, 0.323, 255, 235, CRYSTAL STRUCTURE OF EPHB3
4059, d2c47A_, 0.7463, 3.42, 0.183, 288, 252, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4060, d3i81A_, 0.7462, 3.17, 0.309, 296, 246, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH BMS-754807 [1-(4-((5-CYCLOPROPYL- 1H-PYRAZOL-3-YL)AMINO)PYRROLO[21-F][124]TRIAZIN-2-YL)-N- (6-FLUORO-3-PYRIDINYL)-2-METHYL-L-PROLINAMIDE]
4061, d2qg5B1, 0.7462, 3.44, 0.210, 275, 252, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
4062, d4ek5A_, 0.7461, 3.12, 0.269, 289, 245, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4063, d3zzwA_, 0.7461, 3.24, 0.309, 269, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF ROR2
4064, d3wf6A_, 0.7461, 3.00, 0.264, 277, 242, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-INDOL-3-YL)-36- DIHYDROPYRIDIN-1(2H)-YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
4065, d2fumC_, 0.7461, 2.55, 0.200, 254, 235, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
4066, d1ke5A_, 0.7461, 3.03, 0.267, 281, 243, CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-12-DIHYDRO-3H- INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
4067, d5dlsA_, 0.7460, 3.22, 0.258, 257, 244, IDENTIFICATION OF NOVEL IN VIVO ACTIVE CHK1 INHIBITORS UTILIZING STRUCTURE GUIDED DRUG DESIGN
4068, d4zsjA_, 0.7460, 3.47, 0.206, 344, 253, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
4069, d4hokA_, 0.7460, 3.51, 0.189, 290, 254, CRYSTAL STRUCTURE OF APO CK1E
4070, d4fgbA_, 0.7460, 3.08, 0.238, 282, 248, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I APO FORM
4071, d1f5qA_, 0.7460, 3.22, 0.250, 296, 248, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
4072, p5nzzH_, 0.7459, 3.10, 0.196, 335, 245, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
4073, d5d9lA_, 0.7459, 3.04, 0.242, 299, 244, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BIS-PHENOL PYRAZOLE
4074, d4ae9B_, 0.7459, 3.19, 0.202, 321, 248, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
4075, d1ol6A_, 0.7459, 2.66, 0.207, 245, 237, STRUCTURE OF UNPHOSPHORYLATED D274N MUTANT OF AURORA-A
4076, d5k7iB_, 0.7458, 3.06, 0.243, 271, 239, IRAK4 IN COMPLEX WITH AZ3864
4077, d4usdA_, 0.7458, 2.96, 0.261, 268, 241, HUMAN STK10 (LOK) WITH SB-633825
4078, d3ormA_, 0.7458, 2.70, 0.188, 266, 239, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN D76A MUTANT
4079, d3is5F1, 0.7458, 3.08, 0.225, 259, 244, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4080, d4mneH_, 0.7457, 3.23, 0.242, 275, 248, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4081, d4hokO_, 0.7457, 3.56, 0.184, 290, 255, CRYSTAL STRUCTURE OF APO CK1E
4082, d3wblA_, 0.7457, 3.12, 0.261, 283, 245, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR
4083, d4zsgA_, 0.7456, 3.39, 0.211, 347, 251, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
4084, d4gsbA_, 0.7456, 3.39, 0.227, 343, 251, MONOCLINIC CRYSTAL FORM OF THE APO-ERK2
4085, d4b0gA_, 0.7456, 2.64, 0.239, 247, 238, COMPLEX OF AURORA-A BOUND TO AN IMIDAZOPYRIDINE-BASED INHIBITOR
4086, d3e3pB_, 0.7456, 3.51, 0.201, 337, 249, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
4087, d3e3pA_, 0.7456, 3.46, 0.201, 337, 249, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
4088, d2iwiB_, 0.7456, 2.74, 0.200, 249, 240, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4089, d3uysA_, 0.7455, 3.44, 0.187, 281, 251, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4090, d2ym6A_, 0.7455, 3.11, 0.260, 253, 242, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4091, d2w17A_, 0.7455, 2.91, 0.253, 278, 241, CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE COMPOUND (S)-8B
4092, p5ax3A_, 0.7454, 3.09, 0.221, 329, 244, CRYSTAL STRUCTURE OF ERK2 COMPLEXED WITH ALLOSTERIC AND ATP- COMPETITIVE INHIBITORS.
4093, d4fg8B_, 0.7454, 2.65, 0.241, 268, 237, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
4094, d3vbwA_, 0.7454, 2.73, 0.180, 264, 239, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4095, d3og7A_, 0.7454, 2.65, 0.273, 247, 238, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
4096, d2w06A_, 0.7454, 3.01, 0.263, 282, 243, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5C
4097, d3u9nA_, 0.7453, 3.17, 0.230, 257, 244, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
4098, d3qquB_, 0.7453, 3.25, 0.335, 288, 248, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4099, d3pa3A_, 0.7453, 3.33, 0.220, 259, 246, X-RAY CRYSTAL STRUCTURE OF COMPOUND 70 BOUND TO HUMAN CHK1 KINASE DOMAIN
4100, d3fz1A_, 0.7453, 3.21, 0.265, 284, 245, CRYSTAL STRUCTURE OF A BENZTHIOPHENE INHIBITOR BOUND TO HUMAN CYCLIN-DEPENDENT KINASE-2 (CDK-2)
4101, d2j4zB_, 0.7453, 2.92, 0.222, 269, 243, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
4102, d4acmA_, 0.7452, 2.90, 0.257, 277, 241, CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL] SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
4103, d3wf5A_, 0.7452, 3.00, 0.260, 277, 242, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-BENZIMIDAZOL-2-YL)PIPERIDIN-1- YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
4104, d1ke9A_, 0.7452, 3.05, 0.267, 281, 243, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4- ({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2- OXO-23-DIHYDRO-1H-INDOLE
4105, d1ke7A_, 0.7452, 3.04, 0.267, 281, 243, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(22- DIOXIDO-13-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5- (13-OXAZOL-5-YL)-13-DIHYDRO-2H-INDOL-2-ONE
4106, d5uvfA_, 0.7451, 3.49, 0.157, 317, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4107, d5o12A_, 0.7451, 2.67, 0.176, 264, 238, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
4108, d5n93A1, 0.7450, 3.04, 0.202, 256, 242, TTK KINASE DOMAIN IN COMPLEX WITH TC-MPS1-12
4109, d4gh2A_, 0.7450, 2.96, 0.262, 266, 240, CRYSTAL STRUCTURE OF THE CHK1
4110, d4fkiA_, 0.7450, 3.19, 0.261, 287, 245, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4111, d3oz6A_, 0.7450, 3.20, 0.220, 343, 246, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
4112, d3nw5A_, 0.7450, 3.25, 0.308, 302, 247, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11B)
4113, d5oneA_, 0.7449, 2.74, 0.243, 257, 239, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH FMF-03-145-1 (COMPOUND 2)
4114, d5fxsA1, 0.7449, 3.31, 0.302, 307, 248, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
4115, d3wf7A_, 0.7449, 3.06, 0.256, 288, 246, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PURINE DERIVATIVE 1-(9H-PURIN-6-YL)-N-[3-(TRIFLUOROMETHYL)PHENYL]PIPERIDINE- 4-CARBOXAMIDE
4116, d3lfsA_, 0.7449, 3.16, 0.264, 290, 246, CRYSTAL STRUCTURE OF CDK2 WITH SAR37 AN AMINOINDAZOLE TYPE INHIBITOR
4117, d5jt2C1, 0.7448, 3.02, 0.279, 247, 240, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
4118, d4ek4A_, 0.7448, 3.12, 0.265, 287, 245, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4119, d3sw4A_, 0.7448, 2.98, 0.270, 279, 241, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4120, d3r7uA_, 0.7448, 3.10, 0.266, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-75
4121, d3lokB_, 0.7448, 2.10, 0.351, 242, 228, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
4122, d4jikA_, 0.7447, 3.17, 0.251, 256, 243, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22A (R)-2-(4-CHLOROPHENYL)-8- (PIPERIDIN-3-YLAMINO)IMIDAZO[12-C]PYRIMIDINE-5-CARBOXAMIDE BOUND TO HUMAN CHK1 KINASE DOMAIN
4123, d4ftrA_, 0.7447, 3.24, 0.259, 258, 243, CRYSTAL STRUCTURE OF THE CHK1
4124, d4fklA_, 0.7447, 3.17, 0.264, 290, 246, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4125, d1wccA_, 0.7447, 3.09, 0.266, 283, 244, SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY
4126, d1w0xC_, 0.7447, 2.99, 0.269, 280, 242, CRYSTAL STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE.
4127, d1ke6A_, 0.7447, 3.00, 0.269, 280, 242, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4- [2-(7-OXO-67-DIHYDRO-8H-[13]THIAZOLO[54-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
4128, d3rmfA_, 0.7446, 2.87, 0.254, 278, 240, CDK2 IN COMPLEX WITH INHIBITOR RC-2-33
4129, d3rakA_, 0.7446, 2.82, 0.255, 277, 239, CDK2 IN COMPLEX WITH INHIBITOR RC-2-32
4130, d2r3gA_, 0.7445, 3.03, 0.267, 287, 243, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4131, d2bdwA_, 0.7445, 3.46, 0.220, 309, 254, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
4132, d4fsyA_, 0.7444, 3.24, 0.263, 267, 243, CRYSTAL STRUCTURE OF THE CHK1
4133, d3h10A_, 0.7444, 3.07, 0.196, 268, 245, AURORA A INHIBITOR COMPLEX
4134, d3bizA_, 0.7444, 2.83, 0.187, 250, 240, WEE1 KINASE COMPLEX WITH INHIBITOR PD331618
4135, d2rioA_, 0.7444, 2.65, 0.220, 396, 236, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4136, d6bp0A_, 0.7443, 3.51, 0.153, 317, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4137, d4xoyA_, 0.7442, 3.26, 0.216, 326, 245, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4138, d4lg4B_, 0.7442, 3.05, 0.227, 284, 242, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4139, d3r7iA_, 0.7442, 3.09, 0.266, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-74
4140, d3op5B_, 0.7442, 3.61, 0.151, 319, 259, HUMAN VACCINIA-RELATED KINASE 1
4141, d3h10B_, 0.7442, 3.05, 0.197, 267, 244, AURORA A INHIBITOR COMPLEX
4142, d4fkwA_, 0.7441, 2.93, 0.266, 280, 241, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4143, d1jsvA_, 0.7441, 3.05, 0.267, 287, 243, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE
4144, d4ftjA_, 0.7440, 3.24, 0.259, 266, 243, CRYSTAL STRUCTURE OF THE CHK1
4145, d3lfqA_, 0.7440, 3.12, 0.257, 289, 245, CRYSTAL STRUCTURE OF CDK2 WITH SAR60 AN AMINOINDAZOLE TYPE INHIBITOR
4146, d2iwiA_, 0.7440, 2.63, 0.216, 244, 236, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4147, d5n87A1, 0.7439, 2.88, 0.199, 252, 241, TTK KINASE DOMAIN IN COMPLEX WITH NTRC 0066-0
4148, d5mhqA1, 0.7439, 3.05, 0.254, 288, 244, CCT068127 IN COMPLEX WITH CDK2
4149, d4kbaD_, 0.7439, 3.32, 0.190, 274, 248, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4150, d4d4rA_, 0.7439, 2.97, 0.347, 251, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4151, d2vtaA_, 0.7439, 2.90, 0.271, 278, 240, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4152, d6btwA_, 0.7438, 3.51, 0.157, 317, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4153, d5cswB_, 0.7438, 2.80, 0.283, 252, 240, B-RAF IN COMPLEX WITH DABRAFENIB
4154, d4fg7A_, 0.7438, 2.76, 0.252, 250, 238, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-293 IN COMPLEX WITH ATP
4155, d3s1hA_, 0.7438, 2.83, 0.255, 277, 239, CDK2 IN COMPLEX WITH INHIBITOR RC-2-39
4156, d4b99A_, 0.7437, 3.30, 0.228, 335, 250, CRYSTAL STRUCTURE OF MAPK7 (ERK5) WITH INHIBITOR
4157, d3qtsA_, 0.7437, 3.09, 0.262, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-2-12
4158, d1ungB_, 0.7437, 2.87, 0.205, 268, 239, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
4159, d5ceqA_, 0.7436, 2.66, 0.321, 269, 237, DLK IN COMPLEX WITH INHIBITOR 2-((1-CYCLOPENTYL-5-(1-(OXETAN-3-YL) PIPERIDIN-4-YL)-1H-PYRAZOL-3-YL)AMINO)ISONICOTINONITRILE
4160, d4gvaA_, 0.7435, 3.60, 0.209, 345, 254, ADP-BOUND FORM OF THE ERK2 KINASE
4161, d5mrbA1, 0.7434, 3.05, 0.194, 259, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH CPD-5
4162, d3le6A_, 0.7434, 3.14, 0.257, 283, 245, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR
4163, d3comA_, 0.7434, 3.21, 0.224, 264, 246, CRYSTAL STRUCTURE OF MST1 KINASE
4164, d2jboA_, 0.7434, 2.95, 0.220, 295, 241, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-1 SOAKING)
4165, d4qtdA_, 0.7433, 3.42, 0.185, 355, 249, STRUCTURE OF HUMAN JNK1 IN COMPLEX WITH SCH772984 AND THE AMPPNP- HYDROLYSED TRIPHOSPHATE REVEALING THE SECOND TYPE-I BINDING MODE
4166, d3zfmA_, 0.7433, 2.60, 0.309, 248, 233, CRYSTAL STRUCTURE OF EPHB2
4167, d3sw7A_, 0.7433, 2.87, 0.258, 278, 240, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4168, d2hwoB_, 0.7433, 2.01, 0.339, 242, 227, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR
4169, d5ih8A_, 0.7432, 2.62, 0.266, 306, 237, MELK IN COMPLEX WITH NVS-MELK1
4170, d4zegA_, 0.7432, 3.04, 0.198, 260, 242, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
4171, d3is5B1, 0.7432, 3.04, 0.227, 255, 242, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4172, d2j9mA_, 0.7432, 2.71, 0.262, 275, 237, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE
4173, d1buhA_, 0.7432, 3.21, 0.251, 287, 247, CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1
4174, p5oo0A_, 0.7431, 3.19, 0.260, 288, 246, CDK2(WT) COVALENT ADDUCT WITH D28 AT C177
4175, d4cqeA_, 0.7431, 2.71, 0.272, 250, 239, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
4176, d1szmB_, 0.7431, 3.21, 0.202, 320, 248, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
4177, d4fv4A_, 0.7430, 2.86, 0.234, 329, 239, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK7
4178, d4ek3A_, 0.7430, 3.16, 0.269, 287, 245, CRYSTAL STRUCTURE OF APO CDK2
4179, d3vquA_, 0.7430, 3.10, 0.202, 258, 243, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4- [(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2- YL)AMINO]BENZAMIDE
4180, d4oboA_, 0.7429, 3.20, 0.225, 275, 244, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
4181, d2vtpA_, 0.7429, 3.12, 0.272, 281, 243, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4182, d2r3mA_, 0.7429, 2.98, 0.266, 278, 241, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4183, d4cqeB_, 0.7428, 2.67, 0.261, 248, 238, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
4184, d3v6sA_, 0.7428, 3.11, 0.194, 349, 247, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
4185, d3rpyA_, 0.7428, 2.84, 0.264, 277, 239, CDK2 IN COMPLEX WITH INHIBITOR RC-2-40
4186, d3rprA_, 0.7428, 3.12, 0.262, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-2-49
4187, d4obqA_, 0.7427, 3.00, 0.225, 275, 240, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
4188, d2vtiA_, 0.7427, 3.01, 0.264, 280, 242, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4189, d4rzvB1, 0.7426, 3.12, 0.266, 254, 241, CRYSTAL STRUCTURE OF THE BRAF (R509H) KINASE DOMAIN MONOMER BOUND TO VEMURAFENIB
4190, d4bzdA_, 0.7426, 2.89, 0.259, 277, 239, STRUCTURE OF CDK2 IN COMPLEX WITH A BENZIMIDAZOPYRIMIDINE
4191, d2vtsA_, 0.7426, 3.12, 0.267, 282, 243, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4192, d5k72B_, 0.7425, 2.65, 0.249, 267, 233, IRAK4 IN COMPLEX WITH COMPOUND 21
4193, d2rioB_, 0.7425, 2.52, 0.218, 395, 234, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4194, d1oirA_, 0.7425, 3.09, 0.258, 286, 244, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
4195, d4u41A_, 0.7424, 3.22, 0.225, 275, 244, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
4196, d3oriD_, 0.7424, 2.74, 0.188, 267, 239, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4197, d2o8yA_, 0.7424, 2.95, 0.245, 269, 237, APO IRAK4 KINASE DOMAIN
4198, d3wyyA_, 0.7423, 3.09, 0.198, 258, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH (E)- 3-(4-((6-(((3S5S7S)-ADAMANTAN-1-YL)AMINO)-4-AMINO-5-CYANOPYRIDIN-2- YL)AMINO)-2-(CYANOMETHOXY)PHENYL)-N-(2-METHOXYETHYL)ACRYLAMIDE
4199, p5o7iA_, 0.7422, 3.36, 0.208, 340, 250, ERK5 IN COMPLEX WITH A PYRROLE INHIBITOR 
4200, d5cswA_, 0.7422, 2.83, 0.271, 254, 240, B-RAF IN COMPLEX WITH DABRAFENIB
4201, d3p9jA_, 0.7422, 2.72, 0.206, 249, 238, AURORA A KINASE DOMAIN WITH PHTHALAZINONE PYRAZOLE INHIBITOR
4202, d6bu6B_, 0.7421, 3.66, 0.159, 307, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4203, p4lopD_, 0.7421, 3.41, 0.224, 351, 250, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
4204, d4hokQ_, 0.7421, 3.61, 0.176, 290, 255, CRYSTAL STRUCTURE OF APO CK1E
4205, d2r3qA_, 0.7421, 3.06, 0.263, 286, 243, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4206, d4fkgA_, 0.7420, 3.19, 0.270, 286, 244, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4207, d3ralA_, 0.7420, 2.87, 0.259, 277, 239, CDK2 IN COMPLEX WITH INHIBITOR RC-2-34
4208, d5vo2A_, 0.7419, 2.70, 0.321, 269, 237, DLK IN COMPLEX WITH INHIBITOR 5-(1-ISOPROPYL-5-(1-(OXETAN-3-YL) PIPERIDIN-4-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE (COMPOUND 7)
4209, d5up3B_, 0.7419, 2.55, 0.306, 243, 232, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4210, d3rahA_, 0.7419, 3.13, 0.262, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-2-22
4211, d2xf0A_, 0.7417, 3.06, 0.247, 251, 239, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4212, d1giiA_, 0.7417, 3.00, 0.261, 279, 241, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
4213, d5nttA1, 0.7416, 3.13, 0.197, 268, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604Y MUTANT IN COMPLEX WITH NMS-P715
4214, d4ztlB_, 0.7416, 2.88, 0.248, 269, 234, IRAK4-INHIBITOR CO-STRUCTURE
4215, d3o0gB_, 0.7416, 2.74, 0.221, 264, 235, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
4216, d3r9nA_, 0.7415, 3.12, 0.262, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-2-21
4217, d3pa4A_, 0.7415, 3.25, 0.234, 257, 244, X-RAY CRYSTAL STRUCTURE OF COMPOUND 2A BOUND TO HUMAN CHK1 KINASE DOMAIN
4218, d2uznA_, 0.7415, 2.98, 0.261, 279, 241, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
4219, d2vthA_, 0.7414, 2.93, 0.271, 278, 240, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN
4220, d2r3jA_, 0.7414, 2.90, 0.262, 278, 240, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4221, d4usdB_, 0.7413, 3.00, 0.258, 267, 240, HUMAN STK10 (LOK) WITH SB-633825
4222, d3pxfA1, 0.7413, 3.53, 0.257, 298, 249, CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
4223, d2brhA_, 0.7413, 3.27, 0.225, 257, 244, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4224, d4hokK_, 0.7412, 3.41, 0.187, 290, 252, CRYSTAL STRUCTURE OF APO CK1E
4225, d4fsmA_, 0.7412, 3.21, 0.261, 265, 241, CRYSTAL STRUCTURE OF THE CHK1
4226, d3wyxA_, 0.7412, 3.04, 0.207, 258, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 6- ((3-(CYANOMETHOXY)-4-(1-METHYL-1H-PYRAZOL-4-YL)PHENYL)AMINO)-2- (CYCLOHEXYLAMINO)NICOTINONITRILE
4227, d6b8uB_, 0.7411, 2.86, 0.272, 248, 239, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
4228, d5jq5A_, 0.7411, 3.09, 0.267, 287, 243, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0942
4229, d4d9uA_, 0.7411, 3.01, 0.237, 307, 241, RSK2 C-TERMINAL KINASE DOMAIN (E)-TERT-BUTYL 3-(4-AMINO-7-(3- HYDROXYPROPYL)-5-P-TOLYL-7H-PYRROLO[23-D]PYRIMIDIN-6-YL)-2- CYANOACRYLATE
4230, d3wf9A_, 0.7411, 3.20, 0.260, 287, 246, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 1-OXO-1-[(4-SULFAMOYLPHENYL)AMINO]PROPAN-2-YL-2-METHYL-1 234-TETRAHYDROACRIDINE-9-CARBOXYLATE
4231, d3h0zC_, 0.7411, 2.62, 0.237, 246, 236, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4232, d4nifD_, 0.7410, 3.13, 0.232, 313, 241, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
4233, d2c47C_, 0.7410, 3.37, 0.189, 282, 249, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4234, d4j8mA_, 0.7409, 2.92, 0.240, 265, 242, AURORA A IN COMPLEX WITH CD532
4235, d3wf8A_, 0.7409, 3.21, 0.260, 287, 246, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 2-OXO-2-[(4-SULFAMOYLPHENYL)AMINO]ETHYL 78910- TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE-11-CARBOXYLATE
4236, d3ggfB_, 0.7409, 2.97, 0.270, 270, 244, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
4237, d2r3kA_, 0.7409, 2.92, 0.262, 277, 240, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4238, d5vo1A_, 0.7408, 2.71, 0.321, 269, 237, DLK IN COMPLEX WITH COMPOUND 10 (5-(1-ISOPROPYL-5-(3-(OXETAN-3-YL)-3- AZABICYCLO[3.1.0]HEXAN-6-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL) PYRIDIN-2-AMINE)
4239, d5anoA_, 0.7408, 2.90, 0.272, 277, 239, CRYSTAL STRUCTURE OF CDK2 PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4240, d3pxzA1, 0.7408, 3.54, 0.257, 298, 249, CDK2 TERNARY COMPLEX WITH JWS648 AND ANS
4241, d3oriC_, 0.7408, 2.80, 0.192, 267, 240, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4242, d3ig7A_, 0.7408, 2.96, 0.267, 278, 240, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFP WITH CDK-2
4243, d2r64A_, 0.7408, 3.00, 0.266, 279, 241, CRYSTAL STRUCTURE OF A 3-AMINOINDAZOLE COMPOUND WITH CDK2
4244, d2a4lA_, 0.7408, 3.06, 0.277, 286, 242, HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE
4245, d2qkrA1, 0.7406, 2.80, 0.262, 269, 237, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH INDIRUBIN 3 -MONOXIME BOUND
4246, d4fktA_, 0.7404, 3.11, 0.273, 278, 242, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4247, d3ezvA_, 0.7404, 2.90, 0.264, 277, 239, CDK-2 WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
4248, d3w16A_, 0.7403, 2.72, 0.206, 249, 238, STRUCTURE OF AURORA KINASE A COMPLEXED TO PYRAZOLE-AMINOQUINOLINE INHIBITOR III
4249, d3kc3E_, 0.7403, 2.74, 0.224, 287, 237, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4250, d5ukfC_, 0.7402, 3.65, 0.147, 317, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
4251, p4lopA_, 0.7402, 3.35, 0.217, 351, 249, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
4252, d4ek8A_, 0.7402, 3.01, 0.266, 280, 241, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4253, d5hx6A_, 0.7401, 2.81, 0.258, 259, 236, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
4254, p4looA_, 0.7401, 3.31, 0.226, 349, 248, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (MONOCLINIC CRYSTAL FORM)
4255, d4eqmD_, 0.7400, 2.93, 0.217, 268, 240, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4256, d5eakB_, 0.7399, 2.61, 0.284, 300, 236, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
4257, d5ap1A1, 0.7399, 2.87, 0.204, 264, 240, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4258, d4zy5B_, 0.7399, 3.35, 0.219, 287, 251, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
4259, d4zslA_, 0.7399, 3.48, 0.211, 341, 251, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
4260, d4ftcA_, 0.7399, 3.20, 0.249, 266, 241, CRYSTAL STRUCTURE OF THE CHK1
4261, d4fkpA_, 0.7399, 3.01, 0.270, 279, 241, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4262, d3cohB_, 0.7399, 2.71, 0.211, 247, 237, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
4263, d2w05A_, 0.7399, 2.83, 0.261, 276, 238, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5B
4264, d2qhnA_, 0.7399, 3.29, 0.251, 268, 243, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1A
4265, d5drbA_, 0.7398, 3.31, 0.263, 273, 247, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH WNK463
4266, d4lghA_, 0.7398, 2.16, 0.330, 243, 227, CRYSTAL STRUCTURE OF 1NM-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
4267, d3oroA_, 0.7398, 2.94, 0.183, 272, 241, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 4)
4268, d3hmpA_, 0.7398, 3.02, 0.202, 258, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH A QUINAZOLIN LIGAND COMPOUND 4
4269, d5uvfB_, 0.7397, 3.47, 0.157, 316, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4270, d5o23B1, 0.7397, 3.49, 0.256, 276, 250, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
4271, d4fttA_, 0.7397, 3.26, 0.260, 266, 242, CRYSTAL STRUCTURE OF THE CHK1
4272, d3cohA_, 0.7397, 2.72, 0.211, 247, 237, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
4273, d2qhmA_, 0.7397, 3.28, 0.251, 268, 243, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2A
4274, d2c6eA_, 0.7397, 2.79, 0.225, 251, 240, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
4275, d5na0A1, 0.7396, 2.82, 0.197, 250, 239, TTK KINASE DOMAIN IN COMPLEX WITH A PEG-LINKED PYRIMIDO-INDOLIZINE
4276, d4maoA_, 0.7396, 3.17, 0.243, 298, 243, RSK2 T493M C-TERMINAL KINASE DOMAIN IN COMPLEX WITH RMM58
4277, d4eqmF_, 0.7396, 2.93, 0.221, 268, 240, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4278, d5ap7A1, 0.7395, 3.05, 0.195, 253, 241, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4279, d4bghA_, 0.7395, 2.77, 0.262, 275, 237, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PAN-CDK INHIBITOR
4280, d1vyzA_, 0.7395, 3.08, 0.270, 279, 241, STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
4281, d5fxqA1, 0.7394, 3.36, 0.304, 301, 247, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
4282, d5cepA_, 0.7394, 2.75, 0.321, 269, 237, DLK IN COMPLEX WITH INHIBITOR N-(1-ISOPROPYL-5-(PIPERIDIN-4-YL)-1H- PYRAZOL-3-YL)-4-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE
4283, d4izaC_, 0.7394, 3.00, 0.212, 335, 241, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
4284, d2r3nA_, 0.7394, 2.82, 0.252, 275, 238, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4285, d6bruD_, 0.7393, 3.51, 0.158, 311, 253, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4286, d5bvfA_, 0.7393, 2.64, 0.240, 327, 233, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
4287, d4hokC_, 0.7393, 3.70, 0.184, 289, 256, CRYSTAL STRUCTURE OF APO CK1E
4288, d5aniA_, 0.7392, 3.08, 0.269, 280, 242, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-CHLORO-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4289, p4lopC_, 0.7392, 3.26, 0.202, 341, 247, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
4290, d4hokG_, 0.7392, 3.51, 0.186, 290, 253, CRYSTAL STRUCTURE OF APO CK1E
4291, d2ydjA_, 0.7392, 3.16, 0.257, 252, 241, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4292, d1gihA_, 0.7392, 2.85, 0.269, 276, 238, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
4293, d1ckpA_, 0.7392, 3.01, 0.261, 279, 241, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
4294, d4uzhA1, 0.7391, 2.71, 0.236, 250, 237, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
4295, d6bp0D_, 0.7390, 3.59, 0.161, 311, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4296, d4zy4B_, 0.7390, 3.37, 0.215, 292, 251, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
4297, d4i5hA_, 0.7390, 2.94, 0.244, 335, 238, CRYSTAL STRUCTURE OF A DOUBLE MUTANT RAT ERK2 COMPLEXED WITH A TYPE II QUINAZOLINE INHIBITOR
4298, d5tkdA_, 0.7389, 2.50, 0.210, 248, 233, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH 6-[(35-DIMETHYLPHE NYL)AMINO]-8- (METHYLAMINO) IMIDAZO[12-B]PYRIDAZINE-3-CARBO XAMIDE
4299, d2r0uA_, 0.7389, 3.33, 0.254, 269, 244, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 54
4300, d1h00A_, 0.7389, 2.94, 0.268, 278, 239, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4301, d4jg8A_, 0.7388, 3.17, 0.247, 300, 243, STRUCTURE OF RSK2 T493M CTD MUTANT BOUND TO 2-CYANO-N-(1-HYDROXY-2- METHYLPROPAN-2-YL)-3-(3-(345-TRIMETHOXYPHENYL)-1H-INDAZOL-5-YL) ACRYLAMIDE
4302, d4eqmE_, 0.7388, 2.95, 0.225, 268, 240, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4303, d4fswA_, 0.7387, 3.23, 0.261, 265, 241, CRYSTAL STRUCTURE OF THE CHK1
4304, d3pxqA1, 0.7387, 3.22, 0.258, 294, 244, CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
4305, d2wtvC_, 0.7387, 2.93, 0.207, 261, 241, AURORA-A INHIBITOR STRUCTURE
4306, d2wtvB_, 0.7387, 2.92, 0.212, 261, 241, AURORA-A INHIBITOR STRUCTURE
4307, d3zzwB_, 0.7386, 3.27, 0.300, 265, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF ROR2
4308, d3o50B_, 0.7386, 2.73, 0.207, 249, 237, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4309, d2pmiC_, 0.7385, 3.28, 0.241, 285, 245, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
4310, d4d9tA_, 0.7384, 3.19, 0.243, 299, 243, RSK2 C-TERMINAL KINASE DOMAIN WITH INHIBITOR (E)-METHYL 3-(4-AMINO-7- (3-HYDROXYPROPYL)-5-P-TOLYL-7H-PYRROLO[23-D]PYRIMIDIN-6-YL)-2- CYANOACRYLATE
4311, d3s2pA_, 0.7384, 3.00, 0.257, 279, 241, CRYSTAL STRUCTURE OF CDK2 WITH A 2-AMINOPYRIMIDINE COMPOUND
4312, d3ma3A_, 0.7384, 2.77, 0.181, 266, 238, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A NAPHTHO-DIFURAN LIGAND
4313, d3a62A_, 0.7384, 2.91, 0.265, 263, 238, CRYSTAL STRUCTURE OF PHOSPHORYLATED P70S6K1
4314, d2vtjA_, 0.7384, 2.84, 0.269, 276, 238, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4315, d4fkjA_, 0.7383, 2.97, 0.271, 278, 240, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4316, d4o6lB_, 0.7382, 3.05, 0.195, 256, 241, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
4317, d4kkeA_, 0.7382, 3.25, 0.198, 354, 247, THE CRYSTAL STRUCTURE OF AMP-BOUND JNK3
4318, d4fksA_, 0.7382, 2.90, 0.268, 275, 239, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4319, d3mj1A1, 0.7382, 2.00, 0.317, 226, 224, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR RO5191614
4320, d3jvrA_, 0.7382, 3.29, 0.251, 258, 243, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
4321, d3is5A1, 0.7382, 3.07, 0.227, 254, 242, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4322, d3en7B_, 0.7381, 1.84, 0.345, 237, 223, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH S1 A MULTITARGETED KINASE INHIBITOR
4323, d5nadA1, 0.7380, 2.86, 0.202, 253, 238, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1217389
4324, d5fp6A_, 0.7380, 2.91, 0.255, 278, 239, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 3-(47-DICHLORO-1H-INDOL-3-YL)PROP-2-YN-1-OL (AT17833) IN AN ALTERNATE BINDING SITE.
4325, d1h06A_, 0.7380, 2.90, 0.268, 277, 239,  
4326, d6bp0B_, 0.7379, 3.46, 0.159, 304, 251, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4327, d5ajqB_, 0.7379, 3.12, 0.246, 267, 240, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
4328, d1h01A_, 0.7378, 3.15, 0.262, 286, 244, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4329, d5fxrA1, 0.7377, 3.39, 0.304, 299, 247, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
4330, d4ftaA_, 0.7377, 3.20, 0.262, 264, 240, CRYSTAL STRUCTURE OF THE CHK1
4331, d4aa4A_, 0.7377, 3.28, 0.224, 347, 245, P38ALPHA MAP KINASE BOUND TO CMPD 22
4332, d2xeyA_, 0.7377, 3.18, 0.253, 252, 241, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4333, d2r3lA_, 0.7377, 2.85, 0.265, 275, 238, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4334, d4nifA_, 0.7376, 3.16, 0.228, 313, 241, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
4335, d5ehoA1, 0.7375, 2.80, 0.202, 255, 238, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4336, d4yc6E_, 0.7375, 3.38, 0.259, 285, 247, CDK1/CKS1
4337, d1di9A_, 0.7375, 3.33, 0.223, 348, 247, THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-67- DIMETHOXYQUINAZOLINE
4338, d5n9sA1, 0.7374, 3.09, 0.198, 256, 242, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1161909
4339, d4ft5A_, 0.7374, 3.25, 0.249, 265, 241, CRYSTAL STRUCTURE OF THE CHK1
4340, d3lauA1, 0.7374, 2.76, 0.236, 250, 237, CRYSTAL STRUCTURE OF AURORA2 KINASE IN COMPLEX WITH A GSK3BETA INHIBITOR
4341, d2x9eA_, 0.7374, 2.79, 0.197, 253, 238, HUMAN MPS1 IN COMPLEX WITH NMS-P715
4342, d2wmvA_, 0.7374, 3.10, 0.247, 251, 239, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4343, d5m57A1, 0.7373, 2.81, 0.242, 253, 236, NEK2 BOUND TO ARYLAMINOPURINE 6
4344, d2bvaB_, 0.7373, 3.30, 0.216, 274, 245, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
4345, d5ap4A1, 0.7372, 2.90, 0.201, 253, 239, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4346, d2c6dA_, 0.7372, 3.03, 0.207, 254, 241, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH ADPNP
4347, d5n84A1, 0.7371, 2.95, 0.199, 253, 241, TTK KINASE DOMAIN IN COMPLEX WITH MPS-BAY2B
4348, d5jrqB1, 0.7371, 2.72, 0.281, 245, 235, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
4349, d3qquC_, 0.7371, 3.43, 0.306, 293, 248, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4350, d1g5sA_, 0.7371, 2.86, 0.262, 275, 237, CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717
4351, d5ljjA1, 0.7370, 2.88, 0.205, 260, 239, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH REVERSINE
4352, p4lopB_, 0.7370, 3.31, 0.211, 350, 247, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
4353, d4byjA_, 0.7370, 2.65, 0.242, 246, 236, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
4354, d5ap0A1, 0.7369, 2.87, 0.197, 250, 239, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4355, d4ztqA_, 0.7369, 2.70, 0.236, 247, 237, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK932
4356, d4m8tA_, 0.7369, 3.12, 0.248, 303, 242, RSK2 T493M C-TERMINAL KINASE DOMAIN IN COMPLEX WITH 3-(3-(1H-PYRAZOL- 4-YL)PHENYL)-2-CYANOACRYLAMIDE
4357, d1v0bA_, 0.7369, 3.34, 0.236, 286, 246, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
4358, d1f5qC_, 0.7368, 3.30, 0.257, 288, 245, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
4359, d6bruC_, 0.7367, 3.54, 0.154, 315, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4360, d5imeB_, 0.7367, 3.09, 0.221, 280, 244, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
4361, d5andA_, 0.7367, 2.96, 0.272, 273, 239, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 2-IMIDAZOL-1-YL-1H- BENZIMIDAZOLE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4362, d4knbD_, 0.7367, 3.07, 0.343, 247, 236, C-MET IN COMPLEX WITH OSI LIGAND
4363, d4ftqA_, 0.7367, 3.17, 0.272, 254, 239, CRYSTAL STRUCTURE OF THE CHK1
4364, d6bp0C_, 0.7366, 3.54, 0.154, 315, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4365, d4wo5A1, 0.7366, 3.15, 0.262, 250, 240, CRYSTAL STRUCTURE OF A BRAF KINASE DOMAIN MONOMER
4366, d4l7fA1, 0.7366, 3.05, 0.199, 343, 241, CO-CRYSTAL STRUCTURE OF JNK1 AND AX13587
4367, d3qquD_, 0.7366, 3.47, 0.302, 292, 248, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4368, d2c6eB_, 0.7366, 2.67, 0.216, 246, 236, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
4369, d2btsA_, 0.7366, 2.77, 0.263, 274, 236, STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
4370, d4c4fA1, 0.7365, 2.89, 0.197, 250, 239, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4371, d6bu6C_, 0.7364, 3.55, 0.154, 315, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4372, d3en6B_, 0.7364, 2.11, 0.347, 239, 225, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP102 A MULTITARGETED KINASE INHIBITOR
4373, d4ek6A_, 0.7363, 3.06, 0.275, 278, 240, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4374, d4aotB1, 0.7363, 3.34, 0.235, 277, 243, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
4375, d2wtvD_, 0.7363, 2.96, 0.203, 262, 241, AURORA-A INHIBITOR STRUCTURE
4376, d2wtvA_, 0.7362, 2.96, 0.203, 262, 241, AURORA-A INHIBITOR STRUCTURE
4377, d4bi0A1, 0.7361, 2.87, 0.197, 251, 239, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4378, d3f9nA_, 0.7361, 3.23, 0.249, 253, 241, CRYSTAL STRUCTURE OF CHK1 KINASE IN COMPLEX WITH INHIBITOR 38
4379, d2vtqA_, 0.7361, 2.79, 0.263, 274, 236, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4380, d5jq8A_, 0.7360, 3.09, 0.271, 278, 240, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0943
4381, d5ihaA_, 0.7360, 2.66, 0.272, 303, 235, MELK IN COMPLEX WITH NVS-MELK8F
4382, d4fg9B_, 0.7360, 2.55, 0.240, 279, 233, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
4383, d3dakD_, 0.7360, 3.32, 0.230, 284, 244, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4384, d2wmtA_, 0.7360, 3.04, 0.249, 248, 237, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4385, d1w82A_, 0.7360, 3.35, 0.236, 351, 246, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4386, d1dm2A_, 0.7360, 2.80, 0.267, 274, 236, HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
4387, d4u9aB_, 0.7359, 3.17, 0.233, 270, 236, SULPHUR ANOMALOUS CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4388, d1v1kA_, 0.7359, 2.93, 0.268, 277, 239, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4389, d4js8A_, 0.7358, 3.09, 0.200, 259, 240, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401348
4390, d3ot8A_, 0.7358, 3.18, 0.255, 251, 239, X-RAY CRYSTAL STRUCTURE OF COMPOUND 17R BOUND TO HUMAN CHK1 KINASE DOMAIN
4391, d5w5jB_, 0.7357, 2.36, 0.249, 257, 229, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
4392, d3h10D_, 0.7357, 2.82, 0.206, 255, 238, AURORA A INHIBITOR COMPLEX
4393, d4aacA_, 0.7356, 3.26, 0.225, 350, 244, P38ALPHA MAP KINASE BOUND TO CMPD 29
4394, d1oukA_, 0.7356, 3.38, 0.231, 348, 247, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR
4395, d5deyB_, 0.7355, 3.44, 0.225, 281, 249, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
4396, p5xyyA_, 0.7354, 3.37, 0.239, 350, 247, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
4397, d3en5A_, 0.7354, 1.95, 0.344, 238, 224, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
4398, d2jfmA_, 0.7354, 3.23, 0.233, 287, 240, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (UNLIGANDED FORM)
4399, d2j50B_, 0.7354, 2.81, 0.206, 249, 238, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
4400, d2j50A_, 0.7354, 2.81, 0.206, 249, 238, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
4401, d3w10A_, 0.7352, 3.12, 0.198, 263, 243, AURORA KINASE A COMPLEXED TO PYRAZOLE AMINOQUINOLINE I
4402, d2w99B_, 0.7352, 3.15, 0.266, 291, 241, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4403, d2btrA_, 0.7352, 2.90, 0.278, 275, 237, STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
4404, d2bheA_, 0.7352, 2.80, 0.263, 274, 236, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE
4405, d2j51A_, 0.7351, 3.02, 0.231, 288, 238, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 5- AMINO-3-((4-(AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-124-TRIAZOLE-1-CARBOTHIOAMIDE
4406, d5ew9A_, 0.7350, 3.28, 0.200, 257, 245, CRYSTAL STRUCTURE OF AURORA A KINASE DOMAIN BOUND TO MK-5108
4407, d3kc3F_, 0.7350, 2.89, 0.218, 293, 238, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4408, d1wbwA_, 0.7350, 3.38, 0.223, 351, 247, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
4409, d1urwA_, 0.7350, 2.86, 0.271, 274, 236, CDK2 IN COMPLEX WITH AN IMIDAZO[12-B]PYRIDAZINE
4410, d1ob3A_, 0.7350, 3.25, 0.242, 277, 244, STRUCTURE OF P. FALCIPARUM PFPK5
4411, d1muoA_, 0.7350, 2.94, 0.206, 251, 238, CRYSTAL STRUCTURE OF AURORA-2 AN ONCOGENIC SERINE- THREONINE KINASE
4412, d5tx5A_, 0.7349, 2.91, 0.263, 259, 236, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
4413, d5m51A1, 0.7349, 2.84, 0.246, 253, 236, NEK2 BOUND TO ARYLAMINOPURINE COMPOUND 8
4414, d4u97B_, 0.7349, 2.90, 0.236, 270, 233, CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4415, d4ewqA_, 0.7349, 3.27, 0.220, 346, 246, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A PYRIDAZINE BASED INHIBITOR
4416, d3uysB_, 0.7349, 3.44, 0.198, 279, 248, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4417, d2vtnA_, 0.7349, 2.80, 0.258, 274, 236, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4418, p4loqD_, 0.7348, 3.34, 0.211, 351, 247, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
4419, d3dt1A2, 0.7348, 3.45, 0.221, 352, 249, P38 COMPLEXED WITH A QUINAZOLINE INHIBITOR
4420, d2w9zB_, 0.7348, 3.36, 0.263, 287, 243, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4421, d5ei6A1, 0.7347, 2.99, 0.203, 261, 241, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4422, d2hwpB_, 0.7347, 1.97, 0.330, 239, 224, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
4423, d4y46A_, 0.7346, 3.29, 0.202, 340, 247, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
4424, d4rvlA_, 0.7346, 3.29, 0.249, 258, 241, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 7: 3-(2- HYDROXYPHENYL)-9H-PYRROLO[23-B:54-C ]DIPYRIDINE-6-CARBONITRILE
4425, d4o2zA1, 0.7346, 3.11, 0.228, 357, 241, CRYSTAL STRUCTURE OF MPK3 FROM LEISHMANIA DONOVANI LDBPK_100540 IN THE PRESENCE OF NVP-BBT594
4426, d2ydjB_, 0.7346, 3.17, 0.258, 251, 240, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4427, p4loqA_, 0.7345, 3.31, 0.202, 352, 247, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
4428, d4ftoA_, 0.7345, 3.17, 0.261, 252, 238, CRYSTAL STRUCTURE OF THE CHK1
4429, d4y5hA_, 0.7344, 3.15, 0.209, 349, 244, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
4430, d4un0D_, 0.7344, 3.07, 0.260, 276, 242, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
4431, d4o6lA_, 0.7344, 3.02, 0.197, 257, 239, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
4432, d3dbqA_, 0.7344, 3.09, 0.198, 259, 242, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN
4433, d5ar8A_, 0.7343, 2.27, 0.272, 255, 228, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
4434, d4yc6A_, 0.7343, 3.43, 0.255, 285, 247, CDK1/CKS1
4435, d4kkgA_, 0.7343, 3.25, 0.199, 353, 246, CRYSTAL STRUCTURE OF APO AND AMP-BOUND JNK3
4436, d3pzeA_, 0.7343, 3.18, 0.198, 347, 243, JNK1 IN COMPLEX WITH INHIBITOR
4437, d3kc3L_, 0.7343, 2.80, 0.220, 291, 236, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4438, d2vu3A_, 0.7342, 2.97, 0.262, 285, 237, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4439, d4yc6C_, 0.7341, 3.44, 0.251, 285, 247, CDK1/CKS1
4440, d4kkhA_, 0.7340, 3.29, 0.202, 351, 247, THE CRYSTAL STRUCTURE OF INHIBITOR-BOUND JNK3
4441, d5larA_, 0.7339, 3.67, 0.209, 350, 254, CRYSTAL STRUCTURE OF P38 ALPHA MAPK14 IN COMPLEX WITH VPC00628
4442, d4usfB1, 0.7339, 3.39, 0.230, 283, 243, HUMAN SLK WITH SB-440719
4443, d4nj3A_, 0.7339, 3.10, 0.258, 277, 240, MODULATING THE INTERACTION BETWEEN CDK2 AND CYCLIN A WITH A QUINOLINE- BASED INHIBITOR
4444, d4c4eA1, 0.7339, 2.99, 0.196, 253, 240, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4445, d3kc3A_, 0.7339, 2.80, 0.229, 288, 236, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4446, d3is5C1, 0.7339, 3.19, 0.231, 254, 242, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4447, d1blxA_, 0.7339, 3.49, 0.262, 305, 248, P19INK4D/CDK6 COMPLEX
4448, p4loqC_, 0.7338, 3.35, 0.211, 337, 247, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
4449, d4fstA_, 0.7337, 3.23, 0.259, 253, 239, CRYSTAL STRUCTURE OF THE CHK1
4450, d4awiA_, 0.7337, 3.07, 0.199, 352, 241, HUMAN JNK1ALPHA KINASE WITH 4-PHENYL-7-AZAINDOLE IKK2 INHIBITOR.
4451, d3pa5A_, 0.7337, 3.33, 0.236, 255, 242, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
4452, d4uynA_, 0.7336, 2.80, 0.207, 249, 237, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
4453, d3op5C_, 0.7336, 3.64, 0.157, 308, 254, HUMAN VACCINIA-RELATED KINASE 1
4454, d3bqrA1, 0.7336, 2.78, 0.238, 273, 235, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH AN IMIDAZO-PYRIDAZINE LIGAND
4455, d2zdtA_, 0.7336, 3.21, 0.201, 342, 244, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
4456, d2vttA_, 0.7336, 2.76, 0.265, 272, 234, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4457, d2b55A_, 0.7336, 3.03, 0.256, 276, 238, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH INDENOPYRAXOLE DIN-101312
4458, d6btwC_, 0.7335, 3.51, 0.154, 315, 253, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4459, p4loqB_, 0.7335, 3.45, 0.206, 351, 248, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
4460, d4aa5A_, 0.7335, 3.23, 0.222, 340, 243, P38ALPHA MAP KINASE BOUND TO CMPD 33
4461, d3nnwA_, 0.7335, 3.38, 0.228, 349, 246, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP802
4462, d2jflA_, 0.7335, 3.05, 0.231, 286, 238, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE ( DIPHOSPHORYLATED FORM) BOUND TO 5- AMINO-3-((4-( AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-12 4-TRIAZOLE-1-CARBOTHIOAMIDE
4463, p4e3cF1, 0.7334, 3.13, 0.246, 290, 244, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4464, d2xezA_, 0.7334, 3.16, 0.243, 249, 239, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4465, d2bhhA_, 0.7334, 2.79, 0.280, 274, 236, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE
4466, d1zz2A_, 0.7334, 3.06, 0.237, 337, 240, TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING A COMMON DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT BINDING MODES
4467, d4w4wA_, 0.7333, 3.29, 0.206, 349, 247, JNK2/3 IN COMPLEX WITH N-(2-METHYLPYRIDIN-4-YL)-3-{4- [(PHENYLCARBAMOYL)AMINO]-1H-PYRAZOL-1-YL}BENZAMIDE
4468, d4fg8A_, 0.7333, 2.57, 0.242, 263, 231, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
4469, d1jnkA_, 0.7333, 3.20, 0.197, 346, 244, THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP
4470, d5b2lA_, 0.7332, 3.13, 0.224, 288, 246, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
4471, d4fsqA_, 0.7332, 3.24, 0.255, 263, 239, CRYSTAL STRUCTURE OF THE CHK1
4472, d3kc3B_, 0.7332, 2.81, 0.220, 290, 236, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4473, d5ihcA_, 0.7330, 2.57, 0.262, 305, 233, MELK IN COMPLEX WITH NVS-MELK12B
4474, d4u3zA_, 0.7330, 3.33, 0.212, 282, 245, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
4475, d4ftkA_, 0.7330, 3.23, 0.251, 263, 239, CRYSTAL STRUCTURE OF THE CHK1
4476, d4cv8A1, 0.7330, 3.05, 0.196, 252, 240, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4477, d5d9hA_, 0.7328, 3.33, 0.230, 290, 243, CRYSTAL STRUCTURE OF SPAK (STK39) DIMER IN THE BASAL ACTIVITY STATE
4478, d3hmoA_, 0.7328, 3.06, 0.195, 257, 241, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH THE INHIBITOR STAUROSPORINE
4479, d1aq1A_, 0.7328, 3.04, 0.272, 277, 239, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE
4480, d4cv9A1, 0.7327, 2.97, 0.197, 250, 239, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4481, d4bi2A1, 0.7327, 2.85, 0.197, 250, 238, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4482, d4bi1A1, 0.7327, 2.81, 0.194, 249, 237, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4483, d2ac3A1, 0.7327, 3.22, 0.223, 275, 242, STRUCTURE OF HUMAN MNK2 KINASE DOMAIN
4484, d1ouyA_, 0.7327, 3.41, 0.231, 350, 247, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROPYRIDO- PYRIMIDINE INHIBITOR
4485, d4b8lA_, 0.7326, 2.78, 0.204, 249, 235, AURORA B KINASE P353G MUTANT
4486, p3vumA_, 0.7326, 2.99, 0.213, 347, 239, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M7 IN MAP KINASE JNK1
4487, d3fv8A_, 0.7325, 2.91, 0.202, 331, 238, JNK3 BOUND TO PIPERAZINE AMIDE INHIBITOR SR2774.
4488, d1v0pA_, 0.7325, 3.29, 0.234, 277, 244, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
4489, d5ehyA1, 0.7324, 2.97, 0.196, 251, 240, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4490, d3dakC_, 0.7324, 3.45, 0.237, 281, 245, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4491, d3dajA_, 0.7324, 2.66, 0.234, 245, 235, CRYSTAL STRUCTURE OF AURORA A COMPLEXED WITH AN INHIBITOR DISCOVERED THROUGH SITE-DIRECTED DYNAMIC TETHERING
4492, d6b16B_, 0.7323, 3.29, 0.215, 281, 247, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
4493, d4zy6B_, 0.7323, 3.30, 0.220, 280, 246, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
4494, d3w1fA_, 0.7323, 3.23, 0.193, 259, 243, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 5-(5- ETHOXY-6-(1-METHYL-1H-PYRAZOL-4-YL)-1H-INDAZOL-3-YL)-2- METHYLBENZENESULFONAMIDE
4495, d3jvsA_, 0.7323, 3.29, 0.253, 256, 241, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
4496, d1vzoA_, 0.7323, 3.41, 0.223, 319, 247, THE STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF MSK1 REVEALS A NOVEL AUTOINHIBITORY CONFORMATION FOR A DUAL KINASE PROTEIN
4497, d1gijA_, 0.7323, 2.81, 0.268, 273, 235, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
4498, d5d9hB_, 0.7322, 3.43, 0.234, 293, 244, CRYSTAL STRUCTURE OF SPAK (STK39) DIMER IN THE BASAL ACTIVITY STATE
4499, d5ehlA1, 0.7321, 3.12, 0.189, 254, 243, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4500, d4d1xA_, 0.7321, 2.91, 0.271, 274, 236, CDK2 IN COMPLEX WITH LUCIFERIN
4501, d6btwD_, 0.7320, 3.65, 0.161, 307, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4502, d3kc3I_, 0.7320, 2.87, 0.224, 295, 237, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4503, d3eljA_, 0.7320, 3.18, 0.189, 347, 243, JNK1 COMPLEXED WITH A BIS-ANILINO-PYRROLOPYRIMIDINE INHIBITOR.
4504, d3cgfA_, 0.7320, 3.21, 0.201, 346, 244, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
4505, d5ap3A1, 0.7319, 2.89, 0.197, 250, 238, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4506, d4ftmA_, 0.7319, 3.26, 0.255, 263, 239, CRYSTAL STRUCTURE OF THE CHK1
4507, d2wmxA_, 0.7319, 3.13, 0.256, 248, 238, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4508, d3o50A_, 0.7318, 2.73, 0.209, 246, 235, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4509, d4usfA1, 0.7317, 3.24, 0.233, 275, 240, HUMAN SLK WITH SB-440719
4510, d3en6A_, 0.7317, 1.90, 0.338, 236, 222, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP102 A MULTITARGETED KINASE INHIBITOR
4511, d4lg4E_, 0.7316, 3.23, 0.218, 275, 243, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4512, d3d7zA_, 0.7316, 3.39, 0.232, 348, 246, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
4513, d2qr8A_, 0.7316, 3.11, 0.245, 298, 241, 2.0A X-RAY STRUCTURE OF C-TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2 (RSK2)
4514, d5uvfC_, 0.7315, 3.64, 0.158, 301, 253, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4515, d4ftnA_, 0.7315, 3.21, 0.256, 253, 238, CRYSTAL STRUCTURE OF THE CHK1
4516, d3wzjA_, 0.7315, 3.15, 0.199, 257, 241, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(6- (CYCLOHEXYLAMINO)-8-(((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)AMINO) IMIDAZO[12-B]PYRIDAZIN-3-YL)-N-CYCLOPROPYLBENZAMIDE
4517, d5awmA_, 0.7313, 3.13, 0.198, 345, 243, THE CRYSTAL STRUCTURE OF JNK FROM DROSOPHILA MELANOGASTER REVEALS AN EVOLUTIONARILY CONSERVED TOPOLOGY WITH THAT OF MAMMALIAN JNK PROTEINS.
4518, d4feqA_, 0.7313, 2.12, 0.360, 224, 222, INHIBITOR BOUND STRUCTURE OF THE KINASE DOMAIN OF THE MURINE RECEPTOR TYROSINE KINASE TYRO3 (SKY)
4519, p4e3cC1, 0.7313, 3.17, 0.245, 290, 245, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4520, d2wtkF1, 0.7313, 2.77, 0.238, 250, 235, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
4521, d2fvdA_, 0.7313, 2.88, 0.268, 284, 235, CYCLIN DEPENDENT KINASE 2 (CDK2) WITH DIAMINOPYRIMIDINE INHIBITOR
4522, d1p2aA_, 0.7313, 2.71, 0.266, 271, 233, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A TRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR
4523, d1m7qA_, 0.7313, 3.47, 0.219, 348, 247, CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
4524, d5kbrA_, 0.7312, 2.65, 0.211, 259, 232, PAK1 IN COMPLEX WITH 7-AZAINDOLE INHIBITOR
4525, d3wzkA_, 0.7312, 3.16, 0.199, 258, 241, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH N- CYCLOPROPYL-4-(8-((THIOPHEN-2-YLMETHYL)AMINO)IMIDAZO[12-A]PYRAZIN-3- YL)BENZAMIDE
4526, d3gc0A_, 0.7312, 3.23, 0.250, 278, 244, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA IN COMPLEX WITH AMP
4527, d2ym4A_, 0.7312, 3.30, 0.258, 251, 240, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4528, p3vulA_, 0.7311, 2.94, 0.210, 344, 238, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
4529, d2wqnA_, 0.7311, 2.93, 0.247, 259, 239, STRUCTURE OF ADP-BOUND HUMAN NEK7
4530, d4lg4F_, 0.7310, 3.24, 0.215, 276, 242, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4531, d4w4yA_, 0.7309, 3.27, 0.199, 350, 246, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-METHYLPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
4532, d4c4jA1, 0.7309, 3.10, 0.200, 258, 240, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4533, d4bbmA1, 0.7308, 3.39, 0.256, 306, 242, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
4534, d2zb0A_, 0.7308, 3.35, 0.220, 349, 246, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
4535, d4cvaA1, 0.7307, 3.11, 0.178, 250, 242, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4536, p3hdmA_, 0.7307, 3.44, 0.220, 285, 245, CRYSTAL STRUCTURE OF SERUM AND GLUCOCORTICOID-REGULATED KINASE 1 IN COMPLEX WITH COMPOUND 1
4537, d2uv2A1, 0.7307, 3.00, 0.229, 286, 236, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 4-(4-( 5-CYCLOPROPYL-1H-PYRAZOL-3-YLAMINO)-QUINAZOLIN-2-YLAMINO)- PHENYL)-ACETONITRILE
4538, d1r78A_, 0.7307, 2.84, 0.264, 273, 235, CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR
4539, d2onlB1, 0.7306, 3.25, 0.223, 339, 242, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
4540, d5n7vA1, 0.7305, 3.05, 0.204, 257, 240, TTK KINASE DOMAIN IN COMPLEX WITH MPI-0479605
4541, d4ithA_, 0.7305, 2.78, 0.251, 247, 231, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
4542, d4ftlA_, 0.7305, 3.27, 0.251, 263, 239, CRYSTAL STRUCTURE OF THE CHK1
4543, d4aaaA1, 0.7305, 3.25, 0.253, 290, 241, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN
4544, d3g51A_, 0.7305, 3.07, 0.279, 280, 240, STRUCTURAL DIVERSITY OF THE ACTIVE CONFORMATION OF THE N- TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2
4545, d3w8qA_, 0.7303, 3.37, 0.230, 318, 243, STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1)
4546, d3kc3H_, 0.7302, 2.82, 0.213, 290, 235, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4547, d3dakB_, 0.7302, 3.63, 0.231, 278, 247, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4548, d4yc6G_, 0.7300, 3.42, 0.252, 285, 246, CDK1/CKS1
4549, d2ja0A_, 0.7300, 3.01, 0.229, 285, 236,  
4550, d1wbsA_, 0.7300, 3.39, 0.229, 351, 245, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
4551, d4w4vA_, 0.7299, 3.20, 0.200, 342, 245, JNK2/3 IN COMPLEX WITH 3-(4-{[(2-CHLOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
4552, d2ym7A_, 0.7299, 3.07, 0.254, 248, 236, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4553, d2okrA_, 0.7299, 3.27, 0.223, 339, 242, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
4554, d3g9nA_, 0.7298, 3.21, 0.202, 346, 243, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-PHENYLINDOLIN-2-ONE
4555, d2zduA_, 0.7298, 3.02, 0.196, 330, 240, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
4556, d2wmuA_, 0.7298, 3.09, 0.246, 246, 236, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4557, d5o23A_, 0.7297, 3.48, 0.263, 269, 247, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
4558, d3v6rB_, 0.7297, 3.13, 0.187, 346, 241, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
4559, d3g90X_, 0.7297, 3.18, 0.202, 345, 242, JNK-3 BOUND TO (Z)-5-FLUORO-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL) METHYL)-3-(HYDROXYIMINO)INDOLIN-2-ONE
4560, d3e92A_, 0.7297, 3.43, 0.203, 348, 246, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
4561, d1oitA_, 0.7297, 2.85, 0.277, 273, 235, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
4562, d1lezA_, 0.7296, 3.33, 0.221, 343, 244, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS ACTIVATOR MKK3B
4563, d5ei2A_, 0.7295, 2.97, 0.205, 256, 239, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4564, d4u42B_, 0.7295, 2.99, 0.216, 265, 236, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
4565, d2vwiD_, 0.7295, 3.39, 0.230, 284, 244, STRUCTURE OF THE OSR1 KINASE A HYPERTENSION DRUG TARGET
4566, d4u40B_, 0.7294, 3.54, 0.204, 299, 250, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
4567, d3cgoA_, 0.7294, 3.25, 0.201, 332, 244, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
4568, d1wbtA_, 0.7294, 3.40, 0.229, 351, 245, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
4569, d1pmvA_, 0.7293, 3.22, 0.201, 347, 244, THE STRUCTURE OF JNK3 IN COMPLEX WITH A DIHYDROANTHRAPYRAZOLE INHIBITOR
4570, d4w4xA_, 0.7292, 3.27, 0.195, 342, 246, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-FLUOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
4571, d4u3yA_, 0.7292, 3.71, 0.195, 295, 251, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
4572, d3gfeA_, 0.7292, 3.52, 0.222, 352, 248, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR
4573, d2wajA_, 0.7292, 3.16, 0.198, 348, 243, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH A 1-ARYL-34- DIHYDROISOQUINOLINE INHIBITOR
4574, d5we8A_, 0.7291, 3.41, 0.244, 270, 242, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH N-{(3R)-1-[(4-CHLOROPHENYL) METHYL]PYRROLIDIN-3-YL}-2-(3-METHOXYPHENYL)-N-METHYLQUINOLINE-4- CARBOXAMIDE (COMPOUND 8)
4575, d1wboA_, 0.7291, 3.44, 0.223, 351, 247, FRAGMENT BASED P38 INHIBITORS
4576, d3gc8A_, 0.7290, 3.31, 0.213, 347, 244, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
4577, d2p33A_, 0.7289, 3.26, 0.205, 332, 244, SYNTHESIS AND SAR OF AMINOPYRIMIDINES AS NOVEL C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
4578, d2oidA_, 0.7289, 2.90, 0.242, 263, 231, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
4579, d5ap6A1, 0.7288, 3.07, 0.203, 259, 241, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4580, d5ankA_, 0.7288, 2.97, 0.262, 273, 237, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 246-TRIOXO-1- PHENYL-HEXAHYDROPYRIMIDINE-5-CARBOXAMIDE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4581, d4c4iA1, 0.7288, 3.00, 0.197, 250, 239, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4582, d3gbzA_, 0.7288, 3.09, 0.249, 274, 241, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA
4583, d6bruB_, 0.7287, 3.64, 0.159, 301, 252, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4584, d3dakA_, 0.7287, 3.58, 0.232, 279, 246, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4585, d3cekA1, 0.7287, 3.05, 0.196, 252, 240, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK)
4586, d4eqmB_, 0.7286, 3.08, 0.224, 269, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4587, d3nnvA_, 0.7286, 3.32, 0.225, 348, 244, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP437
4588, d2wmwA_, 0.7286, 3.14, 0.253, 247, 237, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4589, d2onlA1, 0.7286, 3.22, 0.224, 338, 241, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
4590, d5l2sA_, 0.7285, 2.72, 0.279, 263, 233, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND ABEMACICLIB.
4591, d4cjyD_, 0.7285, 2.97, 0.255, 272, 239,  
4592, d4c4gA1, 0.7285, 2.83, 0.199, 247, 236, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4593, d2zmdA_, 0.7285, 3.26, 0.193, 259, 243, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN T686A MUTANT IN COMPLEX WITH SP600125 INHIBITOR
4594, d5hx6B_, 0.7284, 2.85, 0.266, 264, 233, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
4595, d3mvmA_, 0.7284, 3.32, 0.227, 335, 242, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
4596, d1r3cA_, 0.7284, 3.52, 0.223, 349, 247, THE STRUCTURE OF P38ALPHA C162S MUTANT
4597, d2ym5A_, 0.7283, 3.18, 0.244, 248, 238, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4598, d5eymB_, 0.7282, 3.36, 0.252, 292, 242, MEK1 IN COMPLEX WITH BI 847325
4599, d4kb8A_, 0.7282, 3.18, 0.208, 265, 240, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4600, d4u3yB_, 0.7281, 3.81, 0.202, 300, 253, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
4601, d3ocgA_, 0.7281, 3.28, 0.230, 336, 243, P38 ALPHA KINASE COMPLEXED WITH A 5-AMINO-PYRAZOLE BASED INHIBITOR
4602, d2ym8A_, 0.7281, 3.12, 0.246, 246, 236, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4603, d2w5bA1, 0.7281, 3.24, 0.240, 263, 242, HUMAN NEK2 KINASE ATPGAMMAS-BOUND
4604, d4yomB1, 0.7280, 3.24, 0.235, 320, 243, STRUCTURE OF SAD KINASE
4605, d3mptA_, 0.7280, 3.37, 0.216, 347, 245, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A PYRROLE-2- CARBOXAMIDE INHIBITOR
4606, d5eymA_, 0.7279, 3.35, 0.252, 292, 242, MEK1 IN COMPLEX WITH BI 847325
4607, d5etcA_, 0.7279, 3.53, 0.219, 355, 247, STRUCTURE OF INACTIVE MAPK14 WITH ORDERED ACTIVATION LOOP
4608, d4eqmC_, 0.7279, 3.09, 0.224, 269, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4609, d2wmqA_, 0.7279, 3.10, 0.263, 246, 236, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4610, d1lewA_, 0.7279, 3.33, 0.219, 341, 242, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS NUCLEAR SUBSTRATE MEF2A
4611, d4eqmA_, 0.7278, 3.08, 0.224, 269, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4612, d3nnuA_, 0.7278, 3.36, 0.225, 348, 244, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP1376
4613, d1gzoA_, 0.7278, 2.85, 0.261, 271, 234, STRUCTURE OF PROTEIN KINASE B UNPHOSPHORYLATED
4614, d1bl6A_, 0.7278, 3.49, 0.223, 351, 247, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995
4615, d2ym3A_, 0.7277, 3.15, 0.245, 247, 237, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4616, d2duvA_, 0.7276, 2.83, 0.269, 272, 234, STRUCTURE OF CDK2 WITH A 3-HYDROXYCHROMONES
4617, d6btwB_, 0.7275, 3.56, 0.159, 301, 251, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4618, d4o0rB_, 0.7275, 3.43, 0.224, 282, 246, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
4619, d2weiA1, 0.7275, 3.42, 0.264, 269, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE IN COMPLEX WITH 3- MB-PP1
4620, d2ozaB_, 0.7275, 3.40, 0.196, 340, 245, STRUCTURE OF P38ALPHA COMPLEX
4621, d4jg7A_, 0.7274, 3.20, 0.237, 307, 240, STRUCTURE OF RSK2 CTD BOUND TO 3-(3-(1H-PYRROLO[23-B]PYRIDINE-3- CARBONYL)PHENYL)-2-CYANOACRYLAMIDE
4622, d1w84A_, 0.7274, 3.45, 0.207, 351, 246, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4623, d3ma6B_, 0.7273, 3.43, 0.276, 266, 246, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
4624, d2w5aA1, 0.7273, 3.28, 0.240, 259, 242, HUMAN NEK2 KINASE ADP-BOUND
4625, d2r0iB_, 0.7273, 2.79, 0.247, 300, 235, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
4626, d5dewB_, 0.7271, 3.54, 0.221, 281, 249, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
4627, d3hmnA_, 0.7271, 3.14, 0.195, 255, 241, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH ATP
4628, d2zmcA_, 0.7271, 3.27, 0.198, 260, 243, CRYSTAL STRUCTURE OF HUMAN MITOTIC CHECKPOINT KINASE MPS1 CATALYTIC DOMAIN APO FORM
4629, d1gzkA_, 0.7271, 2.91, 0.252, 271, 234, MOLECULAR MECHANISM FOR THE REGULATION OF PROTEIN KINASE B/ AKT BY HYDROPHOBIC MOTIF PHOSPHORYLATION
4630, d5we8B_, 0.7270, 3.38, 0.253, 272, 241, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH N-{(3R)-1-[(4-CHLOROPHENYL) METHYL]PYRROLIDIN-3-YL}-2-(3-METHOXYPHENYL)-N-METHYLQUINOLINE-4- CARBOXAMIDE (COMPOUND 8)
4631, d4ka3A_, 0.7270, 3.25, 0.224, 340, 241, STRUCTURE OF MAP KINASE IN COMPLEX WITH A DOCKING PEPTIDE
4632, d4fg9A_, 0.7270, 2.77, 0.246, 278, 232, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
4633, d3u8wA_, 0.7270, 3.47, 0.223, 349, 247, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A TRIAZOLOPYRIDAZINONE INHIBITOR
4634, d3kvxA_, 0.7270, 2.98, 0.206, 327, 238, JNK3 BOUND TO AMINOPYRIMIDINE INHIBITOR SR-3562
4635, d2pzyA_, 0.7270, 3.06, 0.224, 291, 237, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
4636, d5di1B_, 0.7269, 3.67, 0.204, 300, 250, MAP4K4 IN COMPLEX WITH AN INHIBITOR
4637, d4zp5B_, 0.7269, 3.68, 0.208, 300, 250, MAP4K4 IN COMPLEX WITH INHIBITOR
4638, d5mz3A_, 0.7268, 3.44, 0.229, 350, 245, P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-METHYL-3-(4455- TETRAMETHYL-132-DIOXABOROLAN-2-YL)PHENYL)-3-(TRIFLUOROMETHYL) BENZAMIDE]
4639, d5l8jA_, 0.7268, 3.15, 0.192, 253, 240, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 S93R
4640, d4c3pA_, 0.7268, 3.26, 0.195, 264, 241, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO TPX2 AND AMPPCP
4641, d4kinB_, 0.7267, 3.46, 0.229, 341, 245, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4642, d3fmhA_, 0.7267, 3.48, 0.224, 347, 245, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((R)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
4643, d3nuxA_, 0.7266, 2.70, 0.280, 261, 232, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
4644, d1pmuA_, 0.7266, 3.38, 0.192, 342, 245, THE CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PHENANTROLINE INHIBITOR
4645, d5w84B_, 0.7264, 2.83, 0.253, 261, 229, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 4)
4646, d4rzvA1, 0.7264, 2.80, 0.279, 245, 233, CRYSTAL STRUCTURE OF THE BRAF (R509H) KINASE DOMAIN MONOMER BOUND TO VEMURAFENIB
4647, d4jt3A_, 0.7262, 3.20, 0.187, 254, 241, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 400740
4648, d4fk3B1, 0.7262, 2.66, 0.267, 241, 232, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
4649, d3ttiA_, 0.7262, 3.28, 0.205, 341, 244, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-930 AN ORALLY ACTIVE ANTI-FIBROTIC JNK INHIBITOR
4650, d2bvaA_, 0.7262, 3.25, 0.203, 272, 241, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
4651, d1gznA_, 0.7262, 2.87, 0.256, 271, 234, STRUCTURE OF PKB KINASE DOMAIN
4652, d6eimB_, 0.7261, 3.46, 0.256, 295, 242, HUMAN STK10 BOUND TO GW683134A
4653, d3s3iA_, 0.7261, 3.54, 0.239, 349, 247, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4654, d2pzyB_, 0.7261, 2.78, 0.232, 283, 233, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
4655, d3ttjA_, 0.7259, 3.27, 0.202, 333, 243, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-359 A JNK INHIBITOR FOR THE PREVENTION OF ISCHEMIA-REPERFUSION INJURY
4656, d3nnxA_, 0.7259, 3.28, 0.235, 336, 238, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38 ALPHA IN COMPLEX WITH DP802
4657, d3iphA_, 0.7259, 3.37, 0.225, 345, 244, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH A BIPHENYLAMIDE INHIBITOR
4658, d3ezrA_, 0.7259, 2.90, 0.264, 273, 235, CDK-2 WITH INDAZOLE INHIBITOR 17 BOUND AT ITS ACTIVE SITE
4659, d2j7tA_, 0.7259, 3.35, 0.267, 285, 240, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO SU11274
4660, d1w83A_, 0.7259, 3.45, 0.229, 351, 245, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4661, d4bhzA1, 0.7258, 2.90, 0.195, 248, 236, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4662, d3kc3J_, 0.7258, 2.77, 0.223, 288, 233, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4663, d3itzA1, 0.7258, 3.62, 0.214, 353, 248, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDAZINE INHIBITOR
4664, d2z7sA_, 0.7258, 2.69, 0.260, 256, 231, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO PURVALNOL A
4665, d2pzyC_, 0.7258, 3.14, 0.213, 307, 239, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
4666, d3mvlA_, 0.7255, 3.37, 0.234, 339, 244, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
4667, d1g3nE_, 0.7255, 3.17, 0.273, 293, 238, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
4668, d4kiqA_, 0.7254, 3.47, 0.233, 338, 245, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
4669, d4bc6A_, 0.7254, 3.45, 0.237, 285, 241, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO NOVEL BOSUTINIB ISOFORM 1 PREVIOUSLY THOUGHT TO BE BOSUTINIB
4670, d2r0iA_, 0.7254, 2.84, 0.247, 300, 235, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
4671, d5tx5B_, 0.7252, 2.86, 0.263, 263, 232, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
4672, d5ci6A_, 0.7252, 2.93, 0.252, 335, 234, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
4673, d3gfwA1, 0.7252, 2.99, 0.206, 249, 238, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYROLO-PYRIDIN LIGAND
4674, d5etiA1, 0.7251, 3.55, 0.215, 352, 246, STRUCTURE OF DEAD KINASE MAPK14
4675, d4o0tB_, 0.7251, 3.38, 0.215, 280, 246, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
4676, d4n4sB_, 0.7251, 3.39, 0.212, 337, 245, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
4677, d3ds6D_, 0.7251, 3.50, 0.202, 349, 247, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
4678, d2hw7A1, 0.7251, 3.29, 0.195, 269, 241, CRYSTAL STRUCTURE OF MNK2-D228G IN COMPLEX WITH STAUROSPORINE
4679, d2balA_, 0.7251, 3.18, 0.230, 337, 239, P38ALPHA MAP KINASE BOUND TO PYRAZOLOAMINE
4680, d5l2tA_, 0.7250, 2.64, 0.281, 261, 231, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND RIBOCICLIB.
4681, d3uytD_, 0.7250, 3.38, 0.217, 268, 244, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
4682, d2pzyD_, 0.7250, 2.97, 0.226, 288, 235, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
4683, d5l2iA_, 0.7249, 2.78, 0.280, 260, 232, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND PALBOCICLIB.
4684, d5horA_, 0.7249, 2.57, 0.341, 247, 226, CRYSTAL STRUCTURE OF C-MET-M1250T IN COMPLEX WITH SAR125844.
4685, d3flyA_, 0.7249, 3.51, 0.224, 347, 245, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-ISOPROPYLAMINO-8-METHYL-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
4686, d2z7qA_, 0.7249, 2.66, 0.265, 255, 230, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK-1 BOUND TO AMP-PCP
4687, d2x81A_, 0.7248, 2.71, 0.216, 242, 232, STRUCTURE OF AURORA A IN COMPLEX WITH MLN8054
4688, d1wbvA_, 0.7248, 3.44, 0.229, 351, 245, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
4689, d2zb1A_, 0.7247, 3.37, 0.221, 345, 244, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
4690, d3mvlB_, 0.7246, 3.17, 0.229, 339, 240, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
4691, d2wqmA_, 0.7246, 2.94, 0.245, 258, 237, STRUCTURE OF APO HUMAN NEK7
4692, d2pmiA_, 0.7246, 3.22, 0.238, 284, 239, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
4693, d1g3nA_, 0.7246, 3.19, 0.273, 293, 238, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
4694, d1pmnA_, 0.7245, 3.30, 0.205, 344, 244, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE- PYRIMIDINE INHIBITOR
4695, d4u43B_, 0.7244, 3.75, 0.212, 302, 250, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
4696, d3dxnA_, 0.7244, 3.31, 0.285, 258, 242, CRYSTAL STRUCTURE OF THE CALCIUM-DEPENDENT KINASE FROM TOXOPLASMA GONDII 541.M00134 KINASE DOMAIN.
4697, d3txoA_, 0.7243, 2.89, 0.259, 317, 232, PKC ETA KINASE IN COMPLEX WITH A NAPHTHYRIDINE
4698, d3fpqA_, 0.7242, 3.14, 0.273, 262, 238, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF WNK1
4699, d2xrwA1, 0.7242, 2.98, 0.203, 346, 237, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
4700, d2oidC_, 0.7242, 2.64, 0.243, 256, 226, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
4701, d5j95B_, 0.7241, 3.66, 0.205, 300, 249, MAP4K4 IN COMPLEX WITH INHIBITOR
4702, d5uisD_, 0.7240, 2.72, 0.256, 250, 227, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
4703, d2pk9C_, 0.7240, 2.89, 0.239, 266, 234, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
4704, d2o0uA_, 0.7240, 3.30, 0.201, 331, 244, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-{3-CYANO-6-[3-(1- PIPERIDINYL)PROPANOYL]-4567-TETRAHYDROTHIENO[23-C]PYRIDIN-2-YL}- 1-NAPHTHALENECARBOXAMIDE
4705, d1zy5A1, 0.7240, 3.30, 0.206, 269, 243, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT COMPLEXED WITH AMPPNP.
4706, d3op5D_, 0.7239, 3.62, 0.159, 302, 251, HUMAN VACCINIA-RELATED KINASE 1
4707, d3nwwA_, 0.7239, 3.27, 0.228, 339, 241, P38 ALPHA KINASE COMPLEXED WITH A 2-AMINOTHIAZOL-5-YL-PYRIMIDINE BASED INHIBITOR
4708, d5uvfD_, 0.7238, 3.67, 0.159, 296, 251, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4709, d3wi6F_, 0.7238, 2.82, 0.219, 283, 233, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4710, d3wi6C_, 0.7238, 2.81, 0.219, 283, 233, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4711, d2vwiC_, 0.7238, 3.31, 0.222, 270, 239, STRUCTURE OF THE OSR1 KINASE A HYPERTENSION DRUG TARGET
4712, p5etaB_, 0.7237, 3.28, 0.232, 335, 241, STRUCTURE OF MAPK14 WITH BOUND THE KIM DOMAIN OF THE TOXOPLASMA PROTEIN GRA24
4713, d3wi6B_, 0.7237, 2.81, 0.219, 283, 233, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4714, d3kc3K_, 0.7237, 2.80, 0.223, 280, 233, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4715, d3gc9A_, 0.7237, 3.13, 0.208, 335, 240, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
4716, d3bv3A_, 0.7236, 3.25, 0.226, 338, 239, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 2
4717, d1r39A_, 0.7236, 3.36, 0.210, 345, 243, THE STRUCTURE OF P38ALPHA
4718, d4rvtB_, 0.7235, 3.77, 0.207, 297, 251, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
4719, d2r9sA_, 0.7235, 2.91, 0.209, 325, 235, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
4720, d2hakF_, 0.7235, 3.21, 0.277, 318, 242, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4721, d6b4wA_, 0.7234, 3.04, 0.205, 259, 239, TTK IN COMPLEX WITH INHIBITOR
4722, d5ap5A1, 0.7234, 2.92, 0.198, 248, 237, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4723, d4kipB_, 0.7234, 3.45, 0.230, 338, 244, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
4724, d4kbaA_, 0.7234, 3.17, 0.210, 263, 238, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4725, d4m69B_, 0.7233, 3.29, 0.209, 264, 244, CRYSTAL STRUCTURE OF THE MOUSE RIP3-MLKL COMPLEX
4726, d3ds6A_, 0.7233, 3.47, 0.203, 343, 246, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
4727, d3wi6E_, 0.7232, 2.82, 0.219, 283, 233, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4728, d3flzA_, 0.7232, 3.53, 0.224, 347, 245, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 8-METHYL-6-PHENOXY-2- (TETRAHYDRO-PYRAN-4-YLAMINO)-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
4729, d2cn5A1, 0.7232, 2.89, 0.251, 281, 231, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH ADP
4730, d4useA_, 0.7231, 3.42, 0.237, 286, 240, HUMAN STK10 (LOK) WITH SB-633825
4731, d4u44B_, 0.7231, 3.59, 0.206, 296, 247, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
4732, d2okrD_, 0.7231, 3.24, 0.230, 339, 239, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
4733, d3g33C_, 0.7230, 3.32, 0.266, 291, 241, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
4734, d3e93A_, 0.7230, 3.35, 0.235, 346, 243, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
4735, d1bl7A_, 0.7230, 3.61, 0.215, 351, 247, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025
4736, d3orpA_, 0.7229, 2.87, 0.183, 274, 235, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 5)
4737, d1yqjA2, 0.7228, 3.54, 0.211, 351, 246, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH A SELECTIVE PYRIDAZINE INHIBITOR
4738, d4x21A_, 0.7227, 2.90, 0.204, 336, 235, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
4739, d4zloB_, 0.7226, 2.97, 0.226, 263, 235, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
4740, d4pwnA_, 0.7226, 2.86, 0.276, 245, 232, CRYSTAL STRUCTURE OF ACTIVE WNK1 KINASE
4741, d5fp5A_, 0.7225, 2.73, 0.264, 264, 231, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 4-FLUOROBENZOIC ACID (AT222) IN AN ALTERNATE BINDING SITE.
4742, d3ctqA_, 0.7225, 3.10, 0.224, 336, 237, STRUCTURE OF MAP KINASE P38 IN COMPLEX WITH A 1-O-TOLYL-12 3-TRIAZOLE-4-CARBOXAMIDE
4743, d3kq7A_, 0.7224, 3.30, 0.223, 348, 242, STRUCTURE OF HUMAN P38ALPHA WITH N-[4-METHYL-3-(6-{[2-(1- METHYLPYRROLIDIN-2-YL)ETHYL]AMINO}PYRIDINE-3-AMIDO)PHENYL]- 2-(MORPHOLIN-4-YL)PYRIDINE-4-CARBOXAMIDE
4744, d3gc9B_, 0.7224, 3.29, 0.202, 339, 242, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
4745, d2zazA_, 0.7223, 3.39, 0.230, 345, 243, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH 4-ANILINO QUINOLINE INHIBITOR
4746, d3bv2A_, 0.7222, 3.16, 0.227, 337, 238, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 30
4747, d3wi6D_, 0.7221, 2.79, 0.220, 282, 232, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4748, p5w5qB_, 0.7220, 3.65, 0.205, 297, 249, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
4749, p5o90A_, 0.7220, 3.32, 0.227, 330, 242, CRYSTAL STRUCTURE OF A P38ALPHA T185G MUTANT IN COMPLEX WITH TAB1 PEPTIDE.
4750, d3orkA1, 0.7220, 2.92, 0.196, 272, 235, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 2)
4751, d3a2cF_, 0.7220, 3.28, 0.213, 287, 239, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
4752, d3kc3G_, 0.7219, 2.80, 0.228, 276, 232, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4753, d2oo8X_, 0.7219, 2.45, 0.392, 259, 222, SYNTHESIS STRUCTURAL ANALYSIS AND SAR STUDIES OF TRIAZINE DERIVATIVES AS POTENT SELECTIVE TIE-2 INHIBITORS
4754, d2lgcA1, 0.7219, 3.63, 0.215, 353, 246, JOINT NMR AND X-RAY REFINEMENT REVEALS THE STRUCTURE OF A NOVEL DIBENZO[AD]CYCLOHEPTENONE INHIBITOR/P38 MAP KINASE COMPLEX IN SOLUTION
4755, d5knjB_, 0.7218, 2.78, 0.225, 259, 236, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 1.
4756, d4kinC_, 0.7218, 3.41, 0.223, 338, 242, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4757, d3fklA_, 0.7217, 3.67, 0.220, 344, 246, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO9552
4758, d2w96B_, 0.7217, 3.05, 0.267, 267, 236, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4759, d4zjiD_, 0.7216, 3.67, 0.229, 280, 249, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4760, d3wi6A_, 0.7216, 2.80, 0.220, 282, 232, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4761, d3flwA_, 0.7216, 3.50, 0.217, 345, 244, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH PAMAPIMOD
4762, d3g33A_, 0.7215, 3.29, 0.267, 291, 240, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
4763, d3ptgA_, 0.7214, 3.24, 0.220, 340, 241, DESIGN AND SYNTHESIS OF A NOVEL ORALLY EFFICACIOUS TRI-SUBSTITUTED THIOPHENE BASED JNK INHIBITOR
4764, d3ds6B_, 0.7213, 3.49, 0.203, 343, 246, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
4765, d2r9sB_, 0.7213, 2.93, 0.204, 325, 235, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
4766, d1bmkA_, 0.7213, 3.61, 0.206, 351, 247, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655
4767, d5tf9A_, 0.7212, 3.12, 0.251, 262, 235, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH MN2+AMPPNP AND WNK476
4768, d4a9tA1, 0.7212, 2.88, 0.248, 288, 230, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4769, d2xm9A_, 0.7212, 2.87, 0.248, 287, 230, STRUCTURE OF A SMALL MOLECULE INHIBITOR WITH THE KINASE DOMAIN OF CHK2
4770, d1a9uA_, 0.7212, 3.61, 0.206, 351, 247, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580
4771, d3h9fA1, 0.7210, 3.04, 0.206, 256, 238, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYRIMIDO-DIAZEPIN LIGAND
4772, d1wbnA_, 0.7210, 3.51, 0.229, 351, 245, FRAGMENT BASED P38 INHIBITORS
4773, d4kiqC_, 0.7209, 3.50, 0.237, 338, 245, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
4774, d4jg6A_, 0.7209, 3.25, 0.235, 302, 238, RSK2 CTD BOUND TO 2-CYANO-3-(1H-INDAZOL-5-YL)ACRYLAMIDE
4775, d5wdyA_, 0.7208, 3.14, 0.254, 260, 236, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH 1-CYCLOHEXYL-N-({6-FLUORO-1- [2-(3-METHOXYPHENYL)PYRIDIN-4-YL]-1H-INDOL-3-YL}METHYL)METHANAMINE (COMPOUND 6)
4776, d4zk5B_, 0.7208, 3.55, 0.207, 294, 246, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
4777, d4z9lA_, 0.7208, 3.29, 0.198, 333, 242, THE STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE-PYRIMIDINE INHIBITOR
4778, d3efwB_, 0.7208, 2.69, 0.213, 242, 230, STRUCTURE OF AURORAA WITH PYRIDYL-PYRIMIDINE UREA INHIBITOR
4779, d5hnvA1, 0.7207, 2.74, 0.177, 278, 231, CRYSTAL STRUCTURE OF PPKA
4780, d3zz2A_, 0.7207, 3.39, 0.258, 281, 240,  
4781, d3hllA_, 0.7207, 3.28, 0.221, 337, 240, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH PH-797804
4782, d2gtnA_, 0.7207, 3.28, 0.213, 337, 239, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-951717
4783, d1yojA_, 0.7207, 1.92, 0.338, 233, 219, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN
4784, d3zxtA_, 0.7206, 2.81, 0.251, 249, 231, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN IN COMPLEX WITH AMPPCP-MG
4785, d3q4zB_, 0.7206, 3.40, 0.216, 279, 245, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
4786, d4kiqD_, 0.7205, 3.52, 0.237, 338, 245, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
4787, d4kiqB_, 0.7205, 3.52, 0.237, 338, 245, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
4788, d1ywrA_, 0.7205, 3.29, 0.229, 338, 240, CRYSTAL STRUCTURE ANALYSIS OF INACTIVE P38 KINASE DOMAIN IN COMPLEX WITH A MONOCYCLIC PYRAZOLONE INHIBITOR
4789, d5ap2A1, 0.7204, 3.04, 0.203, 253, 237, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4790, d2rg6A_, 0.7204, 3.39, 0.236, 335, 242, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11J
4791, d2qr7A_, 0.7204, 3.15, 0.245, 292, 237, 2.0A X-RAY STRUCTURE OF C-TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2: SE-MET DERIVATIVE
4792, d4kinD_, 0.7203, 3.49, 0.225, 339, 244, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4793, d4zthA_, 0.7202, 3.37, 0.216, 339, 241, STRUCTURE OF HUMAN P38AMAPK-ARYLPYRIDAZINYLPYRIDINE FRAGMENT COMPLEX USED IN INHIBITOR DISCOVERY
4794, d1zzlA_, 0.7202, 3.65, 0.215, 351, 247, CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE
4795, d3rinA_, 0.7201, 3.64, 0.223, 349, 247, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4796, d3flnC_, 0.7201, 3.36, 0.223, 343, 242, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH R1487
4797, d1zmwA_, 0.7201, 2.99, 0.254, 302, 236, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
4798, d1zmwB_, 0.7200, 3.01, 0.254, 302, 236, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
4799, d4zjiC_, 0.7199, 3.52, 0.224, 281, 246, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4800, d4ez5A_, 0.7199, 2.73, 0.283, 258, 230, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
4801, p4whzA_, 0.7198, 3.31, 0.198, 342, 243, DESIGN AND SYNTHESIS OF HIGHLY POTENT AND ISOFORM SELECTIVE JNK3 INHIBITORS: SAR STUDIES ON AMINOPYRAZOLE DERIVATIVES
4802, d3flsA_, 0.7198, 3.44, 0.219, 343, 242, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((R)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
4803, d4u41B_, 0.7197, 3.73, 0.213, 297, 249, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
4804, d5angA_, 0.7196, 2.89, 0.259, 268, 232, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 7-HYDROXY-4-( MORPHOLINOMETHYL)CHROMEN-2-ONE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4805, d2yixA_, 0.7196, 3.68, 0.206, 351, 247, TRIAZOLOPYRIDINE INHIBITORS OF P38
4806, d2ycfA_, 0.7196, 2.88, 0.252, 286, 230, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV1531
4807, d2w9fB_, 0.7195, 3.08, 0.264, 261, 235, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4808, d1zy4A1, 0.7195, 3.35, 0.202, 269, 243, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT IN APO FORM.
4809, p5yj9D_, 0.7194, 2.87, 0.209, 333, 234, CRYSTAL STRUCTURE OF TRIBOLIUM CASTANEUM PINK1 KINASE DOMAIN IN COMPLEX WITH AMP-PNP 
4810, d4c4hA1, 0.7194, 2.85, 0.197, 245, 234, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4811, d4oboB_, 0.7193, 3.68, 0.210, 297, 248, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
4812, d2xbjA_, 0.7193, 2.90, 0.252, 286, 230, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4813, d2ghmA_, 0.7193, 3.19, 0.235, 336, 238, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-895449
4814, d1p38A_, 0.7193, 3.56, 0.204, 351, 245, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTOMS RESOLUTION
4815, d5m53A1, 0.7192, 2.87, 0.260, 248, 231, NEK2 BOUND TO ARYLAMINOPURINE INHIBITOR 11
4816, d3hv4A_, 0.7191, 3.52, 0.230, 339, 243, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
4817, p2xs0A_, 0.7190, 3.31, 0.204, 346, 240, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
4818, d5tbeA_, 0.7189, 3.14, 0.203, 332, 236, HUMAN P38ALPHA MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 2
4819, d3e7oB_, 0.7189, 2.93, 0.226, 326, 234, CRYSTAL STRUCTURE OF JNK2
4820, d3kc3C_, 0.7188, 2.80, 0.239, 281, 230, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4821, d1yw2A_, 0.7188, 3.44, 0.216, 341, 241, MUTATED MUS MUSCULUS P38 KINASE (MP38)
4822, d3fknA_, 0.7187, 3.54, 0.217, 346, 244, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO7125
4823, d3da6A_, 0.7187, 3.11, 0.197, 328, 239, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-METHYL- 4-(3-(2-(METHYLAMINO)PYRIMIDIN-4-YL)PYRIDIN-2-YLOXY) NAPHTHALEN-1-YL)-1H-BENZO[D]IMIDAZOL-2-AMINE
4824, d3gc8B_, 0.7186, 3.40, 0.202, 346, 242, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
4825, d5a14A_, 0.7185, 3.25, 0.265, 284, 238, HUMAN CDK2 WITH TYPE II INHIBITOR
4826, d3p4kA_, 0.7185, 3.28, 0.233, 338, 240, THE THIRD CONFORMATION OF P38A MAP KINASE OBSERVED IN PHOSPHORYLATED P38A AND IN SOLUTION
4827, d2wmsA_, 0.7185, 3.07, 0.259, 243, 232, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4828, d2qnjB1, 0.7184, 3.21, 0.264, 321, 242, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
4829, d4wo5B1, 0.7183, 2.64, 0.281, 241, 228, CRYSTAL STRUCTURE OF A BRAF KINASE DOMAIN MONOMER
4830, d4kipA_, 0.7181, 3.45, 0.230, 337, 243, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
4831, d3w18A_, 0.7181, 2.75, 0.223, 234, 229, STRUCTURE OF AURORA KINASE A COMPLEXED TO BENZOIMIDAZOLE-INDAZOLE INHIBITOR XIII
4832, d3ds6C_, 0.7180, 3.66, 0.178, 349, 247, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
4833, d4a9uA1, 0.7179, 2.88, 0.245, 286, 229, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4834, d2yitA_, 0.7179, 2.96, 0.251, 286, 231, STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 IN COMPLEX WITH PV1162 A NOVEL INHIBITOR
4835, p4d28C_, 0.7178, 3.45, 0.255, 279, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
4836, d3fe3B_, 0.7178, 3.27, 0.248, 317, 242, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
4837, d2wzjB_, 0.7178, 2.98, 0.267, 310, 236, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4838, d1wfcA_, 0.7178, 3.44, 0.211, 340, 242, STRUCTURE OF APO UNPHOSPHORYLATED P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN
4839, d1mryA_, 0.7178, 3.04, 0.258, 270, 233, CRYSTAL STRUCTURE OF AN INACTIVE AKT2 KINASE DOMAIN
4840, d3rocA_, 0.7177, 3.35, 0.221, 337, 240, CRYSTAL STRUCTURE OF HUMAN P38 ALPHA COMPLEXED WITH A PYRIMIDINONE COMPOUND
4841, d2qnjA1, 0.7177, 3.28, 0.264, 317, 242, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
4842, d2jc6A_, 0.7177, 2.92, 0.244, 278, 234, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4843, d2oscA_, 0.7175, 2.34, 0.386, 255, 220, SYNTHESIS STRUCTURAL ANALYSIS AND SAR STUDIES OF TRIAZINE DERIVATIVES AS POTENT SELECTIVE TIE-2 INHIBITORS
4844, d1jsuA_, 0.7175, 3.34, 0.231, 285, 238, P27(KIP1)/CYCLIN A/CDK2 COMPLEX
4845, d4equB_, 0.7174, 3.15, 0.251, 282, 235, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
4846, d3ckwA_, 0.7174, 2.90, 0.276, 255, 232, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24)
4847, d5a6nA1, 0.7172, 2.99, 0.230, 270, 235, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH COMPOUND 2
4848, d3o8uA_, 0.7172, 3.19, 0.227, 332, 238, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
4849, d3mvmB_, 0.7172, 3.24, 0.218, 332, 239, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
4850, d3v6sB_, 0.7171, 3.14, 0.197, 340, 238, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
4851, d3fmkA_, 0.7171, 3.53, 0.217, 346, 244, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((S)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
4852, d3uvqA_, 0.7170, 3.08, 0.221, 333, 235, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOSUBERONE DERIVATIVE
4853, d3kf7A_, 0.7170, 3.35, 0.212, 337, 240, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A TRIAZOLOPYRIMIDINE COMPOUND
4854, d2w5hA1, 0.7170, 3.22, 0.248, 257, 238, HUMAN NEK2 KINASE APO
4855, d5w5jA_, 0.7169, 2.35, 0.260, 251, 223, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
4856, d4m68A_, 0.7169, 3.48, 0.214, 268, 243, CRYSTAL STRUCTURE OF THE MOUSE MLKL KINASE-LIKE DOMAIN
4857, d4eh7A_, 0.7169, 3.39, 0.222, 337, 239, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F6 AND RL87
4858, d4d2sA_, 0.7169, 2.79, 0.203, 249, 232, HUMAN TTK IN COMPLEX WITH A DYRK1B INHIBITOR
4859, d3p7aA_, 0.7169, 3.03, 0.231, 332, 234, P38 INHIBITOR-BOUND
4860, d3bx5A_, 0.7169, 3.41, 0.222, 338, 243, P38 ALPHA MAP KINASE COMPLEXED WITH BMS-640994
4861, d2y4pC_, 0.7169, 2.89, 0.250, 264, 232, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN
4862, d2wzjF_, 0.7169, 2.99, 0.267, 310, 236, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4863, d1pyeA_, 0.7169, 2.78, 0.261, 266, 230, CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR
4864, d4eh2A_, 0.7168, 3.30, 0.218, 337, 238, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F1 AND RL87
4865, d3hp2A_, 0.7168, 3.49, 0.216, 341, 241, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIDINONE COMPOUND
4866, d3f61A_, 0.7168, 2.96, 0.201, 271, 234, CRYSTAL STRUCTURE OF M. TUBERCULOSIS PKNB LEU33ASP/VAL222ASP DOUBLE MUTANT IN COMPLEX WITH ADP
4867, d2wtjA1, 0.7167, 2.92, 0.253, 286, 229, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4868, d1w7hA_, 0.7167, 3.71, 0.206, 351, 247, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4869, d5tf9B_, 0.7166, 3.41, 0.253, 266, 237, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH MN2+AMPPNP AND WNK476
4870, d3d83A_, 0.7166, 3.50, 0.230, 347, 243, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
4871, d2wqeA_, 0.7166, 2.78, 0.204, 241, 230, STRUCTURE OF S155R AURORA-A SOMATIC MUTANT
4872, d2rg5A_, 0.7166, 3.38, 0.232, 333, 241, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11B
4873, d2yirA_, 0.7165, 3.04, 0.225, 286, 231, STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV1352
4874, d2wzjC_, 0.7164, 2.97, 0.260, 310, 235, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4875, d2o2uA_, 0.7164, 2.94, 0.214, 319, 234, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-CYANO-4567- TETRAHYDRO-1-BENZOTHIEN-2-YL)-2-FLUOROBENZAMIDE
4876, d4x21B_, 0.7163, 3.16, 0.205, 336, 239, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
4877, d3h0zB_, 0.7163, 2.76, 0.217, 240, 230, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4878, d4u45B_, 0.7162, 3.70, 0.211, 295, 247, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
4879, d3ma6A_, 0.7162, 3.56, 0.251, 267, 247, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
4880, d3hl7A_, 0.7162, 3.28, 0.230, 336, 239, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH SD-0006
4881, d3zyaA1, 0.7161, 3.46, 0.199, 341, 241, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO- DIBENZOSUBERONE
4882, d3w18B_, 0.7161, 2.89, 0.241, 236, 232, STRUCTURE OF AURORA KINASE A COMPLEXED TO BENZOIMIDAZOLE-INDAZOLE INHIBITOR XIII
4883, d3hv5A_, 0.7161, 3.44, 0.232, 339, 241, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
4884, d3flqA_, 0.7161, 3.57, 0.226, 345, 243, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((S)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN
4885, d1ua2A_, 0.7161, 3.39, 0.231, 286, 238, CRYSTAL STRUCTURE OF HUMAN CDK7
4886, d4yr8E_, 0.7160, 3.24, 0.202, 317, 238, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
4887, d2excX_, 0.7160, 3.05, 0.195, 335, 236, INHIBITOR COMPLEX OF JNK3
4888, d2dylA_, 0.7160, 2.93, 0.226, 272, 235, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 7 ACTIVATED MUTANT (S287D T291D)
4889, d5hidB1, 0.7159, 3.00, 0.282, 252, 234, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH AZ628
4890, d4zloA_, 0.7159, 3.36, 0.223, 277, 242, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
4891, d3gcuA_, 0.7159, 3.45, 0.232, 339, 241, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
4892, d3fmeA1, 0.7159, 3.16, 0.265, 267, 234, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (MEK6) ACTIVATED MUTANT (S207D T211D)
4893, d2bmcB_, 0.7158, 3.02, 0.196, 258, 235, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4894, d1zmuB_, 0.7158, 2.78, 0.255, 296, 231, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
4895, d4fa2A_, 0.7157, 3.57, 0.205, 339, 244, HUMAN P38 ALPHA MITOGEN-ACTIVATED KINASE IN COMPLEX WITH SB239063
4896, d4bdiA1, 0.7157, 2.98, 0.249, 289, 229, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4897, p3lhjA_, 0.7157, 3.39, 0.203, 341, 241, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR.
4898, d4ehvA_, 0.7156, 3.43, 0.220, 337, 241, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F10 AND RL87
4899, d4auaA_, 0.7156, 2.75, 0.279, 256, 229, LIGANDED X-RAY CRYSTAL STRUCTURE OF CYCLIN DEPENDENT KINASE 6 (CDK6)
4900, d2wtiA_, 0.7156, 2.93, 0.253, 286, 229, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4901, d1oz1A_, 0.7156, 3.46, 0.227, 344, 242, P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR
4902, d4f9yA_, 0.7155, 3.40, 0.221, 339, 240, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
4903, d2ok1A_, 0.7154, 3.07, 0.208, 333, 236, CRYSTAL STRUCTURE OF JNK3 BOUND TO N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
4904, d1oveA_, 0.7154, 3.74, 0.223, 349, 247, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROQUINOLINONE
4905, d5knjA_, 0.7153, 2.82, 0.226, 252, 235, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 1.
4906, d3fmmA_, 0.7153, 3.56, 0.217, 346, 244, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6226
4907, d4c3pD_, 0.7152, 3.42, 0.196, 260, 240, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO TPX2 AND AMPPCP
4908, d3fmjA_, 0.7152, 3.49, 0.223, 344, 242, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 4-(5-METHYL-3-PHENYL- ISOXAZOL-4-YL)-PYRIMIDIN-2-YLAMINE
4909, d2wtcA_, 0.7152, 2.88, 0.246, 284, 228, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4910, d2jc6C_, 0.7152, 2.92, 0.249, 277, 233, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4911, d3hv5B_, 0.7151, 3.49, 0.227, 339, 242, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
4912, d4obqB_, 0.7150, 3.51, 0.209, 293, 244, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
4913, d4f9wA_, 0.7149, 3.22, 0.227, 336, 238, HUMAN P38ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
4914, d3qudA_, 0.7149, 3.45, 0.217, 345, 240, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO-BENZOPHENONE
4915, d2wzjD_, 0.7149, 3.06, 0.267, 313, 236, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4916, d2ghlA_, 0.7149, 3.21, 0.224, 334, 237, MUTANT MUS MUSCULUS P38 KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-874743
4917, d1ukiA_, 0.7149, 3.16, 0.224, 328, 237, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
4918, d2bmcD_, 0.7148, 2.96, 0.197, 256, 233, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4919, d4kinA_, 0.7147, 3.52, 0.234, 338, 244, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4920, d2bmcE_, 0.7147, 2.96, 0.197, 256, 233, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4921, d2p4iB_, 0.7146, 2.42, 0.389, 258, 221, EVOLUTION OF A HIGHLY SELECTIVE AND POTENT 2-(PYRIDIN-2-YL)- 135-TRIAZINE TIE-2 KINASE INHIBITOR
4922, d2j90A1, 0.7146, 2.67, 0.249, 259, 229, CRYSTAL STRUCTURE OF HUMAN ZIP KINASE IN COMPLEX WITH A TETRACYCLIC PYRIDONE INHIBITOR (PYRIDONE 6)
4923, d4yr8A_, 0.7145, 3.21, 0.207, 320, 237, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
4924, d4u79A_, 0.7144, 3.33, 0.220, 337, 241, CRYSTAL STRUCTURE OF HUMAN JNK3 IN COMPLEX WITH A BENZENESULFONAMIDE INHIBITOR.
4925, d3hv4B_, 0.7144, 3.39, 0.225, 338, 240, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
4926, d1zycC1, 0.7143, 3.57, 0.200, 269, 245, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
4927, d3queA_, 0.7141, 3.42, 0.213, 343, 239, HUMAN P38 MAP KINASE IN COMPLEX WITH SKEPINONE-L
4928, d5lohA_, 0.7139, 2.77, 0.237, 248, 228, KINASE DOMAIN OF HUMAN GREATWALL
4929, d3kmuA_, 0.7139, 3.15, 0.262, 253, 237, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (APO)
4930, d3lffA_, 0.7138, 3.40, 0.232, 335, 241, HUMAN P38 MAP KINASE IN COMPLEX WITH RL166
4931, d4fk3A1, 0.7137, 2.75, 0.266, 238, 229, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
4932, d3uvrA_, 0.7137, 3.56, 0.230, 331, 243, HUMAN P38 MAP KINASE IN COMPLEX WITH KM064
4933, d4l8mA_, 0.7136, 3.29, 0.224, 339, 237, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOXEPINONE
4934, d4eh8A_, 0.7136, 3.31, 0.215, 336, 237, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F7 AND RL87
4935, d4a9rA_, 0.7136, 2.86, 0.242, 285, 227, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4936, d3zxtC_, 0.7136, 2.91, 0.251, 259, 231, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN IN COMPLEX WITH AMPPCP-MG
4937, d2wtdA_, 0.7136, 2.89, 0.246, 285, 228, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4938, d4tyhB_, 0.7135, 3.43, 0.199, 335, 241, TERNARY COMPLEX OF P38 AND MK2 WITH A P38 INHIBITOR
4939, d3fkoA_, 0.7135, 3.52, 0.215, 343, 242, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3668
4940, d2ycqA_, 0.7135, 2.97, 0.252, 285, 230, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV1115
4941, d3zxtB_, 0.7134, 2.71, 0.256, 253, 227, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN IN COMPLEX WITH AMPPCP-MG
4942, d5lohB_, 0.7133, 2.85, 0.235, 250, 230, KINASE DOMAIN OF HUMAN GREATWALL
4943, d3oxiA_, 0.7132, 3.24, 0.210, 322, 238, DESIGN AND SYNTHESIS OF DISUBSTITUTED THIOPHENE AND THIAZOLE BASED INHIBITORS OF JNK FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
4944, d2bmcA_, 0.7132, 2.97, 0.197, 256, 233, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4945, d5d1jA_, 0.7131, 2.71, 0.269, 265, 227, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(11-DIMETHYLETHYL)-2-OXAZOLYL] METHYL]THIO]-2-THIAZOLYL]- 4-PIPERIDINECARBOXAMIDE (BMS-387032)
4946, d5jt2D1, 0.7130, 2.68, 0.307, 232, 225, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
4947, d3ortA_, 0.7130, 2.95, 0.185, 271, 233, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 6)
4948, d3dfaA1, 0.7130, 3.47, 0.260, 262, 242, CRYSTAL STRUCTURE OF KINASE DOMAIN OF CALCIUM-DEPENDENT PROTEIN KINASE CGD3_920 FROM CRYPTOSPORIDIUM PARVUM
4949, d1zyjA_, 0.7130, 3.18, 0.228, 331, 237, HUMAN P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1A
4950, d5dbxB_, 0.7129, 3.39, 0.250, 282, 240, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
4951, d2gtmA_, 0.7129, 3.23, 0.216, 341, 236, MUTATED MOUSE P38 MAP KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-892579
4952, d3r2bB_, 0.7128, 2.88, 0.223, 272, 229, MK2 KINASE BOUND TO COMPOUND 5B
4953, d2y4pA_, 0.7128, 2.91, 0.261, 251, 230, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN
4954, d3is5E1, 0.7127, 2.96, 0.242, 243, 231, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4955, d2wzjE_, 0.7127, 2.97, 0.268, 310, 235, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4956, d1zycB1, 0.7127, 3.45, 0.207, 252, 242, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
4957, d1ua2D_, 0.7127, 3.06, 0.227, 286, 233, CRYSTAL STRUCTURE OF HUMAN CDK7
4958, d4yr8C_, 0.7126, 2.98, 0.198, 318, 232, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
4959, d3p7cA_, 0.7126, 3.23, 0.231, 332, 238, P38 INHIBITOR-BOUND
4960, d3g9lX_, 0.7126, 3.27, 0.189, 336, 238, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-STYRYLINDOLIN-2-ONE
4961, d2wzjA_, 0.7126, 2.99, 0.268, 310, 235, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4962, d2vwiB_, 0.7126, 3.40, 0.228, 264, 237, STRUCTURE OF THE OSR1 KINASE A HYPERTENSION DRUG TARGET
4963, d3gc7A_, 0.7125, 3.77, 0.219, 349, 247, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH A DIHYDROQUINAZOLINONE
4964, d2w7xA_, 0.7125, 3.00, 0.240, 285, 229, CELLULAR INHIBITION OF CHECKPOINT KINASE 2 AND POTENTIATION OF CYTOTOXIC DRUGS BY NOVEL CHK2 INHIBITOR PV1019
4965, d3r2bA_, 0.7124, 2.86, 0.218, 272, 229, MK2 KINASE BOUND TO COMPOUND 5B
4966, d1jvpP_, 0.7124, 3.08, 0.241, 268, 232, CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) IN COMPLEX WITH PKF049-365
4967, d4ynzA1, 0.7123, 3.19, 0.256, 306, 238, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
4968, d2xk9A_, 0.7123, 2.94, 0.253, 284, 229, STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 (CHK2) IN COMPLEX WITH INHIBITOR PV1533
4969, d3gp0A1, 0.7122, 3.08, 0.209, 332, 234, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 11 (P38 BETA) IN COMPLEX WITH NILOTINIB
4970, d1oiqA_, 0.7122, 2.77, 0.263, 264, 228, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
4971, d4useB_, 0.7121, 3.45, 0.242, 278, 236, HUMAN STK10 (LOK) WITH SB-633825
4972, d3r2bI_, 0.7121, 2.89, 0.218, 272, 229, MK2 KINASE BOUND TO COMPOUND 5B
4973, d3fl4A_, 0.7120, 3.41, 0.218, 339, 239, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO5634
4974, d1zycD1, 0.7120, 3.58, 0.213, 254, 244, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
4975, d1zmvB_, 0.7120, 2.86, 0.251, 296, 231, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
4976, d3r2bL_, 0.7119, 2.89, 0.223, 272, 229, MK2 KINASE BOUND TO COMPOUND 5B
4977, d2j90B_, 0.7119, 2.73, 0.256, 262, 227, CRYSTAL STRUCTURE OF HUMAN ZIP KINASE IN COMPLEX WITH A TETRACYCLIC PYRIDONE INHIBITOR (PYRIDONE 6)
4978, d1ua2C_, 0.7119, 3.11, 0.233, 286, 232, CRYSTAL STRUCTURE OF HUMAN CDK7
4979, d5kbqB_, 0.7118, 3.32, 0.209, 273, 239, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
4980, d3r2bJ_, 0.7118, 2.89, 0.223, 272, 229, MK2 KINASE BOUND TO COMPOUND 5B
4981, d3r2bC_, 0.7117, 2.90, 0.223, 272, 229, MK2 KINASE BOUND TO COMPOUND 5B
4982, d3gcuB_, 0.7117, 3.35, 0.226, 337, 239, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
4983, d1zmuA_, 0.7117, 2.72, 0.253, 293, 229, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
4984, d5a6nB1, 0.7116, 2.99, 0.232, 265, 233, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH COMPOUND 2
4985, d4eh6A_, 0.7116, 3.26, 0.220, 335, 236, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F5 AND RL87
4986, d3p5kA_, 0.7116, 3.24, 0.218, 332, 238, P38 INHIBITOR-BOUND
4987, d4x7nA_, 0.7115, 3.20, 0.217, 259, 235, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-[2-AMINO-4-METHYL-3-(2- METHYLQUINOLIN-6-YL)BENZOYL]-1-METHYL-25-DIPHENYL-12-DIHYDRO-3H- PYRAZOL-3-ONE INHIBITOR
4988, d3uiuB_, 0.7115, 3.05, 0.263, 255, 232, CRYSTAL STRUCTURE OF APO-PKR KINASE DOMAIN
4989, d3uiuA_, 0.7115, 3.05, 0.263, 255, 232, CRYSTAL STRUCTURE OF APO-PKR KINASE DOMAIN
4990, d3r2bH_, 0.7115, 2.89, 0.227, 272, 229, MK2 KINASE BOUND TO COMPOUND 5B
4991, d3r2bG_, 0.7115, 2.88, 0.223, 272, 229, MK2 KINASE BOUND TO COMPOUND 5B
4992, d3newA_, 0.7115, 3.20, 0.220, 334, 236, P38-ALPHA COMPLEXED WITH COMPOUND 10
4993, d3fi4A_, 0.7115, 3.31, 0.227, 339, 238, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO4499
4994, d3fe3A_, 0.7115, 3.35, 0.260, 317, 242, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
4995, d2pkjA_, 0.7115, 3.20, 0.232, 332, 237,  
4996, d4eh4A_, 0.7114, 3.36, 0.215, 337, 237, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F3 AND RL87
4997, d3efwA_, 0.7114, 2.76, 0.210, 240, 229, STRUCTURE OF AURORAA WITH PYRIDYL-PYRIMIDINE UREA INHIBITOR
4998, d4jvgD1, 0.7113, 2.82, 0.278, 245, 230, B-RAF KINASE IN COMPLEX WITH BIRB796
4999, d4eh3A_, 0.7113, 3.43, 0.214, 339, 238, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F2 AND RL87
5000, d3a2cD_, 0.7113, 3.18, 0.210, 277, 233, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
